Sentence,class,file
Treatment of Small Vessel Disease  http://dx.doi.org/10.5853/jos.2015.17.2.111 120 http://j-stroke.orgsociated with the progression of white matter lesion volumes:  The three-city (3c)-dijon magnetic resonance imaging study.,Non-OADS,/arxiv_data1/oa_pdf/65/c1/jos-17-111.PMC4460330.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.111 http://j-stroke.org  12168.,Non-OADS,/arxiv_data1/oa_pdf/65/c1/jos-17-111.PMC4460330.pdf
Treatment of Small Vessel Disease  http://dx.doi.org/10.5853/jos.2015.17.2.111 122 http://j-stroke.orgStroke  2014;45:1422-1428.,Non-OADS,/arxiv_data1/oa_pdf/65/c1/jos-17-111.PMC4460330.pdf
"Copyright © 2015  Korean Stroke Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/dd/4c/jos-17-123.PMC4460331.pdf
"pISSN: 2287-6391 • eISSN: 2287-6405 http://j-stroke.org  123Endovascular Mechanical Thrombectomy for Acute  Ischemic Stroke: A New Standard of Care Dale Ding Department of Neurosurgery, University of Virginia, Charlottesville, Virginia, USA Correspondence:  Dale Ding University of Virginia Department of  Neurosurgery P.O.",Non-OADS,/arxiv_data1/oa_pdf/dd/4c/jos-17-123.PMC4460331.pdf
Keywords Cerebral ischemia; Endovascular procedures; Revascularization; Reperfusion;  Stroke; StentsExpedited Brief ReviewJournal of Stroke  201 5;17(2):123- 126 http://dx.doi.org/10.5853/jos.2015.17.2.123 Introduction Acute ischemic stroke (AIS) secondary to intracranial larger  artery occlusion (LAO) is associated with significantly worse  outcome than in the absence of LAO.,Non-OADS,/arxiv_data1/oa_pdf/dd/4c/jos-17-123.PMC4460331.pdf
Ding Endovascular Therapy for Acute Ischemic Stroke http://dx.doi.org/10.5853/jos.2015.17.2.123 124 http://j-stroke.orgvention for AIS.,Non-OADS,/arxiv_data1/oa_pdf/dd/4c/jos-17-123.PMC4460331.pdf
3 / September 2015 http://dx.doi.org/10.5853/jos.2015.17.2.123 http://j-stroke.org  125Table 1.,Non-OADS,/arxiv_data1/oa_pdf/dd/4c/jos-17-123.PMC4460331.pdf
"Ding Endovascular Therapy for Acute Ischemic Stroke http://dx.doi.org/10.5853/jos.2015.17.2.123 126 http://j-stroke.orghesitation regarding the benefit of endovascular therapy for AIS  from the MR CLEAN data has been quelled by concordant find - ings from the six subsequent RCT s. A wealth of additional infor - mation from these studies, including the detailed analyses of  THERAPY and THRACE in their respective published manu - scripts as well as pooled subgroup analyses, are forthcoming.",Non-OADS,/arxiv_data1/oa_pdf/dd/4c/jos-17-123.PMC4460331.pdf
"Copyright © 2015  Korean Stroke Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c9/fe/jos-17-127.PMC4460332.pdf
"pISSN: 2287-6391 • eISSN: 2287-6405 http://j-stroke.org  127Evolution of Endovascular Therapy in Acute  Stroke: Implications of Device Development Adithya Balasubramaian, Peter Mitchell, Richard Dowling, Bernard Yan Comprehensive Stroke Centre, Royal Melbourne Hospital, Parkville, Victoria, Australia Correspondence:  Bernard Yan Comprehensive Stroke Centre, Royal  Melbourne Hospital Parkville Melbourne,  Victoria 3050, Australia Tel: +61-3-9349-2477 Fax: +61-3-9349-4489 Email: bernard.yan@mh.org.au@ Received: March 17, 2015 Revised: May 9, 2015 Accepted: May 27, 2015 The authors have no financial conflicts of  interest.Intravenous thrombolysis is an effective treatment for acute ischaemic stroke.",Non-OADS,/arxiv_data1/oa_pdf/c9/fe/jos-17-127.PMC4460332.pdf
"Keywords Mechanical Thrombectomy; Acute Ishemic Stroke; Clot Retrieval; Endovascular;  StentrieverReviewJournal of Stroke  201 5;17(2):127- 137 http://dx.doi.org/10.5853/jos.2015.17.2.127 Introduction Timely administration ( < 4.5 hours) of intravenous recombi - nant tissue plasminogen activator (IV rt-PA or tPA) improves  outcomes in acute ischemic stroke.1,2 However, IV tPA is associat - ed with early recanalization in only 21% of cases,3 with worse rates  in distal internal carotid and basilar artery occlusions, and fre - quent re-occlusions after IV tPA in 12%.4 Furthermore, the nar - row time window and strict exclusion criteria limits the opportu - nity for IV thrombolysis, with a significant proportion of patients  found to breach criteria in a recent randomized control trial.2,5 Despite the perceived intuitive benefit of endovascular thera - py of improved revascularisation and improved outcomes, three  major initial randomized control trials- IMS III,6 MR RESCUE7  and SYNTHESIS8 could not demonstrate this.",Non-OADS,/arxiv_data1/oa_pdf/c9/fe/jos-17-127.PMC4460332.pdf
"Evolution of Endovascular Therapy in Acute Stroke http://dx.doi.org/10.5853/jos.2015.17.2.127 128 http://j-stroke.orgTHRACE17, and THERAPY,18 supporting the superiority of  the intra-arterial approach over IV tPA.",Non-OADS,/arxiv_data1/oa_pdf/c9/fe/jos-17-127.PMC4460332.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.127 http://j-stroke.org  129subjects from the NINDS study.,OADS,/arxiv_data1/oa_pdf/c9/fe/jos-17-127.PMC4460332.pdf
(A) MERCI device.27  Available in the public domain: http://stroke.ahajournals.org/content/39/4/1205.figures-only.,Non-OADS,/arxiv_data1/oa_pdf/c9/fe/jos-17-127.PMC4460332.pdf
(B) CATCH device.28 Available in the pub - lic domain: http://www.ajnr.org/content/32/8/1381/F1.expansion.html.,Non-OADS,/arxiv_data1/oa_pdf/c9/fe/jos-17-127.PMC4460332.pdf
(C) SOLITAIRE device.29 Available in the public domain: http://www.covidien.com/imageServ - er.aspx/doc245416.pdf?contentID = 31741&contenttype = application/pdf.,Non-OADS,/arxiv_data1/oa_pdf/c9/fe/jos-17-127.PMC4460332.pdf
(D) TREVO device.32 Available in the public domain: http://stroke.ahajournals.org/con - tent/43/6/1657/F1.expansion.html.,Non-OADS,/arxiv_data1/oa_pdf/c9/fe/jos-17-127.PMC4460332.pdf
(E) REVIVE device.11 Available in the public domain: http://stroke.ahajournals.org/content/42/10/2954.figures-only.,Non-OADS,/arxiv_data1/oa_pdf/c9/fe/jos-17-127.PMC4460332.pdf
Evolution of Endovascular Therapy in Acute Stroke http://dx.doi.org/10.5853/jos.2015.17.2.127 130 http://j-stroke.orgwith various designs were subsequently developed.,Non-OADS,/arxiv_data1/oa_pdf/c9/fe/jos-17-127.PMC4460332.pdf
Penumbra device.33 Available in the public domain: http://www.ajnr.org/content/29/7/1409/F1.expansion.html.,Non-OADS,/arxiv_data1/oa_pdf/c9/fe/jos-17-127.PMC4460332.pdf
"2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.127 http://j-stroke.org  131However, the rates of symptomatic haemorrhage were much  higher using the CATCH device (18%).28 Being a retrospective  trial, there were several limitations to the study design.",Non-OADS,/arxiv_data1/oa_pdf/c9/fe/jos-17-127.PMC4460332.pdf
"Evolution of Endovascular Therapy in Acute Stroke http://dx.doi.org/10.5853/jos.2015.17.2.127 132 http://j-stroke.orgcompared to the MERCI (61% vs. 24%, P< 0.0001) and a more  favourable 3-month neurological outcome (58% vs. 33%, P=  0.0001) without increasing rates of symptomatic haemorrhagic  transformation (2% vs. 11%)9 TREVO The efficacy and safety of the TREVO device was first evalu - ated through a prospective, single-center study of 60 patients  anterior or posterior circulation strokes.32 Successful revascular - isation (Thrombolysis in Cerebral Infarction 2b-3) was ob - tained in 44 (73.3%) of cases when only the TREVO device  was used and in 52 (86.7%) when other devices or additional  intra-arterial tPA were also required.",Non-OADS,/arxiv_data1/oa_pdf/c9/fe/jos-17-127.PMC4460332.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.127 http://j-stroke.org  133eral advantages.,Non-OADS,/arxiv_data1/oa_pdf/c9/fe/jos-17-127.PMC4460332.pdf
"Evolution of Endovascular Therapy in Acute Stroke http://dx.doi.org/10.5853/jos.2015.17.2.127 134 http://j-stroke.org53.0% vs. 29.3% in the control group), with an associated reduc - tion in mortality (10.4% vs. 19.0%) and no significant difference  in adverse events.14 Given analysis of previous trials illustrating the importance of  time to reperfusion, there was a strong emphasis on delivering  rapid endovascular therapy, with a median time of 84 minutes  from noncontrast CT to first reperfusion.",Non-OADS,/arxiv_data1/oa_pdf/c9/fe/jos-17-127.PMC4460332.pdf
"2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.127 http://j-stroke.org  135occlusion, to IV thrombolysis alone versus additional mechani - cal thrombectomy using a variety of devices.43 IA therapy is  commenced within 6 hours of presentation using an approved  device as per the discretion of the neurointerventionalist.",Non-OADS,/arxiv_data1/oa_pdf/c9/fe/jos-17-127.PMC4460332.pdf
Evolution of Endovascular Therapy in Acute Stroke http://dx.doi.org/10.5853/jos.2015.17.2.127 136 http://j-stroke.org19.,Non-OADS,/arxiv_data1/oa_pdf/c9/fe/jos-17-127.PMC4460332.pdf
Available at: http://www.covidien.com/im - ageServer.aspx/doc245416.pdf?contentID=31741&contentt ype=application/pdf.30.,Non-OADS,/arxiv_data1/oa_pdf/c9/fe/jos-17-127.PMC4460332.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.127 http://j-stroke.org  137therapy for proximal aneterior circulation occlusions beyond 8  h from last seen well.,Non-OADS,/arxiv_data1/oa_pdf/c9/fe/jos-17-127.PMC4460332.pdf
Available at: http://clinicaltrials.gov/ct2/show/study/NCT02142283.,Non-OADS,/arxiv_data1/oa_pdf/c9/fe/jos-17-127.PMC4460332.pdf
Available at: http://www.gla.,Non-OADS,/arxiv_data1/oa_pdf/c9/fe/jos-17-127.PMC4460332.pdf
"138 http://j-stroke.orgCopyright © 2015  Korean Stroke Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/88/0a/jos-17-138.PMC4460333.pdf
Keywords β2-adrenergic receptor gene; β2AR; Ischemic stroke; Cerebral infarction; Poly - morphism; Meta-analysis ReviewJournal of Stroke  201 5;17(2):138- 143 http://dx.doi.org/10.5853/jos.2015.17.2.138 Introduction Stroke is the second common cause of death following isch - emic heart disease.1 Stroke has accounted for nearly 5.7 million  deaths globally and 87% of these deaths take place in low and  middle income nations.2 Stroke is a multi-factorial disease and  epidemiological and animal studies have robustly recommend - ed genetic influences in the pathogenesis of ischemic stroke.3  The genetic influences are probably polygenic whereby multiple  genes exert a small influence or risk on phenotype.,Non-OADS,/arxiv_data1/oa_pdf/88/0a/jos-17-138.PMC4460333.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.138 http://j-stroke.org  139have been recognized at nucleotides 46 (A > G) (rs1042713) and  79 (C > G) (rs1042714) causing changes in amino acid residues  at position 16 (Arg > Gly) and 27 (Gln > Glu) of the amino ter - minus respectively of the fourth intracellular loop.,OADS,/arxiv_data1/oa_pdf/88/0a/jos-17-138.PMC4460333.pdf
Beta Adrenergic Receptor Gene Polymorphism and Ischemic Stroke  http://dx.doi.org/10.5853/jos.2015.17.2.138 140 http://j-stroke.orgmeta-analysis.,Non-OADS,/arxiv_data1/oa_pdf/88/0a/jos-17-138.PMC4460333.pdf
"2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.138 http://j-stroke.org  141in which significant associations were not observed, were report - ed from the American population19,20 while the other two stud - ies,11,12 which showed the significant genotypic association, were  reported from India and Italy.",OADS,/arxiv_data1/oa_pdf/88/0a/jos-17-138.PMC4460333.pdf
Beta Adrenergic Receptor Gene Polymorphism and Ischemic Stroke  http://dx.doi.org/10.5853/jos.2015.17.2.138 142 http://j-stroke.orgation from HWE equilibrium in control subjects in one study in - cluded in this meta-analysis may account for the heterogeneity.,Non-OADS,/arxiv_data1/oa_pdf/88/0a/jos-17-138.PMC4460333.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.138 http://j-stroke.org  143al.,Non-OADS,/arxiv_data1/oa_pdf/88/0a/jos-17-138.PMC4460333.pdf
"144 http://j-stroke.orgCopyright © 2015  Korean Stroke Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/24/fd/jos-17-144.PMC4460334.pdf
Keywords Circle of willis; Embryology; Cerebral arteries; Arterial variants; Stroke; RemodelingReviewJournal of Stroke  201 5;17(2):144- 158 http://dx.doi.org/10.5853/jos.2015.17.2.144 Introduction A large proportion of strokes worldwide are caused by ath - erosclerosis affecting the arteries that supply blood to the brain.,Non-OADS,/arxiv_data1/oa_pdf/24/fd/jos-17-144.PMC4460334.pdf
"2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.144 http://j-stroke.org  145Embriology of the cerebral circulation The development of the vascular system in the embryo hap - pens before the heart starts beating.18 It consists of 2 main stag - es: vasculogenesis and angiogenesis.19 Vasculogenesis can be  understood as the process by which hemangioblasts are differ - entiated into angioblasts and angiogenesis refers to the forma - tion of new vessels.18 The main mechanism of angiogenesis is  sprouting and it is mainly driven by hypoxia/ischemia and re - lated growth factors from the target tissue.18,20,21 As more capil - laries are formed, the impedance to flow is reduced in larger ar - teries thus facilitating flow-induced remodeling of the arteries  supplying this area.22 The development of the circulatory sys - tem supplying blood to the brain begins with the formation of  the 6 pairs of primitive branchial arch arteries at the 1.3 mm  embryonic stage, subsequently undergoing heavy modifications  during development.23,24  The internal carotid arteries (ICA) appear during the 3 mm  embryonic stage (24 days) from the combination of the 3rd branchial arch arteries and the distal segments of the paired  dorsal aortae (Figure 1).",Non-OADS,/arxiv_data1/oa_pdf/24/fd/jos-17-144.PMC4460334.pdf
"Embryology and Anatomy of Cerebral Arteries http://dx.doi.org/10.5853/jos.2015.17.2.144 146 http://j-stroke.orglus for the formation of the posterior circulation, first with the  BA and later with the vertebral arteries (VA).13 At the 4-5-mm  embryonic stage, the hindbrain (i.e., future posterior fossa) is  supplied by two parallel neural arteries (or channels).",Non-OADS,/arxiv_data1/oa_pdf/24/fd/jos-17-144.PMC4460334.pdf
"2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.144 http://j-stroke.org  147artery subsequently splits into two parallel channels that later  rejoin and may or not share an adventitial sheath.32,34,37 Fenes - tration should be distinguished from duplication, which is de - fined as two distinct arteries with separate origins with down - stream fusion in a distal arterial segment.36,38 Duplicated or fe - nestrated arteries are the second most common variants (after  hypoplastic arteries) and are reportedly more frequent in the  anterior circulation.35,39 The most commonly duplicated or fe - nestrated artery is the ACOMM (Figure 3), while fenestrations  of the ICA are exceedingly rare.35,40 Fenestration or duplications  might be due to an incomplete fusion of arteries during devel - opment, however some authors believe fenestrations can be  also induced by the trans-arterial course of a nerve, a bony  structure or enlarged vasa vasorum  along the path of the ar - ter y.32,34,37,41 Except for Digitally Subtracted Angiography  (DSA), fenestrations are best visualized with 3D rotational an - giography (3DRA).42 Hypoplastic arteries Cerebral arteries integrating the adult CoW vary in size.",Non-OADS,/arxiv_data1/oa_pdf/24/fd/jos-17-144.PMC4460334.pdf
Embryology and Anatomy of Cerebral Arteries http://dx.doi.org/10.5853/jos.2015.17.2.144 148 http://j-stroke.orghorizontal cavernous) extends from the meningo-hypophyseal  trunk to the infero-lateral trunk within the cavernous sinus.,Non-OADS,/arxiv_data1/oa_pdf/24/fd/jos-17-144.PMC4460334.pdf
"2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.144 http://j-stroke.org  149persists normally in many vertebrates, but in humans it is con - sidered anomalous and only rarely found in adults (2.5%).14,60 Variants of the ACOMM are common variants in the CoW  with a duplication prevalence of 18% and fenestrations in up to  21%.60 The ACOMM may not appear in angiography, but we  cannot be sure about its real absence.",Non-OADS,/arxiv_data1/oa_pdf/24/fd/jos-17-144.PMC4460334.pdf
"Embryology and Anatomy of Cerebral Arteries http://dx.doi.org/10.5853/jos.2015.17.2.144 150 http://j-stroke.orgplies directly the SCA, AICA, or PICA, respectively, the majori - ty being Type 3b.72,75  Hypoglossal artery The prevalence of a persistent HA is 8 to 10 times less than  the persistent TA with a reported prevalence of 0.02% to 0.10%  (Figure 5A).76 It arises from the cervical ICA at the C1 to C3  level and connects to the BA via the hypoglossal canal (i.e., the  anterior condyloid foramen).",Non-OADS,/arxiv_data1/oa_pdf/24/fd/jos-17-144.PMC4460334.pdf
"2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.144 http://j-stroke.org  151HAs and persistent ProAs appear similar, there are distinguish - ing characteristics that can be used to differentiate these two  variants.",Non-OADS,/arxiv_data1/oa_pdf/24/fd/jos-17-144.PMC4460334.pdf
Embryology and Anatomy of Cerebral Arteries http://dx.doi.org/10.5853/jos.2015.17.2.144 152 http://j-stroke.orgcomes stagnant in some areas of the arterial bifurcation and  stagnation makes this region a preferred site for atheroma for - mation and may predispose to platelet aggregation and throm - bus formation.,Non-OADS,/arxiv_data1/oa_pdf/24/fd/jos-17-144.PMC4460334.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.144 http://j-stroke.org  153and follow them into adulthood or late aging.,Non-OADS,/arxiv_data1/oa_pdf/24/fd/jos-17-144.PMC4460334.pdf
"Embryology and Anatomy of Cerebral Arteries http://dx.doi.org/10.5853/jos.2015.17.2.144 154 http://j-stroke.orglateral ICA occlusion.113 Extracranial carotid surgery in the pres - ence of any carotid-vertebrobasilar anastomosis might lead to  brain stem embolization or ischemia.114  A persistent TA has been associated with aneurysms of the  CoW, carotid and VA agenesis, facial hemangiomas, PCOMM  agenesis, moyamoya disease, and aortic arch vessel anomalies in  up to 25% of the cases.72,115 Recognizing the persistent TA is  critical during the now-infrequently performed Wada test to  avoid embolization or infusion of barbiturates into the posterior  fossa.",Non-OADS,/arxiv_data1/oa_pdf/24/fd/jos-17-144.PMC4460334.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.144 http://j-stroke.org  15518.,Non-OADS,/arxiv_data1/oa_pdf/24/fd/jos-17-144.PMC4460334.pdf
Embryology and Anatomy of Cerebral Arteries http://dx.doi.org/10.5853/jos.2015.17.2.144 156 http://j-stroke.org50.,Non-OADS,/arxiv_data1/oa_pdf/24/fd/jos-17-144.PMC4460334.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.144 http://j-stroke.org  157moses: persistent hypoglossal artery associated with further  variations of the circle of Willis.,Non-OADS,/arxiv_data1/oa_pdf/24/fd/jos-17-144.PMC4460334.pdf
Embryology and Anatomy of Cerebral Arteries http://dx.doi.org/10.5853/jos.2015.17.2.144 158 http://j-stroke.org107.,Non-OADS,/arxiv_data1/oa_pdf/24/fd/jos-17-144.PMC4460334.pdf
"Copyright © 2015  Korean Stroke Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f3/79/jos-17-159.PMC4460335.pdf
"pISSN: 2287-6391 • eISSN: 2287-6405 http://j-stroke.org  159Factors Associated with Early Hospital Arrival in  Patients with Acute Ischemic Stroke Dongbeom Song,a Eijirou T anaka,b Kijeong Lee,a Shoichiro Sato,b Masatoshi Koga,b Y oung Dae Kim,a  Kazuyuki Nagatsuka,c Kazunori T oyoda,b Ji Hoe Heoa aDepartments of Neurology, Severance Stroke Center, Y onsei University College of Medicine, Seoul, Korea bDepartment of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan cDepartment of Neurology, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan Correspondence:  Ji Hoe Heo Department of Neurology, Yonsei  University College of Medicine, 50 Yonsei-ro, Seodaemoon-gu,   Seoul 120-752, Korea Tel: +82-2-2228-1605 Fax: +82-2-393-0705 E-mail: jhheo@yuhs.ac Received: January 23, 2015 Revised: March 31, 2015 Accepted: April 1, 2015 This work was supported by a grant from  the Korea Healthcare Technology Research  and Development Project, Ministry for  Health and Welfare, Republic of Korea  (HI10C2020, HI08C2149).",Non-OADS,/arxiv_data1/oa_pdf/f3/79/jos-17-159.PMC4460335.pdf
"Keywords Acute stroke therapy; Cerebral infarction; Early hospital arrival; Prehospital delay;  Emergency medical service; CountriesOriginal ArticleJournal of Stroke  201 5;17(2):159- 167 http://dx.doi.org/10.5853/jos.2015.17.2.159 Introduction Administration of intravenous (IV) tissue plasminogen activa - tor (tPA) within 4.5 hours,1 and endovascular reperfusion thera - py within 6 hours2 are the proven treatments for acute ischemic  stroke.",Non-OADS,/arxiv_data1/oa_pdf/f3/79/jos-17-159.PMC4460335.pdf
"Factors Associated with Early Hospital Arrival http://dx.doi.org/10.5853/jos.2015.17.2.159 160 http://j-stroke.orgIn an effort to promote early hospital arrival, several studies  have been conducted to determine the factors associated with  early hospital arrival, and have identified demographic, socio - economic, clinical, and personal characteristics related to early  hospital arrival.4,7-10 Early hospital arrival has been associated  with socioeconomic status and the prehospital delivery system,  and may involve factors that differ according to the characteris - tics of the country or hospital.",Non-OADS,/arxiv_data1/oa_pdf/f3/79/jos-17-159.PMC4460335.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.159 http://j-stroke.org  161lowering drugs; more severe stroke at presentation (higher NI - HSS score); more frequent stroke onset during the nighttime;  and more frequent transport by EMS or transfer from another  hospital.,Non-OADS,/arxiv_data1/oa_pdf/f3/79/jos-17-159.PMC4460335.pdf
"Factors Associated with Early Hospital Arrival http://dx.doi.org/10.5853/jos.2015.17.2.159 162 http://j-stroke.orgabdominal circumference, and more frequent history of diabetes  mellitus and previous use of antiplatelet agent and lipid lowering  drugs in the YUHS patients compared to those from the NCVC  may reflect some general features of Korea compared with Japan.",Non-OADS,/arxiv_data1/oa_pdf/f3/79/jos-17-159.PMC4460335.pdf
"2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.159 http://j-stroke.org  163vious studies.4,7-10 Calling an EMS implies that the patient or by - stander recognized the symptom of stroke as being urgent, and  managed the situation properly.",Non-OADS,/arxiv_data1/oa_pdf/f3/79/jos-17-159.PMC4460335.pdf
Factors Associated with Early Hospital Arrival http://dx.doi.org/10.5853/jos.2015.17.2.159 164 http://j-stroke.orgReferences 1.,Non-OADS,/arxiv_data1/oa_pdf/f3/79/jos-17-159.PMC4460335.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.159 http://j-stroke.org  165Supplementary Table 1.,Non-OADS,/arxiv_data1/oa_pdf/f3/79/jos-17-159.PMC4460335.pdf
Factors Associated with Early Hospital Arrival http://dx.doi.org/10.5853/jos.2015.17.2.159 166 http://j-stroke.orgSupplementary Table 2.,Non-OADS,/arxiv_data1/oa_pdf/f3/79/jos-17-159.PMC4460335.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.159 http://j-stroke.org  167Supplementary Table 3.,Non-OADS,/arxiv_data1/oa_pdf/f3/79/jos-17-159.PMC4460335.pdf
"168 http://j-stroke.orgCopyright © 2015  Korean Stroke Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c6/da/jos-17-168.PMC4460336.pdf
"Keywords Fatty acids composition; Docosahexaenoic acid; Eicosapentaenoic acid; ω3- polyunsaturated fatty acids, Stroke outcome Original ArticleJournal of Stroke  201 5;17(2):168- 176 http://dx.doi.org/10.5853/jos.2015.17.2.168 Introduction Fatty acids (FAs), the components of phospholipids in organ - elle and cellular membranes, play important biological roles by maintaining or processing membrane protein function or fluidi - ty.1 In addition, FAs modulate vascular inflammation, a key  mechanism of atherosclerosis, cerebral small vessel pathologies,  and stroke, by altering intracellular signal transduction or con -",Non-OADS,/arxiv_data1/oa_pdf/c6/da/jos-17-168.PMC4460336.pdf
"2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.168 http://j-stroke.org  169trolling lipid mediators such as prostaglandins, thromboxanes, or  leukotrienes.2 Among FAs, ω3-polyunsaturated FAs (ω3-PUFAs),  such as eicosapentaenoic acid (EPA) and docosahexaenoic acid  (DHA), are potent anti-inflammatory molecules.",Non-OADS,/arxiv_data1/oa_pdf/c6/da/jos-17-168.PMC4460336.pdf
"Fatty Acids Composition and Stroke Outcome http://dx.doi.org/10.5853/jos.2015.17.2.168 170 http://j-stroke.orgthe phospholipid fraction was isolated by thin layer chromatog - raphy using a development solvent composed of hexane, diethyl  ether, and acetic acid (80:20:2).",Non-OADS,/arxiv_data1/oa_pdf/c6/da/jos-17-168.PMC4460336.pdf
"2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.168 http://j-stroke.org  171ids), lower proportion of EPA and DHA were independently  associated with stroke severity on admission (β: -0.751, stan - dard error (SE): 0.376, P= 0.048 for EPA, β: -0.610, SE: 0.215,  P= 0.005 for DHA).",Non-OADS,/arxiv_data1/oa_pdf/c6/da/jos-17-168.PMC4460336.pdf
Fatty Acids Composition and Stroke Outcome http://dx.doi.org/10.5853/jos.2015.17.2.168 172 http://j-stroke.orgdid not appear to be correlated in multivariate linear regression  analysis.,Non-OADS,/arxiv_data1/oa_pdf/c6/da/jos-17-168.PMC4460336.pdf
"2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.168 http://j-stroke.org  173sociated with stroke severity on hospital admission and poor  functional outcome even after adjusting for the NIHSS score,  which is considered a strong predictive factor for stroke out - come.",Non-OADS,/arxiv_data1/oa_pdf/c6/da/jos-17-168.PMC4460336.pdf
Fatty Acids Composition and Stroke Outcome http://dx.doi.org/10.5853/jos.2015.17.2.168 174 http://j-stroke.orgReferences 1.,Non-OADS,/arxiv_data1/oa_pdf/c6/da/jos-17-168.PMC4460336.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.168 http://j-stroke.org  175and total and cause-specific mortality in older adults: a cohort  study.,Non-OADS,/arxiv_data1/oa_pdf/c6/da/jos-17-168.PMC4460336.pdf
Fatty Acids Composition and Stroke Outcome http://dx.doi.org/10.5853/jos.2015.17.2.168 176 http://j-stroke.orgSupplementary Table 1.,Non-OADS,/arxiv_data1/oa_pdf/c6/da/jos-17-168.PMC4460336.pdf
"Copyright © 2015  Korean Stroke Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c7/d2/jos-17-177.PMC4460337.pdf
"pISSN: 2287-6391 • eISSN: 2287-6405 http://j-stroke.org  177Smoking is Not a Good Prognostic Factor following  First-Ever Acute Ischemic Stroke  Ju-Hun Lee, Ju Y oung Lee, So Hyun Ahn, Min Uk Jang, Mi Sun Oh, Chul-Ho Kim, Kyung-Ho Yu,  Byung-Chul Lee  Department of Neurology, Hallym University Medical Center, Hallym Neurological Institute, Hallym University College of Medicine, Anyang, Korea Correspondence:  Byung-Chul Lee Department of Neurology, Hyllym  Neurological Iustitute, 22 Gwanpyeong-ro  170 beon-gil, Anyang 431-796, Korea Tel: +82-31-380-3741 Fax: +82-31-381-4659 Email: ssbrain@hallym.ac.kr Received: January 15, 2015 Revised: March 24, 2015 Accepted: March 25, 2015 This study was supported by a grant from  the Korea Health 21 R&D Project, Ministry  of Health, Welfare and Family Affairs,  Republic of Korea (HI10C2020).",Non-OADS,/arxiv_data1/oa_pdf/c7/d2/jos-17-177.PMC4460337.pdf
"Keywords Smoking; Acute ischemic stroke; PrognosisOriginal ArticleJournal of Stroke  201 5;17(2):177- 191 http://dx.doi.org/10.5853/jos.2015.17.2.177 Introduction Smoking is a modifiable and established risk factor for stroke.1,2  The age-standardized prevalence of current smoking in Korean  adults is substantially high when compared with the US popula - tion, in particular in men (48.1% of Korean men vs. 21.2% of US  men).3,4 The population attributable risk of smoking for stroke is  also high in Korean men (26.5%).5 Therefore, antismoking cam -paigns are an important health-related intervention for stroke  prevention in Korea.",Non-OADS,/arxiv_data1/oa_pdf/c7/d2/jos-17-177.PMC4460337.pdf
Effect of Smoking on Acute Ischemic Stroke Outcome http://dx.doi.org/10.5853/jos.2015.17.2.177 178 http://j-stroke.orgchronic exposure to smoking or nicotine may promote angiogen - esis or ischemic preconditioning with enhanced collateral flows.,Non-OADS,/arxiv_data1/oa_pdf/c7/d2/jos-17-177.PMC4460337.pdf
"2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.177 http://j-stroke.org  179(0.3%), smoking status in 4 (0.36%), BMI in 33 (3.0%), WBC  in 1 (0.1%), LDL-C in 22 (2.0%), and fasting glucose in 98  (8.8%) patients.",Non-OADS,/arxiv_data1/oa_pdf/c7/d2/jos-17-177.PMC4460337.pdf
Effect of Smoking on Acute Ischemic Stroke Outcome http://dx.doi.org/10.5853/jos.2015.17.2.177 180 http://j-stroke.orgrent smokers and 58.4% (454/777) of non-smokers (57.9%  [73/126] of former-smokers and 58.5% [381/651] of never- smokers) had a good functional outcome.,Non-OADS,/arxiv_data1/oa_pdf/c7/d2/jos-17-177.PMC4460337.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.177 http://j-stroke.org  181ed with functional outcome and death.,Non-OADS,/arxiv_data1/oa_pdf/c7/d2/jos-17-177.PMC4460337.pdf
"Effect of Smoking on Acute Ischemic Stroke Outcome http://dx.doi.org/10.5853/jos.2015.17.2.177 182 http://j-stroke.orghowever, smoking status was not independently related with  functional outcome after adjustment for demographics and  other prognostic indicators.",OADS,/arxiv_data1/oa_pdf/c7/d2/jos-17-177.PMC4460337.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.177 http://j-stroke.org  183 Figure 3.,Non-OADS,/arxiv_data1/oa_pdf/c7/d2/jos-17-177.PMC4460337.pdf
"Effect of Smoking on Acute Ischemic Stroke Outcome http://dx.doi.org/10.5853/jos.2015.17.2.177 184 http://j-stroke.orgstroke recovery, smoking cessation as a long-term protective mea - sure with respect to mortality and cardiovascular events is well  defined.21,22 Current smokers with mild or no disability may con - tinue smoking compared with those who experienced severe  stroke,23  which may affect the functional outcome.",Non-OADS,/arxiv_data1/oa_pdf/c7/d2/jos-17-177.PMC4460337.pdf
"2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.177 http://j-stroke.org  185den WB, et al.",OADS,/arxiv_data1/oa_pdf/c7/d2/jos-17-177.PMC4460337.pdf
Effect of Smoking on Acute Ischemic Stroke Outcome http://dx.doi.org/10.5853/jos.2015.17.2.177 186 http://j-stroke.orgSupplementary  Table 1.,Non-OADS,/arxiv_data1/oa_pdf/c7/d2/jos-17-177.PMC4460337.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.177 http://j-stroke.org  187Supplementary Table 2.,Non-OADS,/arxiv_data1/oa_pdf/c7/d2/jos-17-177.PMC4460337.pdf
Effect of Smoking on Acute Ischemic Stroke Outcome http://dx.doi.org/10.5853/jos.2015.17.2.177 188 http://j-stroke.orgSupplementary Table 3.,Non-OADS,/arxiv_data1/oa_pdf/c7/d2/jos-17-177.PMC4460337.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.177 http://j-stroke.org  189Supplementary  Table 4.,Non-OADS,/arxiv_data1/oa_pdf/c7/d2/jos-17-177.PMC4460337.pdf
Effect of Smoking on Acute Ischemic Stroke Outcome http://dx.doi.org/10.5853/jos.2015.17.2.177 190 http://j-stroke.orgSupplementary  Table 5.,Non-OADS,/arxiv_data1/oa_pdf/c7/d2/jos-17-177.PMC4460337.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.177 http://j-stroke.org  191Supplementary Table 6.,Non-OADS,/arxiv_data1/oa_pdf/c7/d2/jos-17-177.PMC4460337.pdf
"192 http://j-stroke.orgCopyright © 2015  Korean Stroke Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/de/00/jos-17-192.PMC4460338.pdf
"Keywords  Atrial fibrillation; CYP2C9; VKORC1; Oral anticoagulants; Polymorphism; Interna - tional Normalized Ratio; SAMe-TT 2R2Original ArticleJournal of Stroke  201 5;17(2):192- 198 http://dx.doi.org/10.5853/jos.2015.17.2.192 Introduction Although anticoagulation with the use of warfarin may effec - tively reduce risk of cardioembolic stroke in patients with atrial  fibrillation (AF), warfarin has a narrow therapeutic window.",Non-OADS,/arxiv_data1/oa_pdf/de/00/jos-17-192.PMC4460338.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.192 http://j-stroke.org  193astating consequences.,Non-OADS,/arxiv_data1/oa_pdf/de/00/jos-17-192.PMC4460338.pdf
"Clinical Factor for Anticoagulation Control http://dx.doi.org/10.5853/jos.2015.17.2.192 194 http://j-stroke.orgrhythm control], T obacco use within 2 years [doubled], Race  nonwhite [doubled]).",Non-OADS,/arxiv_data1/oa_pdf/de/00/jos-17-192.PMC4460338.pdf
"2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.192 http://j-stroke.org  195were 9.5% and 16.3%, respectively.",OADS,/arxiv_data1/oa_pdf/de/00/jos-17-192.PMC4460338.pdf
"Clinical Factor for Anticoagulation Control http://dx.doi.org/10.5853/jos.2015.17.2.192 196 http://j-stroke.orgcranial hemorrhage is still evident.24 In a recent meta-analysis  with data for four phase 3 clinical trials of NOACs, the NOACs  had a favorable risk-benefit profile as compared with warfarin  that was consistent across diverse patient groups.22 However, it  also showed a greater relative reduction in major bleeding with  NOACs when TTR was less than 66% than when it was more  than 66%.22 High TTR ( > 70%) are known to be associated  with the best efficacy and safety of warfarin.25 Genotype-guided dosing of warfarin was recently reported to  be associated with a higher percentage of time in the therapeu - tic INR range than standard dosing during the initiation of war - farin therapy.26 However, the relationship of warfarin pharma - cogenetics to long-term TTR during warfarin maintenance is  not well studied.",Non-OADS,/arxiv_data1/oa_pdf/de/00/jos-17-192.PMC4460338.pdf
"2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.192 http://j-stroke.org  197can predict INR control and the population only included whites,  and showed that the SAMe-TT 2R2 score was not predictive of  TTR.",OADS,/arxiv_data1/oa_pdf/de/00/jos-17-192.PMC4460338.pdf
Clinical Factor for Anticoagulation Control http://dx.doi.org/10.5853/jos.2015.17.2.192 198 http://j-stroke.orgciated hemorrhage: the ATRIA (Anticoagulation and Risk  Factors in Atrial Fibrillation) Study.,Non-OADS,/arxiv_data1/oa_pdf/de/00/jos-17-192.PMC4460338.pdf
https://www.nice.org.uk/guidance/cg180 22.,Non-OADS,/arxiv_data1/oa_pdf/de/00/jos-17-192.PMC4460338.pdf
"Copyright © 2015  Korean Stroke Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/12/b6/jos-17-199.PMC4460339.pdf
"pISSN: 2287-6391 • eISSN: 2287-6405 http://j-stroke.org  199A Novel Computerized Clinical Decision Support  System for Treating Thrombolysis in Patients with  Acute Ischemic Stroke Ji Sung Lee,a* Chi Kyung Kim,b* Jihoon Kang,c Jong-Moo Park,d T ai Hwan Park,e Kyung Bok Lee,f   Soo Joo Lee,g Y ong-Jin Cho,h Jaehee Ko,i Jinwook Seo,i Hee-Joon Bae,j Juneyoung Leek aClinical Research Center, Asan Medical Center, Seoul, Korea bDepartment of Neurology, Seoul National University Hospital, Seoul, Korea cDepartment of Neurology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea dDepartment of Neurology, Eulji General Hospital, Eulji University, Seoul, Korea eDepartment of Neurology, Seoul Medical Center, Seoul, Korea fDepartment of Neurology, Soonchunhyang University Hospital Seoul, Seoul, Korea gDepartment of Neurology, Eulji University Hospital, Daejeon, Korea hDepartment of Neurology, Ilsan Paik Hospital, Inje University, Goyang, Korea iHuman-Computer Interaction Lab, Department of Computer Science and Engineering, Seoul National University, Seoul, Korea jDepartment of Neurology, Seoul National University Bundang Hospital, Seongnam, Korea kDepartment of Biostatistics, Korea University College of Medicine, Seoul, Korea Correspondence:  Juneyoung Lee Department of Biostatistics, College of  Medicine, Korea University, 73 Inchon-ro,  Seongbuk-gu, Seoul 136-701, Korea Tel: +82-2-2286-1436 Fax: +82-2-2286-1438 E-mail: jyleeuf@korea.ac.kr Received: December 15, 2014 Revised: March 5, 2015 Accepted: March 5, 2015 *These authors equally contributed to the  work.",Non-OADS,/arxiv_data1/oa_pdf/12/b6/jos-17-199.PMC4460339.pdf
Keywords Acute ischemic stroke; Clinical decision support system; Prediction model;  ThrombolysisOriginal ArticleJournal of Stroke  201 5;17(2):199- 209 http://dx.doi.org/10.5853/jos.2015.17.2.199,Non-OADS,/arxiv_data1/oa_pdf/12/b6/jos-17-199.PMC4460339.pdf
"Prognostic Model for Thrombolysis in AIS http://dx.doi.org/10.5853/jos.2015.17.2.199 200 http://j-stroke.orgIntroduction The rate of thrombolysis for overall ischemic stroke in the  United States and the United Kingdom is less than 5%.1,2 In Ko - rea, this rate was 8.6% among eligible patients within 3 hours of  disease onset in 2010.3 One reason for this low rate is physicians’  reluctance to treat patients with thrombolysis because weak evi - dence exists with respect to the risks and benefits of thrombo - lytic therapy.4 In a survey of emergency physicians, about 40%  reported that they were not likely to use thrombolysis in a case  of stroke, even in an ideal setting, because of the risk of symp - tomatic hemorrhagic transformation (sHT).5 Predicting the benefits and risks using prognostic models on  an individual patient may improve decision-making in clinical  practice.6 Recently, a so-called computerized clinical decision  support system (CDSS) constructed using clinical variables and  sophisticated models, provided more accurate information and  help to physicians than conventional scoring systems.7 More - over, the Johns Hopkins Venous Thromboembolism Prevention  Collaborative showed that a multidisciplinary team approach  using a CDSS could improve clinical practice performance.8  However, most outcome prediction models for thrombolysis  in acute ischemic stroke have used conventional scoring sys - tems and lack enough prediction power.9-13 Furthermore, as no  external validation was performed, the only CDSS-type predic - tion model, the Stroke Thrombolytic Predictive Instrument,9  had several limitations, including the lack of representativeness  because it was developed using clinical trial data and no consid - eration of a safety outcome such as sHT .",Non-OADS,/arxiv_data1/oa_pdf/12/b6/jos-17-199.PMC4460339.pdf
"2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.199 http://j-stroke.org  201Standard protocol approvals, registration, and patient  consents The institutional review boards from all participating centers  approved the collection of clinical information, without the need  for patient’s consent, to the registry database whose purpose was  for monitoring and improving quality-of-care of stroke patients,  based on the anonymization of patient information, minimal  risk to participants, and the retrospective nature of the study.",Non-OADS,/arxiv_data1/oa_pdf/12/b6/jos-17-199.PMC4460339.pdf
Prognostic Model for Thrombolysis in AIS http://dx.doi.org/10.5853/jos.2015.17.2.199 202 http://j-stroke.orgformed using R-project 2.11.1 (package “rms” version 4.11).,Non-OADS,/arxiv_data1/oa_pdf/12/b6/jos-17-199.PMC4460339.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.199 http://j-stroke.org  203method of updating both the calibration intercept and slope  was needed to increase the predictive power of the global out - come model to apply the model to the new population.,OADS,/arxiv_data1/oa_pdf/12/b6/jos-17-199.PMC4460339.pdf
Prognostic Model for Thrombolysis in AIS http://dx.doi.org/10.5853/jos.2015.17.2.199 204 http://j-stroke.orgThere are three points to be noted for selecting potential pre - dictors in this study.,Non-OADS,/arxiv_data1/oa_pdf/12/b6/jos-17-199.PMC4460339.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.199 http://j-stroke.org  205Table 4.,Non-OADS,/arxiv_data1/oa_pdf/12/b6/jos-17-199.PMC4460339.pdf
Prognostic Model for Thrombolysis in AIS http://dx.doi.org/10.5853/jos.2015.17.2.199 206 http://j-stroke.orgTable 5.,Non-OADS,/arxiv_data1/oa_pdf/12/b6/jos-17-199.PMC4460339.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.199 http://j-stroke.org  207curacy are therefore necessary.,Non-OADS,/arxiv_data1/oa_pdf/12/b6/jos-17-199.PMC4460339.pdf
Prognostic Model for Thrombolysis in AIS http://dx.doi.org/10.5853/jos.2015.17.2.199 208 http://j-stroke.orgNeurology  2012;78:421-426.,Non-OADS,/arxiv_data1/oa_pdf/12/b6/jos-17-199.PMC4460339.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.199 http://j-stroke.org  209 1.0 0.8 0.6 0.4 0.2 0  0 0.2 0.4 0.6 0.8 1.0Sensitivity 1-SpecificityROC curve for global outcome A 1.0 0.8 0.6 0.4 0.2 0  0 0.2 0.4 0.6 0.8 1.0Observed outcome in external validation data Predicted probabilityCalibration plot for post-hoc external validation B Supplementary  Figure 1.,OADS,/arxiv_data1/oa_pdf/12/b6/jos-17-199.PMC4460339.pdf
"210 http://j-stroke.orgCopyright © 2015  Korean Stroke Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/73/43/jos-17-210.PMC4460340.pdf
"Keywords Atrial fibrillation; Secondary prevention; Stroke; Warfarin; New anticoagulant GuidelineJournal of Stroke  201 5;17(2):210- 215 http://dx.doi.org/10.5853/jos.2015.17.2.210 Introduction Large nationwide multicenter stroke registry studies in Korea  have shown an increase in cardioembolic stroke, which accounts  for 20% of all ischemic strokes,1 and found that 19% of patients with ischemic stroke have atrial fibrillation.2 Cardioembolic  stroke is also highly associated with severe neurological deficits,  early and late embolic recurrences, and a high mortality.",Non-OADS,/arxiv_data1/oa_pdf/73/43/jos-17-210.PMC4460340.pdf
"2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.210 http://j-stroke.org  211factors including congestive heart failure, old age, hypertension,  diabetes mellitus, and previous stroke further increase the risk  of stroke, and these risk factors are prevalent in patients with  stroke.",Non-OADS,/arxiv_data1/oa_pdf/73/43/jos-17-210.PMC4460340.pdf
"Secondary Prevention in Patients with Nonvalvular Afib http://dx.doi.org/10.5853/jos.2015.17.2.210 212 http://j-stroke.orgincluded catheter ablation, cardioversion, valve replacement  surgery, and left atrial appendage closure.",Non-OADS,/arxiv_data1/oa_pdf/73/43/jos-17-210.PMC4460340.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.210 http://j-stroke.org  213(Recommendation grade: GPP).,Non-OADS,/arxiv_data1/oa_pdf/73/43/jos-17-210.PMC4460340.pdf
"Secondary Prevention in Patients with Nonvalvular Afib http://dx.doi.org/10.5853/jos.2015.17.2.210 214 http://j-stroke.orgFor patients with an ischemic stroke or transient  ischemic attack and atrial fibrillation who cannot use  oral anticoagulants, an antiplatelet agent should be  considered (Evidence level: I, Recommendation grade:  A).",Non-OADS,/arxiv_data1/oa_pdf/73/43/jos-17-210.PMC4460340.pdf
"2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.210 http://j-stroke.org  215brillation and previous stroke or transient ischaemic attack: a  predefined subgroup analysis from AVERROES, a randomised  trial.",Non-OADS,/arxiv_data1/oa_pdf/73/43/jos-17-210.PMC4460340.pdf
"216 http://j-stroke.orgCopyright © 2015  Korean Stroke Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/8e/a8/jos-17-216.PMC4460341.pdf
"pISSN: 2287-6391 • eISSN: 2287-6405Paradoxical Procoagulant Effect of Early Doses of  Warfarin: Possible Role of Non-Vitamin K Oral  Anticoagulant in Patients with Atrial Fibrillation- Related Stroke Y esel Kim, Oh Y oung Bang Department of Neurology, Samsung Medical Center, Sungkyunkwan University, Seoul, KoreaLetter to the EditorJournal of Stroke  201 5;17(2):216- 218 http://dx.doi.org/10.5853/jos.2015.17.2.216 Dear Sir: Patients with atrial fibrillation (AF) seem to be at an increased  risk for ischemic stroke during the initial stages of warfarin pro - phylaxis.",Non-OADS,/arxiv_data1/oa_pdf/8e/a8/jos-17-216.PMC4460341.pdf
"2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.216 http://j-stroke.org  217has a short half-life (8 hours) and warfarin initially decreases  protein C levels faster than the coagulation factors, it can para - doxically increase the coagulation tendency when treatment is  first begun, leading to massive thrombosis with skin necrosis  and gangrene of limbs.4 Supporting this hypothesis, the present  case showed the thrombotic events observed in the first 7 days  of use, which is also concordant with the time of onset of warfa - rin-induced skin necrosis; the levels of protein C and S were de - creased at the time of the thrombotic event.5 On the contrary,  heparin or non-vitamin K oral antagonists block factors Xa and  IIa and do not deactivate protein C and protein S (Figure 2).",Non-OADS,/arxiv_data1/oa_pdf/8e/a8/jos-17-216.PMC4460341.pdf
"Paradoxical Procoagulant Effect of Warfarin http://dx.doi.org/10.5853/jos.2015.17.2.216 218 http://j-stroke.orgCorrespondence: Oh Young Bang Department of Neurology, Samsung Medical Center, Sungkyunkwan  University, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea Tel: +82-2-3410-3599, Fax: +82-2-3410-0052  E-mail: neuroboy50@naver.com Received: January 15, 2015 Revised: February 8, 2015 Accepted: February 16, 2015 The authors have no financial conflicts of interest.This case suggests performing serial echocardiographic or imag - ing studies to monitor thrombus size in patients with low pro - tein C and S levels during the initial stages of warfarin therapy.",Non-OADS,/arxiv_data1/oa_pdf/8e/a8/jos-17-216.PMC4460341.pdf
"Copyright © 2015  Korean Stroke Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2e/44/jos-17-219.PMC4460342.pdf
"pISSN: 2287-6391 • eISSN: 2287-6405 http://j-stroke.org  219Seasonal Variations in Stroke: A Study in a  Hospital in North India Pradeep Kumar, Amit Kumar, Awadh Kishor Pandit, Abhishek Pathak, Kameshwar Prasad Department of Neurology, All India Institute of Medical Sciences, New Delhi, IndiaLetter to the EditorJournal of Stroke  201 5;17(2):219- 220 http://dx.doi.org/10.5853/jos.2015.17.2.219 Dear Sir: Stroke accounts for nearly 5.7 million deaths worldwide; 87%  of these deaths occur in low- and middle-income countries.1,2 In- dia is a tropical country with various seasons that may influence  stroke occurrence.3 The mechanisms underlying these seasonal  variations of stroke are not fully understood, but a possible rea - son may include seasonal variation of biological factors such as  arterial blood pressure, serum lipid levels, and other blood com - ponents.4,5 This study aimed to determine if there is any evi - dence of seasonal variation in the occurrence of various subtypes  of strokes in North India.",Non-OADS,/arxiv_data1/oa_pdf/2e/44/jos-17-219.PMC4460342.pdf
Seasonal Variations in Stroke  http://dx.doi.org/10.5853/jos.2015.17.2.219 220 http://j-stroke.orgReferences 1.,Non-OADS,/arxiv_data1/oa_pdf/2e/44/jos-17-219.PMC4460342.pdf
"Copyright © 2015  Korean Stroke Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c6/ec/jos-17-93.PMC4460343.pdf
pISSN: 2287-6391 • eISSN: 2287-6405 http://j-stroke.org  93Endovascular Therapy: A Standard Treatment?,Non-OADS,/arxiv_data1/oa_pdf/c6/ec/jos-17-93.PMC4460343.pdf
"Jong S. Kim Editor-in-Chief, Journal of StrokeEditorialJournal of Stroke  201 5;17(2):93- 93 http://dx.doi.org/10.5853/jos.2015.17.2.93 MR CLEAN, ESCAPE, EXTEND-IA, SWIFT PRIME, RE - VASCAT , THERAPY, THRACE: we are inundated by positive  trials.",Non-OADS,/arxiv_data1/oa_pdf/c6/ec/jos-17-93.PMC4460343.pdf
"94 http://j-stroke.orgCopyright © 2015  Korean Stroke Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/84/60/jos-17-94.PMC4460344.pdf
"Keywords Stroke; Magnetic resonance imaging; Lacunar infarct; Small vessel diseaseJournal of Stroke  201 5;17(2):94- 100 http://dx.doi.org/10.5853/jos.2015.17.2.94 Introduction Cerebral small vessel disease (SVD) has been recognized since  the 19th century, when it was diagnosed at autopsy and correlat - ed with clinical features.",Non-OADS,/arxiv_data1/oa_pdf/84/60/jos-17-94.PMC4460344.pdf
"2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.94 http://j-stroke.org  95also been critical in delineating other features of the spectrum of  cerebral small vessel disease such as white matter hyperintensi - ties (white matter disease), cerebral microbleeds, cerebral atro - phy and cerebral microinfarcts.",Non-OADS,/arxiv_data1/oa_pdf/84/60/jos-17-94.PMC4460344.pdf
Norrving  Envolving Concept of SVD http://dx.doi.org/10.5853/jos.2015.17.2.94 96 http://j-stroke.orgFurther studies on the sequential imaging appearance of small  acute lacunar infarcts are warrented.,Non-OADS,/arxiv_data1/oa_pdf/84/60/jos-17-94.PMC4460344.pdf
"2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.94 http://j-stroke.org  97incidence between 2% and 4%.24 Silent infarcts are not innocent; they have been shown to in - crease the risk of vascular events (including stroke), cognitive  decline and dementia.",Non-OADS,/arxiv_data1/oa_pdf/84/60/jos-17-94.PMC4460344.pdf
"Norrving  Envolving Concept of SVD http://dx.doi.org/10.5853/jos.2015.17.2.94 98 http://j-stroke.orgNeuroimaging standards for research into  small vessel disease  A report on neuroimaging standards for research into small  vessel disease and its contribution to ageing and neurodegenera - tion was recently published by an international consensus group  from the Centres of Excellence in Neurodegeneration.13 The re - port provides a common advosry about terms and definitions for  features visible on MRI, propose minimum standards for image  acquisition and analysis, agrees on standards for scientific report - ing, and review emerging imaging methods for detection and  quantification of preclinical manifestations of SVD.",Non-OADS,/arxiv_data1/oa_pdf/84/60/jos-17-94.PMC4460344.pdf
2 / May 2015 http://dx.doi.org/10.5853/jos.2015.17.2.94 http://j-stroke.org  99The application of these tools and findings on large-scale stud - ies on interventions and novel therapies is eagerly awaited.,Non-OADS,/arxiv_data1/oa_pdf/84/60/jos-17-94.PMC4460344.pdf
Norrving  Envolving Concept of SVD http://dx.doi.org/10.5853/jos.2015.17.2.94 100 http://j-stroke.orgVascular Cognitive Impairment Study Group.,Non-OADS,/arxiv_data1/oa_pdf/84/60/jos-17-94.PMC4460344.pdf
"Copyright © 2015 The Korean Movement Disorder Society   103LETTER TO THE EDITORhttp://dx.doi.org/10.14802/jmd.15004  /  J Mov Disord  2015 ;8(2):103-105 pISSN 2005-940X / eISSN 2093-4939 Received: January 27, 2015    Revised: February 14, 2015    Accepted: March 25, 2015 Corresponding author: Frederick A. Zeiler, MD, Section of Neurosurgery, Department of Surgery, University of Manitoba, Health Sciences Center, GB-1  820 Sherbrook Street, Winnipeg, Manitoba R3A1R9, Canada / Tel: +12042286623 / Fax: +12047873851 / E-mail: umzeiler@cc.umanitoba.ca cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.JMD Dear Editor, Classical hemifacial spasm (HFS) has been attributed to an  atraumatic pulsatile vascular compression of the facial nerve leading to hyperactivity within the central components of the nerve, alleviated via mobilization of the culprit vessel.",Non-OADS,/arxiv_data1/oa_pdf/8d/25/jmd-8-2-103.PMC4460538.pdf
"106  Copyright © 2015 The Korean Movement Disorder SocietyLETTER TO THE EDITORhttp://dx.doi.org/10.14802/jmd.15013  /  J Mov Disord  2015 ;8(2):106-107 pISSN 2005-940X / eISSN 2093-4939 Received:  April 9, 2015    Revised:  April 22, 2015    Accepted:  April 22, 2015 Corresponding author:  Myung Sik Lee, MD, Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, 211  Eonju-ro, Gangnam-gu, Seoul 135-720 , Korea / Tel: +82-2-2019-3322 / Fax: +82-2-3462-5904 / E-mail:  mslee@yuhs.ac cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.JMD Parkinsonism and Dementia Associated with   Giant Virchow-Robin Spaces Myung Sik Lee,1 Cheol Hyung Lyoo,1 Tae Sub Chung2 1Departments of Neurology and 2Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea Virchow-Robbin space (VRS) denotes dilated subarachnoid  space along the penetrating arteries to the level of capillaries.",Non-OADS,/arxiv_data1/oa_pdf/17/52/jmd-8-2-106.PMC4460539.pdf
"Key Words Neuroacanthocytosis; Chorea;   Chorea-acanthocytosis; McLeod syndrome;  Acanthocytes; Huntington’s disease-like 2.http://dx.doi.org/10.14802/jmd.15009  /  J Mov Disord  2015 ;8(2):41-54 pISSN 2005-940X / eISSN 2093-4939 REVIEW ARTICLE cc This is an Open Access article distributed under the terms of the Creative Commons Attri - bution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which per - mits unrestricted non-commercial use, distribution, and reproduction in any medium, provided  the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/73/be/jmd-8-2-41.PMC4460540.pdf
"The absence of protein  product chorein, in erythrocytes as determined by  Western blot24 confirms the diagnosis (Figure 2) and  is available on a research basis (http://www.euro-hd.",Non-OADS,/arxiv_data1/oa_pdf/73/be/jmd-8-2-41.PMC4460540.pdf
http://dx.doi.org/10.7916/ D8W957X3.,Non-OADS,/arxiv_data1/oa_pdf/73/be/jmd-8-2-41.PMC4460540.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/73/be/jmd-8-2-41.PMC4460540.pdf
"Key Words 123I-metaiodobenzylguanidine scintigraphy; Lewy  body-related disorders; Parkinsonism; Dementia.http://dx.doi.org/10.14802/jmd.15015  /  J Mov Disord  2015 ;8(2):55-66 pISSN 2005-940X / eISSN 2093-4939 REVIEW ARTICLE cc This is an Open Access article distributed under the terms of the Creative Commons Attri - bution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which per - mits unrestricted non-commercial use, distribution, and reproduction in any medium, provided  the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c1/66/jmd-8-2-55.PMC4460541.pdf
http://dx.doi.org/10.1002/gps.4229.,Non-OADS,/arxiv_data1/oa_pdf/c1/66/jmd-8-2-55.PMC4460541.pdf
"Key Words Cerebellar ataxia; Spinocerebellar ataxias; Korea;  Prevalence.http://dx.doi.org/10.14802/jmd.15006  /  J Mov Disord  2015 ;8(2):67-75 pISSN 2005-940X / eISSN 2093-4939 REVIEW ARTICLE cc This is an Open Access article distributed under the terms of the Creative Commons Attri - bution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which per - mits unrestricted non-commercial use, distribution, and reproduction in any medium, provided  the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/24/4f/jmd-8-2-67.PMC4460542.pdf
"Key Words Parkinson’s disease; Gastrointestinal dysfunctions;  Enteric nervous system; Pathophysiology;   Assessment.http://dx.doi.org/10.14802/jmd.15008  /  J Mov Disord  2015 ;8(2):76-82 pISSN 2005-940X / eISSN 2093-4939 REVIEW ARTICLE cc This is an Open Access article distributed under the terms of the Creative Commons Attri - bution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which per - mits unrestricted non-commercial use, distribution, and reproduction in any medium, provided  the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/78/af/jmd-8-2-76.PMC4460543.pdf
"Key Words Parkinson disease; Subthalamic deep brain  stimulation; Nonmotor symptoms; Basal ganglia.http://dx.doi.org/10.14802/jmd.15010  /  J Mov Disord  2015 ;8(2):83-91 pISSN 2005-940X / eISSN 2093-4939 REVIEW ARTICLE cc This is an Open Access article distributed under the terms of the Creative Commons Attri - bution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which per - mits unrestricted non-commercial use, distribution, and reproduction in any medium, provided  the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b0/cc/jmd-8-2-83.PMC4460544.pdf
http://dx.doi.org/10.1002/mds.26199.,Non-OADS,/arxiv_data1/oa_pdf/b0/cc/jmd-8-2-83.PMC4460544.pdf
http://dx.doi.org/10.1001/ja -maneurol.2015.8.,Non-OADS,/arxiv_data1/oa_pdf/b0/cc/jmd-8-2-83.PMC4460544.pdf
"Key Words Parkinson’s disease; Non-motor symptoms.http://dx.doi.org/10.14802/jmd.15003  /  J Mov Disord  2015 ;8(2):92-97 pISSN 2005-940X / eISSN 2093-4939 REVIEW ARTICLE cc This is an Open Access article distributed under the terms of the Creative Commons Attri - bution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which per - mits unrestricted non-commercial use, distribution, and reproduction in any medium, provided  the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ec/43/jmd-8-2-92.PMC4460545.pdf
The Scale for Out - comes in Parkinson’s disease (SCOPA) battery of as - sessments consists of seven sub-rating scales that  cover almost all symptom domains of PD (PROfiling  PARKinson’s disease or PROPARK) (http://www.scopa.propark.eu).,Non-OADS,/arxiv_data1/oa_pdf/ec/43/jmd-8-2-92.PMC4460545.pdf
"Key Words aaParkinson disease; Dementia; Rivastigmine; Neuropsychiatry; Symptoms.ORIGINAL ARTICLEhttp://dx.doi.org/10.14802/jmd.15041  /  J Mov Disord  2015 ;8(2):98-102 pISSN 2005-940X / eISSN 2093-4939 Received:  January 5, 2015    Revised:  February 4, 2015    Accepted:  February 11, 2015 Corresponding author:  Joong-Seok Kim, MD, PhD, Department of Neurology, Seoul St. Mary’s Hospital, The Catholic University of Korea, 222  Banpo-daero, Seocho-gu, Seoul 137-701, Korea / Tel: +82-2-2258-6078 / Fax: +82-2-599-9686 / E-mail:  neuronet@catholic.ac.kr cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.JMD A variety of behavioral and psychological symptoms of de - mentia (BPSD) commonly occur in patients with Parkinson’s  disease (PD) and Parkinson’s disease dementia (PDD).1-3 Ap- proximately 90% of patients exhibit at least one neuropsychiat - ric symptom, and over 70% present with two or more symp - toms.3 These neuropsychiatric disturbances are associated with  reduced quality of life,4,5 increased caregiver burden and stress,2,6,7  disabilities in daily living,8 increased risk of admission to a nurs - ing home,9 and increased mortality in nursing home patients.10 Atypical antipsychotic drugs are widely used to treat delu -sions, hallucinations, aggression, and agitation, although ad - verse effects are frequent and severe;11 gait abnormalities, som - nolence, cerebrovascular adverse events, edema, extrapyramidal  symptoms, urinary tract infections, and mortality have been re - ported.12 These adverse effects are important causes of antipsy - chotic drug discontinuation.",Non-OADS,/arxiv_data1/oa_pdf/e7/e8/jmd-8-2-98.PMC4460546.pdf
Available from: http://users-phys.au.dk/hknudsen/ ad4homepage.,Non-OADS,/arxiv_data1/oa_pdf/d9/ec/JMSS-5-105.PMC4460664.pdf
Available from: http://cern.ch/geant4.,OADS,/arxiv_data1/oa_pdf/d9/ec/JMSS-5-105.PMC4460664.pdf
Available from: http://geant4.cern.ch/support.,OADS,/arxiv_data1/oa_pdf/d9/ec/JMSS-5-105.PMC4460664.pdf
Available from: http://geant4.cern.,OADS,/arxiv_data1/oa_pdf/d9/ec/JMSS-5-105.PMC4460664.pdf
Available from: http://www.farnell.com/datasheets/1673632.pdf.,Non-OADS,/arxiv_data1/oa_pdf/3b/f3/JMSS-5-117.PMC4460666.pdf
Available fr om: http://www.thelancet.com/journals/lancet/issue/ vol379no9833/PIIS0140-6736(12)X6024-0.,Non-OADS,/arxiv_data1/oa_pdf/3b/f3/JMSS-5-117.PMC4460666.pdf
Available from: http://www.scimagojr.com/.,Non-OADS,/arxiv_data1/oa_pdf/48/3c/JMSS-5-75.PMC4460668.pdf
5. http://report.nih.gov/success_rates/Success_ByActivity.cfm.,OADS,/arxiv_data1/oa_pdf/48/3c/JMSS-5-75.PMC4460668.pdf
Available from: http://www.grantcentral.com/workbooks.html.,Non-OADS,/arxiv_data1/oa_pdf/48/3c/JMSS-5-75.PMC4460668.pdf
Start a QR-code reading software (see list of free applications from http://tinyurl.com/ yzlh2tc) and point the camera to the QR-code printed in the journal.,Non-OADS,/arxiv_data1/oa_pdf/48/3c/JMSS-5-75.PMC4460668.pdf
See http://tinyurl.com/2bw7fn3 or http://tinyurl.com/3ysr3me for the free  applications.,Non-OADS,/arxiv_data1/oa_pdf/48/3c/JMSS-5-75.PMC4460668.pdf
E-mail:  K_maghooli@srbiau.ac.ir Author Help: Online submission of the manuscripts Articles can be submitted online from http://www.journalonweb.com.,Non-OADS,/arxiv_data1/oa_pdf/5c/28/JMSS-5-88.PMC4460670.pdf
Additional Information Supplementary information accompanies this paper at http://www.nature.com/srep Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/ba/fa/srep11151.PMC4460893.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/",Non-OADS,/arxiv_data1/oa_pdf/ba/fa/srep11151.PMC4460893.pdf
http://dx.doi.org/10.1016/j.aju.2012.12.002,OADS,/arxiv_data1/oa_pdf/63/d5/main.PMC4461010.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/c0/a4/vhrm-11-297.PMC4461015.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pVascular Health and Risk Management 2015:11 297–302Vascular Health and Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  297Case Repo Rtopen access to scientific and medical research open access Full text article http: //dx.doi.org/10.2147/VHRM.S7377 9High-flow bypass and wrap-clipping for ruptured  blood blister-like aneurysm of the internal carotid  artery using intraoperative monitoring of cerebral  hemodynamics Y oshitaka Kubo takahiro Koji Kenji Y oshida Hideo saito akira ogawa Kuniaki ogasawara Department of Neurosurgery, Iwate  Medical University, Morioka, Japan Correspondence: Yoshitaka Kubo   Department of Neurosurgery, Iwate  Medical University, 19-1 Uchimaru,  Morioka, Iwate 020-8505, Japan   tel +81 19 651 5111   Fax +81 19 625 8799   email yokubo@iwate-med.ac.j pAbstract:  Aneurysms at non-branching sites in the supraclinoid internal carotid artery (ICA)  can be classified as “blood blister-like aneurysms” (BBAs), which have blood blister-like con - figurations and fragile walls.",Non-OADS,/arxiv_data1/oa_pdf/c0/a4/vhrm-11-297.PMC4461015.pdf
"Vascular Health and Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/vascular-health-and-risk-management-journa lVascular Health and Risk Management is an international, peer- reviewed journal of therapeutics and risk management, focusing on  concise rapid reporting of clinical studies on the processes involved  in the maintenance of vascular health; the monitoring, prevention and  treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes.",Non-OADS,/arxiv_data1/oa_pdf/c0/a4/vhrm-11-297.PMC4461015.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/c0/a4/vhrm-11-297.PMC4461015.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/f9/7b/prbm-8-143.PMC4461016.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pPsychology Research and Behavior Management 2015:8 143–151Psychology Research and Behavior Management Dove press submit your manuscript | www.dovepress.co m Dove press  143Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PRBM.S6347 4Williams syndrome and its cognitive profile:   the importance of eye movements Jo van Herwegen Department of Psychology, Kingston  University London, Surrey, UK Correspondence: Jo van Herwegen   Department of Psychology, Kingston  University London, Penrhyn Road,  Kingston upon Thames, Surrey KT1 2ee,  UK  Tel +44 20 8547 2803   email j.vanherwegen@kingston.ac.u kAbstract:  People with Williams syndrome (WS), a rare neurodevelopmental disorder that is  caused by a deletion on the long arm of chromosome 7, often show an uneven cognitive profile  with participants performing better on language and face recognition tasks, in contrast to visu - ospatial and number tasks.",Non-OADS,/arxiv_data1/oa_pdf/f9/7b/prbm-8-143.PMC4461016.pdf
"Psychology Research and Behavior Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/psychology-research-and-behavior-management-journa lPsychology Research and Behavior Management is an international, peer- reviewed, open access journal focusing on the science of psychology and  its application in behavior management to develop improved outcomes  in the clinical, educational, sports and business arenas.",Non-OADS,/arxiv_data1/oa_pdf/f9/7b/prbm-8-143.PMC4461016.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/f9/7b/prbm-8-143.PMC4461016.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/76/63/vhrm-11-303.PMC4461017.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pVascular Health and Risk Management 2015:11 303–310Vascular Health and Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  303ORiginal ReseaRcHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/VHRM.S8271 0Doctors’ knowledge, attitudes, and compliance  with 2013 acc/aHa guidelines for prevention   of atherosclerotic cardiovascular disease   in singapore sajita setia1 selwyn sze-Wang Fung2 David D Waters3 1Medical affairs, Pfizer Pte ltd,  singapore;  2Regional Medical  affairs, Pfizer Pte ltd, Hong Kong;   3Department of Medicine, University  of california, san Francisco, ca, Usa correspondence: sajita setia   Medical Affairs, Pfizer Pte Ltd,  1, science  Park Road #  04-01, The capricorn,  science Park ii, singapore  117528,  singapore   T el +65 6403 8754  Fax +65 6722 4188  email s ajita.setia@pfizer.co mPurpose:  There is an unmet need for strategies to prevent atherosclerotic cardiovascular disease  in Singapore.",Non-OADS,/arxiv_data1/oa_pdf/76/63/vhrm-11-303.PMC4461017.pdf
Available from: http://www.who.int/mediacentre/ factsheets/fs317/en /.,Non-OADS,/arxiv_data1/oa_pdf/76/63/vhrm-11-303.PMC4461017.pdf
"Available from: http://www.who.int/entity/nmh/ publications/ncd-status-report-2014/en/index.htm l. Accessed March  16,   2015.",OADS,/arxiv_data1/oa_pdf/76/63/vhrm-11-303.PMC4461017.pdf
"Available from: http://www.ica.gov.sg/data/resources/ docs/Media%20Releases/SDB/Annual%20RBD%20Report_2013.pd f.  Accessed December  22, 2014.",OADS,/arxiv_data1/oa_pdf/76/63/vhrm-11-303.PMC4461017.pdf
Available from: https://www.moh.gov.sg/content/moh_web/ home/statistics/Health_Facts_Singapore/Disease_Burden.html .,Non-OADS,/arxiv_data1/oa_pdf/76/63/vhrm-11-303.PMC4461017.pdf
"Vascular Health and Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/vascular-health-and-risk-management-journa lVascular Health and Risk Management is an international, peer- reviewed journal of therapeutics and risk management, focusing on  concise rapid reporting of clinical studies on the processes involved  in the maintenance of vascular health; the monitoring, prevention and  treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes.",Non-OADS,/arxiv_data1/oa_pdf/76/63/vhrm-11-303.PMC4461017.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/76/63/vhrm-11-303.PMC4461017.pdf
Available from: https://www.moh.gov.sg/ content/moh_web/home/Publications/guidelines/withdrawn_cpgs.html .,Non-OADS,/arxiv_data1/oa_pdf/76/63/vhrm-11-303.PMC4461017.pdf
Available from: http://www.nice.org.uk/guidance/cg181 .,Non-OADS,/arxiv_data1/oa_pdf/76/63/vhrm-11-303.PMC4461017.pdf
Available from: http://pimedicus.upm.edu.,Non-OADS,/arxiv_data1/oa_pdf/76/63/vhrm-11-303.PMC4461017.pdf
Available from: http://www.medscape.com/viewarticle/790656 .,Non-OADS,/arxiv_data1/oa_pdf/76/63/vhrm-11-303.PMC4461017.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d3/f9/tcrm-11-901.PMC4461018.pdf
Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pTherapeutics and Clinical Risk Management 2015:11 901–903Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  901LeTTeRopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/TCRM.S8332 2GLP-1 reduces metalloproteinase-9 induced by  both hyperglycemia and hypoglycemia in type 1  diabetes.,Non-OADS,/arxiv_data1/oa_pdf/d3/f9/tcrm-11-901.PMC4461018.pdf
"mmol/L), with or without GLP-1 (0.4 pmol ⋅kg-¹⋅min-¹)  infusion.8Correspondence: Antonio Ceriello Insititut d’Investigación Biomédiques  August Pi i Sunyer (IDIBAPS), Carrer  del Rosselló, 149-153, 08036 Barcelona,  Spain Tel +34 93 227 5400 ext 4390 Fax +34 93 227 9240 email aceriell@clinic.ub.e s Journal name: Therapeutics and Clinical Risk Management Article Designation: Letter Y ear: 2015 Volume: 11 Running head verso: Ceriello et al Running head recto: GLP-1 reduces metalloproteinase-9 induced by both hyperglycemia DOI: http://dx.doi.org/10.2147/TCRM.S83322",Non-OADS,/arxiv_data1/oa_pdf/d3/f9/tcrm-11-901.PMC4461018.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/d3/f9/tcrm-11-901.PMC4461018.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/d3/f9/tcrm-11-901.PMC4461018.pdf
"CORRIGENDUM TO: Recent advances inthediagnosis and management ofpre-eclampsia Kate E.Duhig1andAndrew H.Shennan1 Address:1Women ’sHealth Academic Centre, King ’sCollege London, Westminster Bridge Road London, SE17EH, UK ORIGINAL CITATION: F1000Prime Reports 2015,7:24(doi:10.12703/P7-24) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/9f/38/medrep-07-24.1.PMC4461051.pdf
"The electronic version ofthisarticle isthecomplete one andcanbefound at:http://f1000.com/prime/reports/m/7/24.1 The PDF ofthisarticle canbefound at:http://f1000.com/prime/reports/m/7/24.1.pdf CORRIGENDUM: Intheoriginal text, theterm PCR wasdefined aspolymerase chain reaction.",Non-OADS,/arxiv_data1/oa_pdf/9f/38/medrep-07-24.1.PMC4461051.pdf
CO 2obser- vations were downloaded from ftp://aftp.cmdl.noaa.gov/data/trace_gases/co2/ﬂask/surface/.,OADS,/arxiv_data1/oa_pdf/ea/be/gbc0028-1295.PMC4461073.pdf
"NCEP Reanalysis data were provided by the NOAA/OAR/ ESRL PSD, Boulder, Colorado, USA, fromtheir Web site at http://www.esrl.noaa.gov/psd/.",OADS,/arxiv_data1/oa_pdf/ea/be/gbc0028-1295.PMC4461073.pdf
CRU temperature data were retrieved from http://www.cru.uea.ac.,OADS,/arxiv_data1/oa_pdf/ea/be/gbc0028-1295.PMC4461073.pdf
"the Ocean Carbon Model Intercomparison Project protocols (http://www.ipsl.jussieu.fr/OCMIP/), and a weak alkalinityrestoring is applied (see supporting information).",Non-OADS,/arxiv_data1/oa_pdf/d2/5d/gbc0027-1236.PMC4461076.pdf
We use the SAM index from 1948 to 2010 based on the leading EOF of sea level pressure anomalies south of 20 ıS from the NCEP-NCAR Reanalysis (http://jisao.washington.edu/data/aao/slp).,OADS,/arxiv_data1/oa_pdf/d2/5d/gbc0027-1236.PMC4461076.pdf
"MITgcm Group (2012), MITgcm User Manual (online documentation) , MIT/EAPS, Cambridge, Mass., available at http://mitgcm.org/public/r2_ manual/latest/online_documents/manual.html.",OADS,/arxiv_data1/oa_pdf/d2/5d/gbc0027-1236.PMC4461076.pdf
", 2013], from which we use ocean surface forcing ﬁelds, follow the protocol of the model intercomparison PMIP3 (available at http://pmip3.lsce.ipsl.fr/).",Non-OADS,/arxiv_data1/oa_pdf/7c/d0/palo0028-0726.PMC4461077.pdf
"MITgcm Group (2013), MITgcm user manual, online documentation (http://mitgcm.org/public/r2_manual/latest/online_documents), MIT/ EAPS, Cambridge, USA.",OADS,/arxiv_data1/oa_pdf/7c/d0/palo0028-0726.PMC4461077.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/a2/7d/amep-6-431.PMC4461082.pdf
"Information on how to  request permission may be found at: http://www.dovepress.com/permissions.ph pAdvances in Medical Education and Practice 2015:6 431–437Advances in Medical Education and Practice Dove press submit your manuscript | www.dovepress.co m Dove press  431OriginAl rEsEArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AMEP .S7955 7Perceptions of postgraduate trainees on the   impact of objective structured clinical examinations   on their study behavior and clinical practice robert O Opoka1 sarah Kiguli1 Andrew s ssemata2 Marjan govaerts3 Erik W Driessen3 1Department of Paediatrics and child  health,  2Department of Psychiatry,  college of health sciences, Makerere  University, Kampala, Uganda;   3Faculty of health, Medicine and life  sciences, Maastricht University, the  netherlands correspondence: robert O Opoka   Department of Paediatrics and child  health, college of health sciences,  Makerere University, PO Box 7072,  Kampala, Uganda   Tel +256 77 299 6164   Email opokabob@yahoo.co mBackground:  The objective structured clinical examination (OSCE) is a commonly used  method of assessing clinical competence at various levels, including at the postgraduate level.",Non-OADS,/arxiv_data1/oa_pdf/a2/7d/amep-6-431.PMC4461082.pdf
"Advances in Medical Education and Practice Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/advances-in-medical-education-and-practice-journa lAdvances in Medical Education and Practice is an international, peer- reviewed, open access journal that aims to present and publish research  on Medical Education covering medical, dental, nursing and allied  health care professional education.",Non-OADS,/arxiv_data1/oa_pdf/a2/7d/amep-6-431.PMC4461082.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/a2/7d/amep-6-431.PMC4461082.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/bc/fb/ott-8-1327.PMC4461083.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncoTargets and Therapy 2015:8 1327–1334OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1327Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S6783 5The role of nanog expression in tamoxifen- resistant breast cancer cells Khalid arif1 issam hussain1 carol rea1 Mohamed el-sheemy2 1school of life sciences, University  of lincoln, Brayford Pool,  2lincoln  county hospital, greetwell road,   lincoln, lincolnshire, UK correspondence: Khalid arif  school of life sciences, University  of lincoln, Brayford Pool, lincoln,  ln6 7Ts, UK   email karif@lincoln.ac.u kAbstract:  There is an accumulation of evidence that shows a significant role of cancer stem  cells in tumor initiation, proliferation, relapse, and metastasis.",Non-OADS,/arxiv_data1/oa_pdf/bc/fb/ott-8-1327.PMC4461083.pdf
"Available from:  http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/ incidence/uk-breast-cancer-incidence-statistic s. Accessed May  10,  2014.",Non-OADS,/arxiv_data1/oa_pdf/bc/fb/ott-8-1327.PMC4461083.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open access  journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/bc/fb/ott-8-1327.PMC4461083.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/bc/fb/ott-8-1327.PMC4461083.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/7d/2e/copd-10-1043.PMC4461084.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Journal of COPD 2015:10 1043–1052International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  1043OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S7867 0Important, misunderstood, and challenging:  a qualitative study of nurses’ and allied health  professionals’ perceptions of implementing  self-management for patients with COPD hannah M l Y oung1 lindsay D apps1 samantha l harrison1 Vicki l Johnson- Warrington1 nicky hudson2 sally J singh1,3 1national Institute of health  research C lahr C-lnr Pulmonary  rehabilitation research group,   University hospitals of leicester  nhs Trust, 2school of applied social  sciences, De Montfort University,   leicester, 3applied research Centre  in health and lifestyle Interventions,   Coventry University, Coventry, UKBackground:  In light of the growing burden of COPD, there is increasing focus on the role of  self-management for this population.",Non-OADS,/arxiv_data1/oa_pdf/7d/2e/copd-10-1043.PMC4461084.pdf
"Keywords:  self-management, COPD, qualitative, interviews, nurses, allied health  professionals Introduction Background COPD is a global health issue and the fourth-leading cause of death worldwide,  with morbidity and mortality predicted to rise in coming years.1–4 COPD exacerba - tions can result in increased health care utilization and significant burden to the  individual.4–6 Self-management  has been defined as the systematic provision of  supportive interventions designed to increase patients’ skills in decision making,  problem solving, utilizing resources, and taking action.1,7–10 Self-management is an  integral part of good practice models in chronic disease management, as it seeks  to enhance patient confidence, health, and well-being while reducing health care  utilization.11–18 In light of the growing burden of COPD, there is increasing focus Correspondence: hannah Ml Young academic research Unit, leicester  general hospital, gwendolen road,  leicester le5 4PW, UK Tel +44 116 258 4346 email hannah.young@uhl-tr.nhs.u k Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Y oung et al Running head recto: Nurses’ and AHPs’ perceptions of COPD self-management DOI: http://dx.doi.org/10.2147/COPD.S78670",Non-OADS,/arxiv_data1/oa_pdf/7d/2e/copd-10-1043.PMC4461084.pdf
"Available from: https://www.gov.uk/government/ uploads/system/uploads/attachment_data/file/216139/dh_128428.pd f.  Accessed April 21, 2015.",OADS,/arxiv_data1/oa_pdf/7d/2e/copd-10-1043.PMC4461084.pdf
Available  from: http://webarchive.nationalarchives.gov.uk/ +/www.dh.gov.uk/en/ Aboutus/MinistersandDepartmentLeaders/ChiefMedicalOfficer/Pro - gressOnPolicy/ProgressBrowsableDocument/DH_410275 7.,Non-OADS,/arxiv_data1/oa_pdf/7d/2e/copd-10-1043.PMC4461084.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/7d/2e/copd-10-1043.PMC4461084.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/7d/2e/copd-10-1043.PMC4461084.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/80/c7/ott-8-1321.PMC4461085.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncoTargets and Therapy 2015:8 1321–1325OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1321Case repO rTopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S8317 9alectinib for choroidal metastasis in a patient with  crizotinib-resistant ALK rearranged positive   non-small cell lung cancer Yusuke Okuma1,2 Yuichiro Tanaka3 Tina Kamei1 Yukio Hosomi1 Tatsuru Okamura1 1Department of Thoracic Oncology  and respiratory Medicine, Tokyo  Metropolitan Cancer and Infectious  diseases Center Komagome Hospital,    2Division of Oncology, research  Center for Medical sciences, The  Jikei University school of Medicine,   3Department of Ophthalmology, T okyo  Metropolitan Cancer and Infectious  diseases Center Komagome Hospital,   T okyo, JapanAbstract:  Choroidal metastasis is rare in cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/80/c7/ott-8-1321.PMC4461085.pdf
"Case report A 30-year-old female harboring EML4 /ALK rearranged advanced NSCLC with liver  and bone metastases presented with visual disturbance with a left ocular black spot, Correspondence:  Yusuke Okuma Department of Thoracic Oncology  and respiratory Medicine, Tokyo  Metropolitan Cancer and Infectious  diseases Center Komagome Hospital,  3-18-22 Honkomagome, Bunkyo,  Tokyo 113-8677, Japan Tel +81 3 3823 2101 Fax +81 3 3824 1552 email y-okuma@cick.j p Journal name: OncoTargets and Therapy Article Designation: Case report Y ear: 2015 Volume: 8 Running head verso: Okuma et al Running head recto: Alectinib for choroidal metastasis DOI: http://dx.doi.org/10.2147/OTT.S83179",Non-OADS,/arxiv_data1/oa_pdf/80/c7/ott-8-1321.PMC4461085.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/80/c7/ott-8-1321.PMC4461085.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/80/c7/ott-8-1321.PMC4461085.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/49/10/hiv-7-183.PMC4461086.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pHIV/AIDS – Research and Palliative Care 2015:7 183–190HIV/AIDS - Research and Palliative Care Dove press submit your manuscript | www.dovepress.co m Dove press  183ORIGINAL RESEARCHopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/HIV.S7830 0Sexual behaviors and associated factors among  antiretroviral treatment attendees in Ethiopia Kassahun Demissie1 Shifera Asfaw2 Lakew Abebe2 Getachew Kiros2 1Addis Ababa Regional Laboratory,  Ethiopia;  2Department of Health  Education and Behavioral Science,  College of Public Health and Medical  Sciences, Jimma University, Ethiopia Correspondence: Shifera Asfaw   Department of Health Education and   Behavioral Science, College of Public  Health and Medical Sciences, Jimma  University, PO Box 378, Jimma, Ethiopia   Email shifasfaw@gmail.co mBackground:  Human immunodeficiency virus (HIV)/acquired immune deficiency syndrome  is one of the major public health problems throughout the world.",Non-OADS,/arxiv_data1/oa_pdf/49/10/hiv-7-183.PMC4461086.pdf
"HIV/AIDS - Research and Palliative Care Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/hivaids---research-and-palliative-care-journa lHIV/AIDS - Research and Palliative Care is an international, peer- reviewed open-access journal focusing on advances in research in HIV ,  its clinical progression and management options including antiviral  treatment, palliative care and public healthcare policies to control  viral spread.",Non-OADS,/arxiv_data1/oa_pdf/49/10/hiv-7-183.PMC4461086.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/49/10/hiv-7-183.PMC4461086.pdf
"Available from: http://www.etharc.org/aidsineth/publications/ aidsineth6th_en.pd f. Accessed January  30, 2015.",Non-OADS,/arxiv_data1/oa_pdf/49/10/hiv-7-183.PMC4461086.pdf
2011;11:422 http://www.biomedcentral.com/1471- 2458/11/42 2.,Non-OADS,/arxiv_data1/oa_pdf/49/10/hiv-7-183.PMC4461086.pdf
2013;16:17342. http://www.jiasociety.,Non-OADS,/arxiv_data1/oa_pdf/49/10/hiv-7-183.PMC4461086.pdf
org/index.php/jias/article/view/17342http://dx.doi.org/10.7448/ IAS.16.1.1734 2.,Non-OADS,/arxiv_data1/oa_pdf/49/10/hiv-7-183.PMC4461086.pdf
2013;13:430; http://www.biomedcentral.com/1471-2458/13/43 0.,Non-OADS,/arxiv_data1/oa_pdf/49/10/hiv-7-183.PMC4461086.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/4e/6b/ijn-10-3779.PMC4461087.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Journal of Nanomedicine 2015:10 3779–3790International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  3779OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S8327 9Magnetic resonance imaging of folic acid- coated magnetite nanoparticles reflects tissue  biodistribution of long-acting antiretroviral  therapy Tianyuzi li,1 howard e  gendelman,1,2 gang Zhang,1  Pavan Puligujja,1 Joellyn  M McMillan,1 Tatiana K  Bronich,2 Benson edagwa,1 Xin-Ming liu,1,2 Michael D  Boska3 1Department of Pharmacology  and experimental Neuroscience,   2Department of Pharmaceutical  sciences, 3Department of radiology,   University of Nebraska Medical  center, Omaha, N e, UsaAbstract:  Regimen adherence, systemic toxicities, and limited drug penetrance to viral  reservoirs are obstacles limiting the effectiveness of antiretroviral therapy (ART).",Non-OADS,/arxiv_data1/oa_pdf/4e/6b/ijn-10-3779.PMC4461087.pdf
"correspondence: howard e gendelman Department of Pharmacology and  experimental Neuroscience, University  of Nebraska Medical center, 985880  Nebraska Medical center, Omaha,  Ne 68198, Usa Tel +1 402 559 8920 Fax +1 402 559 3744 email hegendel@unmc.ed u Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Li et al Running head recto: MRI of folic acid nanoparticle reflects biodistribution DOI: http://dx.doi.org/10.2147/IJN.S83279 Point your SmartPhone at the code above.",Non-OADS,/arxiv_data1/oa_pdf/4e/6b/ijn-10-3779.PMC4461087.pdf
Or use: http://youtu.be/5F-xjEDWT7 kVideo abstract,Non-OADS,/arxiv_data1/oa_pdf/4e/6b/ijn-10-3779.PMC4461087.pdf
The ROI analyses were  performed using ImageJ ( http://imagej.nih.gov/i j) software.,OADS,/arxiv_data1/oa_pdf/4e/6b/ijn-10-3779.PMC4461087.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/4e/6b/ijn-10-3779.PMC4461087.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/4e/6b/ijn-10-3779.PMC4461087.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d6/74/opth-9-971.PMC4461088.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Ophthalmology 2015:9 971–975Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  971Case repO rtopen access to scientific and medical research Open access Full text article http: //dx.doi.org/10.2147/OPTH.S7124 6Malignant hypertensive retinopathy as a presenting  sign of an occult dead fetus Joana araújo1 João tavares-Ferreira1 susana penas1,2 Luís Figueira1,3 Flávio prézia paiva1 Fernando Falcão-reis1,2 1Ophthalmology Department, são  João Hospital, 2Department of sense  Organs, 3Department of pharmacology  and therapeutics, Faculty of Medicine,   University of porto, porto, portugalAbstract:  We report one case of malignant hypertensive retinopathy as a presenting sign of  fetal death in utero.",Non-OADS,/arxiv_data1/oa_pdf/d6/74/opth-9-971.PMC4461088.pdf
"Although retina and its vasculature are more usually affected, the conjunctiva,  choroid, the optic nerve and visual cortex may be also affected in pre-eclampsia.7  Correspondence: Joana araújo Hospital de são João, serviço de  Oftalmologia, avenida prof Hernâni  Monteiro, 4202, 451 porto, portugal email jrodriaraujo@gmail.co m Journal name: Clinical Ophthalmology Article Designation: Case report Y ear: 2015 Volume: 9 Running head verso: Araújo et al Running head recto: Vision loss reveals occult dead fetus DOI: http://dx.doi.org/10.2147/OPTH.S71246",Non-OADS,/arxiv_data1/oa_pdf/d6/74/opth-9-971.PMC4461088.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/d6/74/opth-9-971.PMC4461088.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/d6/74/opth-9-971.PMC4461088.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/f2/bc/ndt-11-1405.PMC4461089.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2015:11 1405–1411Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1405OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S8466 6cognitive impairment in generalized anxiety  disorder revealed by event-related potential N270 Yingxue Yang1,2 Xiating Zhang1,2 Yu Zhu1,2 Yakang Dai3 Ting liu3 Yuping Wang1,2 1Department of Neurology,   Xuanwu hospital, capital Medical  University, 2Beijing Key laboratory  of Neuromodulation, Beijing, People’s  republic of china; 3suzhou institute  of Biomedical engineering and  Technology, chinese academy of  sciences, suzhou, People’s republic  of chinaBackground:  Cognitive function in anxiety disorders has been the subject of limited  investigation, especially in generalized anxiety disorder (GAD).",Non-OADS,/arxiv_data1/oa_pdf/f2/bc/ndt-11-1405.PMC4461089.pdf
"Previous studies have suggested that N270, an endogenous ERP component,  is an important and sensitive component used for the evaluation of the cognitive status  of patients with Parkinson’s disease, major depression, and transient ischemic attack.8–10  N270 is a negative deflection with a frontocentral scalp distribution that peaks at around  270 ms and is elicited by mismatch trials.11 More specifically, it is evoked by sequentially  presented mismatches but is absent for simultaneously presented mismatches.12 In addi - tion, the amplitude of N270 can be modulated by attention.13 Collectively, these results  suggest that N270 may index multiple cognitive processes, including working memory correspondence: Yuping Wang Department of Neurology, Xuanwu  hospital, capital Medical University,  No 45 changchun street, Xicheng  District, Beijing 100053, People’s  republic of china Tel +86 10 8319 8273 Fax +86 10 8315 7841 email wangyyping@yeah.ne t Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2015 Volume: 11 Running head verso: Y ang et al Running head recto: N270 reveals cognitive impairment in GAD DOI: http://dx.doi.org/10.2147/NDT.S84666",Non-OADS,/arxiv_data1/oa_pdf/f2/bc/ndt-11-1405.PMC4461089.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/f2/bc/ndt-11-1405.PMC4461089.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/f2/bc/ndt-11-1405.PMC4461089.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/b9/86/ndt-11-1381.PMC4461090.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2015:11 1381–1393Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1381OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S8473 6association analysis of the Cadherin13  gene with  schizophrenia in the Japanese population ikuo Otsuka1 Yuichiro Watanabe2 akitoyo hishimoto1 shuken Boku1 Kentaro Mouri1 Kyoichi shiroiwa1 satoshi Okazaki1 ayako Nunokawa2 Osamu shirakawa3 T oshiyuki someya2 ichiro sora1 1Department of Psychiatry,  graduate school of Medicine, Kobe  University, Kobe, 2Department of  Psychiatry, graduate school of  Medical and Dental sciences, Niigata  University, Niigata, 3Department of  Neuropsychiatry, school of Medicine,  Kinki University, Osaka, JapanBackground:  Cadherin13  (CDH13 ) is a glycosylphosphatidylinositol-anchored cell adhesion  molecule that plays a crucial role in morphogenesis and the maintenance of neuronal circuitry.",Non-OADS,/arxiv_data1/oa_pdf/b9/86/ndt-11-1381.PMC4461090.pdf
"Although the causes of schizophrenia are still largely unknown, previous studies  have suggested that the inheritability of schizophrenia is high and that there is a  small but significant environmental effect associated with the susceptibility to  schizophrenia.1,2 Recent genome-wide association study (GWASs) has shown that common vari - ants of single nucleotide polymorphisms (SNPs) with relatively weak effects may be  associated with schizophrenia.3 Meanwhile, it is well established that macroscopic  abnormalities, such as volume reductions of the prefrontal cortex, hippocampus, and  generalized brain, are associated with schizophrenia.4,5 In addition, significant altera - tions in neuron size, morphology, and synaptic connectivity have been reported.6–8 correspondence: akitoyo hishimoto Department of Psychiatry, Kobe  University graduate school of Medicine,  7-5-1, Kusunoki-cho, chuo-ku,  Kobe 650-0017, Japan Tel +81 78 382 6065 Fax +81 78 382 6079 email hishipon@med.kobe-u.ac.j p Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2015 Volume: 11 Running head verso: Otsuka et al Running head recto: Cadherin13 gene and schizophrenia in the Japanese population DOI: http://dx.doi.org/10.2147/NDT.S84736",Non-OADS,/arxiv_data1/oa_pdf/b9/86/ndt-11-1381.PMC4461090.pdf
"Here, we  focused on five tag SNPs from the linkage disequilibrium  (LD) block in the promoter region of CDH13  because we  found neither cis-acting SNPs nor nonsynonymous SNPs  after consulting the databases: mRNA by SNP Browser  (http://www.sph.umich.edu/csg/liang/asthma /)23 and Japanese  SNP (JSNP) DATABASE ( http://snp.ims.u-tokyo.ac.j p).24 Materials and methods subjects The present study was approved by the Ethical Committee  for Genetic Studies of Kobe University Graduate School of  Medicine and the Ethics Committee of Genetics at Niigata  University School of Medicine.",OADS,/arxiv_data1/oa_pdf/b9/86/ndt-11-1381.PMC4461090.pdf
"Neuropsychiatric Disease and Treatment 2015:11submit your manuscript | www.dovepress.co m Dove press Dove press 1383Cadherin13  gene and schizophrenia in the Japanese population frequencies [MAFs] of more than 0.05), using the Hap - loview software program version 4.2 ( http://www.broad.",Non-OADS,/arxiv_data1/oa_pdf/b9/86/ndt-11-1381.PMC4461090.pdf
"In the human adult brain, CDH13  expression is detected  in the prefrontal cortex, hippocampus, hypothalamus,  amygdala, and substantia nigra ( http://www.gtexportal.org /),30   which overlap with regions linked to a variety of psychiatric",Non-OADS,/arxiv_data1/oa_pdf/b9/86/ndt-11-1381.PMC4461090.pdf
"Neuropsychiatric Disease and Treatment 2015:11submit your manuscript | www.dovepress.co m Dove press Dove press 1385Cadherin13  gene and schizophrenia in the Japanese population Table 1  (Continued ) Sample SNP ID   positionaPhen Genotype   distributionMinor allele P-value Power OR (95% CI) MM Mm mm MAF Allele HWE GenotypebAllelec rs736719 scZ 1,037 261 20 0.114 T 0.511 0.999 0.992 0.050 1.00 (0.85–1.18) 81214146 cON 1,103 292 15 0.114 0.462 (1.000) rs6565051 scZ 540 583 197 0.371 g 0.067 0.503 0.520 0.072 0.96 (0.86–1.07) 81216229 cON 547 661 205 0.379 0.909 (0.931) rs7204454 scZ 557 580 176 0.355 c 0.243 0.806 0.788 0.056 1.01 (0.91–1.13) 81216695 cON 603 621 185 0.351 0.245 (0.997) rs8049308 (as the substitute for rs8057927) First set scZ, n=665 cON, n=760rs8049308 scZ 309 267 69 0.314 c 0.357 0.634 0.630 0.066 1.04 (0.89–1.22) 81252503 cON 363 313 72 0.305 0.753 (0.658) Notes:  asNP iD number and positions are available at http://hapmap.ncbi.nlm.nih.gov /.",Non-OADS,/arxiv_data1/oa_pdf/b9/86/ndt-11-1381.PMC4461090.pdf
"Neuropsychiatric Disease and Treatment 2015:11submit your manuscript | www.dovepress.co m Dove press Dove press 1390Otsuka et alTable S1  (Continued ) SNP Population Genotype frequencies Allele frequencies Genotype Freq Count Genotype Freq Count Genotype Freq Count Total Allele Freq Count Allele Freq Count Total rs7204454 JPT g/g 0.319 36 c/g 0.540 61 c/c 0.142 16 113 g 0.588 133 c 0.412 93 226 chB g/g 0.382 52 c/g 0.441 60 c/c 0.176 24 136 g 0.603 164 c 0.397 108 272 chD g/g 0.394 43 c/g 0.486 53 c/c 0.119 13 109 g 0.638 139 c 0.362 79 218 gih g/g 0.158 16 c/g 0.406 41 c/c 0.436 44 101 g 0.361 73 c 0.639 129 202 ceU g/g 0.100 11 c/g 0.436 48 c/c 0.464 51 110 g 0.318 70 c 0.682 150 220 Tsi g/g 0.147 15 c/g 0.598 61 c/c 0.255 26 102 g 0.446 91 c 0.554 113 204 asW g/g 0.263 15 c/g 0.439 25 c/c 0.298 17 57 g 0.482 55 c 0.518 59 114 lWK g/g 0.164 18 c/g 0.536 59 c/c 0.300 33 110 g 0.432 95 c 0.568 125 220 MKK g/g 0.141 22 c/g 0.449 70 c/c 0.410 64 156 g 0.365 114 c 0.635 198 312 Yri g/g 0.284 40 c/g 0.504 71 c/c 0.213 30 141 g 0.535 151 c 0.465 131 282 MeX g/g 0.310 18 c/g 0.500 29 c/c 0.190 11 58 g 0.560 65 c 0.440 51 116 rs8057927 JPT T/T 0.478 54 c/T 0.425 48 c/c 0.097 11 113 T 0.690 156 c 0.310 70 226 chB T/T 0.478 65 c/T 0.412 56 c/c 0.110 15 136 T 0.684 186 c 0.316 86 272 chD T/T 0.514 56 c/T 0.394 43 c/c 0.092 10 109 T 0.711 155 c 0.289 63 218 gih T/T 0.901 91 c/T 0.089 9 c/c 0.010 1 101 T 0.946 191 c 0.054 11 202 ceU T/T 0.876 99 c/T 0.124 14 c/c 0 0 113 T 0.938 212 c 0.062 14 226 Tsi T/T 0.853 87 c/T 0.147 15 c/c 0 0 102 T 0.926 189 c 0.074 15 204 asW T/T 0.632 36 c/T 0.351 20 c/c 0.018 1 57 T 0.807 92 c 0.193 22 114 lWK T/T 0.620 67 c/T 0.324 35 c/c 0.056 6 108 T 0.782 169 c 0.218 47 216 MKK T/T 0.692 108 c/T 0.250 39 c/c 0.058 9 156 T 0.817 255 c 0.183 57 312 Yri T/T 0.623 91 c/T 0.336 49 c/c 0.041 6 146 T 0.791 231 c 0.209 61 292 MeX T/T 0.807 46 c/T 0.175 10 c/c 0.018 1 57 T 0.895 102 c 0.105 12 114 rs8049308 JPT T/T 0.455 20 c/T 0.500 22 c/c 0.045 2 44 T 0.705 62 c 0.295 26 88 chB T/T 0.364 16 c/T 0.477 21 c/c 0.159 7 44 T 0.602 53 c 0.398 35 88 ceU T/T 0.650 39 c/T 0.333 20 c/c 0.017 1 60 T 0.817 98 c 0.183 22 120 Yri T/T 0.583 35 c/T 0.383 23 c/c 0.033 2 60 T 0.775 93 c 0.225 27 120 Note:  genotype frequencies and allele frequencies data were determined by the hapMap database (hapMap data release 28, Phase 2 +3, august 10), on NcBi B36 assembly, dbsNP b126 ( http://hapmap.ncbi.nlm.nih.gov /).",Non-OADS,/arxiv_data1/oa_pdf/b9/86/ndt-11-1381.PMC4461090.pdf
"Neuropsychiatric Disease and Treatment 2015:11submit your manuscript | www.dovepress.co m Dove press Dove press 1391Cadherin13  gene and schizophrenia in the Japanese populationTable S2  haplotype frequencies of CDH13  sNPs (rs12925602–rs7204454) in different ethnic populations1 JPT CHB CHD GIH CEU TSI ASW LWK MKK YRI MEX gacgg 0.355 0.351 0.347 0.233 0.244 0.335 0.286 0.289 0.231 0.287 0.394 cgcac 0.285 0.220 0.206 0.085 aacag 0.151 0.161 0.194 0.119 0.081 0.114 0.127 0.106 0.091 0.130 0.154 ggTac 0.128 0.179 0.135 0.142 0.162 0.114 0.103 0.167 0.154 0.087 0.106 ggcag 0.070 0.077 0.076 ggcgg 0.012 0.006 0.018 0.006 gacag 0.006 0.071 0.067 0.024 0.126 0.010 aacgg 0.006 0.017 ggcgc 0.012 agcag 0.006 aacac 0.004 gacgc 0.017 0.006 0.008 0.004 ggcac 0.009 0.008 0.003 0.019 agTac 0.008 ggTgg 0.014 ggTgc 0.006 0.014 0.022 0.010 gacac 0.006 0.392 0.500 0.415 0.389 0.367 0.469 0.343 0.308 Note:  haplotype frequencies data were determined by the haploview software program (version 4.2; Broad institute, cambridge, Ma, Usa) ( http://www.broad.mit.edu/mpg/haploview /).",Non-OADS,/arxiv_data1/oa_pdf/b9/86/ndt-11-1381.PMC4461090.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/b9/86/ndt-11-1381.PMC4461090.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/b9/86/ndt-11-1381.PMC4461090.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/dc/57/ceor-7-299.PMC4461091.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinicoEconomics and Outcomes Research 2015:7 299–312ClinicoEconomics and Outcomes Research Dove press submit your manuscript | www.dovepress.co m Dove press  299ORiginal REsEaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/CEOR.S8575 6Comparative effectiveness and costs of generic  and brand-name gabapentin and venlafaxine in  patients with neuropathic pain or generalized  anxiety disorder in spain antoni sicras-Mainar1 Javier Rejas-gutiérrez2 Ruth navarro-artieda3 1Planning Directorate, Badalona  serveis assistencials sa, Badalona,   Barcelona, spain; 2Department  of health Economics and  Outcomes Research, Pfizer slU,   alcobendas, Madrid, spain; 3Medical  Documentation, hospital germans  Trias i Pujol, Badalona, Barcelona,   spain Correspondence: antoni sicras-Mainar   Planning Directorate, Badalona serveis  assistencials sa, Calle gaietà soler,   6-8 entlo., 08911, Badalona,   Barcelona, spain   Tel +34 93 507 2684   Fax +34 93 507 2684   Email asicras@bsa.ca tObjective:  To explore adherence/persistence with generic gabapentin/venlafaxine versus  brand-name gabapentin/venlafaxine (Neurontin®/Vandral®) in peripheral neuropathic pain (pNP)  or generalized anxiety disorder (GAD), respectively, and whether it is translated into different  costs and patient outcomes in routine medical practice.",Non-OADS,/arxiv_data1/oa_pdf/dc/57/ceor-7-299.PMC4461091.pdf
"ClinicoEconomics and Outcomes Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinicoeconomics-and-outcomes-research-journa lClinicoEconomics & Outcomes Research is an international, peer- reviewed open-access journal focusing on Health Technology Assess - ment, Pharmacoeconomics and Outcomes Research in the areas of  diagnosis, medical devices, and clinical, surgical and pharmacological  intervention.",Non-OADS,/arxiv_data1/oa_pdf/dc/57/ceor-7-299.PMC4461091.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/dc/57/ceor-7-299.PMC4461091.pdf
Available from: http://www.ine.es/dyngs/INEbase/es/operacion.htm?,Non-OADS,/arxiv_data1/oa_pdf/dc/57/ceor-7-299.PMC4461091.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/23/c5/copd-10-1015.PMC4461092.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of COPD 2015:10 1015–1026International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  1015OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S8443 6lanTern: a randomized study of QV a149  versus salmeterol/fluticasone combination  in patients with COPD nanshan Zhong1 Changzheng Wang2 Xiangdong Zhou3 nuofu Zhang1 Michael humphries4 linda Wang4 Chau Thach5 Francesco Patalano6 Donald Banerji5 On behalf of the LANTERN  Investigators 1State Key Laboratory of Respiratory  Diseases, First affiliated hospital,   guangzhou Medical University,   guangzhou, guangdong, 2Institute  of respiratory Disease, Xin Qiao  hospital, 3Department of respiratory  Medicine, southwest hospital,   Third Military Medical University,   Chongqing City, Chongqing, 4Beijing  novartis Pharma Co. ltd., shanghai,   People’s Republic of China; 5novartis  Pharmaceuticals Corporation, east  Hanover, NJ, USA; 6novartis Pharma  ag, Basel, switzerlandBackground:  The current Global initiative for chronic Obstructive Lung Disease (GOLD)  treatment strategy recommends the use of one or more bronchodilators according to the patient’s  airflow limitation, their history of exacerbations, and symptoms.",Non-OADS,/arxiv_data1/oa_pdf/23/c5/copd-10-1015.PMC4461092.pdf
"The airflow limitation is usually progressive and  associated with an abnormal inflammatory response of the lung to noxious particles  or gases.1 COPD and, more specifically, the frequent and recurrent exacerbations  experienced by patients with COPD, can result in significant health care costs, as well  as causing high morbidity and mortality among this group.2–4Correspondence: nanshan Zhong State Key Laboratory of Respiratory  Diseases, First Affiliated Hospital,  guangzhou Medical University, 151  Yangjiang road, guangzhou 510120,  Guangdong, People’s Republic of China email nanshan@vip.163.co m Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Zhong et al Running head recto: QVA149 versus ICS/LABA therapy in COPD DOI: http://dx.doi.org/10.2147/COPD.S84436",Non-OADS,/arxiv_data1/oa_pdf/23/c5/copd-10-1015.PMC4461092.pdf
"Available from: http://www.goldcopd.org/uploads/users/files/ GOLD_Report_2015_Feb18.pd f. Accessed March 14, 2015.",OADS,/arxiv_data1/oa_pdf/23/c5/copd-10-1015.PMC4461092.pdf
"Available from: http://www.goldcopd.org/uploads/users/files/ GOLDReport_April112011.pd f. Accessed February 12, 2014.",OADS,/arxiv_data1/oa_pdf/23/c5/copd-10-1015.PMC4461092.pdf
"Available from: http://www.goldcopd.org/uploads/users/files/ GOLD_Report_2014_Jan23.pd f. Accessed February 15, 2014.",OADS,/arxiv_data1/oa_pdf/23/c5/copd-10-1015.PMC4461092.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/23/c5/copd-10-1015.PMC4461092.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/23/c5/copd-10-1015.PMC4461092.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/0a/d4/dddt-9-2919.PMC4461093.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpDrug Design, Development and Therapy 2015:9 2919–2925Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  2919Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/DDDT .S6143 6Profile of ceftolozane/tazobactam and its potential  in the treatment of complicated intra-abdominal  infections Marion J Skalweit1,2 1Department of Medicine,   2Department of Biochemistry, Louis  Stokes Cleveland Department of  Veterans Affairs and Case Western  Reserve University School of  Medicine, Cleveland, OH, USAAbstract:  Drug-resistant pathogens have gained a foothold especially in the most vulnerable  patient populations, hospitalized and immunocompromised individuals.",Non-OADS,/arxiv_data1/oa_pdf/0a/d4/dddt-9-2919.PMC4461093.pdf
"The microbiology of cIAI,  emerging resistance in community-acquired/hospital-acquired cIAI and in cIAI in Correspondence: Marion J Skalweit Department of Medicine, Louis Stokes  Cleveland Department of Veterans  Affairs and Case Western Reserve  University School of Medicine, 10701 East  Boulevard, Cleveland, OH 44106, USA Tel +1 216 791 3800 email marion.skalweit@case.ed u Journal name: Drug Design, Development and Therapy Article Designation: Review Y ear: 2015 Volume: 9 Running head verso: Skalweit Running head recto: Ceftolozane/tazobactam and its potential in the treatment of cIAI DOI: http://dx.doi.org/10.2147/DDDT.S61436",Non-OADS,/arxiv_data1/oa_pdf/0a/d4/dddt-9-2919.PMC4461093.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/0a/d4/dddt-9-2919.PMC4461093.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/0a/d4/dddt-9-2919.PMC4461093.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/b0/76/dddt-9-2867.PMC4461094.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pDrug Design, Development and Therapy 2015:9 2867–2881Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  2867Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S8115 7Protective effect of huang gan formula in 5/6  nephrectomized rats by depressing the Wnt/ β-catenin signaling pathway liqian Mo1 Xiaoyan Xiao1 shaolian song1 hui Miao2 shiting liu1 Dan guo1 Xiao li3 can Bu1 lianbing hou1 Xixiao Yang1 1Department of Pharmacy, nanfang  hospital, southern Medical University,  2school of Pharmaceutical sciences,   sun Yat-sen University, guangzhou,   3Department of Pharmacy, The  affiliated hospital of Qingdao  University Medical school, Qingdao,   People’s republic of chinaAbstract:  Huang Gan formula (HGF) is a new traditional Chinese herbal medicine created  according to the basic theory of traditional Chinese medicine.",Non-OADS,/arxiv_data1/oa_pdf/b0/76/dddt-9-2867.PMC4461094.pdf
"Keywords:  Huang Gan formula, traditional Chinese medicine, chronic kidney disease,  Wnt/β-catenin signaling pathway Introduction Chronic kidney disease (CKD) was defined in The National Kidney Foundation Kidney Dis - ease Outcomes Quality Initiative ( KDOQI) clinical practice guidelines as kidney damage  or glomerular filtration rate (GFR) lower than 60 mL/min per 1.73 m2 of tissue for 3  months  or longer.1 Prevalence of CKD is estimated to be 8%–16% worldwide, and its incidence is  increasing in developed and developing nations.2 CKD has become a major public health  problem on a global scale because of its serious complications and poor prognosis, and it  presents huge socioeconomic burdens to patients, families, and societies.3 There are many risk factors leading to CKD, including hypertension, diabetes  mellitus, obesity, infections, xenobiotics, herbal or environmental toxins, mechani - cal obstruction, and deposition of immune complexes.2,4 Despite the different factors  leading to CKD, the kidney will eventually exhibit the same pathologic characteris - tics, including glomerulosclerosis and tubulointerstitial fibrosis, which show main correspondences: lianbing hou;  Xixiao Yang Department of Pharmacy, nanfang  hospital, southern Medical University,  no 1838, guangzhou Boulevard (north),  guangzhou 510515, People’s republic  of china Tel +86 20 6164 2175; +86 20 6278 7215 Fax +86 20 8770 1797 email hlianbing@163.co m; yxixiao@ hotmail.co mJournal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2015 Volume: 9 Running head verso: Mo et al Running head recto: Effects of Huang Gan formula on chronic kidney disease DOI: http://dx.doi.org/10.2147/DDDT.S81157",Non-OADS,/arxiv_data1/oa_pdf/b0/76/dddt-9-2867.PMC4461094.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/b0/76/dddt-9-2867.PMC4461094.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/b0/76/dddt-9-2867.PMC4461094.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/2f/c8/aabc-8-011.PMC4461095.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pAdvances and Applications in Bioinformatics and Chemistry 2015:8 11–22Advances and Applications in Bioinformatics and Chemistry Dove press submit your manuscript | www.dovepress.co m Dove press  11Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AABC.S6353 4T ools for visualization and analysis of molecular  networks, pathways, and -omics data Jose M villaveces Prasanna Koti Bianca H Habermann Max Planck institute of Biochemistry,  Research Group Computational  Biology, Martinsried, Germany Correspondence: Bianca H Habermann   Max Planck institute of Biochemistry,  Research Group Computational   Biology, Am Klopferspitz  18,   82152 Martinsried, Germany   email habermann@biochem.mpg.d eAbstract:  Biological pathways have become the standard way to represent the coordinated  reactions and actions of a series of molecules in a cell.",Non-OADS,/arxiv_data1/oa_pdf/2f/c8/aabc-8-011.PMC4461095.pdf
"The KEGG  pathway web interface ( http://www.genome.jp/kegg/tool/ map_pathway2.htm l),9  provides the possibility to color code  Table  2 Pathway and network visualization and analysis software Name Category Supported   pathway   resources KeGG Mapper9web KeGG KeGG-based Pathway   visualization Tool for   Complex Omics Data11web KeGG MeGU12web KeGG Pathway Projector13web KeGG KeGGviewer15web, BioJS KeGG Pathvisio17Desktop app wikiPathways,   Reactome Reactome2web Reactome Pathview19R-package KeGG iPath22/iPath223web KeGG wikiPathways App44Cytoscape plugin wikiPathways KGMLreader/KeGGscape46Cytoscape plugin KeGG CyKeGGParser45Cytoscape plugin KeGG Reactome Fi62Cytoscape plugin Reactome CluePedia48Cytoscape plugin KeGG, Reactome The SeeD31web KeGG CytoSeeD33Cytoscape plugin COBRA Toolbox34Matlab toolbox Reads SBML-   formatted models COBRApy35Python toolbox Abbreviations:  KeGG, Kyoto encyclopedia of Genes and Genomes; BioJS,  BioJavaScript; Reactome Fi, Reactome Functional interaction.Table  1 Pathway resources Name URL Formats KeGG1 http://www.genome.jp/kegg/ BioPAX, png, KGML Reactome2http://www.reactome.org/ BioPAX, png, pdf Pathway  Commons7http://www.pathwaycommons.",OADS,/arxiv_data1/oa_pdf/2f/c8/aabc-8-011.PMC4461095.pdf
"org/BioPAX, Sif, png PANTHeR  pathway3http://www.pantherdb.org/   pathway /BioPAX, SBML wikiPathways5http://www.wikipathways.org/ BioPAX, svg, png, pdf,  gpml Nature/NCi   Pathway   interaction   Database63http://pid.nci.nih.gov/ BioPAX, jpg, svg BioCyc4http://biocyc.org/ BioPAX, png, SBML iNOH84http://inoh.hgc.jp/ BioPAX, iNOH (xml) Netpath85http://www.netpath.org/ BioPAX, SBML, PSi-Mi PharmGKB86http://www.pharmgkb.org/ BioPAX, pdf, gpml Abbreviations:  BioPAX, Biological Pathway exchange; KGML, KeGG Markup  Language; PSi-Mi, Proteomics Standards initiative Molecular interaction; SBML,  Systems Biology Markup Language; NCi, National Cancer institute; iNOH,  integrating Network Objects with Hierarchies; PharmGKB, Pharmacogenomics  Knowledge Base; KeGG, Kyoto encyclopedia of Genes and Genomes.",OADS,/arxiv_data1/oa_pdf/2f/c8/aabc-8-011.PMC4461095.pdf
"The reader might turn to the website of this  visualization tool, http://www.g-language.org/data/mar - ray/,11 where a comprehensive analysis of expression data  in Escherichia coli  using the software has been performed  and which gives a very good impression on the software’ s  potential.",Non-OADS,/arxiv_data1/oa_pdf/2f/c8/aabc-8-011.PMC4461095.pdf
"Pathway Projector ( http://ws.g-language.or g/g4/),13  another web-based visualization software, allows users to  explore the network of biological pathways in a cell: the user  can zoom into the network, render pathways with experimen - tal data, or predict the enriched pathways for a set of user- provided genes.",OADS,/arxiv_data1/oa_pdf/2f/c8/aabc-8-011.PMC4461095.pdf
Additional tools supporting SBGN  are listed in http://www.sbgn.org /SBGN_Software .,OADS,/arxiv_data1/oa_pdf/2f/c8/aabc-8-011.PMC4461095.pdf
"Additionally, KEGG does not follow the SBGN specification  but rather uses its own graphical representation format KEGG  Markup Language ( http://www.kegg.jp/kegg/xml /).",OADS,/arxiv_data1/oa_pdf/2f/c8/aabc-8-011.PMC4461095.pdf
"Acknowledgments JMV and PK were supported by BMBF-Project  0315759  (The Virtual Liver Network, http://www.virtual-liver.de /).",OADS,/arxiv_data1/oa_pdf/2f/c8/aabc-8-011.PMC4461095.pdf
Available  from: http://opencobra.sourceforge.net/openCOBRA/Welcome.htm l.  Accessed.,Non-OADS,/arxiv_data1/oa_pdf/2f/c8/aabc-8-011.PMC4461095.pdf
"Advances and Applications in Bioinformatics and Chemistry Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com /advances-and-applications-in-bioinformatics-and-chemistry-journalAdvances and Applications in Bioinformatics and Chemistry is an inter - national, peer-reviewed open-access journal that publishes articles in the  following fields: Computational biomodeling; Bioinformatics; Compu - tational genomics; Molecular modeling; Protein structure modeling and  structural genomics; Systems Biology; Computational Biochemistry; Computational Biophysics; Chemoinformatics and Drug Design; In silico  ADME/Tox prediction.",Non-OADS,/arxiv_data1/oa_pdf/2f/c8/aabc-8-011.PMC4461095.pdf
Visit http://www.dovepress.com/testimonials.ph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/2f/c8/aabc-8-011.PMC4461095.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/3e/7b/amep-6-407.PMC4461096.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pAdvances in Medical Education and Practice 2015:6 407–420Advances in Medical Education and Practice Dove press submit your manuscript | www.dovepress.co m Dove press  407OriginAl rEsEArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AMEP .S8230 6Medical students’ knowledge, attitude, and practice  of complementary and alternative medicine: a pre-  and post-exposure survey in Majmaah University,  saudi Arabia Mohammed Abdullah Al  Mansour1 Abdullah M n Al-Bedah2 Mohammed Othman  Alrukban3 ibrahim s Elsubai2 Elsadiq Y ousif Mohamed4 Ahmed Tawfik El Olemy2 Asim Ah Khalil2 Mohamed KM Khalil2 Meshari saleh Alqaed2 Abdullah Almudaiheem2 Waqas sami Mahmoud4 Khalid Altohami Medani4 naseem Akhtar Qureshi2 1college of Medicine, Majmaah  University, Al Majma’ah, 2national  center of complementary and  Alternative Medicine, Ministry of  health, 3Department of Family  Medicine and community Medicine,  college of Medicine, King saud  University, riyadh, 4Department  of community Medicine and Public  health, college of Medicine, Majmaah  University, Al Majma’ah, saudi Arabia correspondence: naseem Akhtar Qureshi   national center for complementary   and Alternative Medicine, PO box 88300,  riyadh 11662, saudi Arabia   Tel +966 1 1450 0147   Fax +966 1 1470 9602   Email qureshinaseem@live.co mBackground:  Evidently, complementary and alternative medicine (CAM) is a recognized  medical practice that efficiently uses multiple treatment therapies and techniques in the preven - tion and management of a variety of human disorders.",Non-OADS,/arxiv_data1/oa_pdf/3e/7b/amep-6-407.PMC4461096.pdf
"Available from: http://www.whccamp.hhs.gov/fr4.htm l. Accessed  January 2, 2015.",Non-OADS,/arxiv_data1/oa_pdf/3e/7b/amep-6-407.PMC4461096.pdf
Available from: http://www.who.int/ bulletin/volumes/86/8/07-042820/en /.,Non-OADS,/arxiv_data1/oa_pdf/3e/7b/amep-6-407.PMC4461096.pdf
Available from: http://www.webmd.com/a-to-z-guides/ features/alter - native-medicine-integrative-medicine.,Non-OADS,/arxiv_data1/oa_pdf/3e/7b/amep-6-407.PMC4461096.pdf
Available from:  http://innersource.net/em/images/downloads/pdf_files/Basic_Grid_ Booklet-feb-2014.pdf.,OADS,/arxiv_data1/oa_pdf/3e/7b/amep-6-407.PMC4461096.pdf
Available from: http://www.camdoc.eu/Pdf/Model%20Guidelines%20 CAM%20Practice.pdf.,Non-OADS,/arxiv_data1/oa_pdf/3e/7b/amep-6-407.PMC4461096.pdf
"Advances in Medical Education and Practice Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/advances-in-medical-education-and-practice-journa lAdvances in Medical Education and Practice is an international, peer- reviewed, open access journal that aims to present and publish research  on Medical Education covering medical, dental, nursing and allied  health care professional education.",Non-OADS,/arxiv_data1/oa_pdf/3e/7b/amep-6-407.PMC4461096.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/3e/7b/amep-6-407.PMC4461096.pdf
Available from: http://www.nccpa.net/pdfs/competencies%20Self%20 Evaluation%20Tool.pdf.,Non-OADS,/arxiv_data1/oa_pdf/3e/7b/amep-6-407.PMC4461096.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/4b/29/ott-8-1335.PMC4461118.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncoTargets and Therapy 2015:8 1335–1340OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1335Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S8232 9elevated pretreatment plasma D-dimer levels  and platelet counts predict poor prognosis  in pancreatic adenocarcinoma Peng liu Yuan Zhu luying liu Department of radiotherapy, Zhejiang  cancer hospital, hangzhou, Zhejiang,   People’s republic of chinaAbstract:  This retrospective study was conducted to evaluate the prognostic significance of  the preoperative plasma D-dimer levels and platelet counts in patients with pancreatic adenocar - cinoma.",Non-OADS,/arxiv_data1/oa_pdf/4b/29/ott-8-1335.PMC4461118.pdf
"Therefore, the aim of this  study was to determine whether the plasma D-dimer levels and platelet counts before  chemoradiotherapy are predictors of mortality in patients with locally advanced unre - sectable pancreatic adenocarcinoma.correspondence: Peng liu Department of radiotherapy, Zhejiang  cancer hospital, 38 guangji road,  hangzhou, Zhejiang 310022, People’s  republic of china Tel +86 571 8812 8181 Fax +86 571 8812 2587 email sololiup@126.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2015 Volume: 8 Running head verso: Liu et al Running head recto: D-dimer and platelet in PAC DOI: http://dx.doi.org/10.2147/OTT.S82329",Non-OADS,/arxiv_data1/oa_pdf/4b/29/ott-8-1335.PMC4461118.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/4b/29/ott-8-1335.PMC4461118.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/4b/29/ott-8-1335.PMC4461118.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/4b/2b/amep-6-421.PMC4461119.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pAdvances in Medical Education and Practice 2015:6 421–429Advances in Medical Education and Practice Dove press submit your manuscript | www.dovepress.co m Dove press  421OriginAl rEsEArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AMEP .S8340 7The status of bedside teaching in the United  Kingdom: the student perspective Patrick Jones Bhavan Prasad rai Department of surgery, ninewells  hospital, Dundee, UK correspondence: Patrick Jones   Department of surgery, ninewells  hospital, ninewells Avenue, Dundee,   DD1 9sY, UK   Tel +44 1382 554 010   Fax +44 1382 632 327   Email patrick.jones1@nhs.ne tPurpose:  Bedside teaching holds a strong tradition as a key-learning platform for clinical  examination in the basic medical clerkship.",Non-OADS,/arxiv_data1/oa_pdf/4b/2b/amep-6-421.PMC4461119.pdf
The final nine-item survey ( Figure   S1) was distributed via Facebook ( https://www.facebook.,Non-OADS,/arxiv_data1/oa_pdf/4b/2b/amep-6-421.PMC4461119.pdf
"In carrying out this study, the Checklist for  Reporting Results of Internet E-Surveys (CHERRIES)  statement was incorporated, a validated quality improve - ment tool for internet-based surveys.6 Data were collected  over a 7-day period using the web-based tool Survey - Monkey® (http://www.surveymonkey.co m).",OADS,/arxiv_data1/oa_pdf/4b/2b/amep-6-421.PMC4461119.pdf
"Advances in Medical Education and Practice Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/advances-in-medical-education-and-practice-journa lAdvances in Medical Education and Practice is an international, peer- reviewed, open access journal that aims to present and publish research  on Medical Education covering medical, dental, nursing and allied  health care professional education.",Non-OADS,/arxiv_data1/oa_pdf/4b/2b/amep-6-421.PMC4461119.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/4b/2b/amep-6-421.PMC4461119.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/01/ee/cmar-7-145.PMC4461120.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pCancer Management and Research 2015:7 145–151Cancer Management and Research Dove press submit your manuscript | www.dovepress.co m Dove press  145Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CMAR.S8535 1New developments in the treatment of peripheral  T -cell lymphoma – role of Belinostat Peter Reimer Clinic for Hematology, Medical  Oncology and Stem Cell  Transplantation, evangelisches  Krankenhaus essen-w erden gGmbH,   essen, Germany Correspondence: Peter Reimer   Clinic for Hematology, Medical  Oncology and Stem Cell Transplantation,  evangelisches Krankenhaus essen- werden gGmbH, Pattbergstr.",Non-OADS,/arxiv_data1/oa_pdf/01/ee/cmar-7-145.PMC4461120.pdf
"Cancer Management and Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/cancer-management-and-research-journa lCancer Management and Research is an international, peer-reviewed  open access journal focusing on cancer research and the optimal use of  preventative and integrated treatment interventions to achieve improved  outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/01/ee/cmar-7-145.PMC4461120.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/01/ee/cmar-7-145.PMC4461120.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/52/96/mder-8-255.PMC4461121.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pMedical Devices: Evidence and Research 2015:8 255–264Medical Devices: Evidence and Research Dove press submit your manuscript | www.dovepress.co m Dove press  255ORiginal REsEaRchopen access to scientific and medical research Open access Full T ext article http: //dx.dio.org/10.2147/MDER.S8593 8Usability of a new disposable autoinjector  platform device: results of a formative study  conducted with a broad user population Jakob lange1 Philipp Richard1 nick Bradley2 1Ypsomed ag, Burgdorf, switzerland;   2BERgO UK, Bearsden, glasgow, UK correspondence: Jakob lange   Ypsomed ag, Brunnmattstrasse  6,  ch-3401 Burgdorf, switzerland   Tel +41 34 424 3187  Fax +41 34 424 3151  Email jakob.lange@ypsomed.co mAbstract:  This article presents a late-stage formative usability study of an autoinjector platform  device.",Non-OADS,/arxiv_data1/oa_pdf/52/96/mder-8-255.PMC4461121.pdf
"Medical Devices: Evidence and Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/medical-devices-evidence-and-research-journa lMedical Devices: Evidence and Research is an international, peer- reviewed, open access journal that focuses on the evidence, technology,  research, and expert opinion supporting the use and application of  medical devices in the diagnosis, treatment and management of clini - cal conditions and physiological processes.",Non-OADS,/arxiv_data1/oa_pdf/52/96/mder-8-255.PMC4461121.pdf
"Available from: http://www.ondrugdelivery.com/publications/ Injec table %20Devices%202012/Ypsomed.pd f. Accessed April  1,  2015.",Non-OADS,/arxiv_data1/oa_pdf/52/96/mder-8-255.PMC4461121.pdf
"Available from: http://www.fda.gov/ medicaldevices /deviceregulationandguidance /guidancedocuments/ ucm259748.ht m. Accessed April  1, 2015.",Non-OADS,/arxiv_data1/oa_pdf/52/96/mder-8-255.PMC4461121.pdf
"Available  from: http://www.life-saver.org/wordpress/wp-content/uploads/2010/08/ Lombardelli-poster-EAACI-2010.pd f. Accessed April  1, 2015.",Non-OADS,/arxiv_data1/oa_pdf/52/96/mder-8-255.PMC4461121.pdf
"Available from: https://www.avonex.com/pdfs/A VONEX-pen.pd f.  Accessed April  1, 2015.",Non-OADS,/arxiv_data1/oa_pdf/52/96/mder-8-255.PMC4461121.pdf
"Available from: http://pi.amgen.com/united_states/ enbrel/derm/enbrel_piu.pd f. Accessed April  1, 2015.",Non-OADS,/arxiv_data1/oa_pdf/52/96/mder-8-255.PMC4461121.pdf
"Available from: http://www.rebif.com/resources/pdf/Rebif%20 Rebidose%20IFU_Final.pd f. Accessed April  1, 2015.",Non-OADS,/arxiv_data1/oa_pdf/52/96/mder-8-255.PMC4461121.pdf
"Available  from: https://www.epipen.com/en/prescribing-information#Patien t.  Accessed April  1, 2015.",Non-OADS,/arxiv_data1/oa_pdf/52/96/mder-8-255.PMC4461121.pdf
Available from: http://www.evzio.com/pdfs/Evzio-Patient-Information.,Non-OADS,/arxiv_data1/oa_pdf/52/96/mder-8-255.PMC4461121.pdf
"Available from: http://www.simponi.com/shared/ product/simponi/medication-guide.pd f. Accessed April  1, 2015.",Non-OADS,/arxiv_data1/oa_pdf/52/96/mder-8-255.PMC4461121.pdf
Available from: http://prod.pegasys.,Non-OADS,/arxiv_data1/oa_pdf/52/96/mder-8-255.PMC4461121.pdf
"Available from: http://pi.lilly.com/us/ trulicity-lowdose-ai-ifu.pd f. Accessed April  1, 2015.",Non-OADS,/arxiv_data1/oa_pdf/52/96/mder-8-255.PMC4461121.pdf
Available from: http://www.accessdata.fda.,OADS,/arxiv_data1/oa_pdf/52/96/mder-8-255.PMC4461121.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/36/8b/hmer-7-029.PMC4461125.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pHepatic Medicine: Evidence and Research 2015:7 29–35Hepatic Medicine: Evidence and Research Dove press submit your manuscript | www.dovepress.co m Dove press  29ORiginal REsEaRcHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/HMER.S7910 0Tyrosine levels are associated with insulin  resistance in patients with nonalcoholic fatty   liver disease Miwa Kawanaka1 Ken nishino1 Takahito Oka1 noriyo Urata1 Jun nakamura1 Mitsuhiko suehiro1 Hirofumi Kawamoto1 Yasutaka chiba2 gotaro Yamada1 1Department of general internal  Medicine 2, Kawasaki Hospital,   Kawasaki Medical school, Okayama,   Japan; 2clinical Research center, Kinki  University Hospital, sayama, Japan correspondence: Miwa Kawanaka   Department of general internal   Medicine 2, Kawasaki Hospital,   Kawasaki Medical school, 2-1-80   nakasange, Kita-ku, Okayama city,   Okayama 700-8505, Japan   Tel +81 86 225 2111   Fax +81 86 232 8343   Email m.kawanaka@med.kawasaki-m.ac.j pObjective:  Amino acid imbalance is often found in patients with cirrhosis, and this imbal - ance is associated with insulin resistance.",Non-OADS,/arxiv_data1/oa_pdf/36/8b/hmer-7-029.PMC4461125.pdf
"Hepatic Medicine: Evidence and Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/hepatic-medicine-evidence-and-research-journa lHepatic Medicine: Evidence and Research is an international, peer- reviewed, open access journal covering all aspects of adult and pedi - atric hepatology in the clinic and laboratory including the following  topics: Pathology, pathophysiology of hepatic disease; Investigation  and treatment of hepatic disease; Pharmacology of drugs used for the treatment of hepatic disease.",Non-OADS,/arxiv_data1/oa_pdf/36/8b/hmer-7-029.PMC4461125.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/36/8b/hmer-7-029.PMC4461125.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/2b/28/ijn-10-3843.PMC4461127.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2015:10 3843–3853International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  3843OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S7610 4Magnetic nanoparticles enhance the anticancer  activity of cathelicidin ll-37 peptide against colon  cancer cells Katarzyna Niemirowicz1 Izabela Prokop2 agnieszka Z Wilczewska3 Urszula Wnorowska1 ewelina Piktel1 Marzena Wątek4 Paul B savage5 robert Bucki1,6 1Department of Microbiological  and Nanobiomedical engineering,   Medical University of Bialystok,   2Department of Medicinal  chemistry, Medical University of  Bialystok, 3Institute of chemistry,   University of Bialystok, Bialystok,   4Department of hematology, holy  cross Oncology center of Kielce,   Kielce, Poland; 5Department of  chemistry and Biochemistry,   Brigham Y oung University, Provo, UT,   Usa; 6Department of Physiology,   Pathophysiology and Microbiology  of Infections, The Faculty of health  sciences of the Jan Kochanowski  University in Kielce, Kielce, PolandAbstract:  The pleiotropic activity of human cathelicidin LL-37 peptide includes an ability to  suppress development of colon cancer cells.",Non-OADS,/arxiv_data1/oa_pdf/2b/28/ijn-10-3843.PMC4461127.pdf
"Mickiewicza  2c, 15-222 Bialystok, Poland Tel +48 85 748 5483 Fax +48 85 748 5492 email buckirobert@gmail.co m Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Niemirowicz et al Running head recto: Activity of MNP@LL-37 against colon cancer cells DOI: http://dx.doi.org/10.2147/IJN.S76104",Non-OADS,/arxiv_data1/oa_pdf/2b/28/ijn-10-3843.PMC4461127.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/2b/28/ijn-10-3843.PMC4461127.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/2b/28/ijn-10-3843.PMC4461127.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/11/77/ceor-7-281.PMC4461128.pdf
"Information on how to  request permission may be found at: http://www.dovepress.com/permissions.ph pClinicoEconomics and Outcomes Research 2015:7 281–286ClinicoEconomics and Outcomes Research Dove press submit your manuscript | www.dovepress.co m Dove press  281ORiginal REsEaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/CEOR.S8010 4Prevalence and cost of imaging in inpatient falls:  the rising cost of falling Jessica Fields1 Tahani alturkistani2 neal Kumar3 arjun Kanuri3 Deeb n salem1 samson Munn2 Deborah Blazey-Martin1 1Department of Medicine, Tufts  Medical Center, Boston, M a, Usa;   2Department of Radiology, Tufts  Medical Center, Boston, M a, Usa;   3Tufts University school of Medicine,  Boston, M a, Usa Correspondence: Deborah Blazey-Martin   Department of Medicine, Tufts Medical  Center,  800 Washington street, Box  212,  Boston, Ma  02111, Usa   Tel +1 617 636 1083  Fax +1 617 636 8319  Email dblazey-martin@ tuftsmedicalcenter.or gObjective:  To quantify the type, prevalence, and cost of imaging following inpatient falls,  identify factors associated with post-fall imaging, and determine correlates of positive versus  negative imaging.",Non-OADS,/arxiv_data1/oa_pdf/11/77/ceor-7-281.PMC4461128.pdf
"ClinicoEconomics and Outcomes Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinicoeconomics-and-outcomes-research-journa lClinicoEconomics & Outcomes Research is an international, peer- reviewed open-access journal focusing on Health Technology Assess - ment, Pharmacoeconomics and Outcomes Research in the areas of  diagnosis, medical devices, and clinical, surgical and pharmacological  intervention.",Non-OADS,/arxiv_data1/oa_pdf/11/77/ceor-7-281.PMC4461128.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/11/77/ceor-7-281.PMC4461128.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/41/df/dddt-9-2883.PMC4461129.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpDrug Design, Development and Therapy 2015:9 2883–2886Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  2883Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/DDDT .S7803 6Spotlight on pembrolizumab in the treatment  of advanced melanoma Thanashan Rajakulendran1 David N Adam2 1Department of Medicine, Division  of Dermatology, Postgraduate Medical  education, 2Department of Medicine,   Division of Dermatology, St Michael’s  Hospital, University of T oronto,   T oronto, ON, CanadaAbstract:  Metastatic melanoma is an aggressive cancer with a poor prognosis.",Non-OADS,/arxiv_data1/oa_pdf/41/df/dddt-9-2883.PMC4461129.pdf
"Immune Correspondence: Thanashan  Rajakulendran Division of Dermatology, Sunnybrook  Health Sciences Centre, 2075 Bayview  Avenue, Suite M1-700, Toronto, Ontario,  M4N 3M5, Canada  email t.rajakulendran@mail.utoronto.c a  David N Adam Department of Medicine, Division  of Dermatology, St Michael’s Hospital,  30 Bond Street, Fourth Floor Cardinal  Carter North, Toronto, ON M5B 1w8,  Canada email david.adam@utoronto.c a Journal name: Drug Design, Development and Therapy Article Designation: Review Y ear: 2015 Volume: 9 Running head verso: Rajakulendran and Adam Running head recto: Pembrolizumab in the treatment of advanced melanoma DOI: http://dx.doi.org/10.2147/DDDT.S78036",Non-OADS,/arxiv_data1/oa_pdf/41/df/dddt-9-2883.PMC4461129.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/41/df/dddt-9-2883.PMC4461129.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/41/df/dddt-9-2883.PMC4461129.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/43/2d/dddt-9-2855.PMC4461130.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pDrug Design, Development and Therapy 2015:9 2855–2865Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  2855Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S7635 8Clinicopathological significance and potential drug  target of r UnX3 in non-small cell lung cancer:  a meta-analysis lijun Xu1 hongwen lan1 Yushu su1 Jun li1 Jingwen Wan2 1Department of cardiothoracic  surgery, Tongji hospital, Tongji  Medical college, huazhong University  of science and T echnology, Wuhan,   2Department of surgery (Operation  room), Tongji hospital, Tongji Medical  college, huazhong University of  science and  T echnology, hubei,   People’s republic of chinaBackground:  Emerging evidence indicates that RUNX3 is a candidate tumor suppressor in  several types of human tumors, including non-small cell lung cancer (NSCLC).",Non-OADS,/arxiv_data1/oa_pdf/43/2d/dddt-9-2855.PMC4461130.pdf
"Keywords:  RUNX3 , methylation, lung cancer, tumor suppressor gene, meta-analysis, odds  ratio, hazard ratio Introduction Non-small cell lung cancer (NSCLC) includes several histological types, including  adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and mixed histologies,  and accounts for approximately 85% of all lung cancers, making NSCLC the leading  cause of cancer-related deaths worldwide.1,2 Despite advances in early detection, radical  curative surgery, and multimodal therapeutic modalities, about 80% of NSCLC cases  are in an advanced stage at diagnosis; systemic chemotherapy remains the standard  care but provides marginal improvement in survival.3 Therefore, further investigation  on the mechanism of initiation, progression, and identification of prognostic markers correspondence: Jingwen Wan Department of surgery (Operation  room), Tongji hospital, Tongji Medical  college, huazhong University of science  and Technology, 1095 Jiefang avenue,  hubei 430030, People’s republic of china Tel +86 138 8617 1930 Fax +86 8366 5400 email jingwenwan@yeah.ne t Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2015 Volume: 9 Running head verso: Xu et al Running head recto: Potential drug target of RUNX3 in NSCLC DOI: http://dx.doi.org/10.2147/DDDT.S76358",Non-OADS,/arxiv_data1/oa_pdf/43/2d/dddt-9-2855.PMC4461130.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/43/2d/dddt-9-2855.PMC4461130.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/43/2d/dddt-9-2855.PMC4461130.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/3b/64/ndt-11-1395.PMC4461131.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pNeuropsychiatric Disease and Treatment 2015:11 1395–1403Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1395OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S8205 2Triptolide attenuates cerebral ischemia and  reperfusion injury in rats through the inhibition  the nuclear factor kappa B signaling pathway Xiao-Qing Jin1,2 Fei Ye1 Jun-Jian Zhang1 Yan Zhao2 Xian-long Zhou2 1Department of Neurology,   2emergency center, Zhongnan  hospital of Wuhan University, Wuhan,   hubei, People’s republic of chinaAbstract:  Inflammation plays critical roles in the acute progression of the pathology of ischemic  injury.",Non-OADS,/arxiv_data1/oa_pdf/3b/64/ndt-11-1395.PMC4461131.pdf
"Keywords:  ischemic stroke, inflammation, rat model, NF- κB pathway Introduction Stroke is one of the most common causes of death and long-term disability in the adult  population worldwide.1 Ischemic stroke, which is caused by a reduction in cerebral  blood flow and can result in fatal brain damage, accounts for approximately 80% of  all strokes.2 Thrombolysis and interventional recanalization are regularly applied  approaches for the management of acute ischemic stroke.3,4 Although reperfusion  leads to the temporary survival of cerebral cells in the ischemic region through the  restoration of blood flow, these therapies have achieved limited clinical success  because of their narrow therapeutic time window and the occurrence of reperfusion  injury following recovery from ischemia.4 Ischemia reperfusion injury (IRI) is a  complex disorder caused by oxidative damage, inflammation, and cerebral edema.5,6  In addition, both experimental and clinical evidence has indicated that inflammation  is essential for the progression of cerebral IRI.7,8 Previous studies have suggested  that treatment with anti-inflammatory agents could reduce tissue edema and improve  outcome in stroke models.9 Triptolide, a bioactive ingredient extracted from Chinese medicinal plants, has  been reported to exhibit anti-inflammatory activities in several disorders including  arthritis,10 pulmonary hypertension,11 and traumatic brain injury.12 In vitro studies have  also shown that triptolide is able to suppress the production of inflammatory cytokines  in various cell lines.13,14 Those previous findings lend support to the possibility that correspondence: Jun-Jian Zhang Department of Neurology, Zhongnan  hospital of Wuhan University,  169 Donghu road, Wuhan, hubei  430071, People’s republic of china Tel +86 27 6781 3068   Fax +86 27 6781 3052   email xsssm@sina.c n Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2015 Volume: 11 Running head verso: Jin et al Running head recto: Triptolide attenuates cerebral IRI DOI: http://dx.doi.org/10.2147/NDT.S82052",Non-OADS,/arxiv_data1/oa_pdf/3b/64/ndt-11-1395.PMC4461131.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/3b/64/ndt-11-1395.PMC4461131.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/3b/64/ndt-11-1395.PMC4461131.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/8f/cc/ijn-10-3829.PMC4461132.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2015:10 3829–3841International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  3829OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S8176 2Transactivator of transcription (T aT) peptide– chitosan functionalized multiwalled carbon  nanotubes as a potential drug delivery vehicle  for cancer therapy Xia Dong lanxia liu Dunwan Zhu hailing Zhang Xigang leng laboratory of Bioengineering,   Institute of Biomedical engineering,   chinese academy of Medical sciences  and Peking Union Medical college,   Tianjin Key laboratory of Biomedical  Materials, Tianjin, People’s republic  of chinaAbstract:  Carbon nanotube (CNT)-based drug delivery vehicles might find great potential  in cancer therapy via the combination of chemotherapy with photothermal therapy due to the  strong optical absorbance of CNTs in the near-infrared region.",Non-OADS,/arxiv_data1/oa_pdf/8f/cc/ijn-10-3829.PMC4461132.pdf
"Further chemical  reactions with various functional molecules including therapeutic agents or targeting  moieties have been demonstrated to significantly improve their performance as drug/ gene delivery vehicles.10–14correspondence: Xigang leng laboratory of Bioengineering, Institute  of Biomedical engineering, chinese  academy of Medical sciences and Peking  Union Medical college, 236 Baidi road,  Nankai District, Tianjin 300192, People’s  republic of china email lengxgyky@163.co m Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Dong et al Running head recto: Carbon nanotubes and cancer therapy DOI: http://dx.doi.org/10.2147/IJN.S81762",Non-OADS,/arxiv_data1/oa_pdf/8f/cc/ijn-10-3829.PMC4461132.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/8f/cc/ijn-10-3829.PMC4461132.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/8f/cc/ijn-10-3829.PMC4461132.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/f1/d3/dhps-7-103.PMC4461133.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pDrug, Healthcare and Patient Safety 2015:7 103–111Drug, Healthcare and Patient Safety Dove press submit your manuscript | www.dovepress.co m Dove press  103Original reSearcHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DHPS.S8377 0Prevalence and predictors of antibiotic  prescription errors in an emergency   department, central Saudi arabia Menyfah Q alanazi1 Majed i al-Jeraisy2,3 Mahmoud Salam2 1Drug Policy and economic center,   2King abdullah international Medical  research center (K aiMrc), 3King  Saud bin abdulaziz University for  Health Sciences (KSaU-HS), riyadh,  Saudi arabia correspondence: Mahmoud Salam   Saudi national Biobanking Section, King   abdullah international Medical research  center, Mail code  1515, King abdulaziz  Medical city, national guard Health  affairs, PO Box  22490, riyadh  11426,  Saudi arabia   email mahmoudsalam@hotmail.co mBackground:  Inappropriate antibiotic (ATB) prescriptions are a threat to patients, leading to  adverse drug reactions, bacterial resistance, and subsequently, elevated hospital costs.",Non-OADS,/arxiv_data1/oa_pdf/f1/d3/dhps-7-103.PMC4461133.pdf
"Available from: http://www.moh.gov.sa/en/ Ministry/Statistics/Indicator/Pages/Indicator-2012-01-10-0001.asp x.  Accessed March  18, 2015.",OADS,/arxiv_data1/oa_pdf/f1/d3/dhps-7-103.PMC4461133.pdf
"Available from: http://www.livescience.com/43845- antibiotics-hospitals-infections.htm l. Accessed March  22, 2015.",Non-OADS,/arxiv_data1/oa_pdf/f1/d3/dhps-7-103.PMC4461133.pdf
"Drug, Healthcare and Patient Safety Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-healthcare-and-patient-safety-journa lDrug, Healthcare and Patient Safety is an international, peer-reviewed  open-access journal exploring patient safety issues in the healthcare  continuum from diagnostic and screening interventions through to treat - ment, drug therapy and surgery.",Non-OADS,/arxiv_data1/oa_pdf/f1/d3/dhps-7-103.PMC4461133.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/f1/d3/dhps-7-103.PMC4461133.pdf
Available  from: http://www.mayoclinic.org/healthy-living/consumer-health/in- depth/antibiotics/art-2004572 0.,Non-OADS,/arxiv_data1/oa_pdf/f1/d3/dhps-7-103.PMC4461133.pdf
"Available from: http://www.cidrap.umn.edu/news-perspective/2014/03/ cdc-calls-out-antibiotic-prescribing-problem s. Accessed March  23,  2015.",Non-OADS,/arxiv_data1/oa_pdf/f1/d3/dhps-7-103.PMC4461133.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/e0/47/ceor-7-287.PMC4461134.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinicoEconomics and Outcomes Research 2015:7 287–298ClinicoEconomics and Outcomes Research Dove press submit your manuscript | www.dovepress.co m Dove press  287ORiginal REsEaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/CEOR.S8254 9Evolution of health technology assessment:   best practices of the pan-Canadian Oncology  Drug Review angela Rocchi1 isabelle Chabot2 Judith glennie3 1athena Research inc., Burlington,  On, 2Evaccess inc., Vaudreuil- Dorion, QC,  3Jl glennie Consulting  inc., aurora, On , Canada Correspondence: angela Rocchi   athena Research inc.,  2068 Waterbridge  Drive, Burlington, On, Canada l7M  3W2  Tel +1 905 522 2961  Fax +1 866 272 9699  Email angela@athenaresearch.c aBackground:  In 2007, Canada chose to develop a separate and distinct path for oncology  drug health technology assessment (HTA).",Non-OADS,/arxiv_data1/oa_pdf/e0/47/ceor-7-287.PMC4461134.pdf
Ottawa: CaDTh; 2015. available from: https://www.cadth.ca/pcodr/process-in-brie f.11 CaDTh pan-Canadian Oncology Drug Review.,Non-OADS,/arxiv_data1/oa_pdf/e0/47/ceor-7-287.PMC4461134.pdf
Ottawa: CaDTh; 2015. available from: https://www.cadth.ca/pcodr/advisory-bodie s.12 CaDTh pan-Canadian  Oncology Drug Review.,Non-OADS,/arxiv_data1/oa_pdf/e0/47/ceor-7-287.PMC4461134.pdf
"Ottawa: CaDTh; 2015. available from: https://www.cadth.ca/pcodr/find-a-revie w.13 Abbreviations:  PCPa, pan-Canadian Pharmaceutical alliance; hTa, health technology assessment; pCODR, pan-Canadian Oncology Drug Review; pERC, pCODR Expert  Review Committee; Pag, Provincial advisory group; niCE, national institute for health and Care Excellence.",Non-OADS,/arxiv_data1/oa_pdf/e0/47/ceor-7-287.PMC4461134.pdf
"Available from: https://secure.cihi.ca/free_products/ NHEXTrendsReport2012EN.pd f. Accessed January  27, 2015.",OADS,/arxiv_data1/oa_pdf/e0/47/ceor-7-287.PMC4461134.pdf
Available  from: http://www.gov.sk.ca/news?newsId =78c1248b-7ed0-4f47-ba8d- c9d44f65372 8.,Non-OADS,/arxiv_data1/oa_pdf/e0/47/ceor-7-287.PMC4461134.pdf
"Available from: http://www.cadth.ca/ media/cdr/cdr_evaluation_firstyear_oct2005.pd f. Accessed January  27,  2015.",OADS,/arxiv_data1/oa_pdf/e0/47/ceor-7-287.PMC4461134.pdf
Available from: http://www.parl.,Non-OADS,/arxiv_data1/oa_pdf/e0/47/ceor-7-287.PMC4461134.pdf
"Available from: http://www.ohsu.edu/xd/ research/centers-institutes/evidence-based-policy-center/med/upload/ Health-Technology-Assessment_Public_RR_Final_08_18_2011.pd f.  Accessed January  27, 2015.",Non-OADS,/arxiv_data1/oa_pdf/e0/47/ceor-7-287.PMC4461134.pdf
"Available from: https://www.cadth.ca/pcodr/process-in-brie f. Accessed  April 16, 2015.",OADS,/arxiv_data1/oa_pdf/e0/47/ceor-7-287.PMC4461134.pdf
"Available from: https://www.cadth.ca/pcodr/advisory-bodie s. Accessed  April 16, 2015.",Non-OADS,/arxiv_data1/oa_pdf/e0/47/ceor-7-287.PMC4461134.pdf
"Available  from: https://www.cadth.ca/pcodr/find-a-revie w. Accessed April 16,  2015.",Non-OADS,/arxiv_data1/oa_pdf/e0/47/ceor-7-287.PMC4461134.pdf
Available from: http://www.cadth.,Non-OADS,/arxiv_data1/oa_pdf/e0/47/ceor-7-287.PMC4461134.pdf
"Available from: https://www.cadth.ca/cd r. Accessed April 16,  2015.",Non-OADS,/arxiv_data1/oa_pdf/e0/47/ceor-7-287.PMC4461134.pdf
"Available from: https://www.cadth.ca/pcodr/process-in-brie f. Accessed  April 16, 2015.",OADS,/arxiv_data1/oa_pdf/e0/47/ceor-7-287.PMC4461134.pdf
"Available  from: https://www.cadth.ca/pcodr/advisory-bodie s. Accessed April 16,  2015.",Non-OADS,/arxiv_data1/oa_pdf/e0/47/ceor-7-287.PMC4461134.pdf
"Available from:  https://www.cadth.ca/pcodr/find-a-revie w. Accessed April 16, 2015.",Non-OADS,/arxiv_data1/oa_pdf/e0/47/ceor-7-287.PMC4461134.pdf
"ClinicoEconomics and Outcomes Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinicoeconomics-and-outcomes-research-journa lClinicoEconomics & Outcomes Research is an international, peer- reviewed open-access journal focusing on Health Technology Assess - ment, Pharmacoeconomics and Outcomes Research in the areas of  diagnosis, medical devices, and clinical, surgical and pharmacological  intervention.",Non-OADS,/arxiv_data1/oa_pdf/e0/47/ceor-7-287.PMC4461134.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/e0/47/ceor-7-287.PMC4461134.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/a8/d6/jmdh-8-271.PMC4461135.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Multidisciplinary Healthcare 2015:8 271–277Journal of Multidisciplinary Healthcare Dove press submit your manuscript | www.dovepress.co m Dove press  271Original researcHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/JMDH.S8223 9Being “on the alert” and “a forced volunteer”:   a qualitative study of the invisible care provided  by the next of kin of patients with chronic heart  failure anita strøm1 Kirsti lauvli andersen2 Kari Korneliussen3 May solveig Fagermoen4 1Department of Masters and  continuing education, lovisenberg  Diaconal University college, Oslo,   norway; 2Faculty of Health and social  Work studies, Østfold University  college, Halden, norway; 3Heart  Failure clinic, Vestfold Hospital Trust,   Tønsberg, norway; 4institute of  Health and society, University of Oslo,   Oslo, norway correspondence: anita strøm   lovisenberg Diaconal University college,  lovisenberggt 15B, 0456 Oslo, norway   Tel +47 9502 1491   email anita.strom@ldh.n oBackground:  Relatives’ support is an important factor in how well people with chronic heart  failure (CHF) manage their illness and everyday life.",Non-OADS,/arxiv_data1/oa_pdf/a8/d6/jmdh-8-271.PMC4461135.pdf
Available from http://www.fhi.no/dokumenter/2057fd7048.pd f.  Accessed 6 May 2015.,Non-OADS,/arxiv_data1/oa_pdf/a8/d6/jmdh-8-271.PMC4461135.pdf
"Journal of Multidisciplinary Healthcare Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-multidisciplinary-healthcare-journa lThe Journal of Multidisciplinary Healthcare is an international, peer- reviewed open-access journal that aims to represent and publish research  in healthcare areas delivered by practitioners of different disciplines.",Non-OADS,/arxiv_data1/oa_pdf/a8/d6/jmdh-8-271.PMC4461135.pdf
Visit http://www.dove - press.com/testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/a8/d6/jmdh-8-271.PMC4461135.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/0a/7c/ccid-8-295.PMC4461136.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinical, Cosmetic and Investigational Dermatology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journa lClinical, Cosmetic and Investigational Dermatology is an interna - tional, peer-reviewed, open access, online journal that focuses on  the latest clinical and experimental research in all aspects of skin  disease and cosmetic interventions.",Non-OADS,/arxiv_data1/oa_pdf/0a/7c/ccid-8-295.PMC4461136.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/0a/7c/ccid-8-295.PMC4461136.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/8c/ff/opth-9-977.PMC4461137.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Ophthalmology 2015:9 977–983Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  977Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S8382 0Outcomes of ahmed glaucoma valve implantation  in advanced primary congenital glaucoma  with previous surgical failure Jingjing huang1 Jialiu lin1 Ziqiang Wu2 hongzhi Xu3 Chengguo Zuo1 Jian ge1 1state Key laboratory of  Ophthalmology, Department of  glaucoma, Zhongshan Ophthalmic  Center, sun Yat-sen University,   guangzhou, People’s republic of  China; 2Center for advanced eye  Care, Carson City, nV, Usa; 3institute  of Child health Policy, University  of Florida, gainesville, Fl, UsaPurpose:  The purpose of this study was to evaluate the intermediate surgical results of Ahmed  glaucoma valve (AGV) implantation in patients less than 7 years of age, with advanced primary  congenital glaucoma who have failed previous surgeries.",Non-OADS,/arxiv_data1/oa_pdf/8c/ff/opth-9-977.PMC4461137.pdf
"However, even in the best of hands, up to 15%–30% of primary surgeries failed.3–6 The  use of intraoperative mitomycin C (MMC) improved the survival of trabeculectomy  blebs,8,9 but it is associated with a high incidence of bleb-related infections.9 In the recent decades, Ahmed glaucoma valves (AGVs) have been implanted in  patients with pediatric glaucoma.10,11 It demonstrated slight superiority compared to Correspondence: Jingjing huang state Key laboratory of Ophthalmology,  Department of glaucoma, Zhongshan  Ophthalmic Center, sun Yat-sen  University, 54 Xianlienan road,  guangzhou 510060, People’s republic  of China Tel +86 20 8733 1545 Fax +86 20 8733 3271 email hjjing@mail.sysu.edu.c n Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2015 Volume: 9 Running head verso: Huang et al Running head recto: Valve implant in refractory primary congenital glaucoma DOI: http://dx.doi.org/10.2147/OPTH.S83820",Non-OADS,/arxiv_data1/oa_pdf/8c/ff/opth-9-977.PMC4461137.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/8c/ff/opth-9-977.PMC4461137.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/8c/ff/opth-9-977.PMC4461137.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/88/df/cmar-7-133.PMC4461138.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pCancer Management and Research 2015:7 133–143Cancer Management and Research Dove press submit your manuscript | www.dovepress.co m Dove press  133Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CMAR.S7740 0Cancer therapy and cardiovascular risk: focus on  bevacizumab Panagiota economopoulou1 Athanasios Kotsakis2 ioannis Kapiris3 Nikolaos Kentepozidis3 1Medical Oncology Unit,  2nd  Department of internal Medicine,  Attikon University Hospital, Haidari,  Athens,  2Department of Medical  Oncology, University Hospital of  Heraklion, Crete,  3251 Airforce  General Hospital, Department of  Medical Oncology, Athens, Greece Correspondence: Panagiota  economopoulou   Medical Oncology Unit,  2nd Department  of internal Medicine, Attikon University  Hospital, National Kapodistrian  University of Athens,  1st Rimini St,   12462, Haidari, Athens, Greece   Tel +30 210 583 1655  Fax +30 210 583 1690  email panagiota_oiko@hotmail.co mAbstract:  Recognition and management of treatment-related cardiovascular toxicity, defined as  either an acute cardiac event or a chronic condition, has been tightly integrated into routine cancer  care and has become an important component in treatment selection.",Non-OADS,/arxiv_data1/oa_pdf/88/df/cmar-7-133.PMC4461138.pdf
Available from:  http://ctep.cancer.gov/protocoldevelopment/electronic_applications/ docs/ctcv20_4e30e992.pdf .,Non-OADS,/arxiv_data1/oa_pdf/88/df/cmar-7-133.PMC4461138.pdf
"Cancer Management and Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/cancer-management-and-research-journa lCancer Management and Research is an international, peer-reviewed  open access journal focusing on cancer research and the optimal use of  preventative and integrated treatment interventions to achieve improved  outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/88/df/cmar-7-133.PMC4461138.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/88/df/cmar-7-133.PMC4461138.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/5a/17/copd-10-1053.PMC4461139.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Journal of COPD 2015:10 1053–1059International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  1053OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S7986 4The reasons for triple therapy in stable COPD  patients in Japanese clinical practice Masaki Miyazaki1 hidetoshi nakamura1,2 saeko Takahashi1 shotaro Chubachi1 Mamoru sasaki1 Mizuha haraguchi1 hideki T erai1 Makoto Ishii1 Koichi Fukunaga1 sadatomo Tasaka1 Kenzo soejima1 Koichiro asano3 T omoko Betsuyaku1 On behalf of the Keio  COPD Comorbidity  research (K-CCr) group 1Division of Pulmonary Medicine,   Department of Medicine, Keio  University school of Medicine,   T okyo, 2Department of respiratory  Medicine, saitama Medical University,   saitama, 3Division of Pulmonary  Medicine, Department of Medicine,   T okai University school of Medicine,   Kanagawa, JapanBackground:  Triple combination therapy involving long-acting muscarinic antagonists  long-acting β2 agonists, and inhaled corticosteroids has recently become an option for  maintenance treatment of COPD.",Non-OADS,/arxiv_data1/oa_pdf/5a/17/copd-10-1053.PMC4461139.pdf
"Current guidelines provide  recommendations concerning stepwise intensification of therapy with combined use of  long-acting bronchodilators and inhaled corticosteroids (ICS) to optimize outcomes in  patients with inadequate control on monotherapy, but do not address “stepping down”  therapy in COPD.1 It has been demonstrated that, in some patients, triple therapy,  which adds an anticholinergic to an ICS and LABA, has been associated with greater  improvements in lung function and quality of life and reduced rates of hospitalization Correspondence: hidetoshi nakamura Department of respiratory Medicine,  saitama Medical University, 38 Morohongo,  Moroyama-machi, Iruma-gun, saitama   350-0495, Japan Tel/fax +81 49 276 1319 email hnakamur@saitama-med.ac.j pJournal name: International Journal of COPD Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Miyazaki et al Running head recto: Reasons for triple therapy in COPD patients DOI: http://dx.doi.org/10.2147/COPD.S79864",Non-OADS,/arxiv_data1/oa_pdf/5a/17/copd-10-1053.PMC4461139.pdf
"Available from:  http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis- management.htm l. Accessed December 6, 2014.",Non-OADS,/arxiv_data1/oa_pdf/5a/17/copd-10-1053.PMC4461139.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/5a/17/copd-10-1053.PMC4461139.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/5a/17/copd-10-1053.PMC4461139.pdf
"http://homes.bio.psu.edu/expansins/ Deluc, L., Grimplet, J., Wheatley, M., Tillett, R., Quilici, D., Osborne, C., et al.",OADS,/arxiv_data1/oa_pdf/c5/cc/10658_2013_Article_173.PMC4461154.pdf
http://www.sus-chain.org/results/WP5/NL%20De%20Hoeve%20-%20Final%20report.pdf .,Non-OADS,/arxiv_data1/oa_pdf/22/37/10806_2010_Article_9286.PMC4461178.pdf
SUS-CHAIN case study methodology .http://www.sus-chain.org/ results/WP4/WP4%20SUS-CHAIN%20case%20study%20methodology.pdf .,Non-OADS,/arxiv_data1/oa_pdf/22/37/10806_2010_Article_9286.PMC4461178.pdf
Macro -level analysis of food supply chain dynamics and diversity in Europe —synthesis report .http://www.sus-chain.org/results/WP2/ suschain%20deliverable%2010%20(wp2%20synthesis%20report).pdf .,OADS,/arxiv_data1/oa_pdf/22/37/10806_2010_Article_9286.PMC4461178.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d6/76/hyv045.PMC4461239.pdf
Available at: http://www.info.pmda.go.jp/iyaku/file/h220729-001.,Non-OADS,/arxiv_data1/oa_pdf/d6/76/hyv045.PMC4461239.pdf
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1016/j.neuroimage.2015.02.067 1053-8119/© 2015 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
"Independent component analysis Data were further analysed using MELODIC (Multivariate Explorato- ry Linear Optimized Decomposition into Independent Components, part of FSL http://www.fmrib.ox.ac.uk/fsl/melodic/ ).",OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
"For presenta- tion purposes, statistical parametric activation maps were projected on an averaged in ﬂated surface cortex, using Connectome Work- bench ( http://www.humanconnectome.org/software/connectome- workbench.html ).",OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1523/JNEUROSCI.,OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1371/journal.pone.0106133 .,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1177/1073858409343961 .,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1098/rstb.2005.1634 .,OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
Neural Repair http://dx.doi.org/10.1177/1545968311429687 .,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1196/annals.1440.011 .,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1038/nn.3423 .,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1093/brain/awt176 .,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1093/brain/awr279 .,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1016/j.neuroimage.2006.01.018 .,OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/ 10.1016/j.neuroimage.2011.11.063 .,OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
"Nature 375, 482 –484.http://dx.doi.org/10.1038/375482a0 .",Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1038/nrn1991 .,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
EJP http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
"13, 5 –14.http://dx.doi.org/10.1038/jcbfm.1993.4 .",Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
"NeuroImage 48, 63 –72.http://dx.doi.org/10.1016/j.neuroimage.",OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
eLife 4. http://dx.doi.org/10.7554/eLife.04605 .,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
"Comparison of functional conn ectivity in default mode and sensorimotor networks at 3 and 7 T. MAGMA 23, 339 –349.http://dx.doi.or g/10.1007/s10334-010-0220-0 .",OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1523/JNEUROSCI.,OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1093/brain/awn124 .,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
"21, 55 –57.http://dx.doi.org/10.1177/0956797609354739 .",Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
eLife 2. http://dx.doi.org/10.7554/eLife.01273 .,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
"4, 1570. http://dx.doi.org/10.1038/ncomms2571 .",Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1016/j.cortex.2014.12.004 .,OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
"Science 342, 1238406. http://dx.doi.org/10.1126/science.1238406 .",Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1002/art.27497 .,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1016/ B978-0-444-53839-0.00017-X .,OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1038/nn.2886 .,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1038/nrneurol.2014.178 .,OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/ 10.1093/brain/awp135 .,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1007/ s00221-003-1588-0 .,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1002/hbm.,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1073/ pnas.1121329109 .,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
Pain http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1097/NRL.0b013e3181edf128 .,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
"4, 591. http://dx.doi.org/10.3389/fpsyg.2013.00591 .",Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1152/jn.00338.2011 .,Non-OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
http://dx.doi.org/10.1016/j.brainres.2013.12.025 .225 T.R.,OADS,/arxiv_data1/oa_pdf/5b/59/main.PMC4461307.pdf
"In contrast to the  trends observed at the lesions of the posterior wall, the Endo - Lifter appeared to prolong procedure times with a retroflex  approach (i.e., ESD with a lesser curvature): although not sta - tistically different, the submucosal dissection speed was 1.06  min/cm2 with the EndoLifter versus 0.48 min/cm2 without the Open Access Received:  April 21, 2015    Revised:  April 25, 2015 Accepted:  April 25, 2015 Correspondence:  Joo Y oung Cho Digestive Disease Center, CHA Bundang Medical Center, CHA University, 59  Y atap-ro, Bundang-gu, Seongnam 463-712, Korea Tel: +82-31-780-5005, Fax: +82-31-780-5000, E-mail:  cjy6695@dreamwiz.com cc This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution,  and reproduction in any medium, provided the original work is properly cited.Is the Endoscopic Grasp-and-Traction Device Useful for Endoscopic  Submucosal Dissection in Treating Early Gastric Cancer?",Non-OADS,/arxiv_data1/oa_pdf/a5/d8/ce-48-181.PMC4461658.pdf
"Joo Young Cho Digestive Disease Center, CHA Bundang Medical Center, CHA University, Seongnam, KoreaClin Endosc  2015 ;48:181-182COMMENTARY Print ISSN 2234-2400 / On-line ISSN 2234-2443 http://dx.doi.org/10.5946/ce.2015.48.3.181  See “The Efficacy of an Endoscopic Grasp-and-Traction Device for Gastric Endoscopic Submucosal Dissection: An Ex Vivo   Comparative Study (with Video)” by Dirk W .",Non-OADS,/arxiv_data1/oa_pdf/a5/d8/ce-48-181.PMC4461658.pdf
"The overall evidence base for small bowel VCE is im - mature and validated scales for quality of cleansing are not yet Open Access Received:  April 21, 2015    Accepted:  April 27, 2015 Correspondence:  Ki-Nam Shim Department of Internal Medicine, Ewha Womans University School of Medicine,  1071 Anyangcheon-ro, Y angcheon-gu, Seoul 158-710, Korea Tel: +82-2-2650-2632, Fax: +82-2-2655-2076, E-mail:  shimkn@ewha.ac.kr cc This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution,  and reproduction in any medium, provided the original work is properly cited.What Is the Optimal Timing of Bowel Preparation for   Video Capsule Endoscopy?",Non-OADS,/arxiv_data1/oa_pdf/fa/59/ce-48-183.PMC4461659.pdf
"Hyun Joo Song1 and Ki-Nam Shim2 1Department of Internal Medicine, Jeju National University School of Medicine, Jeju, 2Department of Internal Medicine, Ewha Womans University  School of Medicine, Seoul, KoreaClin Endosc  2015 ;48:183-184COMMENTARY Print ISSN 2234-2400 / On-line ISSN 2234-2443 http://dx.doi.org/10.5946/ce.2015.48.3.183  See “ A Single-Center Randomized Controlled Trial Evaluating Timing of Preparation for Capsule Enteroscopy” by Kather - ine R. Black, Wiley Truss, Cynthia I. Joiner, Shajan Peter and Frederick H. Weber Jr, on page 234-238.",Non-OADS,/arxiv_data1/oa_pdf/fa/59/ce-48-183.PMC4461659.pdf
"http://dx.doi.Open Access Received:  April 27, 2015    Accepted:  May 7, 2015 Correspondence:  Jin-Hyeok Hwang Department of Internal Medicine, Seoul National University Bundang Hospital,  Seoul National University College of Medicine, 82 Gumi-ro 173beon-gil, Bun - dang-gu, Seongnam 463-707, Korea Tel: +82-31-787-7009, Fax: +82-31-787-4051, E-mail:  woltoong@snu.ac.kr cc This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution,  and reproduction in any medium, provided the original work is properly cited.How to Improve Diagnostic Accuracy in Suspicious Ampullary   Lesions?",Non-OADS,/arxiv_data1/oa_pdf/6f/ec/ce-48-185.PMC4461660.pdf
"Woo Hyun Paik1 and Jin-Hyeok Hwang2 1Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, 2Department of Internal Medicine,  Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, KoreaClin Endosc  2015 ;48:185-186COMMENTARY Print ISSN 2234-2400 / On-line ISSN 2234-2443 http://dx.doi.org/10.5946/ce.2015.48.3.185  See “Diagnostic Accuracy of the Initial Endoscopy for Ampullary Tumors” by Hee Seung Lee, Jong Soon Jang, Seungho  Lee, et al., on page 239-246.",Non-OADS,/arxiv_data1/oa_pdf/6f/ec/ce-48-185.PMC4461660.pdf
"Key Words :  Upper gastrointestinal tract; Stents; Obstruction; Malignant; BenignOpen Access Received:  April 19, 2015    Accepted:  April 22, 2015 Correspondence:  Sang Gyun Kim Department of Internal Medicine and Liver Research Institute, Seoul National  University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 110-744, Korea Tel: +82-2-740-8112, Fax: +82-2-743-6701, E-mail:  harley@snu.ac.kr cc This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution,  and reproduction in any medium, provided the original work is properly cited.Print ISSN 2234-2400 / On-line ISSN 2234-2443 http://dx.doi.org/10.5946/ce.2015.48.3.187FOCUSED REVIEW SERIES:  Updates on Gastrointestinal and Pancreaticobiliary Stents",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/ce-48-187.PMC4461661.pdf
"Key Words : Colon; Stents; Colorectal neoplasms; ObstructionOpen Access Received:  April 3, 2015    Accepted:  April 7, 2015 Correspondence:  Jeong-Sik Byeon Department of Gastroenterology, Asan Medical Center, University of Ulsan  College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Korea Tel: +82-2-3010-3905, Fax: +82-2-476-0824, E-mail:  jsbyeon@amc.seoul.kr cc This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution,  and reproduction in any medium, provided the original work is properly cited.Print ISSN 2234-2400 / On-line ISSN 2234-2443 http://dx.doi.org/10.5946/ce.2015.48.3.194FOCUSED REVIEW SERIES:  Updates on Gastrointestinal and Pancreaticobiliary Stents",Non-OADS,/arxiv_data1/oa_pdf/87/0e/ce-48-194.PMC4461662.pdf
"Key Words : Hilar cholangiocarcinoma; Cholangiocarcinoma; Klatskin’s tumor; Palliation; Biliary stentingOpen Access Received:  April 10, 2015    Revised:  May 11, 2015 Accepted:  May 11, 2015 Correspondence:  Dong Ki Lee Department of Internal Medicine, Gangnam Severance Hospital, Y onsei Uni - versity College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul 135-720, Korea  Tel: +82-2-2019-3214, Fax: +82-2-3463-3882, E-mail:  dklee@yuhs.ac cc This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution,  and reproduction in any medium, provided the original work is properly cited.Print ISSN 2234-2400 / On-line ISSN 2234-2443 http://dx.doi.org/10.5946/ce.2015.48.3.201FOCUSED REVIEW SERIES:  Updates on Gastrointestinal and Pancreaticobiliary Stents",Non-OADS,/arxiv_data1/oa_pdf/65/52/ce-48-201.PMC4461663.pdf
"Key Words :  Stents; Drug-eluting stents; Endoscopy, gastrointestinalOpen Access Received:  April 27, 2015    Accepted:  May 6, 2015 Correspondence:  Don Haeng Lee Digestive Disease Center, Department of Internal Medicine, Inha University  School of Medicine, 27 Inhang-ro, Jung-gu, Incheon 400-711, Korea Tel: +82-32-890-2548, Fax: +82-32-890-2549, E-mail:  ldh@inha.ac.kr cc This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution,  and reproduction in any medium, provided the original work is properly cited.Print ISSN 2234-2400 / On-line ISSN 2234-2443 http://dx.doi.org/10.5946/ce.2015.48.3.209FOCUSED REVIEW SERIES:  Updates on Gastrointestinal and Pancreaticobiliary Stents",Non-OADS,/arxiv_data1/oa_pdf/df/c4/ce-48-209.PMC4461664.pdf
"Adapted from http://www.stent.net, with permission from Tae - woong.24",Non-OADS,/arxiv_data1/oa_pdf/df/c4/ce-48-209.PMC4461664.pdf
"Adapted from http://www.stent.net, with permis - sion from Taewoong.24",Non-OADS,/arxiv_data1/oa_pdf/df/c4/ce-48-209.PMC4461664.pdf
"Adapted from http://www.stent.net,  with permission from Taewoong.24",Non-OADS,/arxiv_data1/oa_pdf/df/c4/ce-48-209.PMC4461664.pdf
"cc This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution,  and reproduction in any medium, provided the original work is properly cited.Print ISSN 2234-2400 / On-line ISSN 2234-2443 http://dx.doi.org/10.5946/ce.2015.48.3.216",Non-OADS,/arxiv_data1/oa_pdf/ce/b6/ce-48-216.PMC4461665.pdf
"Schölvinck Department of Gastroenterology and Hepatology, St. Antonius Hospital, Koe- koekslaan 1, 3435 CM, Nieuwegein, The Netherlands Tel: +31-20-566-4571, Fax: +31-20-691-7033 E-mail:  d.scholvink@antoniusziekenhuis.nl cc This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution,  and reproduction in any medium, provided the original work is properly cited.Print ISSN 2234-2400 / On-line ISSN 2234-2443 http://dx.doi.org/10.5946/ce.2015.48.3.221 INTRODUCTION Early cancer in the gastrointestinal tract can be effectively  removed by endoscopic resection.",Non-OADS,/arxiv_data1/oa_pdf/63/87/ce-48-221.PMC4461666.pdf
Supplementary  Video 1 (available online at http://www.e-ce.org/) demon - strates the EndoLifter.,Non-OADS,/arxiv_data1/oa_pdf/63/87/ce-48-221.PMC4461666.pdf
"Key Words :  Dieulafoy; Gastrointestinal bleeding; Endoscopic treatment; Antiplatelet agents; AlcoholsOpen Access Received:  July 14, 2014    Revised:  October 13, 2014 Accepted:  October 19, 2014 Correspondence:  Sun Hyung Kang Department of Gastroenterology, Chungnam National University Hospital,  Chungnam National University School of Medicine, 282 Munhwa-ro, Jung- gu, Daejeon 301-721, Korea Tel: +82-42-280-7207, Fax: +82-42-257-5753, E-mail:  porrtos@cnuh.co.kr cc This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution,  and reproduction in any medium, provided the original work is properly cited.Print ISSN 2234-2400 / On-line ISSN 2234-2443 http://dx.doi.org/10.5946/ce.2015.48.3.228",Non-OADS,/arxiv_data1/oa_pdf/0c/c2/ce-48-228.PMC4461667.pdf
"Key Words : Capsule enteroscopy; Bowel preparationOpen Access Received:  March 2, 2014    Revised:  June 29, 2014 Accepted:  September 22, 2014 Correspondence:  Frederick H. Weber Jr  Division of Gastroenterology and Hepatology, University of Alabama at Bir - mingham, The Kirklin Clinic, 1st Floor, Digestive Disease Center, 2000 6th Av - enue South, Birmingham, AL 35233, USA Tel: +1-205-801-8681, Fax: +1-205-801-7912, E-mail:  fweber@uab.edu cc This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution,  and reproduction in any medium, provided the original work is properly cited.Print ISSN 2234-2400 / On-line ISSN 2234-2443 http://dx.doi.org/10.5946/ce.2015.48.3.234ORIGINAL ARTICLE See commentary on page 183-184",Non-OADS,/arxiv_data1/oa_pdf/71/15/ce-48-234.PMC4461668.pdf
"Key Words :  Papillary tumors; Endoscopic examination; Diagnostic accuracyOpen Access Received:  June 16, 2014    Revised:  August 4, 2014 Accepted:  August 5, 2014 Correspondence:  Seon Mee Park Department of Internal Medicine, Chungbuk National University College of  Medicine, 776 il sunhwan-ro, Heungdeok-gu, Cheongju 361-711, Korea Tel: +82-43-269-6019, Fax: +82-43-273-3252 E-mail:  smpark@chungbuk.ac.kr cc This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution,  and reproduction in any medium, provided the original work is properly cited.Print ISSN 2234-2400 / On-line ISSN 2234-2443 http://dx.doi.org/10.5946/ce.2015.48.3.239 INTRODUCTION The number of cases diagnosed with ampullary tumors  have recently increased because of the widespread use of rou - tine endoscopy for health surveillance.",Non-OADS,/arxiv_data1/oa_pdf/ef/d9/ce-48-239.PMC4461669.pdf
"Key Words : Early gastric cancer; Mixed histology; Endoscopic submucosal dissectionOpen Access Received:  June 3, 2014    Revised:  July 18, 2014 Accepted:  September 7, 2014 Correspondence:  Jong Kyu Park  Department of Internal Medicine, Gangneung Asan Hospital, University of Ul - san College of Medicine, 38 Bangdong-gil, Gangneung 210-711, Korea  Tel: +82-33-610-3949, Fax: +82-33-641-8130, E-mail:  sajahoooo@naver.com cc This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution,  and reproduction in any medium, provided the original work is properly cited.Print ISSN 2234-2400 / On-line ISSN 2234-2443 http://dx.doi.org/10.5946/ce.2015.48.3.247CASE REPORT",Non-OADS,/arxiv_data1/oa_pdf/7d/05/ce-48-247.PMC4461670.pdf
"Key Words :  Coagulation; Endoscopy; Perforation; Stomach neoplasms; SurgeryOpen Access Received:  May 21, 2014    Revised:  July 10, 2014 Accepted:  August 11, 2014 Correspondence:  Byung-Hoon Min Department of Medicine, Samsung Medical Center, Sungkyunkwan University  School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea Tel: +82-2-3410-3409, Fax: +82-2-3410-6983, E-mail:  bhmin@skku.edu cc This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution,  and reproduction in any medium, provided the original work is properly cited.Print ISSN 2234-2400 / On-line ISSN 2234-2443 http://dx.doi.org/10.5946/ce.2015.48.3.251",Non-OADS,/arxiv_data1/oa_pdf/78/03/ce-48-251.PMC4461671.pdf
"Key Words : Glomerulonephritis, membranous; Stomach; Syphilis Open Access Received:  March 4, 2014    Revised:  May 2, 2014 Accepted:  June 16, 2014 Correspondence:  Joo Hyun Sohn  Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang  University College of Medicine, 153 Gyeongchun-ro, Guri 471-701, Korea  Tel: +82-31-560-2177, Fax: +82-31-560-2598, E-mail:  sonjh@hanyang.ac.kr cc This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution,  and reproduction in any medium, provided the original work is properly cited.Print ISSN 2234-2400 / On-line ISSN 2234-2443 http://dx.doi.org/10.5946/ce.2015.48.3.256CASE REPORT",Non-OADS,/arxiv_data1/oa_pdf/d6/6c/ce-48-256.PMC4461672.pdf
"Key Words :  Ectopic opening; Common bile duct; Duodenal bulb; Acute cholangitis; Gallbladder neoplasmsOpen Access Received:  April 1, 2014    Revised:  May 19, 2014 Accepted:  May 20, 2014 Correspondence:  Hong Jun Kim Department of Internal Medicine, Gyeongsang National University Hospital,  Gyeongsang National University School of Medicine, 79 Gangnam-ro, Jinju  660-702, Korea Tel: +82-55-750-8726, Fax: +82-55-755-9078, E-mail:  khj9454@hanmail.net cc This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution,  and reproduction in any medium, provided the original work is properly cited.Print ISSN 2234-2400 / On-line ISSN 2234-2443 http://dx.doi.org/10.5946/ce.2015.48.3.260 INTRODUCTION The major papilla of Vater is typically located in the pos - teromedial wall of the second portion of the duodenum, and  is the main exit for the bile and pancreatic juices that flow  down the common bile duct (CBD) and the main pancreatic  duct (MPD).",Non-OADS,/arxiv_data1/oa_pdf/57/0c/ce-48-260.PMC4461673.pdf
"Key Words :  Biliary fistula; Cholangitis; Duodenal ulcerOpen Access Received:  April 11, 2014    Revised:  July 23, 2014 Accepted:  February 12, 2015 Correspondence:  Byung-Wook Kim Division of Gastroenterology, Department of Internal Medicine, Incheon St.  Mary’s Hospital, College of Medicine, The Catholic University of Korea, 56  Dongsu-ro, Bupyeong-gu, Incheon 403-720, Korea Tel: +82-32-280-5052, Fax: +82-32-280-5987, E-mail:  gastro@catholic.ac.kr cc This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution,  and reproduction in any medium, provided the original work is properly cited.Print ISSN 2234-2400 / On-line ISSN 2234-2443 http://dx.doi.org/10.5946/ce.2015.48.3.265",Non-OADS,/arxiv_data1/oa_pdf/03/e7/ce-48-265.PMC4461674.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution- NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permitting all non-commercial use, distributio n, and reproduction in any medium, provided the original work is properly cited.1 Citation: Libyan J Med 2015, 10: 28351 - http://dx.doi.org/10.3402/ljm.v10.28351 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/70/47/LJM-10-28351.PMC4461757.pdf
"2 (page number not for citation purpose)Citation: Libyan J Med 2015, 10: 28351 - http://dx.doi.org/10.3402/ljm.v10.28351",Non-OADS,/arxiv_data1/oa_pdf/70/47/LJM-10-28351.PMC4461757.pdf
"(1) Collected data VJT height 40-m sprint time4/C2910-m run time sum 6/C2940-m run time 6/C2940-m performance decrement (%) 3,000-m run timeBody massSkinfold measurement, caloric intake (kcal/day)% of carbohydratesFats and proteinsIntense physical activity (h/week) Sleep habits (week BR, last week of Ramadan) (h/day) Total sleeping hoursEnergy intake in a regular month and during RamadanBest time in a single sprint Cumulated sprint timesSprint decrement score Body composition (body fat%, lean mass, fat mass)Objective daily activityEstimated energy expenditureCaloric intake% of proteinsFat and carbohydratesSquat jump CMJ heightsEstimated V ˙O 2max Perceived exertion Food intakes over a span of 3 daysfor each week of physical testing6MWD VJT heightHJT distance 20-m sprint time 30-m sprint timeMBT distance Test instructions Standard warm-up procedure 15/C120 min period separated the different tests on each day Each run started from a standing positionComplete all sprints as fast as possiblePlayers familiarized with the VJT and the multistage 20-m shuttle run testActive warm-up after 30-min rest in aseated positionSubjects familiarized with all the study tests Test encouragementNR Strong verbal encouragement during all sprintsNR Verbally encouragement during short-term exercises and during the 6MWT (5) Physical performanceresultsNon-significant change in body mass Significant increase in the sum of skinfoldsReduced aerobic endurance (increased 3,000-mrunning time)Reduced speed endurance (increased sum of 6 /C2940-m run time and performance decrement) Reduced CMJ performance Non-significant effect on the 40-m sprint time or agilityperformanceReduced intense physical activityNon-significant changes in sleeping hours or total caloricintake (including the relative consumption of carbohydrates,fats and proteins)Compared to BR, cumulated sprint times lengthened duringRamadan (R1; R4) andremained elevated AR (AR2and AR4)Initial best sprint performance and sprint decrement score did not changeBody mass (but not body fat,lean mass and fat mass) waselevated at R4 and AR2compared with BR, whereasenergy expenditure remainedconstantJumping heights during the squat jump and the CMJ tests and estimatedV˙O 2max were lower during Ramadan than BR in the afternoon, and theirdiurnal variations observed BR were notapparent during the fasting period6MWD (mean or % predicted) was lowerduring R2 and R4compared with BR.6MWD (% predicted) wassignificantly lower during R2 and during R4 compared with ARBody mass was lowerduring R2 and R4compared with ARNon-significant effect onVJT height, HJT distance,20- and 30-m sprint time and MBT distanceLetter to the editor Citation: Libyan J Med 2015, 10: 28351 - http://dx.doi.org/10.3402/ljm.v10.28351 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/70/47/LJM-10-28351.PMC4461757.pdf
"4 (page number not for citation purpose)Citation: Libyan J Med 2015, 10: 28351 - http://dx.doi.org/10.3402/ljm.v10.28351",Non-OADS,/arxiv_data1/oa_pdf/70/47/LJM-10-28351.PMC4461757.pdf
"Mohamed Amine Fenneni* Research Unit ‘Exercise Physiology and Pathophysiology/C1from the Integrated to the Molecular Biology, Medicine and Health’ UR12ES06 Faculty of Medicine of Sousse University of Sousse Sousse, Tunisia Laboratory of PhysiologyLetter to the editor Citation: Libyan J Med 2015, 10: 28351 - http://dx.doi.org/10.3402/ljm.v10.28351 5 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/70/47/LJM-10-28351.PMC4461757.pdf
"2014; 9: 25391, doi: http://dx.doi.org/10.3402/ljm.v9.25391 2.",Non-OADS,/arxiv_data1/oa_pdf/70/47/LJM-10-28351.PMC4461757.pdf
"6 (page number not for citation purpose)Citation: Libyan J Med 2015, 10: 28351 - http://dx.doi.org/10.3402/ljm.v10.28351",Non-OADS,/arxiv_data1/oa_pdf/70/47/LJM-10-28351.PMC4461757.pdf
OMICSGroup eBooks; 2013. p. 2 /C18 [downloaded 2015 May 15].Available from: http://www.esciencecentral.org/ebooks/effectsof- ramadan-fasting/ramadan-fasting-sport-performance.php [cited 25 July 2013].,Non-OADS,/arxiv_data1/oa_pdf/70/47/LJM-10-28351.PMC4461757.pdf
"2015; 10: 26229, doi: http://dx.doi.org/10.3402/ljm.v10.26229 24.",Non-OADS,/arxiv_data1/oa_pdf/70/47/LJM-10-28351.PMC4461757.pdf
"Available from: http://link.springer.com/article/10.1186%2Fs40798-015-0012-1#page-1[cited 30 May 2015].Letter to the editor Citation: Libyan J Med 2015, 10: 28351 - http://dx.doi.org/10.3402/ljm.v10.28351 7 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/70/47/LJM-10-28351.PMC4461757.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which per- mits any noncommercial use, distribution, and reproduction in anymedium, provided you give appropriate credit to the original author(s)and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/cd/b6/40292_2015_Article_87.PMC4461797.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/9c/b0/main.PMC4461857.pdf
"7 The putative mechanisms underlying the bene ﬁcial effects of levosimendan may be related to its vasodilatory and antiischemic properties,1,8improved endothelial function,9and antiaggregatory effect on platelets.10Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/cuthreCurrent Therapeutic Research http://dx.doi.org/10.1016/j.curtheres.2015.01.001 0011-393X/ &2015.",Non-OADS,/arxiv_data1/oa_pdf/9c/b0/main.PMC4461857.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/9c/b0/main.PMC4461857.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/74/86/main.PMC4461879.pdf
12Studies have indicated that higher plasma concentrations of MMP9 may be aContents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/cuthreCurrent Therapeutic Research http://dx.doi.org/10.1016/j.curtheres.2014.05.001 0011-393X/ &2014.,Non-OADS,/arxiv_data1/oa_pdf/74/86/main.PMC4461879.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/74/86/main.PMC4461879.pdf
Available from: http://www.rcsb.org/pdb/home/home.do.,Non-OADS,/arxiv_data1/oa_pdf/22/09/PM-11-123.PMC4461951.pdf
Available from: http://www.cvpharmacology.com.,Non-OADS,/arxiv_data1/oa_pdf/22/09/PM-11-123.PMC4461951.pdf
Available from: http://www.who.int/cancer/detection/ breastcancer/en/index1.html.,Non-OADS,/arxiv_data1/oa_pdf/69/06/PM-11-148.PMC4461954.pdf
Available from: http://www.globocan.iarc.fr.,Non-OADS,/arxiv_data1/oa_pdf/90/64/PM-11-156.PMC4461955.pdf
"Available from: http://www.bdpa.cnptia.embrapa.br/busca?b=ad &id=15175&biblioteca=vazio&busca=autoria:%22LORENZI,%20 H.%22&qFacets=autoria:%22LORENZI,%20H.%22&sort=&pagi nacao=t&paginaAtual=1.",Non-OADS,/arxiv_data1/oa_pdf/90/7a/PM-11-161.PMC4461956.pdf
Available  from: http://www.worldcat.org/title/dicionario-das-plantas-uteis-do- brasil-e-das-exoticas-cultivadas/oclc/21880710&referer=brief_ results.,Non-OADS,/arxiv_data1/oa_pdf/90/7a/PM-11-161.PMC4461956.pdf
Available from: http://www.teses.,Non-OADS,/arxiv_data1/oa_pdf/90/7a/PM-11-161.PMC4461956.pdf
Available  from: http://www.teses.,Non-OADS,/arxiv_data1/oa_pdf/90/7a/PM-11-161.PMC4461956.pdf
Available from:  http://www.eolss.net.,Non-OADS,/arxiv_data1/oa_pdf/78/52/PM-11-190.PMC4461961.pdf
Available from: http://www.idf.org/diabetes atlas.,Non-OADS,/arxiv_data1/oa_pdf/15/e0/PM-11-53.PMC4461968.pdf
Available from:  http://www.plantdatabase.co.uk/Bergenia_cordifolia.,Non-OADS,/arxiv_data1/oa_pdf/9c/45/PM-11-60.PMC4461970.pdf
Available from: http://www.en.wikipedia.,Non-OADS,/arxiv_data1/oa_pdf/44/aa/PM-11-73.PMC4461972.pdf
http://www.uomustansiriyah.edu.iq/008/phar/ readpdf.php?id=5.,Non-OADS,/arxiv_data1/oa_pdf/44/aa/PM-11-73.PMC4461972.pdf
"To view a copy of this  license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/",Non-OADS,/arxiv_data1/oa_pdf/0c/d5/mtna201445a.PMC4461991.pdf
"DOI: http://dx.doi.org/ 10.1210/edrv-8-1-1 [7] Zhao, J.; Bauman, W.A.",OADS,/arxiv_data1/oa_pdf/43/71/CN-13-101.PMC4462035.pdf
"DOI: http://dx.doi.org/10.1093/eurpub/11.2.195 [29] Rachoń, D.; Pokrywka, L.; Suchecka-Rachoń, K. Prevalence and risk factors of anabolic-androgenic steroids (AAS) abuse among adolescents and young adults in Poland.",Non-OADS,/arxiv_data1/oa_pdf/43/71/CN-13-101.PMC4462035.pdf
"J. Psychiatry, 1996, 153, 9 7 4-984. http://dx.doi.org/10.1176/ajp.",Non-OADS,/arxiv_data1/oa_pdf/43/71/CN-13-101.PMC4462035.pdf
"J. Psychiatry, 1988, 145, 487-490. http://dx.doi.org/10.1176/ajp.145.4.487 [54] Pope, H.G.",Non-OADS,/arxiv_data1/oa_pdf/43/71/CN-13-101.PMC4462035.pdf
"J. Psychiatry, 1989, 146,  1075. http://dx.doi.org/10.1176/ajp.146.8.1075a [64] Brower, K.J.",Non-OADS,/arxiv_data1/oa_pdf/43/71/CN-13-101.PMC4462035.pdf
"J. Psychiatry, 1990, 147, 510-512. http://dx.doi.org/10.1176/ajp.147.4.510 [65] Lindström, M.; Nilsson, A.L.",OADS,/arxiv_data1/oa_pdf/43/71/CN-13-101.PMC4462035.pdf
"DOI: http://dx.doi.org/10.1017/S1461145706007243 [68] Matrisciano, F.; Modafferi, A.M.; Togna, G.I.",OADS,/arxiv_data1/oa_pdf/43/71/CN-13-101.PMC4462035.pdf
"Psychiatry, 1999, 11, 223-231. http://dx.doi.org/ 10.1176/ajp.146.8.1075a [75] Thiblin, I.; Lindquist, O.; Rajs, J.",Non-OADS,/arxiv_data1/oa_pdf/43/71/CN-13-101.PMC4462035.pdf
"J. Psychiatry, 2005, 162, 380-382. http://dx.doi.org/10.1176/appi.ajp.",Non-OADS,/arxiv_data1/oa_pdf/43/71/CN-13-101.PMC4462035.pdf
"J. Psychiatry, 1989, 146, 679. http://dx.doi.org/10.1176/ajp.146.5.679b [113] Archer, J. Testosterone and human aggression: an evaluation of the challenge hypothesis.",Non-OADS,/arxiv_data1/oa_pdf/43/71/CN-13-101.PMC4462035.pdf
"J. Psychiatry, 1995, 152, 1 6 7 2-1674. http://dx.doi.org/ 10.1176/ajp.152.11.1672 [136] Noll, S.M.",Non-OADS,/arxiv_data1/oa_pdf/43/71/CN-13-101.PMC4462035.pdf
"http://www.deadiversion.usdoj.gov/nflis/2012midyear.pdf [Accessed on: 4th October, 2014].",Non-OADS,/arxiv_data1/oa_pdf/79/38/CN-13-12.PMC4462036.pdf
"http://www.aapcc.org/alerts/bath-salts/ [Accessed on: 4th O c t o b e r ,  2014].",Non-OADS,/arxiv_data1/oa_pdf/79/38/CN-13-12.PMC4462036.pdf
"Arrêté du 27 juillet 2012 modifiant les arrêtés du 22 février 1990 fixant la liste des substances classées comme stupéfiants et la liste des substances psychotropes.http://www.legifrance.gouv.fr/affichTexte.do?cid Texte=JORFTEXT000026246525&dateTexte=&categorieLien=id [Accessed on: 4th October, 2014].",Non-OADS,/arxiv_data1/oa_pdf/79/38/CN-13-12.PMC4462036.pdf
"98-100. http://www.vice.com/en_ca/read/ hamilton-s-pharmacopeia-455-v17n6 [Accessed on: 4th O c t o b e r ,  2014].",Non-OADS,/arxiv_data1/oa_pdf/79/38/CN-13-12.PMC4462036.pdf
"http://www.emcdda.europa.eu/publications/ drugnet/online/2010/69/article3 [Accessed on: 4th October, 2014].",Non-OADS,/arxiv_data1/oa_pdf/79/38/CN-13-12.PMC4462036.pdf
"http://www.emcdda.europa.eu/publications/annual-report/ 2012 [Accessed on: 4th October, 2014].",Non-OADS,/arxiv_data1/oa_pdf/79/38/CN-13-12.PMC4462036.pdf
"http://www.erowid.org/chemicals/methylone/methylone_ info1.shtml [Accessed on: 4th October, 2014].",Non-OADS,/arxiv_data1/oa_pdf/79/38/CN-13-12.PMC4462036.pdf
"http://www.samhsa.gov/data/spotlight/spot117-bath-salts-2013.pdf [Accessed on: 4th October, 2014].",OADS,/arxiv_data1/oa_pdf/79/38/CN-13-12.PMC4462036.pdf
DOI: http://dx.doi.org/10.1093/qjmed/hcq134 [32] EMCDDA–Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA.,Non-OADS,/arxiv_data1/oa_pdf/79/38/CN-13-12.PMC4462036.pdf
"http://www.emcdda.europa.eu/ publications/implementation-reports/2012 [Accessed on: 4th October, 2014].",Non-OADS,/arxiv_data1/oa_pdf/79/38/CN-13-12.PMC4462036.pdf
"http://www.emcdda.europa.eu/topics/pods/synthetic-cathinones-injection [Accessed on: 4th October, 2014].",Non-OADS,/arxiv_data1/oa_pdf/79/38/CN-13-12.PMC4462036.pdf
"http://www.sigmaresearch.org.uk/chemsex [Accessed on: 4th October, 2014].",Non-OADS,/arxiv_data1/oa_pdf/79/38/CN-13-12.PMC4462036.pdf
"DOI: http://dx.doi.org/10.1093/qjmed/hcs107 [37] Prosser, J.M.",OADS,/arxiv_data1/oa_pdf/79/38/CN-13-12.PMC4462036.pdf
"http://crew2000.org.uk [Accessed on: 4th October, 2014].",Non-OADS,/arxiv_data1/oa_pdf/79/38/CN-13-12.PMC4462036.pdf
"http://www.aides.org/ download.php?filepath=/sites/default/files/doc/Rapport_SLAM.pdf [Accessed on: 4th October, 2014].",Non-OADS,/arxiv_data1/oa_pdf/79/38/CN-13-12.PMC4462036.pdf
"Metab., 1986, 15 ( 2 ) ,  2 5 9-78. http://dx.doi.org/ 10.1016/s0300-595x(86)80024- [2] Basaria, S.; Wahlstrom, J. T.; Dobs, A. S. Clinical review 138: Anabolic-androgenic steroid therapy in the treatment of chronic diseases.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Metab., 2001, 86 ( 1 1 ) ,  5108-17. http://dx.doi.org/10.1210/jcem.86.11.7983 [3] Riezzo, I.; Turillazzi, E.; Bello, S.; Cantatore, S.; Cerretani, D.; Di Paolo, M.; Fiaschi, A.I.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Pharmacol., 2014, 280 (1), 97-106. http://dx.doi.org/10.1016/ j.taap.2014.06.031 [4] Bahrke, M. S.; Yesalis, C. E., 3rd; Wright, J. E. Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"An update Sports Med., 1996, 22 (6), 367-90. http://dx.doi.org/10.2165/00007256-199622060-00005   Fig.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"NEJM, 1993, 328 (13), 922-6. http://dx.doi.org/ 10.1056/nejm199304013281304 [7] Kopera, H. The history of anabolic steroids and a review of clinical experience with anabolic steroids.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Endocrinol., 2001, 1 7 0 ( 1 ) ,  4 9-54. http://dx.doi.org/ 10.1677/joe.0.1700049 [10] Shahidi, N. T. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Ther., 2001, 2 3 ( 9 ) ,  1 3 5 5-90. http://dx.doi.org/10.1016/s0149-2918(01) 80114-4 [11] Ryan, K. J.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Psychiatry, 1996, 20 (5), 839-56.  http://dx.doi.org/10.1016/0278-5846(96)00063-2  [14] Breuer, M. E.; McGinnis, M. Y.; Lumia, A. R.; Possidente, B. P. Aggression in Male Rats Receiving Anabolic Androgenic Steroids: Effects of Social and Environmental Provocation.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Behav., 2001, 40 (3), 409-418. http://dx.doi.org/10.1006/hbeh.2001.1706  [15] McGinnis, M. Y.; Lumia, A. R.; Breuer, M. E.; Possidente, B.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Behav., 2002, 41 (1), 101-110. http://dx.doi.org/10.1006/hbeh.2001.1742 [16] McGinnis, M. Y.; Lumia, A. R.; Possidente, B. P. Effects of withdrawal from anabolic androgenic steroids on aggression i n  adult male rats.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Neurosci., 2003, 117 (5), 904-11. http://dx.doi.org/10.1037/0735-7044.117.5.904  [18] Wesson, D. W.; McGinnis, M. Y. Stacking anabolic androgenic steroids (AAS) during puberty in rats: a neuroendocrine and behavioral assessment.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Behav., 2006, 83 (3), 410-9. http://dx.doi.org/10.1016/j.pbb.2006.03.001  [19] Albert, D. J.; Walsh, M. L.; Jonik, R. H. Aggression in humans: what is its biological foundation?",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Rev., 1993, 17 (4), 405-25. http://dx.doi.org/10.1016/s0149-7634(05)80117-4  [20] McGinnis, M. Y. Anabolic androgenic steroids and aggression: studies using animal models.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Sci., 2004, 1036, 399-415.  http://dx.doi.org/10.1196/annals.1330.024  [21] Farrell, S. F.; McGinnis, M. Y.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Behav., 2004, 46 (2), 193-203.  http://dx.doi.org/10.1016/j.yhbeh.2004.03.012  [22] Lindqvist, A. S.; Johansson-Steensland, P.; Nyberg, F.; Fahlke, C. Anabolic androgenic steroid affects competitive behaviour, behavioural response to ethanol and brain serotonin levels.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Brain Res., 2002, 133 ( 1 ) ,  2 1-9. http://dx.doi.org/10.1016/s0166-4328(01)00408-9 [23] Melloni, R. H., Jr.; Ferris, C. F. Adolescent anabolic steroid  use and aggressive behavior in golden hamsters.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Sci., 1996, 794, 372-5. http://dx.doi.org/10.1111/j.1749-6632.1996.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Behav., 1997, 6 1 ( 3 ) ,  3 5 9-64. http://dx.doi.org/10.1016/s0031-9384(96)00373-3 [25] Clark, A. S.; Henderson, L. P. Behavioral and physiological responses to anabolic-androgenic steroids.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Rev., 2003, 2 7 ( 5 ) ,  4 1 3-36.  http://dx.doi.org/10.1016/s0149-7634(03)00064-2  [26] DeLeon, K. R.; Grimes, J. M.; Melloni, R. H., Jr.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Behav., 2002, 42 ( 2 ) ,  1 8 2-91. http://dx.doi.org/10.1006/hbeh.2002.1802  [27] Grimes, J. M.; Melloni, R. H., Jr. Serotonin modulates offensive attack in adolescent anabolic steroid-treated hamsters.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Behav., 2002, 73 ( 3 ) ,  7 1 3-21. http://dx.doi.org/10.1016/ s0091-3057(02)00880-8 [28] Harrison, R. J.; Connor, D. F.; Nowak, C.; Nash, K.; Melloni, R. H., Jr.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Psychoneuroendocrinology, 2000, 25 (4), 317-38. http://dx.doi.org/10.1016/s0306-4530(99)00057-8 [29] Grimes, J. M.; Ricci, L. A.; Melloni, R. H., Jr. Plasticity in anterior hypothalamic vasopressin correlates with aggression during anabolic-androgenic steroid withdrawal in h a m s t e r s .",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Neurosci., 2006, 120 ( 1 ) ,  1 1 5-24.  http://dx.doi.org/10.1037/0735-7044.120.1.115  [30] Rossbach, U. L.; Steensland, P.; Nyberg, F.; Le Greves, P. Nandrolone-induced hippocampal phosphorylation of NMDA receptor subunits and ERKs.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Commun., 2007, 3 5 7 ( 4 ) ,  1 0 2 8-33. http://dx.doi.org/10.1016/j.bbrc.2007.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Brain Res., 1992, 581 ( 1 ) ,  1 2 3-32. http://dx.doi.org/10.1016/0006-8993(92)90351-9  [32] Le Greves, P.; Huang, W.; Johansson, P.; Thornwall, M.; Zhou, Q.; Nyberg, F. Effects of an anabolic-androgenic steroid o n  t h e  regulation of the NMDA receptor NR1, NR2A and NR2B subunit mRNAs in brain regions of the male rat.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Lett., 1997, 226 (1), 61-4. http://dx.doi.org/10.1016/s0304-3940(97)00244-9 [33] Tamaki, T.; Shiraishi, T.; Takeda, H.; Matsumiya, T.; Roy, R. R.; Edgerton, V. R. Nandrolone decanoate enhances hypothalamic biogenic amines in rats.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Sports Exerc., 2003, 35 (1), 32-8. http://dx.doi.org/10.1097/00005768-200301000-00006 [34] Hallberg, M.; Johansson, P.; Kindlundh, A. M.; Nyberg, F. Anabolic-androgenic steroids affect the content of substance P and substance P(1-7) in the rat brain.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Peptides, 2000, 21 ( 6 ) ,  8 4 5-52. http://dx.doi.org/10.1016/s0196-9781(00)00218-7 [35] Pernow, B.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"New Biol., 1971, 232 (29), 86-7. http://dx.doi.org/ 10.1038/newbio232086a0 [37] Kindlundh, A. M.; Lindblom, J.; Bergstrom, L.; Wikberg, J. E.; Nyberg, F. The anabolic-androgenic steroid nandrolone decanoate affects the density of dopamine receptors in the male rat brain.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Neurosci., 2001, 13 (2), 291-6. http://dx.doi.org/10.1046/j.0953-816x.2000.01402.x [38] Carrillo, M.; Ricci, L. A.; Melloni, R. H., Jr. Adolescent anabolic androgenic steroids reorganize the glutamatergic neural circuitry in the hypothalamus.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Brain Res., 2009, 1249, 118-27. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Brain Res., 2007, 1 8 0 ( 1 ) ,  7 7-85. http://dx.doi.org/10.1016/j.bbr.2007.02.025 [40] Eisenberg, E.; Gordan, G. S. The levator ani muscle of the rat as an index of myotrophic activity of steroidal hormones.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Brain Res., 1998, 792 ( 2 ) ,  2 7 1-6. http://dx.doi.org/10.1016/ s0006-8993(98)00148-6 [42] Orlando, R.; Caruso, A.; Molinaro, G.; Motolese, M.; Matrisciano, F.; Togna, G.; Melchiorri, D.; Nicoletti, F.; Bruno, V. Nanomolar",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Brain Res., 2007, 1165, 21-9. http://dx.doi.org/10.1016/j.brainres.2007.06.047 [43] Minkin, D. M.; Meyer, M. E.; van Haaren, F. Behavioral effects of long-term administration of an anabolic steroid in intact and castrated male Wistar rats.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Behav., 1993, 44 (4), 959-63. http://dx.doi.org/10.1016/0091-3057(93)90031-n [44] Aikey, J. L.; Nyby, J. G.; Anmuth, D. M.; James, P. J. Testosterone rapidly reduces anxiety in male house mice (Mus musculus).",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Behav., 2002, 42 (4), 448-60. http://dx.doi.org/10.1006/hbeh.2002.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
",  2006, 50 (2), 216-22. http://dx.doi.org/10.1016/j.yhbeh.2006.03.003 [47] McCarthy, M. M., Frank A.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Behav., 1995, 29 (2), 131-40.  http://dx.doi.org/10.1006/hbeh.1995.1010  [48] Shekhar, A. GABA receptors in the region of the dorsomedial hypothalamus of rats regulate anxiety in the elevated plus-maze test.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Brain Res., 1993, 627 ( 1 ) ,  9-16. http://dx.doi.org/10.1016/0006-8993(93)90742-6 [49] Shekhar, A.; Katner, J. S. Dorsomedial hypothalamic GABA regulates anxiety in the social interaction test.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Behav., 1995, 5 0 ( 2 ) ,  2 5 3-8. http://dx.doi.org/10.1016/ 0091-3057(94)00307-5 [50] Giros, B.; Jaber, M.; Jones, S. R.; Wightman, R. M.; Caron, M. G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Nature, 1996, 379 ( 656 6), 606-12.  http://dx.doi.org/10.1038/379606a0  [51] Kindlundh, A. M.; Rahman, S.; Lindblom, J.; Nyberg, F. Increased dopamine transporter density in the male rat brain following chronic nandrolone decanoate administration.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Lett., 2004, 356 ( 2 ) ,  1 3 1-4. http://dx.doi.org/10.1016/j.neulet.2003.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Psychiatry, 2002, 26 (7-8), 1303-8. http://dx.doi.org/10.1016/ s0278-5846(02)00293-2 [53] Jaber, M.; Jones, S.; Giros, B.; Caron, M. G. The dopamine transporter: a crucial component regulating dopamine transmission.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Disord., 1997, 12 (5), 629-33. http://dx.doi.org/10.1002/mds.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Behav., 1996, 5 3 ( 3 ) ,  7 4 1-5. http://dx.doi.org/10.1016/0091-3057(95)02082-9 [55] Kailanto, S.; Kankaanpaa, A.; Seppala, T. Subchronic steroid administration induces long lasting changes in neurochemical and behavioral response to cocaine in rats.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Steroids, 2011, 76 ( 1 2 ) ,  1310-6.  http://dx.doi.org/10.1016/j.steroids.2011.06.011  [56] Kurling, S.; Kankaanpaa, A.; Seppala, T. Sub-chronic nandrolone treatment modifies neurochemical and behavioral effects of amphetamine and 3, 4-methylenedioxymethamphetamine (MDMA) in rats.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Brain Res., 2008, 1 8 9 ( 1 ) ,  1 9 1-201. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Pharmacol., 2003, 465 (1-2), 69-81.  http://dx.doi.org/10.1016/s0014-2999(03)01462-6  [58] Celerier, E.; Ahdepil, T.; Wikander, H.; Berrendero, F.; Nyberg, F.; Maldonado, R. Influence of the anabolic-androgenic steroid nandrolone on cannabinoid dependence.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Neuropharmacology, 2006, 5 0 ( 7 ) ,  7 8 8-806. http://dx.doi.org/10.1016/j.neuropharm.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Psychopharmacology (Berl), 2010, 209 ( 3 ) ,  2 7 1-81. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Neuroendocrinol., 2008, 29 (4), 490-506. http://dx.doi.org/10.1038/sj.bjp.0702412  [62] Johansson, P.; Ray, A.; Zhou, Q.; Huang, W.; Karlsson, K.; Nyberg, F. Anabolic androgenic steroids increase beta-endorphin levels in the ventral tegmental area in the male rat brain.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Res., 1997, 27 (2), 185-9. http://dx.doi.org/10.1016/s0168-0102(96) 01141-8 [63] Triemstra, J. L.; Sato, S. M.; Wood, R. I. Testosterone and nucleus accumbens dopamine in the male Syrian hamster.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Psycho- neuroendocrinology, 2008, 33 ( 3 ) ,  3 8 6-94. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Lett., 2009, 467 (3), 189-93. http://dx.doi.org/10.1016/j.neulet.2009.09.041  [65] Kerr, J. E.; Allore, R. J.; Beck, S. G.; Handa, R. J.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Endocrinology, 1995, 136 (8), 3213-21.  http://dx.doi.org/10.1210/endo.136.8.7628354  [66] Svensson, J.; Diez, M.; Engel, J.; Wass, C.; Tivesten, A.; Jansson, J.O.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Behav., 1990, 35 ( 2 ) ,  4 2 9-35. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Neuroscience, 1998, 85 (2), 375-82. http://dx.doi.org/10.1016/s0306-4522(97)00605-2 [69] Daumas, S.; Betourne, A.; Halley, H.; Wolfer, D.P.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Mem., 2007, 88 (1), 94-103. http://dx.doi.org/10.1016/j.nlm.2007.02.001 [70] McGinnis, M. Y.; Lumia, A. R.; Tetel, M. J.; Molenda-Figueira, H. A.; Possidente, B.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Behav., 2007, 92 (5), 1010-8. http://dx.doi.org/10.1016/j.physbeh.2007.07.010 [71] Salvador, A.; Moya-Albiol, L.; Martinez-Sanchis, S.; Simon, V. M. Lack of effects of anabolic-androgenic steroids on locomotor activity in intact male mice.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Skills, 1999, 88 (1), 319-28. http://dx.doi.org/10.2466/pms.1999.88.1.319 [72] Van Zyl, C. G.; Noakes, T. D.; Lambert, M. I. Anabolic-androgenic steroid increases running endurance in rats.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Exerc., 1995, 27 (10), 1385-9. http://dx.doi.org/10.1249/00005768-199510000-00006 [73] Racca, S.; Piccione, F.; Spaccamiglio, A.; Carriero, V.M.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Psychoneuroendocrinology, 2012, 37 ( 8 ) ,  1 2 3 4-47. http://dx.doi.org/10.1016/j.psyneuen.2011.12.017 [74] Alsio, J.; Birgner, C.; Bjorkblom, L.; Isaksson, P.; Bergström, L.; Schiöth, H.B.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Toxicol., 2009, 105 (5), 307-14. http://dx.doi.org/10.1111/j.1742-7843.2009.00439.x [75] Schlussman, S. D.; Zhou, Y.; Johansson, P.; Kiuru, A.; Ho, A.; Nyberg, F.; Kreek, M.J.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Lett., 2000, 2 8 4 ( 3 ) ,  190-4. http://dx.doi.org/10.1016/s0304-3940(00)01016-8 [76] Nishizawa, H.; Shimomura, I.; Kishida, K.; Maeda, N.; Kuriyama, H.; Nagaretani, H.; Matsuda, M.; Kondo, H.; Furuyama, N.; Kihara, S.; Nakamura, T.; Tochino, Y.; Funahashi, T.; Matsuzawa, Y. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Risk, 1997, 4 (5-6), 363-6. http://dx.doi.org/10.1097/00043798-199710000-00008  [79] Lenders, J. W.; Demacker, P. N.; Vos, J.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Sports Med., 1988, 9 ( 1 ) ,  1 9-23. http://dx.doi.org/10.1055/s-2007-1024972 [80] Maravelias, C.; Dona, A.; Stefanidou, M.; Spiliopoulou, C. Adverse effects of anabolic steroids in athletes.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Lett., 2005, 158 ( 3 ) ,  1 6 7-75. http://dx.doi.org/10.1016/ j.toxlet.2005.06.005  [81] Nishida, M.; Funahashi, T.; Shimomura, I. Pathophysiological significance of adiponectin.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Res., 2007, 56 ( 6 ) ,  4 5 9-67. http://dx.doi.org/10.1016/ j.phrs.2007.09.014 [83] Masonis, A. E.; McCarthy, M. P. Direct effects of the anabolic/ androgenic steroids, stanozolol and 17 alpha-methyltestosterone, on benzodiazepine binding to the.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Lett., 1995, 189 ( 1 ) ,  3 5-8. http://dx.doi.org/ 10.1016/0304-3940(95)11445-3 [84] Oberlander, J. G.; Henderson, L. P. Corticotropin-releasing factor modulation of forebrain GABAergic transmission has a pivotal role in the expression of anabolic steroid-induced anxiety in the female mouse.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Neuropsychopharmacology, 2012, 3 7 ( 6 ) ,  1 4 8 3-99. http://dx.doi.org/10.1038/npp.2011.334 [85] Siegel, A.; Roeling, T. A.; Gregg, T. R.; Kruk, M. R. Neuro- pharmacology of brain-stimulation-evoked aggression.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Rev., 1999, 23 ( 3 ) ,  3 5 9-89. http://dx.doi.org/10.1016/ s0149-7634(98)00040-2 [86] Jones, B. L.; Whiting, P. J.; Henderson, L. P. Mechanisms of anabolic androgenic steroid inhibition of mammalian epsilon-subunit-containing GABAA receptors.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Physiol., 2006, 573 (Pt 3), 571-93. http://dx.doi.org/10.1113/jphysiol.2006.106534  [87] Lin, Y. S.; Li, X. F.; Shao, B. Hu, M.H.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Neuroendocrinol., 2012, 24 ( 3 ) ,  4 7 7-88. http://dx.doi.org/10.1111/j.1365-2826.2011.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
",  2009, 29 ( 4 0 ) ,  1 2 4 8 4-96.  http://dx.doi.org/10.1523/jneurosci.3108-09.2009  [91] Leshner, A. I.; Koob, G. F. Drugs of abuse and the brain.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Physicians, 1999, 111 ( 2 ) ,  9 9-108. http://dx.doi.org/ 10.1046/j.1525-1381.1999.09218.x [92] Menard, C. S.; Hebert, T. J.; Dohanich, G. P.; Harlan, R. E. Androgenic-anabolic steroids modify beta-endorphin immuno- reactivity in the rat brain.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Brain Res., 1995, 669 ( 2 ) ,  2 5 5-62. http://dx.doi.org/10.1016/0006-8993(94)01266-k [93] Penatti, C. A.; Costine, B.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Neuroscience, 2009, 161 (2), 526-37. http://dx.doi.org/10.1016/j.neuroscience.2009.03.039 [94] McIntyre, K. L.; Porter, D. M.; Henderson, L. P. Anabolic androgenic steroids induce age-, sex-, and dose-dependent changes in GABA(A) receptor subunit mRNAs in the mouse forebrain.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Neuropharmacology, 2002, 43 ( 4 ) ,  6 3 4-45. http://dx.doi.org/ 10.1016/s0028-3908(02)00154-5 [95] Pibiri, F.; Nelson, M.; Carboni, G.; Pinna, G. Neurosteroids regulate mouse aggression induced by anabolic androgenic steroids.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Neuroreport, 2006, 17 (14), 1537-41. http://dx.doi.org/ 10.1097/01.wnr.0000234752.03808.b2 [96] Jorge-Rivera, J. C.; McIntyre, K. L.; Henderson, L. P. Anabolic steroids induce region- a n d  s u b u n i t-specific rapid modulation of GABA(A) receptor-mediated currents in the rat forebrain.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Neurosci., 1995, 15  (3 Pt 2), 2328-37. http://dx.doi.org/10.1016/j.brainres.2010.08.006 [98] Zhang, L.; Chang, Y. H.; Feldman, A. N.; Ma, W.; Lahjouji, F.; Barker, J. L.; Hu, Q.; Maric, D.; Li, B.S.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Lett., 1999, 265 (1), 25-8. http://dx.doi.org/10.1016/s0304-3940(99)00193-7  [99] Mehta, A. K.; Ticku, M. K. An update on GABAA receptors.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Rev., 1999, 29 ( 2-3), 196-217. http://dx.doi.org/10.1016/s0165-0173(98)00052-6 [100] Herve, D.; Pickel, V. M.; Joh, T. H.; Beaudet, A. Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Brain Res., 1987, 435 (1-2), 71-83. http://dx.doi.org/10.1016/0006-8993(87)91588-5 [101] Azmitia, E. C.; Segal, M. An autoradiographic analysis of the differential ascending projections of the dorsal and m e d i a n  r a p h e  nuclei in the rat.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Neurol., 1978, 179 ( 3 ) ,  6 4 1-67. http://dx.doi.org/10.1002/cne.901790311  [102] Bonasera, S. J.; Tecott, L. H. Mouse models of serotonin receptor function: toward a genetic dissection of serotonin systems.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Ther., 2000, 88 (2), 133-42. http://dx.doi.org/10.1016/ s0163-7258(00)00087-5 [103] Matte, A. C.; Tornow, H. Parachlorophenylalanine produces dissociated effects on aggression ""emotionality"" and motor activity.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Neuropharmacology, 1978, 17 ( 8 ) ,  5 5 5-8. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Psychopharmacology (Berl), 2002, 163 (3-4), 434-58.  http://dx.doi.org/10.1007/s00213-002-1139-6  [105] Kurling, S.; Kankaanpaa, A.; Ellermaa, S.; Karila, T.; Seppala, T. The effect of sub-chronic nandrolone decanoate treatment on dopaminergic and serotonergic neuronal systems in the brains of rats.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Brain Res., 2005, 1044 ( 1 ) ,  6 7-75. http://dx.doi.org/10.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"C., 1985, 80 (2), 411-4. http://dx.doi.org/10.1016/0742-8413(85)90077-5 [107] Bonson, K. R.; Winter, J. C. Reversal of testosterone-induced dominance by the serotonergic agonist quipazine.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Behav., 1992, 4 2 ( 4 ) ,  8 0 9-13. http://dx.doi.org/10.1016/ 0091-3057(92)90034-d [108] Ferris, C. F.; Melloni, R. H., Jr.; Koppel, G.; Perry, K. W.; Fuller, R. W.; Delville, Y. Vasopressin/serotonin interactions i n  t h e  anterior hypothalamus control aggressive behavior in golden hamsters.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"1    131 Pharmacol., 2010, 2 1 ( 4 ) ,  3 1 4-22. http://dx.doi.org/10.1097/ fbp.0b013e32833b10f1 [110] Birgner, C.; Kindlundh-Hogberg, A. M.; Alsio, J.; Lindblom, J.; Schioth, H. B.; Bergstrom, L. The anabolic androgenic steroid nandrolone decanoate affects mRNA expression of dopaminergic but not serotonergic receptors.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Brain Res., 2008, 1240, 221-8. http://dx.doi.org/10.1016/j.brainres.2008.09.003  [111] Ricci, L. A.; Schwartzer, J. J.; Melloni, R. H., Jr. Alterations in the anterior h y p o t h a l a m i c  d o p a m i n e  s y s t e m  i n  a g g r e s s i v e  a d o l e s c e n t  AAS-treated hamsters.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Behav., 2009, 55 (2), 348-55. http://dx.doi.org/10.1016/j.yhbeh.2008.10.011 [112] Ghuman, S. P.; Prabhakar, S.; Smith, R. F.; Dobson, H. gamma-amino butyric acid control of arginine vasopressin release from the ewe hypothalamus in vitro: sensitivity to estradiol.",OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Anim., 2007, 42 (5), 527-35. http://dx.doi.org/10.1111/j.1439-0531.",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Pharmacol., 1998, 76 (3), 252-8. http://dx.doi.org/ 10.1139/cjpp-76-3-252   Received: July 26, 2014 Revised: October 10, 2014 Accepted: October 25, 2014",Non-OADS,/arxiv_data1/oa_pdf/52/d0/CN-13-122.PMC4462037.pdf
"Sports Med., 2004, 32(2), 534-542. http://dx.doi.org/10.1177/ 0363546503262202 [3] Foster, Z.J.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Rep., 2004, 3(4), 234-241. http://dx.doi.org/10.1249/00149619-200408000-00011  [4] Maravelias, C.; Dona, A.; Stefanidou, M.; Spiliopoulou, C. Adverse effects of anabolic steroids in athletes.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Lett., 2005, 158(3), 167-175. http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Ther., 2001, 23(9), 1355-1390. http://dx.doi.org/10.1016/s0149-2918(01) 80114-4 [6] Sjöqvist, F.; Garle, M.; Rane, A.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Lancet, 2008, 371(9627), 1872-1882. http://dx.doi.org/10.1016/s0140-6736(08)60801-6  [7] Woerdeman, J.; de Hon, O.; Levi, M.; de Ronde, W.P.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Biol., 2000, 74(1-2), 63-71. http://dx.doi.org/10.1016/s0960-0760(00)00089-3  [9] Hall, R.C.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Psychosomatics, 2005, 46(4), 285-290. http://dx.doi.org/10.1176/appi.psy.46.4.285  [10] Nasr, J.; Ahmad, J.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Sci., 2009, 54(5), 1144-1146. http://dx.doi.org/10.1007/s10620-008-0457-x [11] Wade, N. Anabolic steroids: doctors denounce them but athletes aren’t listening.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Drug Alcohol Depend., 2008, 98(1-2), 1-12. http://dx.doi.org/10.1016/j.drugalcdep.2008.05.004 [13] Pope, H.G.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"1419-1431. http://dx.doi.org/10.1016/ j.jpsychires.2010.01.001 [14] Hildebrandt, T.; Alfano, L.; Langenbucher, J.W.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Res., 2010, 44(13), 841-846. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"JAMA, 1988, 260(23), 3441-3445. http://dx.doi.org/10.1001/jama.260.23.3441 [16] Kanayama, G.; Pope, H.G.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Psychosom., 2001, 70(2), 61-65.  http://dx.doi.org/10.1159/000056228  [17] Parkinson.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Sports Exerc., 2006, 38(4), 644-651. http://dx.doi.org/10.1249/01.mss.0000210194.56834.5d  [18] Kanayama, G.; Hudson, J.I.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Drug Alcohol Depend., 2009, 102(1-3), 130-137. http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Sports Med., 2004, 34(8), 513-554. http://dx.doi.org/ 10.2165/00007256-200434080-00003 [20] O'Malley, P.A.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Nurse Spec., 2013, 27(3), 117-120. http://dx.doi.org/10.1097/ nur.0b013e31828c83db [21] Kersey, R.D.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Pharmacol., 2005, 19(1), 27-44. http://dx.doi.org/10.1111/j.1472-8206.2004.00298.x  [23] Turillazzi, E.; Perilli, G.; Di Paolo, M.; Neri, M.; Riezzo, I.; Fineschi, V. Side effects o f  A A S  a b u s e :  a n  o v e r v i e w .",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Chem., 2011, 11(5), 374-389. http://dx.doi.org/10.2174/ 138955711795445925 [24] van Amsterdam, J.; Opperhuizen, A.; Hartgens, F. Adverse health effects of anabolic-androgenic steroids.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Pharmacol., 2010, 57(1), 117-123. http://dx.doi.org/10.1016/j.yrtph.2010.02.001 [25] Brower, K.J.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Psychiatry Rep., 2002, 4(5), 377-387. http://dx.doi.org/10.1007/ s11920-002-0086-6 [26] Pope, H.G.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Metab., 2010, 95(4), 1533-1543. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Psychoneuroendocrinology, 2003, 28(3), 317-331. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Rev., 2007, 17(3), 363-380. http://dx.doi.org/10.1007/s11065-007-9037-7  [30] Pope, H.G.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Drug Alcohol Depend., 2008, 98(1-2), 1-12. http://dx.doi.org/10.1016/j.drugalcdep.2008.05.004 [33] Pope, H.G.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Psychosom., 2000, 69(1), 19-26. http://dx.doi.org/10.1159/000012362 [35] Choi, P.Y.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Psychiatry, 1994, 6(1), 21-25. http://dx.doi.org/10.3109/10401239409148835  [36] Perry, P.J.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Drug Alcohol Depend., 2006, 81(3), 215- 220. http://dx.doi.org/10.1016/j.drugalcdep.2005.07.001 [38] Petersson, A.; Garle, M.; Holmgren, P.; Druid, H.; Krantz, P.; Thiblin, I. Toxicological findings and manner of death in autopsied users of anabolic androgenic steroids.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Drug Alcohol Depend., 2006, 81(3), 241-249. http://dx.doi.org/10.1016/j.drugalcdep.2005.07.003 [39] Thiblin, I.; Kristiansson, M.; Rajs, J. Anabolic androgenic  steroids and behavioral patterns http://dx.doi.org/10.1080/ 09585189708412012 a m o n g  violent offenders.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Suppl., 2002, 106(412), 125-128. http://dx.doi.org/10.1034/j.1600-0447.106.s412.27.x  [41] Klotz, F.; G a r l e ,  M .",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Psychiatry, 1999, 45(3), 254-460. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Rev., 2003, 27(5), 413-436. http://dx.doi.org/10.1016/s0149-7634(03)00064-2  [45] Pope, H.G.J.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"J. Psychiatry, 1988, 145(4), 487-490. http://dx.doi.org/10.1176/ajp.145.4.487 [46] Perry, P.J.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Psychiatry, 1990, 2, 11- 17. http://dx.doi.org/10.3109/ 10401239009150000 [47] Freinhar, J.P.; Alvarez, W. Androgen-induced hypomania.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Dis., 1979, 167(4), 229-236. http://dx.doi.org/10.1097/00005053-197904000-00006  [49] Parssinen, M.; Kujala, U.; Vartiainen, E.; Sarna, S.; Seppala, T. Increased premature mortality of competitive powerlifters suspected to have used anabolic agents.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Sports Med., 2000, 21(3), 225-227. http://dx.doi.org/10.1055/s-2000-304 [50] Kanayama, G.; Hudson, J.I.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Behav., 2010, 58(1), 111-121. http://dx.doi.org/10.1016/j.yhbeh.2009.09.006  [51] Oberlander, J.G.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Trends Neurosci., 2012, 35(6), 382-392. http://dx.doi.org/10.1016/j.tins.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"CNS Drugs, 2005, 19(7), 571-595. http://dx.doi.org/10.2165/00023210-200519070-00002  [53] Henderson, L.P.; Penatti, C.A.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neuroscience, 2006, 138(3), 793-799. http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Lett., 2004, 356(2), 131-134. http://dx.doi.org/10.1016/j.neulet.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Brain Res., 2005, 1044(1), 67-75. http://dx.doi.org/10.1016/ j.brainres.2005.02.071 [56] Penatti, C.A.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neuroscience, 2009, 161(2), 526-537. http://dx.doi.org/10.1016/j.neuroscience.2009.03.039 [57] Rossbach, U.L.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Commun., 2007, 357(4), 1028-1033. http://dx.doi.org/10.1016/j.bbrc.2007.04.037 [58] Thiblin, I.; Finn, A.; Ross, S.B.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Pharmacol., 1999, 126(6), 1301-1306. http://dx.doi.org/10.1038/ sj.bjp.0702412  [59] Kanayama, G .",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Drug Alcohol Depend., 2013, 130(1-3), 208-214. http://dx.doi.org/10.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Sports Exerc., 2013, 45(1), 29-35. http://dx.doi.org/10.1249/mss.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Science, 1981, 211(4488), 1303-1311. http://dx.doi.org/10.1126/science.6259728  [63] McEwen, B.S.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Sci., 1994, 743, 1-16. http://dx.doi.org/10.1111/j.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neuroscience, 2006, 138(3), 733-739. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Endocrinology, 1984, 114(6), 2100-2106. http://dx.doi.org/10.1210/endo-114-6-2100  [67] Roselli, C. The effect of anabolic-androgenic steroids on aromatase activity and androgen receptor binding in the rat preoptic area.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Brain Res., 1998, 792(2), 271-276. http://dx.doi.org/10.1016/ s0006-8993(98)00148-6 [68] Fragkaki, A.G.; Angelis, Y.S.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Steroid, 2009, 74(2), 172-197. http://dx.doi.org/10.1016/j.steroids.2008.10.016  [69] Lippi, G.; Franchini, M.; Banfi, G. Biochemistry and physiology of anabolic androgenic steroids doping.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Chem., 2011, 11(5), 362-373. http://dx.doi.org/10.2174/138955711795445952  [70] Melcangi, R.C.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Rev., 2005, 48(2), 328-338. http://dx.doi.org/10.1016/j.brainresrev.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neuroscience, 2006, 138(3), 821-829. http://dx.doi.org/ 10.1016/j.neuroscience.2005.07.021  [72] Frye, C.A.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neuroscience, 2006, 138(3), 1007-1014. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neuroscience, 2006, 138(3), 1 0 3 1-1039. http://dx.doi.org/10.1016/j.neuroscience.2005.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Brain Res., 1996, 742(1-2), 163-171. http://dx.doi.org/10.1016/s0006-8993(96) 01005-0 [76] Sagrillo, C.A.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neuroendocrinol., 1997, 9(9), 699-706. http://dx.doi.org/10.1046/j.1365-2826.1997.00630.x  [77] Penatti, C.A.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neuroscience, 2005, 135(2), 533-543. http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neuroendocrinol., 2012, 24(1), 202-214. http://dx.doi.org/10.1111/j.1365-2826.2011.02151.x [79] Winters, S.J.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Endocrinol., 1967, 37(1), 37-55. http://dx.doi.org/10.1677/joe.0.0370037 [82] Dimick, D.F.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Acta, 1961, 6, 63-71. http://dx.doi.org/10.1016/0009-8981(61)90037-7 [83] Schänzer, W. Metabolism of anabolic androgenic steroids.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Biol., 2009, 115(1-2), 44-61. http://dx.doi.org/10.1016/j.jsbmb.2009.02.016 [85] Penatti, C.A.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neurosci., 2009, 29(40), 12484-12496. http://dx.doi.org/10.1523/jneurosci.3108-09.2009  [86] Luzardo, O.P.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Endocrinology, 2000, 141(9), 3377-3387. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"CRC Press LLC, 2004. p. 119-141. http://dx.doi.org/10.1016/j.brainres.2006.08.081  [88] Clark, A.S.; Costine, B.A.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Brain Res., 2006, 1126(1), 122-138. http://dx.doi.org/10.1016/ j.brainres.2006.08.081 [89] Henderson, L.P. Steroid modulation of GABAA receptor-mediated transmission in the hypothalamus: Effects on reproductive function.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neuropharmacology, 2007, 52(7), 1439-1453. http://dx.doi.org/ 10.1016/j.neuropharm.2007.01.022 [90] Pinna, G.; Costa, E.; Guidotti, A.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"U.S.A., 2005, 102(6), 2135-2140. http://dx.doi.org/ 10.1073/pnas.0409643102 [91] Pinna, G.; Agis-Balboa, R.C.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Res., 2008, 33(10), 1990-2007. http://dx.doi.org/10.1007/s11064-008-9718-5 [92] Baulieu, E.E.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neuroendocrinol., 2008, 29(2), 169-181. http://dx.doi.org/10.1016/j.yfrne.2007.10.005  [94] Kicman, A.T. Pharmacology of anabolic steroids.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Pharmacol., 2008, 154(3), 502-521. http://dx.doi.org/10.1038/bjp.2008.165 [95] Michels, G.; Hoppe, U.C.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Front.Neuroendocrinol., 2008, 29(2), 182-198. http://dx.doi.org/ 10.1016/j.yfrne.2007.08.004 [96] Lieberherr, M; Grosse, B. Androgens increase intracellular calcium concentration and inositol 1, 4, 5-trisphosphate and diacylglycerol formation via a pertussis toxin-sensitive G-protein.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Endocrinology, 1995, 136(5), 2052-2059. http://dx.doi.org/10.1210/endo.136.5.7720654 [98] Steinsapir, J.; Socci, R.; Reinach, P. Effects of androgen on intracellular calcium of LNCaP cells.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Commun., 1991, 179(1), 90-96. http://dx.doi.org/10.1016/0006-291x(91)91338-d [99] Benten, W.P.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Cell., 1999, 10(10), 3113-3123. http://dx.doi.org/10.1091/ mbc.10.10.3113 [100] Benten, W.P.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"FEBS Lett., 1997, 407(2), 211-214. http://dx.doi.org/10.1016/s0014-5793(97)00346-3 [101] Benten, W.P.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neuroscience, 2007, 149(1), 155-164. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Chem., 2011, 11(5), 390-398. http://dx.doi.org/10.2174/138955711795445880 [104] Berridge, M.J.; Bootman, M.D.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Nature, 1998, 395(6703), 645-648. http://dx.doi.org/10.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Brain Res., 2009, 175, 443-452. http://dx.doi.org/10.1016/s0079-6123(09)17529-5  [106] Pang, Z.P.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Cell Biol., 2010, 22(4), 496-505. http://dx.doi.org/10.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Cerebellum, 2006, 5(1), 36-42. http://dx.doi.org/10.1080/14734220600554438  [109] Abramov, A.Y.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Cell Calcium, 2010, 47(2), 112-121. http://dx.doi.org/ 10.1016/j.ceca.2009.12.013 [111] Harr, M.W.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"http://dx.doi.org/10.1101/ cshperspect.a005579  [112] Cabeza, M.; Flores, M.; Bratoeff, E.; de la Pena, A.; Mendez, E.; Ceballos, G. Intracellular Ca2+ stimulates the binding to androgen  receptors in platelets.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Steroids, 2004, 69(11-12), 767-772. http://dx.doi.org/10.1016/j.steroids.2004.09.006 [113] Estrada, M.; Espinosa, A.; Muller, M.; Jaimovich, E. Testosterone stimulates intracellular calcium release and mitogen-activated protein kinases via a G protein-coupled receptor in skeletal muscle cells.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Endocrinology, 2003, 144(8), 3586-3597. http://dx.doi.org/ 10.1210/en.2002-0164 [114] Migliaccio, A.; Castoria, G.; Di Domenico, M.; et al.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"EMBO J., 2000, 19(20), 5406-5417. http://dx.doi.org/10.1093/emboj/19.20.5406 [115] Gong, Y.; Blok, L.J.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Endocrinology, 1995, 136(5), 2172-2178. http://dx.doi.org/10.1210/endo.136.5.7720667  [116] Matsumoto, A.; Arai, Y.; Urano, A.; Hyodo, S. Androgen regulates gene expression of cytoskeletal proteins in adult rat motoneurons.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Behav., 1994, 28(4), 357-366. http://dx.doi.org/10.1006/ hbeh.1994.1032  [117] Rubinow, D.R.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"J. Psychiatry, 1996, 153(8), 974-984. http://dx.doi.org/10.1176/ ajp.153.8.974 [118] Cunningham, R.L.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Cell Sci., 2005, 119(Pt4), 733-743. http://dx.doi.org/10.1242/jcs.02775  [120] Goldberg, J.L.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neurosci., 2000, 23, 579-612. http://dx.doi.org/10.1146/annurev.neuro.23.1.579  [121] Kerr, J.F.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Cell Death Differ., 2012, 19(1), 107-120. http://dx.doi.org/10.1038/cdd.2011.96 [124] Janjic, M.M.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Toxicol., 2012, 34(4), 686-693. http://dx.doi.org/10.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Chem., 2011, 11(5), 409-424. http://dx.doi.org/10.2174/138955711795445862 [126] Shokri, S.; Aitken, R.J.; Abdolvahhabi, M.; Abolhasani, F.; Ghasemi, F.M.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Toxicol., 2010, 106(4), 324-330. http://dx.doi.org/10.1111/j.1742-7843.2009.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Health, 2011, 27(8), 711-718. http://dx.doi.org/ 10.1177/0748233710395350 [128] Fineschi, V.; Di Paolo, M.; Neri, M.; Bello, S.; D'Errico, S.; Dinucci, D.; Parente, R.; Pomara, C.; Rabozzi, R.; Riezzo, I.; Turillazzi, E. Anabolic steroid- a n d  e x e r c i s e-induced cardio-depressant cytokines and myocardial β1 receptor expression in CD1 mice.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Bone, 2006, 38(5), 637-651.  http://dx.doi.org/10.1016/j.bone.2005.10.029  [130] Zaugg, M.; Jamali, N.Z.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Cell Physiol., 2001, 187(1), 90-95. http://dx.doi.org/10.1002/1097-4652(2001) 9999:9999<00::aid-jcp1057>3.0.co;2-y [131] Abu-Shakra, S.; Alhalabi, M.S.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Res., 1997, 47(2), 186-197. http://dx.doi.org/10.1002/(sici)1097-4547(19970115)47:2<186:: aid-jnr7>3.3.co;2-h [132] Becker, C.; Riedmaier, I.; Reiter, M.; Tichopad, A.; Groot, M.J.; Stolker, A.A.; Pfaffl, M.W.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Lett., 2007, 169(2), 129-136. http://dx.doi.org/10.1016/ j.toxlet.2006.12.008  [135] Fanton, L.; Belhani, D.; Vaillant, F.; Tabib, A.; Gomez, L.; Descotes, J.; Dehina, L.; Bui-Xuan, B.; Malicier, D.; Timour, Q.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Pathol., 2009, 61(4), 317-323. http://dx.doi.org/10.1016/j.etp.2008.09.007 [136] Estrada, M.; Varshney, A.; Ehrlich, B.E.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Chem., 2006, 281(35), 25492-25501. http://dx.doi.org/10.1074/jbc.m603193200 [137] Orlando, R.; Caruso, A.; Molinaro, G.; Motolese, M.; Matrisciano, F.; Togna, G.; Melchiorri, D.; Nicoletti, F.; Bruno, V. Nanomolar concentrations of anabolic-androgenic steroids amplify excitotoxic neuronal death in mixed mouse cortical cultures.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Brain Res., 2007, 1165, 21-29. http://dx.doi.org/10.1016/j.brainres.2007.06.047  [138] Olney, J.W.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Science, 1969, 164(3880), 719-721. http://dx.doi.org/10.1126/science.164.3880.719  [139] Olney, J.W.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neurochem., 2006, 97(6), 1611-1626. http://dx.doi.org/10.1111/j.1471-4159.2006.03991.x [143] Cunningham, R.L.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Endocrinology, 2009, 150(2), 5539-5548. http://dx.doi.org/10.1210/en.2009-0640 [144] Caraci, F.; Pistara`, V.; Corsaro, A.; Tomasello, F.; Giuffrida, M.L.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"http://dx.doi.org/10.1002/jnr.22578 [145] Tugyan, K.; Ozbal, S.; Cilaker, S.; Kiray, M.; Pekcetin, C.; Ergur, B.U.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Lett., 2013, 533, 28-33. http://dx.doi.org/10.1016/j.neulet.2012.10.004 [146] Basile, J.R.; Binmadi, N.O.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Endocrinol., 2002, 16(10), 2181-2187. http://dx.doi.org/10.1210/ me.2002-0070  [148] Nicotera, P.; Lipton, S.A. Excitotoxins in Neuronal Apoptosis and Necrosis.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Drug Discov., 2004, 3(3), 205-214. http://dx.doi.org/10.1038/nrd1330 [151] Muchowski, P.J.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neuron, 2002, 35(1), 9-12. http://dx.doi.org/10.1016/s0896-6273(02) 00761-4 [152] Emerit, J.; Edeas, M.; Bricaire, F. Neurodegenerative diseases and oxidative stress.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neurosci., 2001, 2(5), 325-334. http://dx.doi.org/10.1038/35072550 [154] Kroemer, G.; Galluzzi, L.; Brenner, C. Mitochondrial membrane permeabilization in cell death.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Rev., 2007, 87(1), 99-163. http://dx.doi.org/10.1152/physrev.00013.2006 [155] Bonfoco, E.; Krainc, D.; Ankarcrona, M.; Nicotera, P.; Lipton, S.A. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/ superoxide in cortical cell cultures.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Cell Death Differ., 1999, 6(10), 931-933. http://dx.doi.org/10.1038/sj.cdd.4400583  [157] Cadenas, E.; Davies, K.J.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Med., 2000, 29(3-4), 222-230. http://dx.doi.org/10.1016/s0891-5849(00)00317-8  [158] Nakamuraa, T.; Chob, D.H.; Lipton, S.A. Redox regulation of protein misfolding, mitochondrial dysfunction, synaptic damage, and cell death in neurodegenerative diseases.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neurol., 2012, 238(1), 12-21.  http://dx.doi.org/10.1016/j.expneurol.2012.06.032  [159] Nakamura, T.; L i p t o n ,  S .",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Apoptosis, 2010, 15(11), 1354-1363. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Sect., 1993, 6(1), 45-52. http://dx.doi.org/10.1007/bf02252622  [163] Przedborski, S.; Kostic, V.; Jackson-Lewis, V.; Naini, A.B.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Aging Neurosci., 2014, 6, 77. http://dx.doi.org/10.3389/fnagi.2014.00077  [168] Xie, A.; Gao, J.; Xu, L.; Meng, D. Shared mechanisms of neurodegeneration in Alzheimer's disease and Parkinson's disease.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Bull., 2014, 30(2), 243-252. http://dx.doi.org/10.1007/s12264-013-1424-x [170] Bhasker, A.S.; Sant, B.; Yadav, P.; Agrawal, M.; Lakshmana  Rao, P.V.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neurotoxicology, 2014, 44C, 194-203. http://dx.doi.org/10.1016/j.neuro.2014.06.015  [171] Deng, Y.; Jiao, C.; Mi, C.; Xu, B.; Li, Y.; Wang, F.; Liu, W.; Xu, Z. Melatonin Inhibits Manganese-Induced Motor Dysfunction and Neuronal Loss in Mice: Involvement o f  O x i d a t i v e  S t r e s s  a n d  Dopaminergic Neurodegeneration.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
http://dx.doi.org/10.1007/s12035-014-8789-3,Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Chem., 2014, 289(31), 21205-21216. http://dx.doi.org/10.1074/jbc.m114.563403 [173] Chege, P.M.; McColl, G. Caenorhabditis elegans: a model to investigate oxidative stress and metal dyshomeostasis in Parkinson's disease.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Aging Neurosci., 2014, 6, 89. http://dx.doi.org/10.3389/fnagi.2014.00089 [174] Nirmaladevi, D.; Venkataramana, M.; Chandranayaka, S.; Ramesha, A.; Jameel, N.M.; Srinivas, C. Neuroprotective Effects of Bikaverin on H2O 2-Induced Oxidative Stress Mediated Neuronal Damage in SH-SY5Y Cell Line.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Chem., 2011, 11(5), 430-437. http://dx.doi.org/10.2174/138955711795445916 [177] Cerretani, D.; Neri, M.; Cantatore, S.; Ciallella, C.; Riezzo, I.; Turillazzi, E; Fineschi V. Looking for Organ Damages Due to Anabolic-androgenic Steroids (AAS): is Oxidative Stress the Culprit?.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Endocrinology, 2013, 154(11), 4281-4292. http://dx.doi.org/10.1210/en.2013-1242 [179] Cunningham, R.L.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Behav., 2011, 60(5), 617-624. http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neuropharmacology, 2008, 55(3), 310-318. http://dx.doi.org/10.1016/j.neuropharm.2008.01.005  [182] Mehta, S.L.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Rev., 2007, 54(1), 34-66. http://dx.doi.org/10.1016/j.brainresrev.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neuroepidemiology, 1989, 8(6), 296-299. http://dx.doi.org/10.1159/000110197 [185] Van Den Eeden, S.; Tanner, C.; Bernstein, A.; et al.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Epidemiol., 2003, 157(11), 1015-1022. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neurochem., 2001, 77(5), 1319-1326. http://dx.doi.org/10.1046/j.1471-4159.2001.00345.x [187] Nguyen, T.V.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neurochem., 2005, 94(6), 1639-1651. http://dx.doi.org/10.1111/ j.1471-4159.2005.03318.x  [188] Ramsden, M.; Shin, T.M.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neuroscience, 2003, 122(3), 573-578. http://dx.doi.org/10.1016/j.neuroscience.2003.08.048 [189] Nguyen, T.V.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neuroendocrinol., 2010, 22(9), 1013-1022. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Brain Res., 2001, 892(2), 255-262. http://dx.doi.org/10.1016/s0006-8993(00)03155-3 [194] Matrisciano, F.; Modafferi, A.M.; Togna, G.I.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Neuropharmacology, 2010, 58(7), 1078-1084. http://dx.doi.org/ 10.1016/j.neuropharm.2010.01.015  [195] Krishnan, V.; Nestler, E.J.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Nature, 2008, 455(7215), 894-902. http://dx.doi.org/ 10.1038/nature07455 [196] Tucci, P.; Morgese, M.G.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Steroids, 2012, 77(3), 269-275. http://dx.doi.org/10.1016/j.steroids.2011.12.014 [197] Tirassa, P.; Thiblin, I.; Agren, G.; Vigneti, E.; Aloe, L.; Stenfors, C. High-dose anabolic androgenic steroids modulate concentrations of nerve growth factor and expression of its low affinity receptor (p75-NGFr) in male rat brain.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Res., 1997, 47(2),  198-207. http://dx.doi.org/10.1002/(sici)1097-4547(19970115)47: 2<198::aid-jnr8>3.0.co;2-a  [198] Handa, R.J.; Pak, T.R.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Behav., 2008, 53(5), 741-752. http://dx.doi.org/10.1016/j.yhbeh.2007.09.012 [199] Dodge, T.; Hoagland, M.F.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Drug Metab Toxicol., 2009, 5(7), 731-744. http://dx.doi.org/10.1517/17425250902976862 [201] Townsend, D.M.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Interv., 2007, 7, 313-324. http://dx.doi.org/10.1124/mi.7.6.7  [202] Xiong, Y.; Uys, J.D.",OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"2011, 15, 233-270. http://dx.doi.org/10.1089/ars.2010.3540  [203] Virmani, A.; Ali, S.; Binienda, Z. Neuroprotective strategies in drug abuse-evoked encephalopathy.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Sci., 2010, 1199, 52-68. http://dx.doi.org/10.1111/j.1749-6632.2009.05171.x [204] Akram, Y.; Copello, A.; Moore, D. Family-based interventions for substance misuse: a systematic review of systematic reviews--protocol.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"2014, 3, 90. http://dx.doi.org/10.1186/2046-4053-3-90 [205] Uys, J.D.",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"Res., 2012, 21, 49-56. http://dx.doi.org/10.1007/s12640-011-9265-8   Received: July 25, 2014 Revised: September 30, 2014 Accepted: October 25, 2014",Non-OADS,/arxiv_data1/oa_pdf/2b/e4/CN-13-132.PMC4462038.pdf
"DOI: http://dx.doi.org/10.1093/cvr/27.11.2011 [64] Du, X. J.; Woodcock, E. A.; Little, P. J.; Esler, M. D.; Dart, A. M. Protection of neuronal uptake-1 inhibitors in ischemic and anoxic hearts by norepinephrine-dependent and -independent mechanisms.",Non-OADS,/arxiv_data1/oa_pdf/df/e6/CN-13-146.PMC4462039.pdf
"TrAC, 2012, 32, 15-30. http://dx.doi.org/10.1016/j.trac.2011.09.009  [3] Musselman, M.E.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Pharmacotherapy, 2014, 34(7), 745-757. http://dx.doi.org/10.1002/phar.1424  [4] Davies, S.; Wood, D.M.",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"QJM, 2010, 103(7), 489-493. http://dx.doi.org/10.1093/qjmed/hcq056  [5] Arnold, C. The new danger of synthetic drugs.",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Lancet, 2013, 382(9886), 15-16. http://dx.doi.org/10.1016/s0140-6736(13)61512-3 [6] Available from: https://www.gov.uk/government/uploads/system/ uploads/attachment_data/file/119139/acmdnps2011.pdf [Last access on 24th July, 2014].",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
", 2004, 36(4), 675-691. http://dx.doi.org/10.1016/j.jpba.2004.08.022 [8] Martins, P.B.C.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"T r A C, 2010, 29(4), 285-296. http://dx.doi.org/10.1016/j.trac.2010.01.009 [9] Jones, R.S.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Neurobiol., 1982, 19(1-2), 117-139. http://dx.doi.org/10.1016/0301-0082(82)90023-5 [10] Corkery, J.M.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Psychiatry, 2012, 39(2), 259-262. http://dx.doi.org/10.1016/ j.pnpbp.2012.05.022 [11] Gibbons, S. ‘Legal Highs’ - N o v e l  a n d  e m e r g i n g  p s y c h o a c t i v e  drugs: a chemical overview for the toxicologist.",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Toxicol., 2012, 50(1), 15-24. http://dx.doi.org/10.3109/15563650.2011.",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"J. Psychedelic Drugs, 1979,11(1-2), 61-69. http://dx.doi.org/10.1080/02791072.",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"J. Psychoactive Drugs, 1996, 28(3): 267-290. http://dx.doi.org/10.1080/02791072.",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Toxicol., 2011, 49(8), 705-719. http://dx.doi.org/10.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Pharmacol., 2008, 75(1), 17-33. http://dx.doi.org/10.1016/j.bcp.2007.07.018  [16] Nagai, F.; Nonaka, R.; Satoh, K.; Kaminura, H. The effects of non-medically used psychoactive drugs on monoamine neurotrans- mission in rat brain.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Pharmacol., 2007, 559(2-3), 132-137. http://dx.doi.org/10.1016/j.ejphar.2006.11.075",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Chemoter., 1965, 24, 49-67. http://dx.doi.org/10.1111/j.1476-5381.",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"[21] Available from: http://www.deadiversion.usdoj.gov/drug_chem_ info/amt.pdf [Last access on 1th August, 2014] [22] Available from: https://legal-high-inhaltsstoffe.de/sites/default/files/ uploads/amt.pdf [Last access on 1th August August, 2014] [23] Wilcox, J. Psychoactive properties of alpha-methyltryptamine: analysis from self reports of users.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"http://dx.doi.org/10.1080/02791072.2012.704592  [24] Available from: https://www.gov.uk/government/uploads/system/ uploads/attachment_data/file/318693/ [Last access on 5th A u g u s t ,  2014] [25] Available from: http://www.sgul.ac.uk/research/projects/icdp/our-work-programmes/pdfs/drd_ar_2013.pdf [Last access on 11th August, 2014] [26] Huang, X.M.",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Pharmacol., 1991, 200(1), 187-90. http://dx.doi.org/10.1016/0014-2999(91)90686-k  [27] Greig, M.E.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Brain Res., 1 9 9 6, 73(1-2), 121-124. http://dx.doi.org/10.1016/0166-4328(96)00081-2 [30] Gable, R.S.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
http://dx.doi.org/10.1111/j.1360-0443.2006.,Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"http://dx.doi.org/10.1159/000085649  [35] Grof, S.; Soskin, R.A.; Richards, W.A.",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"http://dx.doi.org/10.1007/s00213-012-2891-x  [37] Gatch, M.B.",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Ther., 2011, 338(1), 280-289. http://dx.doi.org/10.1124/jpet.",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"http://dx.doi.org/10.1016/j.pharmthera.2003.11.002 [39] Shulgin, A.T.; Carter, M.F.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"http://dx.doi.org/ 10.1016/s0378-4347(98)00067-x [42] Halpern, J.H.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"J., 1 9 8 1, 5 7(671), 543-545. http://dx.doi.org/10.1136/pgmj.",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
org/10.1007/s00213-003-1640-6 [46] Available from: http://www.erowid.org/experiences/exp.php?,Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Neuropharmacology, 1995, 34(7), 799-804. http://dx.doi.org/ 10.1016/0028-3908(95)00049-c [50] Ott, J. Pharmacology of Bufotenine.",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"J. Psychoactive Drugs, 2001, 33(3), 273-81. http://dx.doi.org/10.1080/02791072.2001.10400574  [51] Available from: http://www.erowid.org/chemicals/5meo_amt/ 5meo_amt_info2.shtml [Last access on 25th August, 2014].",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Chem., 1990, 33(10), 2777–2784.12 http://dx.doi.org/10.1021/jm00172a016  [53] Tomaszewski, Z.; Johnson, M.P.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"http://dx.doi.org/10.1021/jm00089a017 [54] Available from: http://www.erowid.org/chemicals/5meo_amt/ 5meo_amt_info1.shtml [Last access on 25th August, 2014].",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
[55] Available from: http://www.erowid.org/chemicals/lsd/lsd_media2.,Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"1285-1287.  http://dx.doi.org/10.1021/jo01091a032  [57] Shen, H.W.",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Drug  Metab., 2010, 11(8), 659-666. http://dx.doi.org/10.2174/ 138920010794233495 [58] Ott, J. Pharmepena-Psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine.",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"J. Psychoactive Drugs, 2001, 33(4), 403-407. http://dx.doi.org/ 10.1080/02791072.2001.10399925 [59] Sogawa, C.; Sogawa, N.; Tagawa, J.; Fujino, A.; Ohyama, K.; Asanuma, M.; Funada, M.; Kitayama S. 5-Methoxy-N,N-diisopropyltryptamine (Foxy), a selective and high affinity inhibitor of serotonin transporter.",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"http://dx.doi.org/10.1016/j.toxlet.2007.02.007  [60] Muller, A.A. New drugs of abuse update: Foxy Methoxy.",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Nurs., 2004, 30(5), 507-508. http://dx.doi.org/10.1016/j.jen.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"http://dx.doi.org/10.1016/j.pbb.2005.12.015  [62] Tanaka, E.; Kamata, T.; Katagi, M.; Tsuchihashi, H.; Honda, K. A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, Foxy.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Int., 2006, 163(1-2), 152-154. http://dx.doi.org/ 10.1016/j.forsciint.2005.11.026 [63] Nonaka, R.; Nagal, F.; Ogata, A.; Satoh, K. In vitro screening of psycgoactive drugs by [35S] GTPγS binding in rat brain membranes.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"doi.org/10.1248/bpb.30.2328 [64] Available from: http://www.erowid.org/chemicals/5meo_mipt/ 5meo_mipt_effects.shtml [Last access on 25th August, 2014].",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Med., 1999, 159(17), 2090. http://dx.doi.org/10.1001/archinte.159.17.2090  [66] Available from: https://www.erowid.org/plants/hbw/hbw_effects.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"[67] Available from: https://www.erowid.org/plants/morning_glory/ morning_glory.shtml [Last access on 25th August, 2014].",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"[68] Available from: http://www.ehow.com/about_5073540_psychedelic-effects-morning-glory-seeds.html [Last access on 25th A u g u s t ,  2014].",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Behavior., 2008, 88(3), 358-365.  http://dx.doi.org/10.1016/ j.pbb.2007.09.007 [73] Sitaram, B.R.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Pharmacol., 1987, 36(9), 1509-1512. http://dx.doi.org/10.1016/0006-2952(87) 90118-3 [74] Available from: www.erowid.org/experiences/exp_front.shtml [Last access on 26th August, 2014].",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"[77] Available from: http://www.erowid.org/chemicals/5meo_dalt/ 5meo_dalt_info1.shtml [Last access on 26th August, 2014].",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
[79] Available from: http://www.erowid.org/chemicals/lsa/lsa_effects.,OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"J., 2011, 28(5), 387-389. http://dx.doi.org/10.1136/emj.2009.088344  [81] Holstege, C.P., Baer, A.B.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Toxicol., 2003, 41(5), 641-752. http://dx.doi.org/10.1081/clt-120030949 [82] Long, H.; Hoffman, R.S.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Toxicol., 2004, 42(2), 191-195. http://dx.doi.org/10.1081/clt-120030949  [85] Wilson, J.M.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Proc., 2006, 81(4), 550-551. http://dx.doi.org/10.4065/81.",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Toxicol., 2003, 27(5), 313-317. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"org/10.1093/jat/27.5.313 [89] Available from: http://www.aapcc.org/annual-reports/ [Last access on 26th August, 2014].",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Psychiatry, 2007, 31(1), 288-291. http://dx.doi.org/10.1016/ j.pnpbp.2006.06.012 [91] Jovel, A.; Felthous, A.; Bhattacharyya, A. Delirium Due to Intoxication from the Novel Synthetic Tryptamine 5-MeO-DALT.",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"J. Forensic Sci., 2014, 59(3), 844-846. http://dx.doi.org/10.1111/ 1556-4029.12367 [92] Boland, D.M.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Toxicol., 2005, 29(5), 394-397.  http://dx.doi.org/10.1093/jat/29.5.394  [93] Butin, J.W.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Soc., 1962, 63, 338-340. http://dx.doi.org/10.1016/0002-9343(86)90274-3  [94] Morano, R.A.; Spies, C.; Walker, F.B.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Toxicol., 2005, 29(8), 838-841.  http://dx.doi.org/10.1093/jat/29.8.838  [97] Available from: http://www.erowid.org/chemicals/5meo_dipt/ 5meo_dipt_media1.shtml [Last access on 26th August, 2014].",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Ergoline Alkaloids in Tropical Wood Roses, Science, 1965, 148(3669), 499-500. http://dx.doi.org/ 10.1126/science.148.3669.499 [99] Available from: https://www.erowid.org/experiences/exp.php?",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Praxis., 2003, 30(4), 223-224. http://dx.doi.org/10.1055/ s-2003-39490  [101] Montesano, C.; Sergi, M.; Moro, M.; Napoletano, S.; Romolo, F.S.",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Mass Spectrom., 2013, 48(1), 49-59. http://dx.doi.org/ 10.1002/jms.3115 [102] Strano-Rossi, S.; Anzillotti, L.; Castrignanò, E.; Romolo, F.S.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"A, 2012, 1258, 37-42. http://dx.doi.org/10.1016/j.chroma.2012.07.098  [103] Favretto, D.; Pascali, J.P.; Tagliaro, F. New challenges and innovation in forensic toxicology: Focus on the “New Psychoactive Substances”, J. Chromatogr.",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"A, 2013, 1287, 84-95. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"http://dx.doi.org/10.1093/jat/28.6.407  [105] Wohlfarth, A.; Weinmann, W.; Dresen, S. LC-MS/MS screening method for designer amphetamines, tryptamines, and piperazines in serum.",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Chem., 2014, 406(1), 225-237. http://dx.doi.org/10.1007/s00216-013-7425-9  [107] Chen, B.H.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Talanta, 2008, 74(4), 512-517. http://dx.doi.org/10.1016/j.talanta.2007.06.012 [108] Ishida, T.; Kudo, K.; Kiyoshima, A.; Inoue, H.; Tsuji, A., Ikeda, N. Sensitive determination of alpha-methyltryptamine (AMT) and 5-methoxy-N,N-diisopropyltryptamine (5MeO-DiPT) in whole blood and urine using gas chromatography-mass spectrometry.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Life Sci., 2 0 0 5, 823(1), 47-52. http://dx.doi.org/10.1016/j.jchromb.2004.10.067  [109] Pichini, S.; Pujadas, M.; Marchei, E.; Pellegrini, M.; Fiz, J.; Pacifici, R.; Zuccaro, P.; Farré, M.; de la Torre, R. Liquid chromatography-atmospheric pressure ionization electrospray mass spectrometry determination of ""hallucinogenic designer drugs"" in urine of consumers.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Anal., 2008, 47(2), 335-342. http://dx.doi.org/10.1016/j.jpba.2007.12.039  [110] Helander, A.; Bäckberg, M.; Hultén, P., Al-Saffar, Y., Beck, O.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Int., 2014, 243C, 23-29. http://dx.doi.org/10.1016/ j.forsciint.2014.02.022 [111] Al-Saffar, Y.; Stephanson, N.N.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Life Sci., 2013, 930, 112-120. http://dx.doi.org/10.1016/j.jchromb.2013.04.043 [112] Katagi, M.; Kamata, T.; Zaitsu, K.; Shima, N.; Kamata, H.; Nakanishi, K.; Nishioka, H.; Miki, A.; Tsuchihashi, H. Metabolism and toxicologic analysis of tryptamine-derived drugs of abuse.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Drug Monit., 2010, 32(3), 328-331. http://dx.doi.org/ 10.1097/ftd.0b013e3181dcb40c [113] Wang, M.J.; Liu, J.T.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"A., 2008, 1181(1-2), 131-136.  http://dx.doi.org/10.1016/j.chroma.2007.12.031  [114] Strano Rossi, S.; Odoardi, S.; Gregori, A.; Peluso, G.; Ripani L.; Ortar, G.; Serpelloni, G.; Romolo, F.S.",Non-OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Mass Spectrom., 2014, 28(17), 1904-1916. http://dx.doi.org/10.1002/ rcm.6969 [115] Hugel, J.; Meyers, F.A.",OADS,/arxiv_data1/oa_pdf/80/6f/CN-13-26.PMC4462041.pdf
"Med., 2000, 108 (6), 518-9. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Drug Alcohol Depend., 2001, 63 (1), 1-22. http://dx.doi.org/ 10.1016/s0376-8716(00)00191-5 [4] Caldicott, D.G., Chow, F.Y., Burns, B.J., Felgate, P.D., Byard, R.W.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"(Phila), 2008, 46 (3), 187-92.  http://dx.doi.org/10.1080/15563650701263633  [6] Knudsen, K., Jonsson, U., Abrahamsson, J. Twenty-three deaths with gamma-hydroxybutyrate overdose in western Sweden between 2000 and 2007.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Scand., 2010, 5 4 ( 8 ) ,  9 8 7-92. http://dx.doi.org/10.1111/j.1399-6576.2010.02278.x  [7] Gable, R.S.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Addiction, 2004, 99 (6), 686-96. http://dx.doi.org/10.1111/j.1360-0443.2004.00744.x  [8] Schulz, M., Iwersen-Bergmann, S., Andresen, H., Schmoldt, A.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Drug Monit., 2004, 26 (4), 432-40. http://dx.doi.org/10.1097/00007691-200408000-00014 [10] Galicia, M., Nogue, S., Miro, O.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"J., 2011, 28 ( 6 ) ,  4 6 2-6. http://dx.doi.org/10.1136/ emj.2008.068403 [11] Schep, L.J., Knudsen, K., Slaughter, R .",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Toxicol (Phila), 2012, 5 0 (6), 458-70. http://dx.doi.org/10.3109/15563650.2012.702218  [12] Anderson, I.B., Kim, S.Y., Dyer, J.E., Burkhardt, C.B., Iknoian, J.C., Walsh, M.J., Blanc, P.D.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Med., 2006, 47 ( 2 ) ,  1 7 7-83. http://dx.doi.org/10.1016/j.annemergmed.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Drug Test Anal., 2011, 3 ( 9 ) ,  5 6 0-8. http://dx.doi.org/10.1002/dta.254  [14] Zvosec, D.L., Smith, S.W., Hall, B.J.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Sleep Med., 2009, 10 (4), 490-3. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Chem., 2007, 388 (7), 1467-74. http://dx.doi.org/10.1007/s00216-007-1209-z [16] Negrusz, A., Gaensslen, R.E.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Anal Bioanal Chem., 2003, 376 ( 8 ) ,  1 1 9 2-7. http://dx.doi.org/10.1007/ s00216-003-1896-z [17] Stillwell, M.E.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Med., Pathol., 2008, 4 (4), 205-11. http://dx.doi.org/10.1007/s12024-008-9040-1 [20] Kugelberg, F.C., Holmgren, A., Eklund, A., Jones, A.W.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Legal Med., 2010, 124 ( 1 ) ,  1-6. http://dx.doi.org/10.1007/ s00414-008-0299-2 [21] Zvosec, D.L., Smith, S.W., Porrata, T., Strobl, A.Q., Dyer, J.E.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Med., 2011, 29 (3), 319-32. http://dx.doi.org/10.1016/j.ajem.2009.11.008 [22] Brunt, T.M., Van Amsterdam, J.G., Van Den Brink, W. GHB, GBL and 1,4-BD addiction.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Des., 2014, 20 (25), 4076-85.  http://dx.doi.org/10.2174/13816128113199990624  [23] Wood, D.M., Warren-Gash, C., Ashraf, T., Greene, S.L., Shather, Z., Trivedy, C., Clarke, S., Ramsey, J., Holt, D.W., Dargan, P.I.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"QJM, 2008, 101 (1), 23-9. http://dx.doi.org/10.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"(Phila), 2011, 49 (4), 311-5. http://dx.doi.org/10.3109/15563650.2011.576253  [25] Drasbek, K.R., Christensen, J., Jensen, K. Gamma-hydroxybutyrate - a d r u g  o f  a b u s e .",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Scand., 2006, 114, 145-156. http://dx.doi.org/10.1111/j.1600-0404.2006.00712.x  [26] Palmer, R.B.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Rev., 2004, 2 3 ( 1 ) ,  3-20. http://dx.doi.org/10.2165/ 00139709-200423010-00003 [28] Tunnicliff, G. Sites of action of gamma-hydroxybutyrate (GHB) -  a neuroactive drug with abuse potential.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Toxicol., 1997, 35 (6), 581-90. http://dx.doi.org/10.3109/ 15563659709001236 [29] Trudell, J.R., Messing, R.O., Mayfield, J., Harris, R.A. Alcohol dependence: Molecular and behavioral evidence.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Sci., 2014, 35 (7), 317-323. http://dx.doi.org/10.1016/ j.tips.2014.04.009 [30] Whiting, P.J.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Today, 2003, 8 (1 0), 445-50. http://dx.doi.org/10.1016/s1359-6446(03)02703-x [31] Pardi, D., Black, J. Gamma-hydroxybutyrate/sodium oxybate: Neurobiology, and i m p a c t  o n  s l e e p  a n d  w a k e f u l n e s s .",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"CNS Drugs 2006, 20 ( 1 2 ) ,  9 9 3-1018. http://dx.doi.org/10.2165/00023210-200620120-00004 [32] Robinson, D.M., Keating, G.M.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"CNS Drugs, 2007, 21 ( 4 ) ,  337-54. http://dx.doi.org/10.2165/00023210-200721040-00007  [33] Carter, L.P., Pardi, D., Gorsline, J., Griffiths, R.R.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Drug Alcohol Depend., 2009, 104 (1-2), 1-10. http://dx.doi.org/10.1016/j.drugalcdep.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Lancet, 2007, 3 6 9 ( 9 5 6 0 ) ,  4 9 9-511. http://dx.doi.org/10.1016/ s0140-6736(07)60237-2 [35] Ferrara, S.D., Zotti, S., Tedeschi, L., Frison, G., Castagna, F., Gallimberti, L., Gessa, G.L., Palatini, P. Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Pharmacol., 1992, 34 (3), 231-5. http://dx.doi.org/10.1111/j.1365-2125.1992.tb04129.x [36] Keating, G.M.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Drug Investig., 2014, 34 ( 1 ) ,  6 3-80. http://dx.doi.org/10.1007/s40261-013-0158-x  [37] Skala, K., Caputo, F., Mirijello, A., Vassallo, G., Antonelli, M., Ferrulli, A., Walter, H., Lesch, O., Addolorato, G. Sodium oxybate in the treatment of alcohol dependence: From the alcohol withdrawal syndrome to the alcohol relapse prevention.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Pharmacother., 2014, 1 5 ( 2 ) ,  2 4 5-57. http://dx.doi.org/ 10.1517/14656566.2014.863278 [38] Chick, J., Nutt, D.J.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Chem., 2014, 4 0 6 ( 1 5 ) ,  3 5 5 3-77. http://dx.doi.org/10.1007/s00216-013-7586-6  [40] Mari, F., Politi, L., Trignano, C., Di Milia, M.G., Di Padua, M., Bertol, E. What constitutes a normal ante-mortem urine GHB concentration?",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"J. Forensic Leg Med., 2009, 16 ( 3 ) ,  1 4 8-51.  http://dx.doi.org/10.1016/j.jflm.2008.08.014  [41] Bessman, S.P., Fishbein, W.N.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Int., 2010, 200 (1-3), 93-9. http://dx.doi.org/10.1016/ j.forsciint.2010.03.035 [43] Berankova, K., Mutnanska, K., Balikova, M. Gamma-hydroxybutyric acid stability and formation in blood and urine.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Int., 2006, 1 6 1 ( 2-3), 158-62. http://dx.doi.org/10.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Int., 2003, 133 ( 1-2), 9-16. http://dx.doi.org/10.1016/s0379-0738(03)00043-4  [47] Elliott, S.P.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Toxicol., 2004, 2 8 ( 1 ) ,  2 0-6. http://dx.doi.org/ 10.1093/jat/28.1.20",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Drug Test Anal., 2011, 3 (7-8), 417-25. http://dx.doi.org/ 10.1002/dta.292 [49] Marinetti, L.J., Lebeau, M.A.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Med., 2005, 352 (2 6), 2721-32. http://dx.doi.org/10.1056/ nejmra044047 [51] Zvosec, D.L., Smith, S.W., Mccutcheon, J.R., Spillane, J., Hall, B.J., Peacock, E.A.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Med., 2001, 344 ( 2 ) ,   87-94. http://dx.doi.org/10.1056/nejm200101113440202  [52] EMCDDA, GHB and its precursor GBL: An emerging trend case study European Monitoring Centre for Drugs and Drug Addiction, Lisbon 2008.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"(Phila) 2012, 5 0 ( 7 ) ,  5 5 5-61. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"B i o a n a l y s i s ,  2009, 1 ( 5 ) ,  1 0 0 1-13. http://dx.doi.org/10.4155/bio.09.70  [59] Mccambridge, J., Mitcheson, L., Winstock, A., Hunt, N. Five- year trends in patterns of drug use among people who use stimulants in dance contexts in the united kingdom.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Addiction, 2005, 100 (8), 1140-9. http://dx.doi.org/10.1111/j.1360-0443.2005.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Subst  Use M i s u s e , 2009, 44 ( 1 1 ) ,  1 4 9 5-502. http://dx.doi.org/10.3109/ 10826080802543580 [61] Talbert, J.J. Club drugs: Coming to a patient near you.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Nurse Pract 2014, 39 (3), 20-25. http://dx.doi.org/10.1097/01.npr.0000443227.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Psychopharmacol., 2005, 1 9 ( 2 ) ,  1 9 5-204. http://dx.doi.org/10.1177/0269881105049041  [63] Al-Samarraie, M.S., Karinen, R., Morland, J., Stokke Opdal, M. Blood GHB concentrations and results of medical examinations  in 25 car drivers in Norway.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Pharmacol., 2010, 66 (10), 987-98. http://dx.doi.org/10.1007/s00228-010-0870-x  [64] Jones, A.W., Holmgren, A., Kugelberg, F.C.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Toxicol., 2007, 31 (9), 566-72. http://dx.doi.org/10.1093/jat/31.9.566  [65] Johnston, L.D., O'Malley, P.M., Bachman, J.G., Schulenberg, J.E.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Use Misuse 2005, 40 (9-10), 1189-201.  http://dx.doi.org/10.1081/ja-200066730  [68] Bosch, O.G., Quednow, B.B., Seifritz, E., Wetter, T.C.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"J. Psycho- pharmacol., 2012, 2 6 ( 5 ) ,  6 1 8-28. http://dx.doi.org/10.1177/ 0269881111421975 [69] Saytzeff, A. Ueber die reduction des succinylchlorids.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Chemie, 1874, 171, 2 5 8-290. http://dx.doi.org/10.1002/jlac.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Low-carb diets, fasting and euphoria: Is there a link between ketosis and gamma-hydroxybutyr http://dx.doi.org/ 10.1016/j.mehy.2006.07.043 ate (GHB)?",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Anesthesiology, 1964, 25, 7 7 1-5. http://dx.doi.org/10.1097/ 00000542-196411000-00007  [73] Abramowitz, M.Z.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"J. Psychiatry, 2004, 185, 176-7. http://dx.doi.org/10.1192/bjp.185.2.176 [74] Varela, M., Nogue, S., Oros, M., Miro, O. Gamma hydroxybutirate use for sexual assault.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"J., 2004, 2 1 ( 2 ) ,  2 5 5-6. http://dx.doi.org/10.1136/emj.2002.002402  [75] De Paoli, G., Walker, K.M., Pounder, D.J.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Toxicol., 2011, 35 (3), 148-52. http://dx.doi.org/10.1093/anatox/35.3.148  [76] Marinetti, L.J., Isenschmid, D.S., Hepler, B.R., Kanluen, S. Analysis of GHB and 4-methyl-GHB in postmortem matrices after long-term storage.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Toxicol., 2005, 29 (5), 398-400. http://dx.doi.org/10.1093/jat/29.5.398  [78] Moriya, F., Hashimoto, Y. Site-dependent production of gamma-hydroxybutyric acid in the early postmortem period.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Chem., 2010, 398 ( 5 ) ,  2 1 7 3-82. http://dx.doi.org/10.1007/s00216-010-4183-9 [81] Bertol, E., Argo, A., Procaccianti, P., Vaiano, F., Di Milia, M.G., Furlanetto, S., Mari, F. Detection of gamma-hydroxybutyrate  in hair: Validation of GC-MS and LC-MS/MS methods and application to a real case.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Anal., 2012, 70, 518-22. http://dx.doi.org/10.1016/j.jpba.2012.07.009  [82] Mion, G., Tourtier, J.P., Diraison, Y. Gamma-hydroxybutyric acid in hair.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Med., 2006, 354 (1), 96-7. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Toxicol., 2003, 2 7 (8), 574-80. http://dx.doi.org/10.1093/jat/27.8.574  [85] Couper, F.J., Logan, B.K.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Toxicol., 2000, 24 (1), 1-7. http://dx.doi.org/ 10.1093/jat/24.1.1 [86] Ingels, A.S., Neels, H., Lambert, W.E., Stove, C.P.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"A 2013, 1296, 84-92. http://dx.doi.org/10.1016/j.chroma.2013.04.023 [87] Elian, A.A. GC-MS determination of gamma-hydroxybutyric acid (GHB) in blood.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Int., 2001, 122 ( 1 ) ,  4 3-7. http://dx.doi.org/10.1016/s0379-0738(01)00441-8",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Life Sci., 2012, 885-886, 37-42. http://dx.doi.org/ 10.1016/j.jchromb.2011.12.009 [89] Elian, A.A., Hackett, J. Anion exchange SPE and liquid chromatography-tandem mass spectrometry in GHB analysis.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Life Sci., 2011, 879 (31), 3752-8. http://dx.doi.org/10.1016/j.jchromb.2011.09.018  [90] Sorensen, L.K., Hasselstrom, J.B. A hydrophilic interaction liquid chromatography electrospray tandem mass spectrometry method for the simultaneous determination of gamma-hydroxybutyrate and its precursors in forensic whole blood.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"J. Forensic Sci., 2010, 55 ( 2 ) ,  5 3 1-7. http://dx.doi.org/10.1111/j.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Toxicol., 2011, 35 (1), 8-14. http://dx.doi.org/10.1093/anatox/35.1.8  [94] Kaufmann, E., Alt, A.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Toxicol., 2000, 24 (6), 421-8. http://dx.doi.org/10.1093/jat/ 24.6.421 [96] Meyer, M.R., Weber, A.A., Maurer, H.H.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Chem., 2011, 400 ( 2 ) ,  4 1 1-4. http://dx.doi.org/10.1007/s00216-011-4760-6 [97] Grenier, V., Huppe, G., Lamarche, M., Mireault, P. Enzymatic assay for GHB determination in forensic matrices.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"2012, 36 (7), 523-8. http://dx.doi.org/10.1093/jat/bks053  [98] Hasan, L., Jermann, T.M., Weber, J.M., Abrahamsson, L., Sciotti, M.A., Bottcher, M., Jochle, W., Gygax, D., Scholer, A.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Drug Monit., 2011, 33 ( 6 ) ,  7 5 7-65. http://dx.doi.org/10.1097/ftd.0b013e318239a41a  [99] Bravo, D.T., Harris, D.O., Parsons, S.M.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Toxicol., 2013, 37 ( 5 ) ,   291-7.  http://dx.doi.org/10.1093/jat/bkt027  [101] Crunelle, C.L., Cappelle, D., Covaci, A., Van Nuijs, A.L., Maudens, K.E., Sabbe, B., Dom, G., Michielsen, P., Yegles, M., Neels, H. Hair ethyl glucuronide as a biomarker of alcohol consumption in alcohol-dependent patients: Role of gender differences.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Pharmacol., 2001, 4 2 8 ( 3 ) ,  315-21. http://dx.doi.org/10.1016/ s0014-2999(01)01334-6  [104] Crunelli, V., Emri, Z., Leresche, N. Unravelling the brain targets  of gamma-hydroxybutyric acid.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Pharmacol., 2002, 441 ( 3 ) ,  1 5 7-63. http://dx.doi.org/10.1016/s0014-2999(02)01502-9  [106] Chalifoux, J.R., Carter, A.G. GABA-B r e c e p t o r  m o d u l a t i o n  o f  synaptic function.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Neurobiol., 2011, 21 ( 2 ) ,  3 3 9-44.  http://dx.doi.org/10.1016/j.conb.2011.02.004  [107] Snead, O.C., 3rd.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Epilepsia, 1990, 31 ( 4 ) ,  3 6 3-8. http://dx.doi.org/10.1111/j.1528-1157.1990.tb05489.x [108] Snead, O.C., 3rd.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Neurochem., 2000, 75 ( 5 ) ,  1 9 8 6-96. http://dx.doi.org/10.1046/j.1471-4159.2000.0751986.x [109] Tabakoff, B., Hoffman, P.L.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Behav., 2013, 113, 20-37. http://dx.doi.org/10.1016/ j.pbb.2013.10.009 [110] Tyacke, R.J., Lingford-Hughes, A., Reed, L.J., Nutt, D.J.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Pharmacol., 2010, 58, 373-96. http://dx.doi.org/10.1016/s1054-3589(10)58014-1  [111] Carter, L.P., Koek, W., France, C.P.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Ther., 2009, 121 ( 1 ) ,  1 0 0-14. http://dx.doi.org/10.1016/j.pharmthera.2008.10.003 [112] Snead, O.C., 3rd.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Neurobiol., 1996, 50 (1), 1-7. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"P s y c h o p h a r m a c o l o g y (Berl) 2008, 199 (2), 191-8. http://dx.doi.org/10.1007/s00213-008-1160-5  [115] Bay, T., Eghorn, L.F., Klein, A.B., Wellendorph, P. GHB receptor targets in the CNS: Focus on high-affinity binding sites.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Pharmacol., 2014, 8 7 ( 2 ) ,  2 2 0-8. http://dx.doi.org/10.1016/j.bcp.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Neurosci., 2003, 18 ( 1 0 ) ,  2 7 2 2-30. http://dx.doi.org/10.1111/j.1460-9568.2003.03013.x  [117] Schrock, A., Hari, Y., Konig, S., Auwarter, V., Schurch, S., Weinmann, W. Pharmacokinetics of GHB and detection window in serum and urine after single uptake of a low dose of GBL - a n  experiment with two volunteers.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Drug Test Anal., 2014, 6 (4), 363-6. http://dx.doi.org/10.1002/dta.1498  [118] Brailsford, A.D., Cowan, D.A., Kicman, A.T. Pharmacokinetic properties of gamma-hydroxybutyrate (GHB) in whole blood, serum, and urine.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Toxicol., 2012, 36 ( 2 ) ,  8 8-95. http://dx.doi.org/10.1093/jat/bkr023 [119] Hefele, B., Naumann, N., Trollmann, R., Dittrich, K., Rascher, W. Fast-in, fast-out.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Lancet, 2009, 373 (9672), 1398. http://dx.doi.org/ 10.1016/s0140-6736(09)60570-5",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Toxicol., 1996, 20 (3), 171-8. http://dx.doi.org/ 10.1093/jat/20.3.171 [121] Iffland, R., West, A., Bilzer, N., Schuff, A. Zur zuverlässigkeit der blutalkohol bestimmung.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"R e c h t s m e d i z i n, 1999, 9, 1 2 3-130.  http://dx.doi.org/10.1007/s001940050094  [122] Abanades, S., Farre, M., Segura, M., Pichini, S., Barral, D., Pacifici, R., Pellegrini, M., Fonseca, F., Langohr, K., De La Torre, R. Gamma-hydroxybutyrate (GHB) in humans: Pharmacodynamics and pharmacokinetics.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Sci., 2006, 1074, 5 59-76. http://dx.doi.org/10.1196/annals.1369.065  [123] Jones, A.W., Eklund, A., Kronstrand, R. Concentration-time profiles of gamma-hydroxybutyrate in blood after recreational doses are best described by zero-order rather than first-order kinetics.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Toxicol., 2009, 33 (6), 332-5. http://dx.doi.org/10.1093/jat/33.6.332 [124] Palatini, P., Tedeschi, L., Frison, G .",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Pharmacol., 2003, 43 (1), 59-65. http://dx.doi.org/10.1177/0091270002239707  [126] Ferrara, S.D., Tedeschi, L., Frison, G., Orlando, R., Mazzo,  M., Zordan, R., Padrini, R., Palatini, P. Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Pharmacol., 1996, 5 0 (4), 305-10.  http://dx.doi.org/10.1007/s002280050113  [127] Scharf, M.B., Lai, A.A., Branigan, B., Stover, R., Berkowitz, D.B.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Pharmacol., 2004, 44 (3), 253-7. http://dx.doi.org/10.1177/0091270003262795  [129] Morse, B.L., Felmlee, M.A., Morris, M.E.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Dispos., 2012, 40 (1), 64-9. http://dx.doi.org/10.1124/dmd.111.041285  [130] Abanades, S., Farre, M., Segura, M., Pichini, S., Pastor, A., Pacifici, R., Pellegrini, M., De La Torre, R. Disposition of gamma-hydroxybutyric acid in conventional and nonconventional biologic fluids after single drug administration: Issues in methodology and drug monitoring.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Drug Monit., 2007, 29 (1), 64-70. http://dx.doi.org/10.1097/ftd.0b013e3180307e5e  [131] Thai, D., Dyer, J.E., Benowitz, N.L., Haller, C.A.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Psychopharmacol., 2006, 2 6 ( 5 ) ,  5 2 4-9. http://dx.doi.org/ 10.1097/01.jcp.0000237944.57893.28 [132] Brenneisen, R., Elsohly, M.A., Murphy, T.P., Passarelli, J., Russmann, S., Salamone, S.J., Watson, D.E.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Toxicol., 2004, 2 8 ( 8 ) ,  6 25-30. http://dx.doi.org/10.1093/ jat/28.8.625 [133] Kavanagh, P.V., Kenny, P., Feely, J.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Pharmacol., 2001, 53 (3), 399-402. http://dx.doi.org/10.1211/0022357011775460  [134] Morse, B.L., Morris, M.E.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Ther., 2013, 346 (3), 504-13. http://dx.doi.org/10.1124/jpet.113.206250  [135] Thai, D., Dyer, J.E., Jacob, P., Haller, C.A.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Ther., 2 0 0 7, 81 (2), 178-84. http://dx.doi.org/10.1038/sj.clpt.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Toxicol., 2004, 28 (8), 644-9.  http://dx.doi.org/10.1093/jat/28.8.644  [138] Elian, A.A.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Int., 2002, 128 ( 3 ) ,  1 2 0-2. http://dx.doi.org/10.1016/s0379-0738(02)00183-4  [139] Zorntlein, S.W., Kopp, A., Becker, J., Kaufmann, T.J., Rohrich, J., Urban, R. In vitro production of GHB in blood and serum samples under various storage conditions.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Toxicol., 2006, 30 ( 2 ) ,  9 8-105.  http://dx.doi.org/10.1093/jat/30.2.98  [141] Yeatman, D.T., Reid, K. A study of urinary endogenous gamma-hydroxybutyrate (GHB) levels.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"J Anal Toxicol 2003, 27 (1), 40-2. http://dx.doi.org/10.1093/jat/27.1.40  [142] Shima, N., Miki, A., Kamata, T., Katagi, M., Tsuchihashi, H. Urinary endogenous concentrations of GHB and its isomers in healthy humans and diabetics.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Toxicol., 2010, 34 ( 9 ) ,  5 5 5-61. http://dx.doi.org/10.1093/jat/ 34.9.555 [145] Elliott, S., Burgess, V. The presence of gamma-hydroxybutyric acid (GHB) and gamma-butyrolactone (GBL) in alcoholic and non-alcoholic beverages.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Leg Med (Tokyo)., 2006, 8 (4), 231-4. http://dx.doi.org/10.1016/j.legalmed.2006.05.001 [147] Raknes, G., Aronsen, L., Fuskevag, O.M.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Toxicol.,2010, 34 (7), 394-9. http://dx.doi.org/10.1093/jat/ 34.7.394 [148] Kerrigan, S. In vitro p r o d u c t i o n  o f  g a m m a-hydroxybutyrate in antemortem urine samples.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Forensic Toxicol., 2009, 27, 55-60. http://dx.doi.org/10.1007/s11419-009-0067-0  [152] Elliot, S. The presence of gamma-hydroxybutyric acid (GHB) in postmortem biological fluids.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Toxicol., 2001, 25 ( 2), 15 2. http://dx.doi.org/10.1093/jat/25.2.152  [153] Marinetti, L.J., Isenschmid, D.S., Hepler, B.R., Commissaris, R.L.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Med., 1998, 31 ( 6 ) ,  7 1 6-22. http://dx.doi.org/10.1016/s0196-0644(98)70230-6  [158] Miro, O., Nogue, S., Espinosa, G., To-Figueras, J., Sanchez, M. Trends in illicit drug emergencies: The emerging role of gamma-hydroxybutyrate.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"T o x i c o l., 2002, 4 0 ( 2 ) ,  1 2 9-35. http://dx.doi.org/10.1081/clt-120004400  [159] Couper, F.J., Thatcher, J.E., Logan, B.K.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Toxicol., 2004, 28 (6), 481-4. http://dx.doi.org/10.1093/jat/28.6.481  [160] Van Sassenbroeck, D.K., De Neve, N., De Paepe, P., Belpaire, F.M., Verstraete, A.G., Calle, P.A., Buylaert, W.A.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"(Phila)., 2007, 45 ( 5 ) ,  5 3 3-8. http://dx.doi.org/10.1080/15563650701365818  [161] Degenhardt, L., Darke, S., Dillon, P. GHB use among australians: Characteristics, use patterns and associated harm.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Drug Alcohol Depend., 2002, 67 (1), 89-94. http://dx.doi.org/10.1016/s0376-8716(02)00017-0 [162] Ortmann, L.A., Jaeger, M.W., James, L.P., Schexnayder, S.M.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Care, 2009, 25 (11), 758-60. http://dx.doi.org/ 10.1097/pec.0b013e3181bec93b [163] Gunja, N., Doyle, E., Carpenter, K., Chan, O.T., Gilmore, S., Browne, G., Graudins, A. Gamma-hydroxybutyrate poisoning from toy beads.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Med., 1998, 31 (6), 729-36. http://dx.doi.org/10.1016/s0196-0644(98)70232-x  [165] Caldicott, D.G., Kuhn, M. Gamma-hydroxybutyrate overdose and physostigmine: Teaching new tricks to an old drug?",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Med., 2001, 37 (1), 99-102. http://dx.doi.org/10.1067/mem.2001.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"(Phila), 2007, 45 ( 3 ) ,  2 6 1-5. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Pharmacol., 1994, 252 (3), 321-4. http://dx.doi.org/ 10.1016/0014-2999(94)90179-1 [169] Lee, D.C., Satz, W.A., Dougherty, T., Greene, T. An investigation of flumazenil to antagonize gamma-hydroxybutyrate intoxication in a murine model.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Med., 2005, 45 (6), 614-9. http://dx.doi.org/10.1016/j.annemergmed.2004.12.013  [171] Mcdaniel, C.H., Miotto, K.A.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"J Psychoactive Drugs, 2001, 33 ( 2 ) ,  1 4 3-9. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Drug Alcohol Depend., 2013, 132 ( 3 ) ,  4 2 7-33. http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Addiction, 1997, 92 (1), 89-96. http://dx.doi.org/10.1111/j.1360-0443.1997.tb03640.x [174] Ghio, L., Cervetti, A., Respino, M., Belvederi Murri, M., Amore, M. Management and treatment of gamma butyrolactone withdrawal syndrome: A case report and review.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Pract., 2014, 20 (4), 294-300. http://dx.doi.org/10.1097/01.pra.0000452567.84825.07 [175] Wojtowicz, J.M., Yarema, M.C., Wax, P.M. Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: A case report and systematic review.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Med., 2001, 21 (1), 31-3. http://dx.doi.org/10.1016/s0736-4679(01)00324-9  [177] Chew, G., Fernando, A., 3rd.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Australas Psychiatry 2004, 12 (4), 410-1. http://dx.doi.org/ 10.1111/j.1440-1665.2004.02142.x [178] Rosenberg, M.H., Deerfield, L.J., Baruch, E.M. Two cases of severe gamma-hydroxybutyrate withdrawal delirium on a psychiatric unit: Recommend ations for manag ement.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Drug Alcohol Abuse 2003, 29 (2), 487-96. http://dx.doi.org/10.1081/ada-120020529 [179] Dyer, J.E., Roth, B., Hyma, B.A.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Med., 2001, 37 ( 2 ) ,  1 4 7-53. http://dx.doi.org/10.1067/mem.2001.112985  [180] Mcdonough, M., Kennedy, N., Glasper, A., Bearn, J.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Drug Alcohol Depend., 2004, 75 (1), 3-9.  http://dx.doi.org/10.1080/02791072.2007.10400616  [181] Bennett, W.R., Wilson, L.G., Roy-Byrne, P.P.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"J. Psychoactive Drugs 2007, 3 9 ( 3 ) ,  2 9 3-6. http://dx.doi.org/10.1080/02791072.2007.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Med., 2006, 48 ( 2 ) ,  2 1 9-20. http://dx.doi.org/10.1016/j.annemergmed.2006.03.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Sci., 2006, 1074, 545-58. http://dx.doi.org/ 10.1196/annals.1369.055 [184] Sivilotti, M.L., Burns, M.J., Aaron, C.K., Greenberg, M.J. Pentobarbital for severe gamma-butyrolactone withdrawal.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Med., 2001, 38 (6), 660-5. http://dx.doi.org/10.1067/mem.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"J. Forensic Leg Med., 2010, 17 ( 6 ) ,  3 3 3-8. http://dx.doi.org/10.1016/j.jflm.2010.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Acta, 2012, 413 (3-4), 365-77. http://dx.doi.org/10.1016/j.cca.2011.10.034  [189] Megarbane, B., Fompeydie, D., Garnier, R., Baud, F.J.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Toxicol., 2002, 4 0 ( 1 ) ,  7 7-80. http://dx.doi.org/10.1081/clt-120002888  [190] Caputo, F., Bernardi, M. Sodium oxybate to treat alcohol dependence: 20 years of clinical experience.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Biol., 2013, 18(6), 901-3. http://dx.doi.org/10.1111/adb.12113 [191] Caputo, F., Vignoli, T., Maremmani, I., Bernardi, M., Zoli, G. Gamma hydroxybutyric acid (GHB) for the treatment of alcohol dependence: A review.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Public Health, 2009, 6 (6), 1917-29. http://dx.doi.org/10.3390/ijerph6061917",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Drug Alcohol Rev., 2014, 33 ( 1 ) ,   27-32. http://dx.doi.org/10.1111/dar.12084 [193] Wikner, B.N., Ohman, I., Selden, T., Druid, H., Brandt, L., Kieler, H. Opioid-related mortality and filled prescriptions for buprenorphine and methadone.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"J.Med., 2012, 1 2 5 ( 9 ) ,  8 5 4-8.  http://dx.doi.org/10.1016/j.amjmed.2012.02.019  [195] Wohlfarth, A., Weinmann, W. Bioanalysis of new designer drugs.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Bioanalysis, 2010, 2 (5), 965-79. http://dx.doi.org/10.4155/bio.10.32 [196] Zawilska, J.B., Wojcieszak, J.",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Med., 2000, 18 (1), 65-70. http://dx.doi.org/ 10.1016/s0736-4679(99)00163-8  [199] Chin, R.L.",OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Med., 2001, 37 (5), 551-2. http://dx.doi.org/10.1067/ mem.2001.114466   Received: August 01, 2014 Revised: October 01, 2014 Accepted: October 25, 2014",Non-OADS,/arxiv_data1/oa_pdf/e0/ec/CN-13-47.PMC4462042.pdf
"Neurosci., 2002, 3, 9 7 5-9. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"Neurosci., 2004, 5, 421-5. http://dx.doi.org/10.1038/nrn1390  [5] Chatterjee, A.",Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"Neurosci., 2008, 258, 110e14 http://dx.doi.org/10.1007/s00406-008-5022-2  [7] Morton, W.A.",Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"Psychiatry, 2000, 2, 159-164. http://dx.doi.org/10.4088/pcc.v02n0502  [8] Leonard, B.E.",Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"Exp., 2004, 19, 151-180. http://dx.doi.org/10.1002/hup.579  [9] Lange, K.W.",OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"Disord., 2010, 2(4), 241-255. http://dx.doi.org/10.1007/ s12402-010-0045-8 [10] Heal, D.J.",OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"CNS Drugs, 2006, 20 ( 9 ) ,  7 1 3-38. http://dx.doi.org/10.2165/00023210-200620090-00002  [11] Iversen, L. Neurotransmitter transporters and their impact on the development of psychopharmacology.",Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"http://dx.doi.org/10.1038/sj.bjp.0706428  [12] Viggiano, D.; Vallone, D.; Sadile, A. Dysfunctions in dopamine systems and ADHD: evidence from animals and modeling.",OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"Plast., 2004, 11 (1-2), 97-114. http://dx.doi.org/10.1155/np.2004.97 [13] Miller, G.M.",Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"Neurochem., 2011, 116 (2), 164-76. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"Psychiatry, 2005, 57, 1377-1384.  http://dx.doi.org/10.1016/j.",Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"Neurosci., 2014, 8, 38. http://dx.doi.org/10.3389/fnsys.2014.00038  [18] Lee, M, J.; Yang, P.B.",OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"Neuropharmacology, 2009, 57(3), 201-207. http://dx.doi.org/10.1016/j.neuropharm.2009.06.",Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"Psychiatry, 2012, 15, 72(10), 880-888. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"http://dx.doi.org/10.1037/e567272009-001 [22] Babcock, Q.; Byrne, T. Student perceptions of methylphenidate abuse at a public liberal arts college.",Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"Health, 2000, 49, 143-145. http://dx.doi.org/10.1080/07448480009596296  [23] Teter, C.J.",Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"Pharmacotherapy, 2003, 23, 609-617. http://dx.doi.org/10.1592/phco.23.5.609.34187  [24] White, B.P.",Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"Metab., 2010, 95(4), 1533-1543. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"Chem., 2011, 1 1(5), 374-89. http://dx.doi.org/10.2174/ 138955711795445925 [27] Casavant, M.J.; Blake, K.; Griffith, J.; Yates, A.; Copley, L.M.",Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"North Am., 2007, 54(4), 677-90. http://dx.doi.org/10.1016/j.pcl.",OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"Pharmacol., 2008, 154, 502-521. http://dx.doi.org/10.1038/bjp.",Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"Metab., 1992, 74, 465-469. http://dx.doi.org/10.1210/ jcem.74.3.1740476 [31] Kersey, R.D.",Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"Sports Med., 1990, 10(5), 303-37. http://dx.doi.org/10.2165/00007256-199010050-00003 [38] Graham, M.R.",Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"Psychiatry, 2003, 15, 121-30. http://dx.doi.org/10.3109/10401230309085677  [44] Thiblin, I.; Runeson, B.; Rajs, J. Anabolic androgenic steroids and suicide.",Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"Ethics, 2009, 15(3), 311-41. http://dx.doi.org/10.1007/s11948-009-9142-5  [47] Brown N. Hope against hypedaccountability in biopasts, presents and futures.",Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"http://dx.doi.org/10.1177/03063127030333002  [49] Rose, N. The politics of life itself.",Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
http://dx.doi.org/10.1177/02632760122052020,Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"Ethics, 2009, 35, 6 1 1-615 http://dx.doi.org/10.1136/jme.2009.",Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"511-19. http://dx.doi.org/10.1002/9780470510544.ch70 [52] Bertol, E.; Mari, F.; Vaiano, F.; Romano, G.; Zaami, S.; Baglìo, G.; Busardò, F.P.",Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"Invest., 1997, 100(3), 745-53. http://dx.doi.org/10.1172/jci119587 [54] World Anti-Doping Agency.",Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"Health Care Philos., 2014, 17, 239-240. http://dx.doi.org/10.1007/s11019-013-9497-x    Received: July 30, 2014 Revised: October 14, 2014 Accepted: October 15, 2014",Non-OADS,/arxiv_data1/oa_pdf/a6/5f/CN-13-5.PMC4462043.pdf
"Explore (NY), 2006, 2(1), 55-59. http://dx.doi.org/10.1016/j.explore.2005.10.012  [2] Weinberg, B.A.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Int., 2013, 6 3(6), 594-609. http://dx.doi.org/10.1016/j.neuint.2013.09.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Neurol., 2007, 203, 241-245. http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Psychopharmacology (Berl), 2013, 225(2), 251-274. http://dx.doi.org/10.1007/s00213-012-2917-4 [9] Rogers, P.J.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Psychopharmacology (Berl), 2013, 226(2), 229-240. http://dx.doi.org/10.1007/s00213-012-2889-4 [10] Griffiths, R.R.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"315-341. http://dx.doi.org/10.1007/978-3-642-60963-3_9 [11] Postuma, R.B.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
Available at: http://www.cancer.org/cancer/news/expertvoices/post/2011/05/25/another-reason-to-have-a-second-cup-of-coffee.aspx.,Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Cancer Causes Control., 2004, 15(8), 743-757. http://dx.doi.org/10.1023/b:caco.0000043415.28319.c1  [16] Green Tea.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
Available at: http://www.cancer.org/treatment/ treatmentsandsideeffects/complementaryandalternativemedicine/herbsvitaminsandminerals/green-tea.,Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Epidemiol., 1998, 147(5), 503-510. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Med., 1990, 41, 277-278. http://dx.doi.org/10.1146/annurev.me.41.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Clinical Chem., 2005, 51(8), 1493-1498. http://dx.doi.org/10.1373/ clinchem.2005.048033 [24] Mandel, H.G.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Toxicol., 2002, 40(9), 1231-1234. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Med., 1999, 341 (22), 1639-1644. http://dx.doi.org/10.1056/nejm199911253412202 [26] Kalow, W.; Tang, B.K.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Ther., 1991, 49(1), 44-48. http://dx.doi.org/10.1038/ clpt.1991.8 [27] Eteng, M.U.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Ther., 1983, 34(4), 546-555. http://dx.doi.org/10.1038/clpt.1983.212 [29] Shively, C.A.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Ther., 1985, 37(4), 415-424. http://dx.doi.org/10.1038/clpt.1985.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Pharmacogenetics, 1996, 6(2), 121-149. http://dx.doi.org/10.1097/00008571-199604000-00001  [31] Lelo, A.; Birkett, D.J.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Pharmacol., 1986, 22(2), 177-182. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Pharmacol., 1999, 47(3), 299-305. http://dx.doi.org/10.1046/j.1365-2125.1999.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Toxic., 1988, 26(6), 541-565. http://dx.doi.org/ 10.1016/0278-6915(88)90007-5 [35] Aldridge, A.; Bailey, J.; Neims, A.H.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"http://dx.doi.org/ 10.1038/clpt.1988.63 [38] Cook, D.G.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Trends Neurosci., 1997, 20(10), 482-487. http://dx.doi.org/10.1016/s0166-2236(97)01096-5 [43] Smits, P.; Boekema, P.; De Abreu, R.; Thien, T.; van 't Laar, A.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Pharmacol., 1987, 10(2), 136-143. http://dx.doi.org/10.1097/00005344-198708000-00002 [44] Cameron, O.G.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"PLoS One, 2009, 4(5), 5665. http://dx.doi.org/10.1016/0024-3205(90)90174-p [46] Fastbom, J.; Pazos, A.; Palacios, J. M. The distribution of adenosine A1 receptors and 5’-nucleotidase in the brain of some commonly used experimental animals.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Neuroscience, 1987, 2 2(3), 813-826. http://dx.doi.org/10.1016/0306-4522(87)92961-7  [47] Goodman, R.R.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Neuroscience, 1997, 7 9(3), 753-764. http://dx.doi.org/10.1016/s0306-4522(97)00046-8 [50] Supinski, G.S.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Metab., 2008, 33(6), 1284-1289. http://dx.doi.org/10.1139/h08-121  [53] Goldstein, E.R.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Sports Nutr., 2010, 7(1), 5. http://dx.doi.org/10.1186/1550-2783-7-5 [54] Osswald, H.; Schnermann, J. Methylxanthines and the kidney.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Pharmacol., 2011, 200, 391-412. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Cardiol., 2006, 98(11), 1538-1541. http://dx.doi.org/10.1016/j.amjcard.2006.06.058 [56] Chesley, A.; Hultman, E.; Spriet, L.L.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Sports Med., 2001, 31(11), 785-807. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"(1985), 2004, 96(3), 943-950. http://dx.doi.org/10.1152/japplphysiol.00745.2003 [60] Pedersen, D.J.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"(1985), 2008, 105(1), 7-13. http://dx.doi.org/10.1152/japplphysiol.01121.2007 [61] Spriet, L.L.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Scand., 2010, 54(4), 521-523. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
http://dx.doi.org/10.1152/ajpheart.,Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Med., 2011, 124, 284-289. http://dx.doi.org/10.1016/j.amjmed.2010.10.017 [70] Prineas, R.J.; Jacobs, D.R.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Pharmacol., 1979, 19(1), 46-55. http://dx.doi.org/10.1002/j.1552-4604.1979.tb01616.x [72] Dobmeyer, D.J.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Med., 1983, 3 0 8(14), 814-816. http://dx.doi.org/10.1056/ nejm198304073081405  [73] Caron, M.F.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Pharmacother., 2009, 43(4), 596-602. http://dx.doi.org/10.1345/aph.1l614  [75] Ammar, R.; Song, J.C.; Kluger, J.; White, C.M.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Pharmacotherapy., 2001, 21(4), 437-442.  http://dx.doi.org/10.1592/phco.21.5.437.34502  [76] Donnerstein, R.L.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Heart J., 1998, 136(4 Pt 1), 643-646. http://dx.doi.org/10.1016/s0002-8703(98)70011-0  [77] Sutherland, D.J.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Cardiol., 2014, 30(4), 448-454. http://dx.doi.org/10.1016/j.cjca.2013.12.026  [81] Corti, R.; Binggeli, C.; Sudano, I.; Spieker, L.; Hänseler, E.; Ruschitzka, F.; Chaplin, W.F.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Circulation, 2002, 106(23), 2935-2940. http://dx.doi.org/10.1161/01.cir.0000046228.97025.3a  [82] Swartz, M.F.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Hepatol., 2012, 57(5), 1090-1096. http://dx.doi.org/10.1016/j.jhep.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Toxicol., 2013, 33(9), 970-979. http://dx.doi.org/10.1002/jat.2788  [85] Arauz, J.; Zarco, N.; Segovia, J.; Shibayama, M.; Tsutsumi, V.; Muriel, P. Caffeine prevents experimental liver fibrosis by blocking the expression of TGF-β.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Cardiol., 2004, 93(8), 1022-1026. http://dx.doi.org/10.1016/j.amjcard.2003.12.057 [88] Savoca, M.R.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Hypertens., 2005, 18(1), 116-120. http://dx.doi.org/10.1016/j.amjhyper.2004.08.011  [89] Palatini, P.; Ceolotto, G.; Ragazzo, F; Dorigatti, F.; Saladini, F.; Papparella, I.; Mos, L.; Zanata, G.; Santonastaso, M. CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Hypertens., 2009, 27(8), 1594-1601. http://dx.doi.org/10.1097/hjh.0b013e32832ba850 [90] Whitsett, T.L.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Cardiol., 1984, 5 3(7), 918-922. http://dx.doi.org/10.1016/0002-9149(84)90525-3  [91] Böttcher, M.; Czernin, J.; Sun, K.T.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Hypertension, 2001, 38(2), 227-231. http://dx.doi.org/10.1161/01.hyp.38.2.227  [93] Hatano, Y.; Mizumoto, K.; Yoshiyama, T.; Yamamoto, M.; Iranami, H. Endothelium-dependent and -independent vasodilation of isolated rat aorta induced by caffeine.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Cardiol., 2005, 98(3), 425-430. http://dx.doi.org/10.1016/j.ijcard.2003.11.013 [96] Forman, J.; Aizer, A.; Young, C.R.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Med., 1997, 2 9(1), 178-180.  http://dx.doi.org/10.1016/s0196-0644(97) 70326-3 [97] Wilson, R.E.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Toxicol., 2012, 12(2), 175-179. http://dx.doi.org/10.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Amino Acids, 2001, 20(1), 75-82. http://dx.doi.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Circulation, 2012, 125(11), 1447-1448. http://dx.doi.org/10.1161/circulationaha.111.086017 [100] Worthley, M.I.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Med., 2010, 123(2), 184-187. http://dx.doi.org/10.1016/j.amjmed.2009.09.013  [101] Grobbee, D.E.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Diabetes Care, 2009, 32(6), 1043-1045. http://dx.doi.org/10.2337/dc08-2251  [103] Lopez-Garcia, E.; van Dam, R.M.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Circulation, 2006, 113(17), 2045-2053. http://dx.doi.org/10.1161/circulationaha.105.598664 [104] Hirsch, A.T.; Gervino, E.V.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Behav., 1989, 32(1), 181-186. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Psychopharmacology (Berl), 1985, 87(3), 344-350. http://dx.doi.org/10.1007/bf00432719  [110] Sicard, B.A.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"J. Alzheimers Dis., 2010, 20 (Suppl 1), 85-94. http://dx.doi.org/10.1007/s00213-005-0084-6 [112] James, J.E.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Psychopharmacology (Berl), 2005, 182(1), 1-8. http://dx.doi.org/ 10.1007/s00213-005-0084-6 [113] Jarvis, M.J.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Psychopharmacology (Berl), 1993, 110(1-2), 45-52. http://dx.doi.org/10.1007/bf02246949  [114] Committee on Military Nutrition Research.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Psychopharmacol., 1997, 11(3), 219-224. http://dx.doi.org/10.1177/026988119701100304 [116] El Yacoubi, M.; Ledent, C.; Parmentier, M.; Costentin, J.; Vaugeois, J.M.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Psycho- pharmacology (Berl), 2000, 148(2), 153-163. http://dx.doi.org/ 10.1007/s002130050037 [117] Sawyer, D.A.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Med., 1982, 5(4), 415-439. http://dx.doi.org/10.1007/bf00845371  [118] Rogers, P.J.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Behav., 2011, 99(1), 81-86. http://dx.doi.org/10.1016/ j.pbb.2011.04.001 [120] Kaplan, G.B.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Pharmacol., 1997, 37(8), 693-703. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Med., 2001, 132(6), 1177-1179. http://dx.doi.org/10.1023/a:1014511415473  [122] Maia, L.; de Mendonça, A.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Neurology, 2007, 69(6), 536-545. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Disord., 2004, 10(8), 465-468. http://dx.doi.org/10.1016/j.parkreldis.2004.06.004  [125] Glade, M.J. Caffeine-Not just a stimulant.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Nutrition, 2010, 26(10), 932-938. http://dx.doi.org/10.1016/j.nut.2010.08.004  [126] Snel, J.; Lorist, M.M.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Pharmacol., 2009, 193, 471-534. http://dx.doi.org/10.1007/978-3-540-89615-9_16 [129] Federico, S.; Spalluto, G. Therapeutic potential of A2 and A3 adenosine receptor: a review of novel patented ligands.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Pat., 2012, 22(4), 369-390. http://dx.doi.org/10.1517/ 13543776.2012.669375 [130] Eskelinen, M.H.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Epilepsy Behav., 2011, 22(2), 207-213. http://dx.doi.org/10.1016/j.yebeh.2011.07.004 [132] Schenone, S.; Brullo, C.; Musumeci, F.; Bruno, O.; Botta, M.  A1 receptors ligands: past, present,and future trends.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Chem., 2010, 10(9), 878-901. http://dx.doi.org/10.2174/ 156802610791268729 [133] Xiao, D.; Cassin, J.J.; Healy, B.; Burdett, T.C.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Brain Res., 2011, 1367, 310-318. http://dx.doi.org/10.1016/j.brainres.2010.08.099 [134] Camilo, F.; Goldstein, L.B.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Stroke, 2004, 35(7), 1769-1775. http://dx.doi.org/10.1161/ 01.str.0000130989.17100.96 [135] Chen, J.F.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Pharmacol., 2011, 200, 267-310. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Stroke Res., 2014, 5(3), 330-337. http://dx.doi.org/10.1007/s12975-013-0309-7  [137] Salvemini, D.; Kim, S.F.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Physiol., 2013, 304(7), 473-487. http://dx.doi.org/10.1152/ ajpregu.00355.2012 [138] Yadav, S.; Gupta, S.P.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Res., 2012, 37(4), 875-884. http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Food Chem., 2012, 135(3), 2095-2102. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Disord., 2012, 27(10), 1276-1282. http://dx.doi.org/10.1002/mds.25076 [141] Sonsalla, P.K.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Neurol., 2012, 234(2), 482-487. http://dx.doi.org/10.1016/j.expneurol.2012.01.022  [142] Prasanthi, J.R.; Dasari, B.; Marwarha, G. Caffeine protects against oxidative stress and Alzheimer's disease-like pathology in rabbit hippocampus induced by cholesterol-enriched diet.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Med., 2010, 49(7), 1212-1220. http://dx.doi.org/10.1016/ j.freeradbiomed.2010.07.007 [143] Chen, X.; Ghribi, O.; Geiger, J.D.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Neuropharmacology, 2012, 63(8), 1368-1379. http://dx.doi.org/10.1016/j.neuropharm.2012.08.018 [145] Gao, Y.; Phillis, J.W.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Life Sci., 1994, 5 5(3), 61-65. http://dx.doi.org/10.1016/ 0024-3205(94)00889-2 [146] Laska, E.M.; Sunshine, A.; Mueller, F.; Elvers, W.B.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"JAMA, 1984, 251(13), 1711-1718. http://dx.doi.org/10.1001/jama.251.13.1711  [147] Diamond, S.; Balm, T.K.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Ther., 2000, 68(3), 312-319. http://dx.doi.org/10.1067/mcp.2000.109353 [148] Ward, N.; Whitney, C.; Avery, D.; Dunner, D. The analgesic effects of caffeine in headache.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Pain Med., 1999, 24(1), 51-54. http://dx.doi.org/10.1097/00115550-199924010-00010  [150] Esmaoglu, A.; Akpinar, H.; Uğur, F. Oral multidose caffeine-paracetamol combination is not effective for the prophylaxis of postdural puncture headache.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Anesth., 2005, 17(1), 58-61. http://dx.doi.org/10.1016/j.jclinane.2004.04.003  [151] Shapiro, R.E.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Pain Headache Rep., 2008, 12(4), 311-315. http://dx.doi.org/10.1007/s11916-008-0052-z [152] Griffiths, R.R.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Psychopharmacology (Berl), 1988, 94(4), 437-451. http://dx.doi.org/10.1007/bf00212836 [153] Griffiths, R.R.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Med., 2004, 66(1), 63-71. http://dx.doi.org/10.1097/10.psy.0000107884.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Hypertension, 2004, 43(4), 760-765. http://dx.doi.org/10.1161/ 01.hyp.0000120965.63962.93 [158] Eisenberg, S. Looking for the Perfect Brew.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Contam., 2003, 20(1), 1-30. http://dx.doi.org/10.1080/ 0265203021000007840 [169] Higdon, J.V.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Nutr., 2006, 46(2), 101-123. http://dx.doi.org/10.1080/10408390500400009  [170] Moffatt, A.C.; Osselton, M.D.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Forensic Sci., 1974, 3(3), 275-278. http://dx.doi.org/10.1016/0300-9432(74)90056-9 [172] Turner, J.E.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Toxicol., 1977, 1 0(3), 341-344. http://dx.doi.org/10.3109/ 15563657708992428 [173] McGee, M.B.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Int., 1983, 23(2-3), 265-275. http://dx.doi.org/10.1016/0379-0738(83)90155-x [176] Garriott, J.C.; Simmons, L .",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Toxicol., 1985, 9(3), 141-143. http://dx.doi.org/10.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Int., 1999, 103, 49-52. http://dx.doi.org/10.1016/s0379-0738(99)00073-0  [181] Holmgren, P.; Nordén-Pettersson, L.; Ahlner, J. Caffeine fatalities--four case reports.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Int., 2005, 153(1), 67-69. http://dx.doi.org/10.1016/ j.forsciint.2005.04.016 [183] Thelander, G.; Jönsson, A.K.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"(Phila)., 2010, 48(4), 354-358.  http://dx.doi.org/10.3109/15563650903586752  [184] Jabbar, S.B.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Pathol., 2013, 34(4), 321-324. http://dx.doi.org/10.1097/paf.0000000000000058  [185] Jantos, R.; Stein, K.M.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Anal., 2013, 5(9-10), 773-776. http://dx.doi.org/10.1002/dta.1485  [186] Bonsignore, A.; S b l a n o ,  S .",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Pathol., 2014, 10 ( 3 ) ,  4 4 8-451. http://dx.doi.org/ 10.1007/s12024-014-9571-6 [187] Bernstein, G.A.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Drug Alcohol Depend., 2002, 66(1), 1-6. http://dx.doi.org/10.1016/s0376-8716(01)00181-8 [188] Oberstar, J.V.",OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"Psychopharmacol., 2002, 12(2), 127-135. http://dx.doi.org/10.1089/ 104454602760219162 [189] Strain, E.C.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"JAMA, 1994, 2 7 2(13), 1043-1048. http://dx.doi.org/10.1001/jama.272.13.1043  [190] Svikis, D.S.",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"J. Psychiatry, 2005, 162(12), 2344-2351. http://dx.doi.org/10.1176/ appi.ajp.162.12.2344   Received: July 31, 2014 Revised: October 10, 2014 Accepted: October 25, 2014",Non-OADS,/arxiv_data1/oa_pdf/9b/ee/CN-13-71.PMC4462044.pdf
"[Online] 2014, 1-10. http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/2014/WADA-prohibited-list-2014-EN.pdf [Accessed on: 31.07.].",Non-OADS,/arxiv_data1/oa_pdf/bd/9f/CN-13-89.PMC4462045.pdf
[Online] 2014. http://www.wada-ama.org/ Documents/Resources/Testing-Figures/WADA-2013-Anti-Doping-Testing-Figures-LABORATORY-REPORT.pdf [Accessed on: 31.07].,Non-OADS,/arxiv_data1/oa_pdf/bd/9f/CN-13-89.PMC4462045.pdf
"DOI: http://dx.doi.org/10.1210/er.2013-1058 [11] Carreau, S.; Wolczynski, S.; Galeraud-Denis, I. Aromatase, oestrogens and human male reproduction.",OADS,/arxiv_data1/oa_pdf/bd/9f/CN-13-89.PMC4462045.pdf
"DOI: http://dx.doi.org/10.1210/er.2011-1033 [20] Weigel, N.L.",Non-OADS,/arxiv_data1/oa_pdf/bd/9f/CN-13-89.PMC4462045.pdf
"DOI: http://dx.doi.org/10.1210/me.2007-0101 [21] Heemers, H.V.",OADS,/arxiv_data1/oa_pdf/bd/9f/CN-13-89.PMC4462045.pdf
"DOI: http://dx.doi.org/10.1210/er.2007-0019 [22] Stashi, E.; York, B.; O’Malley, B.W.",Non-OADS,/arxiv_data1/oa_pdf/bd/9f/CN-13-89.PMC4462045.pdf
"D O I :  http://dx.doi.org/10.1210/me.2002-0070 [32] Foradori, C.D.",Non-OADS,/arxiv_data1/oa_pdf/bd/9f/CN-13-89.PMC4462045.pdf
"D O I :  http://dx.doi.org/10.1210/jc.2004-0084 [39] Herbst, K.L.",OADS,/arxiv_data1/oa_pdf/bd/9f/CN-13-89.PMC4462045.pdf
"D O I :  http://dx.doi.org/10.1093/brain/aws284 [53] Vest, R.S.",OADS,/arxiv_data1/oa_pdf/bd/9f/CN-13-89.PMC4462045.pdf
".http://dx.doi.org/10.1155/2014/451520 [65] Severo, C.B.",Non-OADS,/arxiv_data1/oa_pdf/bd/9f/CN-13-89.PMC4462045.pdf
"DOI: http://dx.doi.org/10.1210/en.2009-0640 [73] Caraci, F.; Pistarà, V.; Corsaro, A.; Tomasello, F.; Giuffrida, M.L.",Non-OADS,/arxiv_data1/oa_pdf/bd/9f/CN-13-89.PMC4462045.pdf
Available  from: http://www.cochrane‑handbook.org.,OADS,/arxiv_data1/oa_pdf/8b/fa/IJNMR-20-293.PMC4462052.pdf
Stage two aimed to determine the expert panel’s  consensus level with each component of neonatal  palliative clinical care guideline through conducting  Table 1: Combination of key words used in systematic research Key word Combination Palliative care Palliative care and neonatal Palliative care and newborn Palliative care and NICU Guideline Guideline and palliative care Guideline and palliative care and neonatal Guideline and palliative care and NICU End of life care End of life care and neonatal End of life care and guideline NICU: Neonatal intensive care unit Table 2: Research database Guideline international network (GIN) (http://www.g‑i‑n.net) National guidelines clearing house (NGC) (http://www.guideline.gov.),Non-OADS,/arxiv_data1/oa_pdf/df/b4/IJNMR-20-309.PMC4462054.pdf
National institute for clinical excellence (NICE)   (htpp://www.nice.org.uk/guidance/) Clinical practice guideline (CPGs)   (http://www.acponline.org/clinical information/guidelines/) Scottish intercollegiate guidelines network (SING)   (http://www.sing.ac.uk/guidelines/) Ovid Elsevier science Springer PubMed Google scholar SID Iran doc Magiran SID: Scientific information database,Non-OADS,/arxiv_data1/oa_pdf/df/b4/IJNMR-20-309.PMC4462054.pdf
Available from:  http://www.who.int/bulletin/volumes/88/1/08‑062554/en/[Last  accessed on 2013 Jan].,Non-OADS,/arxiv_data1/oa_pdf/0f/0d/IJNMR-20-322.PMC4462056.pdf
Available from:http://www.aifs.gov.,Non-OADS,/arxiv_data1/oa_pdf/0d/0b/IJNMR-20-371.PMC4462064.pdf
Available from: http://www.elsevier.com/nedt.,Non-OADS,/arxiv_data1/oa_pdf/06/4b/IJNMR-20-378.PMC4462065.pdf
Available  from: http://www.intl.elsevierhealth.com/journals/nedt.,Non-OADS,/arxiv_data1/oa_pdf/06/4b/IJNMR-20-378.PMC4462065.pdf
": 9670‑86)  and by coordinating with the authorities, as well as taking  into consideration the “Research Provisions Frameworks  of Isfahan University of Medical Sciences.” Call for  participation in the project was publicized online on the  hospital’s website (http://www.alzahra.mui.ac.ir), on Health  Office link, and the project website (www.nurseeducator.ir).",Non-OADS,/arxiv_data1/oa_pdf/7b/ae/IJNMR-20-387.PMC4462066.pdf
Available from: http://www.naccho.org/ MAPP [Last cited on 2013].,OADS,/arxiv_data1/oa_pdf/7b/ae/IJNMR-20-387.PMC4462066.pdf
Available from: http://www.ctb.ku.edu/en/ tablecontents/chapter 2_section13_main.aspx [Last cited on  2012].,Non-OADS,/arxiv_data1/oa_pdf/7b/ae/IJNMR-20-387.PMC4462066.pdf
Available from: http://www.hbi.ir/ [Last accessed on 2012 Jun 12].,OADS,/arxiv_data1/oa_pdf/ca/9e/IJNMR-20-398.PMC4462067.pdf
Available from: http://www.behdasht.,Non-OADS,/arxiv_data1/oa_pdf/ca/9e/IJNMR-20-398.PMC4462067.pdf
Available from: http://www.who.,Non-OADS,/arxiv_data1/oa_pdf/ca/9e/IJNMR-20-398.PMC4462067.pdf
"Ministry of Health and Medical Education, Strategic Policy,  Ministry of Health and Medical Education in the Third  Development Plan, Available from: http://www.behdasht.gov.",Non-OADS,/arxiv_data1/oa_pdf/ca/9e/IJNMR-20-398.PMC4462067.pdf
Available from: http://www.siasat.behdasht.gov.,Non-OADS,/arxiv_data1/oa_pdf/ca/9e/IJNMR-20-398.PMC4462067.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ ),whichpermitsnon-commercialre-use,distribution,andreproductioninanymedium,pro- vided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/67/1a/ftv036.PMC4462183.pdf
"This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/90/44/S0047279415000069a.PMC4462201.pdf
"Care Act 2014 (c.23), London: The Stationery Ofﬁce (TSO), http://www.legislation.gov.uk/ ukpga/ 2014 /23/contents/enacted/data.htm Carmichael, F., Charles, S. and Hulme, C. ( 2010 ), ‘Who will care?",Non-OADS,/arxiv_data1/oa_pdf/90/44/S0047279415000069a.PMC4462201.pdf
"Children and Families Act 2014 (c.6), London: TSO, http://www.legislation.gov.uk/ ukpga/ 2014 /6/contents/enacted .",Non-OADS,/arxiv_data1/oa_pdf/90/44/S0047279415000069a.PMC4462201.pdf
"London: NIHR SSCR, http://www.sscr.nihr.ac.uk/PDF/Insights/IN 35.pdf.",Non-OADS,/arxiv_data1/oa_pdf/90/44/S0047279415000069a.PMC4462201.pdf
"Work and Families Act 2006 (c.18), London: TSO, http://www.legislation.gov.uk/ukpga/ 2006 /18/pdfs/ukpga_ 20060018 _en.pdf .",Non-OADS,/arxiv_data1/oa_pdf/90/44/S0047279415000069a.PMC4462201.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ab/b3/kwu468.PMC4462334.pdf
"dSelf-reported physical activity in a typical week, assessed using an interviewer-administered modified Global Physical Activity Ques- tionnaire (available at https://www2.cscc.unc.edu/hchs/system/files/ forms/UNLICOMMPhysicalActivityPAE02182008.pdf ).",OADS,/arxiv_data1/oa_pdf/ab/b3/kwu468.PMC4462334.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b8/10/kwv010.PMC4462336.pdf
"We picked up proteins directly connected with GBP1on the network such as GBP2, GBP3, GBP5, TAP1 and IL-15in reference to COXPRESdb (http://coxpresdb.jp/).",OADS,/arxiv_data1/oa_pdf/2e/51/cas0105-1351.PMC4462352.pdf
"[cited 21 November 2013] Available from URL: http://ganjoho.jp/public/sta- tistics/pub/statistics01.html [In Japanese] 4 Burris HA III, Moore MJ, Anderson J et al.",OADS,/arxiv_data1/oa_pdf/e3/62/cas0105-1321.PMC4462360.pdf
Potential transcription factor binding site motifs were searched using TFSEARCH (http://mbs.cbrc.jp/research/db/TFSEARCH.,OADS,/arxiv_data1/oa_pdf/fe/20/cas0105-1261.PMC4462363.pdf
html) and TESS (http://www.cbil.upenn.edu/tess) programs29.,Non-OADS,/arxiv_data1/oa_pdf/fe/20/cas0105-1261.PMC4462363.pdf
Clini- cal data for the AML cohort were downloaded from the TCGA repository website (http://cancergenome.nih.gov/).,OADS,/arxiv_data1/oa_pdf/d3/5a/cas0105-1457.PMC4462368.pdf
"Statistical analysis was carried out with SPSS 19.0 (SPSS Inc., Chicago, IL, USA) and R software (http://www.r-project.org/).",OADS,/arxiv_data1/oa_pdf/9c/2c/cas0105-1447.PMC4462371.pdf
The statistical analysis was carried out by using the R 1.6 package for Windows (http://cran.ism.ac.jp/).,OADS,/arxiv_data1/oa_pdf/1c/33/cas0105-1496.PMC4462375.pdf
Available from URL: http://investor.intuitivesurgical.com/.,Non-OADS,/arxiv_data1/oa_pdf/1a/e8/cas0105-1421.PMC4462377.pdf
Available from URL: http://www.R-project.org/.,Non-OADS,/arxiv_data1/oa_pdf/1a/e8/cas0105-1421.PMC4462377.pdf
Available from URL: http://CRAN.R-project.org/package=rms.,Non-OADS,/arxiv_data1/oa_pdf/1a/e8/cas0105-1421.PMC4462377.pdf
Avail- able from URL: http://gking.harvard.edu/zelig.,Non-OADS,/arxiv_data1/oa_pdf/1a/e8/cas0105-1421.PMC4462377.pdf
"The whole report of thisresearch project, which includes all statistics of 10-year sur-vival by period, sex, and cancer site and the latest 10-year sur- vival and conditional survival by sex, cancer site, age group, and stage at diagnosis is available on the website: http://www.mc.pref.osaka.jp/ocr/data/data2/j-cansis.html (in Japanese).",OADS,/arxiv_data1/oa_pdf/e0/ce/cas0105-1480.PMC4462379.pdf
Available from URL:http://www.lshtm.ac.uk/eph/ncde/cancersurvival/research/concord/index.html Supporting Information Additional supporting information may be found in the online version of this article: Table S1.1.,OADS,/arxiv_data1/oa_pdf/e0/ce/cas0105-1480.PMC4462379.pdf
Data analyses were carried out with the web-based soft- ware package for the RT 2Proﬁler PCR Array Data Analysis (http://www.sabiosciences.com/pcr/arrayanalysis.php).,OADS,/arxiv_data1/oa_pdf/87/5f/cas0105-1503.PMC4462384.pdf
The number of spheroids (at least60lm in diameter) and their perimeters were measured with ImageJ (http://imagej.nih.gov/ij/) at different time points and spheroids were dissociated and recultured to assess their spher-oid-forming ability at successive generations.,OADS,/arxiv_data1/oa_pdf/53/02/cas0105-1142.PMC4462388.pdf
Available from http://www.alz.co.uk/research/ files/WorldAlzheimerReport.,Non-OADS,/arxiv_data1/oa_pdf/df/fb/cm-87-102.PMC4462422.pdf
Available from http://www.nia.nih.,Non-OADS,/arxiv_data1/oa_pdf/df/fb/cm-87-102.PMC4462422.pdf
2[cited 2013 January 2nd] Available from: http://www2.pub - licationsduquebec.gouv.qc.ca/dynamicSearch/telecharge.php  ?type=2&file=/P_10/P10.HTM 19.,OADS,/arxiv_data1/oa_pdf/44/31/cm-87-119.PMC4462424.pdf
http://www.op.nysed.gov/prof/pharm/ar - ticle137.htm 20.,Non-OADS,/arxiv_data1/oa_pdf/44/31/cm-87-119.PMC4462424.pdf
Available from: http://www.dreptonline.,Non-OADS,/arxiv_data1/oa_pdf/44/31/cm-87-119.PMC4462424.pdf
Available from:  http://www.recensamantromania.ro/rezultate-2/.,OADS,/arxiv_data1/oa_pdf/44/31/cm-87-119.PMC4462424.pdf
"Available from: http://www.google.ro/url?sa=t&rct= j&q=&esrc=s&source=web&cd=1&ved=0CcoQFjAA&url=http %3A%2F%2Fwww.insp.gov.ro%2Fcnepss%2Fwp-content%2Fu ploads%2F2012%2F03%2FCNPV .doc&ei=_jkyUvT0A4nIswbL 64GIBQ&usg=AFQjCNGvLWuM9Ej-R4Hd2s0Y_-c6CqwEJw &sig2=qEqw3Py3ieCXj5Dl1whvzw&bvm=bv.52164340,d.Yms.",OADS,/arxiv_data1/oa_pdf/44/31/cm-87-119.PMC4462424.pdf
Available from: http://www.pharmacy.wisc.edu/ sites/default/files/content/american-institute-history-pharmacy/ resources-teaching/EthicResp.pdf.,Non-OADS,/arxiv_data1/oa_pdf/44/31/cm-87-119.PMC4462424.pdf
Available from:  http://www.floriskraaimaat.nl/tests-icq.html.,Non-OADS,/arxiv_data1/oa_pdf/f9/4a/cm-86-133.PMC4462437.pdf
Available at:  http://www.idf.org/2011-guideline-management-postmeal- glucose-diabetes .,Non-OADS,/arxiv_data1/oa_pdf/dd/ce/cm-86-93.PMC4462439.pdf
Available at: http://www.idf.org/ webdata/docs/Pregnancy_EN_RTP.pdf .,Non-OADS,/arxiv_data1/oa_pdf/dd/ce/cm-86-93.PMC4462439.pdf
Available at: http://www.endo-society.,Non-OADS,/arxiv_data1/oa_pdf/dd/ce/cm-86-93.PMC4462439.pdf
2. http://florideportocal.blogspot.ro/2012 3.,Non-OADS,/arxiv_data1/oa_pdf/25/97/cm-86-160.PMC4462440.pdf
“Railway safety statistics” - Statistics Explained (2013/4/6)  <http://epp.eurostat.ec.europa.eu/statistics_explained/index.php/ Railway �safety �statistics �Three �Member �States �responsible � lway �safety �statistics �Three �Member �States �responsible � for_almost_half_of_the_victims_in_the_EU-27>  2.,Non-OADS,/arxiv_data1/oa_pdf/ed/69/cm-86-144.PMC4462444.pdf
4http://emedicine.medscape.com/article/283039-overview .,Non-OADS,/arxiv_data1/oa_pdf/2a/dc/cm-86-377.PMC4462452.pdf
1993; avalaible from URL:  http://www.ncbi.nlm.nih.gov/pubmed/20301717 in dilated cardiom yopathy .,Non-OADS,/arxiv_data1/oa_pdf/0c/74/cm-86-309.PMC4462456.pdf
Opus I: Muscular  system; 2002; Available from: http://www.anatomyatlases.org 3.,Non-OADS,/arxiv_data1/oa_pdf/ba/7f/cm-86-327.PMC4462457.pdf
"Council Directive 91/439/EEC, OJ L 237, 24.8.1991, p. 0001  – 0024, Available from: http://eur-lex.europa.eu/LexUriServ/ LexUriServ.do?uri=CELEX:31991L0439:EN:HTML  32.",Non-OADS,/arxiv_data1/oa_pdf/18/73/cm-86-10.PMC4462468.pdf
6. http://dexonline.ro/definitie/discriminare 7.,Non-OADS,/arxiv_data1/oa_pdf/c7/96/cm-86-53.PMC4462472.pdf
"Directive2006/52/EC of the European Parliament and of the  council amending Directive 95/2/EC on food additives other than  colours and sweeteners and Directive 94/35/EC on sweeteners  for use in foodstuffs, http://eur-lex.europa.eu/LexUriServ/ LexUriServ.do?uri=OJ:L:2006:204:0010:0022:EN:PDF ,  accessed on 20th of October, 2012.",Non-OADS,/arxiv_data1/oa_pdf/c6/25/cm-86-16.PMC4462476.pdf
"FDA, U.S. Department of Health & Human Services,  21CFR172.110, http://www.accessdata.fda.gov/scripts/cdrh/ cfdocs/cfcfr/CFRSearch.cfm?fr=172.110 , accessed on 20th of  October, 2012.",OADS,/arxiv_data1/oa_pdf/c6/25/cm-86-16.PMC4462476.pdf
"Household Products Database, U.S. Department of Health &  Human Services, http://householdproducts.nlm.nih.gov/ , accessed  on 20th of October, 2012.",OADS,/arxiv_data1/oa_pdf/c6/25/cm-86-16.PMC4462476.pdf
Available from : http://www.who.int/whosis/ whostat/EN_WHS2011_Full.pdf 6.,OADS,/arxiv_data1/oa_pdf/76/6d/cm-86-48.PMC4462482.pdf
"Harvard Stem Cell  Institute, ( http://www.stembook.org/node/551 ), 2008.",Non-OADS,/arxiv_data1/oa_pdf/38/d1/cm-86-196.PMC4462493.pdf
"Available from, URL:  http://www.exsys.com/pdf/ CorvidManual.pdf 10.",Non-OADS,/arxiv_data1/oa_pdf/14/0b/cm-86-208.PMC4462497.pdf
Available at http://www.R-project.org .,Non-OADS,/arxiv_data1/oa_pdf/af/09/cm-86-245.PMC4462499.pdf
14. http://www.arthritistoday.org/where-it-hurts/foot-heel-and- toe-pain/treatment/heel-pain-arthritis.php,Non-OADS,/arxiv_data1/oa_pdf/0d/62/cm-86-200.PMC4462504.pdf
Available from: URL:http://www.eurofound.europa.eu/ pubdocs/2006/63/en/1/ef0663en.pdf 11.,Non-OADS,/arxiv_data1/oa_pdf/13/77/cm-86-274.PMC4462505.pdf
Available  from: http://data.unaids.org/pub/Report/2009/JC1700.,OADS,/arxiv_data1/oa_pdf/63/6c/cm-86-181.PMC4462508.pdf
http://dx.doi.org/10.4102/curationis.v35i1.30 5.,Non-OADS,/arxiv_data1/oa_pdf/63/6c/cm-86-181.PMC4462508.pdf
Available from: http://www.uspreventiveservicestaskforce.org/ uspstf/uspshivi.htm .,Non-OADS,/arxiv_data1/oa_pdf/63/6c/cm-86-181.PMC4462508.pdf
"2012;19(5):394 –401, http://dx.doi.org/10.1097/MED.",Non-OADS,/arxiv_data1/oa_pdf/0c/81/clin-70-06-453.PMC4462563.pdf
"2012;18 (4):360 –73, http://dx.doi.org/10.1093/humupd/dms007.",Non-OADS,/arxiv_data1/oa_pdf/0c/81/clin-70-06-453.PMC4462563.pdf
"2011; 17(5):605 –19, http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/0c/81/clin-70-06-453.PMC4462563.pdf
"2011;164(6):871 –6, http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/0c/81/clin-70-06-453.PMC4462563.pdf
"2010;95(11):E337 –41, http://dx.doi.org/ 10.1210/jc.2010-0652.",Non-OADS,/arxiv_data1/oa_pdf/0c/81/clin-70-06-453.PMC4462563.pdf
"2001;64(5):262 –6, http://dx.doi.org/10.1002/(ISSN)1096- 9926.",Non-OADS,/arxiv_data1/oa_pdf/0c/81/clin-70-06-453.PMC4462563.pdf
"1999;83(1):43 –6, http://dx.doi.org/10.1002/(ISSN)1096-8628.",Non-OADS,/arxiv_data1/oa_pdf/0c/81/clin-70-06-453.PMC4462563.pdf
"2010;74(5):305 –11, http://dx.doi.org/10.1159/ 000320028.",Non-OADS,/arxiv_data1/oa_pdf/0c/81/clin-70-06-453.PMC4462563.pdf
"2012;105(2):189 –93, http://dx.doi.org/10.1093/qjmed/hcq248.",Non-OADS,/arxiv_data1/oa_pdf/0c/81/clin-70-06-453.PMC4462563.pdf
"2012;97(7):2396 –403, http://dx.doi.org/10.1210/ jc.2011-2860.",Non-OADS,/arxiv_data1/oa_pdf/0c/81/clin-70-06-453.PMC4462563.pdf
"2007; 370(9596):1453 –7, http://dx.doi.org/ 10.1016/S0140-6736(07)61602-X.",Non-OADS,/arxiv_data1/oa_pdf/0c/81/clin-70-06-453.PMC4462563.pdf
"2010;1(2):100 –7, http://dx.doi.org/10.4103/0976-500X.72352.",Non-OADS,/arxiv_data1/oa_pdf/0c/81/clin-70-06-453.PMC4462563.pdf
"2013;98(11):4373 –81, http://dx.doi.org/10.1210/jc.2013-2831.18.",Non-OADS,/arxiv_data1/oa_pdf/0c/81/clin-70-06-453.PMC4462563.pdf
"2011; 118(11):1365 –73, http://dx.doi.org/10.1111/bjo.2011.118.issue-11.",Non-OADS,/arxiv_data1/oa_pdf/0c/81/clin-70-06-453.PMC4462563.pdf
"2009;68 (4):609 –17, http://dx.doi.org/10.1111/bcp.2009.68.issue-4.",Non-OADS,/arxiv_data1/oa_pdf/0c/81/clin-70-06-453.PMC4462563.pdf
"2006;28 (4):477 –83, http://dx.doi.org/10.1097/00007691-200608000-00001.",Non-OADS,/arxiv_data1/oa_pdf/0c/81/clin-70-06-453.PMC4462563.pdf
"2013;1(3):238 –49, http://dx.doi.org/10.1016/S2213-8587(13) 70086-X.",OADS,/arxiv_data1/oa_pdf/0c/81/clin-70-06-453.PMC4462563.pdf
"2010;95(5):2227 –33, http://dx.doi.org/10.1210/jc.2009-2752.",Non-OADS,/arxiv_data1/oa_pdf/0c/81/clin-70-06-453.PMC4462563.pdf
"2006;28(4): 576;author reply 576, http://dx.doi.org/10.1097/00007691-200608000- 00014.",Non-OADS,/arxiv_data1/oa_pdf/0c/81/clin-70-06-453.PMC4462563.pdf
"2002;65(1):38 –44, http://dx.doi.org/10.1002/(ISSN)1096-9926.",Non-OADS,/arxiv_data1/oa_pdf/0c/81/clin-70-06-453.PMC4462563.pdf
"2004;57(12):1254 –7, http://dx.doi.org/10.1136/jcp.2003.013581.",Non-OADS,/arxiv_data1/oa_pdf/8c/35/clin-70-06-441.PMC4462567.pdf
"2002;162(11):1245 –8, http://dx.doi.org/10.1001/archinte.162.11.",Non-OADS,/arxiv_data1/oa_pdf/8c/35/clin-70-06-441.PMC4462567.pdf
"2008;29(18):2276 –315, http://dx.doi.org/10.1093/eurheartj/ ehn475.",Non-OADS,/arxiv_data1/oa_pdf/8c/35/clin-70-06-441.PMC4462567.pdf
"1998;129(12):1006 – 11, http://dx.doi.org/10.7326/0003-4819-129-12-199812150-00003.",Non-OADS,/arxiv_data1/oa_pdf/8c/35/clin-70-06-441.PMC4462567.pdf
"1985;145 (7):1270 –2, http://dx.doi.org/10.1001/archinte.1985.00360070150025.",Non-OADS,/arxiv_data1/oa_pdf/8c/35/clin-70-06-441.PMC4462567.pdf
"2007;50(1):40 –7, http://dx.doi.org/10.1016/j.jacc.2007.02.067.",OADS,/arxiv_data1/oa_pdf/8c/35/clin-70-06-441.PMC4462567.pdf
"2010;105(3):312 –7, http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/8c/35/clin-70-06-441.PMC4462567.pdf
"2009;104(6):868 –72, http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/8c/35/clin-70-06-441.PMC4462567.pdf
"2012;109(1):128 –34, http://dx.doi.org/10.1016/j.amjcard.2011.08.015.",OADS,/arxiv_data1/oa_pdf/8c/35/clin-70-06-441.PMC4462567.pdf
"1996;199(1):31 –5, http://dx.doi.org/ 10.1148/radiology.199.1.8633168.",Non-OADS,/arxiv_data1/oa_pdf/8c/35/clin-70-06-441.PMC4462567.pdf
"2010;11:149 –54, http://dx.doi.org/ 10.5152/ttd.",Non-OADS,/arxiv_data1/oa_pdf/8c/35/clin-70-06-441.PMC4462567.pdf
"2005;352(17):1760 –8, http://dx.doi.org/ 10.1056/NEJMoa042905.",Non-OADS,/arxiv_data1/oa_pdf/8c/35/clin-70-06-441.PMC4462567.pdf
"1999;353(9162):1386 –9, http://dx.doi.org/10.1016/ S0140-6736(98)07534-5.",Non-OADS,/arxiv_data1/oa_pdf/8c/35/clin-70-06-441.PMC4462567.pdf
"2003;32(6):601 –5, http://dx.doi.org/10.1093/ageing/afg098.",Non-OADS,/arxiv_data1/oa_pdf/8c/35/clin-70-06-441.PMC4462567.pdf
"2005;3(11):2457 – 64, http://dx.doi.org/10.1111/jth.2005.3.issue-11.",Non-OADS,/arxiv_data1/oa_pdf/8c/35/clin-70-06-441.PMC4462567.pdf
"2002;165(3):345 –8, http://dx.doi.org/10.1164/ajrccm.165.3.2104099.26.",Non-OADS,/arxiv_data1/oa_pdf/8c/35/clin-70-06-441.PMC4462567.pdf
"2010;11:160 –6, http://dx.doi.org/10.5152/ttd.. 27.",Non-OADS,/arxiv_data1/oa_pdf/8c/35/clin-70-06-441.PMC4462567.pdf
"2007;120(2):281 –8, http://dx.doi.org/10.1016/j.thromres.2006.08.006.",OADS,/arxiv_data1/oa_pdf/8c/35/clin-70-06-441.PMC4462567.pdf
"2014;20(4):365 –70, http://dx.doi.org/10.1177/10760296 12464901.",Non-OADS,/arxiv_data1/oa_pdf/8c/35/clin-70-06-441.PMC4462567.pdf
"2013;24(7):727 –31, http://dx.doi.org/10.1097/ MBC.0b013e32836261fe.",Non-OADS,/arxiv_data1/oa_pdf/8c/35/clin-70-06-441.PMC4462567.pdf
"2014;99(1):194 –200, http://dx.doi.org/10.3324/haematol.2013.083840.",Non-OADS,/arxiv_data1/oa_pdf/8c/35/clin-70-06-441.PMC4462567.pdf
"1983;14(5):497 –506, http://dx.doi.org/10.1002/(ISSN)1531- 8249.",Non-OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"1994;44(9):1593 –600, http://dx.doi.org/10.1212/ WNL.44.9.1593.",Non-OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"2011;7(3):263 –9, http://dx.doi.org/10.1016/j.jalz.2011.03.005.",OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"2011;23(3):404 –12, http://dx.doi.org/10.1017/ S1041610210001092.",Non-OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"1983;19(1):98 –114, http://dx.doi.org/10.1016/0093-934X(83) 90057-3.",Non-OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"1992;30(4):301 –14, http://dx.doi.org/10.1016/0028-3932 (92)90104-T. 8.",Non-OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"2001;77(2):176 – 86, http://dx.doi.org/10.1006/brln.2000.2427.",Non-OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"2004;18(3):526 –36, http://dx.doi.org/10.1037/0894-4105.18.3.526.",Non-OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"2004;91(2):223 –34, http://dx.doi.org/10.1016/j.bandl.2004.02.008.",OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"2009;47(12):2574 –83, http://dx.doi.org/10.1016/j.",Non-OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"2008;46(6):1732 –7, http://dx.doi.org/ 10.1016/j.neuropsychologia.2008.02.015.",Non-OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"2012;22(2):215 – 34, http://dx.doi.org/10.1080/09602011.2012.655002.",Non-OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"1984;34(7):939 –44, http://dx.doi.org/10.1212/WNL.34.7.939.",Non-OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"1975;12(3):189 –98, http://dx.doi.org/10.1016/0022-3956 (75)90026-6.",Non-OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"2003;61(3B):777 –81, http://dx.doi.org/ 10.1590/S0004-282X2003000500014.",Non-OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"2001;59(3-A):532 –6, http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"1999;53(5):471 –81, http://dx.doi.org/ 10.5014/ajot.53.5.471.",Non-OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"2007;65(3B):916 –9, http://dx.doi.org/10.1590/S0004-282X2007000500038.",Non-OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"2008;23(1):49 –54, http://dx.doi.org/10.1002/(ISSN)1099-1166.",Non-OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"1998;36(5):397 –405, http://dx.doi.org/10.1016/S0028- 3932(97)00124-3.",Non-OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"1999;53(1):108 –17, http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"2012;63(1):348 –55, http://dx.doi.org/ 10.1016/j.neuroimage.2012.06.018.",OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"2009;24(8):885 –93, http://dx.doi.org/10.1002/gps.v24:8.",Non-OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"2004;127(Pt3):628 –49, http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"2010;23(4):231 –9, http://dx.doi.org/10.1097/WNN.0b013e3181e61cf1.",Non-OADS,/arxiv_data1/oa_pdf/4a/ed/clin-70-06-423.PMC4462568.pdf
"2003;17(5):401 –11, http://dx.doi.org/10.1034/j.1399-0012.",Non-OADS,/arxiv_data1/oa_pdf/d1/ac/clin-70-06-413.PMC4462569.pdf
"1998;30(6):2880 –2, http://dx.doi.org/10.1016/ S0041-1345(98)00853-7.",OADS,/arxiv_data1/oa_pdf/d1/ac/clin-70-06-413.PMC4462569.pdf
"2009;23(2):220 –7, http://dx.doi.org/10.1111/ctr.2009.23.issue-2.",Non-OADS,/arxiv_data1/oa_pdf/d1/ac/clin-70-06-413.PMC4462569.pdf
"1991;38(3):374 –83, http://dx.doi.org/10.1007/BF03007629.",Non-OADS,/arxiv_data1/oa_pdf/d1/ac/clin-70-06-413.PMC4462569.pdf
"1973;60(8):646 –9, http://dx.doi.org/10.1002/(ISSN)1365-2168.",Non-OADS,/arxiv_data1/oa_pdf/d1/ac/clin-70-06-413.PMC4462569.pdf
"1160 of May 29, 2006 –available inohttp://dtr2001.saude.gov.br/sas/PORTARIAS/Port2006/GM/ GM-1160.htm 4.",OADS,/arxiv_data1/oa_pdf/d1/ac/clin-70-06-413.PMC4462569.pdf
"2001;33(2):464 –70, http://dx.doi.org/10.1053/ jhep.2001.22172.",Non-OADS,/arxiv_data1/oa_pdf/d1/ac/clin-70-06-413.PMC4462569.pdf
"2006; 6(4):783 –90, http://dx.doi.org/ 10.1111/ajt.2006.6.issue-4.12.",Non-OADS,/arxiv_data1/oa_pdf/d1/ac/clin-70-06-413.PMC4462569.pdf
"2002;236(3):315 –23, http://dx.doi.org/ 10.1097/00000658-200209000-00008.",Non-OADS,/arxiv_data1/oa_pdf/d1/ac/clin-70-06-413.PMC4462569.pdf
"2004;10(7):903 –7, http://dx.doi.org/ 10.1002/(ISSN)1527-6473.",Non-OADS,/arxiv_data1/oa_pdf/d1/ac/clin-70-06-413.PMC4462569.pdf
"2005;11(7):814 –25, http://dx.doi.org/10.1002/ (ISSN)1527-6473.",Non-OADS,/arxiv_data1/oa_pdf/d1/ac/clin-70-06-413.PMC4462569.pdf
"2006;12(3):440 –7, http://dx.doi.org/10.1002/(ISSN)1527-6473.",Non-OADS,/arxiv_data1/oa_pdf/d1/ac/clin-70-06-413.PMC4462569.pdf
"2006;12(7):1049 –61, http://dx.doi.org/10.1002/(ISSN)1527-6473.",Non-OADS,/arxiv_data1/oa_pdf/d1/ac/clin-70-06-413.PMC4462569.pdf
"2007;45(3):797 –805, http://dx.doi.org/10 .1002/(ISSN)1 527-3350.",Non-OADS,/arxiv_data1/oa_pdf/d1/ac/clin-70-06-413.PMC4462569.pdf
"2007; 44(3):189 – 94, http://dx.doi.org/ 10.1590/S0004-28032007000300002.",Non-OADS,/arxiv_data1/oa_pdf/d1/ac/clin-70-06-413.PMC4462569.pdf
"2004; 77(1):99 –106, http://dx.doi.org/10.1097/01.",Non-OADS,/arxiv_data1/oa_pdf/d1/ac/clin-70-06-413.PMC4462569.pdf
"2005;17 (8):849 –56, http://dx.doi.org/10.1097/00042737-200508000-00012.",Non-OADS,/arxiv_data1/oa_pdf/d1/ac/clin-70-06-413.PMC4462569.pdf
"2007;7(4):990 –7, http://dx.doi.org/10.1111/ ajt.2007.7.issue-4.",Non-OADS,/arxiv_data1/oa_pdf/d1/ac/clin-70-06-413.PMC4462569.pdf
"2007;7(8):1984 –8, http://dx.doi.org/10.1111/ajt.2007.7.issue-8.",Non-OADS,/arxiv_data1/oa_pdf/d1/ac/clin-70-06-413.PMC4462569.pdf
"2009;87 (12):1859 –63, http://dx.doi.org/10.1097/TP.0b013e3181a75b37.",Non-OADS,/arxiv_data1/oa_pdf/d1/ac/clin-70-06-413.PMC4462569.pdf
"2008;8(2):419 –25, http://dx.doi.org/10.1111/j.1600-6143.2007.02086.x.",Non-OADS,/arxiv_data1/oa_pdf/d1/ac/clin-70-06-413.PMC4462569.pdf
"2008; 8(12):2537 –46, http://dx.doi.org/10.1111/ ajt.2008.8.issue-12.",Non-OADS,/arxiv_data1/oa_pdf/d1/ac/clin-70-06-413.PMC4462569.pdf
"2012;7(3):e31256, http://dx.doi.org/10.1371/journal.pone.0031256.",Non-OADS,/arxiv_data1/oa_pdf/d1/ac/clin-70-06-413.PMC4462569.pdf
"2013;82(3):e120 –41, http://dx.doi.org/10.1016/j.ejrad.2012.09.019.",OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"2005;128(1):162 –6, http://dx.doi.org/10.1378/chest.128.1.162.",Non-OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"1990;174(1):211 –3, http://dx.doi.org/10.1148/ radiology.174.1.2294550.",Non-OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"1989;153(1):41 –5, http://dx.doi.org/10.2214/ajr.153.1.41.",Non-OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"2001;37(3):190 –4, http://dx.doi.org/10.1016/S0720-048X(00)00254-0.",OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"2014;108 (1):1 –8, http://dx.doi.org/10.1016/j.rmed.2013.10.012.",OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"1986;146(10):1913 –6, http://dx.doi.org/10.1001/archinte.1986.00360220057011.",Non-OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"1998;26 (6):1434 –8, http://dx.doi.org/10.1086/cid.1998.26.issue-6.",Non-OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"2012;12(11):881 –7, http://dx.doi.org/10.1016/S1473-3099(12)70205-0.",Non-OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"2007;54(6):578 – 83, http://dx.doi.org/10.1016/j.jinf.2006.11.008.",OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"2011;41(5):e103 –5, http://dx.doi.org/10.1016/j.jemermed.2008.04.041.",OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"2013;41(3):681 –6, http://dx.doi.org/ 10.1007/s15010-013-0408-0.",Non-OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"2013;51(3):1049 –51, http://dx.doi.org/ 10.1128/JCM.02853-12.",Non-OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"2007;45(3):284 –93, http://dx.doi.org/10.1086/519262.",Non-OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"2013;19(8):717 –22, http://dx.doi.org/10.1111/1469-0691.12027.",Non-OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"2007;54(3):230 –4, http://dx.doi.org/10.1016/ j.jinf.2006.04.008.",OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"Intern Med.1995;34(1):42 –5, http://dx.doi.org/10.2169/internal medicine.34.42.",Non-OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"2007;11(2):R31, http://dx.doi.org/10.1186/cc5713.",Non-OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"1999;14(2):109 –13, http://dx.doi.org/ 10.1097/00005382-199904000-00008.",Non-OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"2006;259(6):606 –14, http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"2007;45(3):284 –93, http://dx.doi.org/10.1086/519262.",Non-OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"2002;50(3): 420–4, http://dx.doi.org/10.1136/gut.50.3.420.",Non-OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"1999;23(4):622 –6, http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"1994;190(2):513 –5, http://dx.doi.org/10.1148/ radiology.190.2.8284408.",Non-OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"1997;17(6):1359 –71, http://dx.doi.org/10.1148/radiographics.",Non-OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"1989;13(6):941 –5, http://dx.doi.org/10.1097/00004728-198911 000-00001.",Non-OADS,/arxiv_data1/oa_pdf/3a/92/clin-70-06-400.PMC4462570.pdf
"2012;34(6):e421 –44, http://dx.doi.org/10.3109/0142159X.",Non-OADS,/arxiv_data1/oa_pdf/2b/f1/clin-70-06-393.PMC4462571.pdf
"2011;35(2):47 –51, http://dx.doi.org/ 10.1053/j.semperi.2011.01.002.",Non-OADS,/arxiv_data1/oa_pdf/2b/f1/clin-70-06-393.PMC4462571.pdf
"2004;11 (11):1149 –54, http://dx.doi.org/10.1197/j.aem.2004.08.003.",Non-OADS,/arxiv_data1/oa_pdf/2b/f1/clin-70-06-393.PMC4462571.pdf
"2005;27(1):10 –28, http://dx.doi.org/10.1080/01421590500046924.",Non-OADS,/arxiv_data1/oa_pdf/2b/f1/clin-70-06-393.PMC4462571.pdf
"2009;54(5):684–91, http://dx.doi.org/10.1016/j.annemergmed.2009.03.025.",OADS,/arxiv_data1/oa_pdf/2b/f1/clin-70-06-393.PMC4462571.pdf
"2012;76(5):86, http://dx.doi.org/ 10.5688/ajpe76586.",Non-OADS,/arxiv_data1/oa_pdf/2b/f1/clin-70-06-393.PMC4462571.pdf
"2011;82(11):1440 –3, http://dx.doi.org/ 10.1016/j.resuscitation.2011.06.017.",OADS,/arxiv_data1/oa_pdf/2b/f1/clin-70-06-393.PMC4462571.pdf
"2012;7(5):308 –20, http://dx.doi.org/10.1097/SIH.",Non-OADS,/arxiv_data1/oa_pdf/2b/f1/clin-70-06-393.PMC4462571.pdf
"2012;83 (9):1055 –60, http://dx.doi.org/10.1016/j.resuscitation.2012.02.027.",Non-OADS,/arxiv_data1/oa_pdf/2b/f1/clin-70-06-393.PMC4462571.pdf
"2010;26(7):475 –80, http://dx.doi.org/ 10.1097/PEC.0b013e3181e5841b.",Non-OADS,/arxiv_data1/oa_pdf/2b/f1/clin-70-06-393.PMC4462571.pdf
"2011;127(3):587 –93.e1-22, http://dx.doi.org/10.1016/ j.jaci.2011.01.038.",OADS,/arxiv_data1/oa_pdf/2b/f1/clin-70-06-393.PMC4462571.pdf
"2010;122(18 Suppl 3):S706 –19, http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/2b/f1/clin-70-06-393.PMC4462571.pdf
"2013;35(8):e1380 –95, http://dx.doi.org/10.3109/0142159X.2012.733451.",Non-OADS,/arxiv_data1/oa_pdf/2b/f1/clin-70-06-393.PMC4462571.pdf
"2005;80(6):541 –8, http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/2b/f1/clin-70-06-393.PMC4462571.pdf
"2005;12(1):19 –24, http://dx.doi.org/10.1016/S1322-7696(08)60478-3.",Non-OADS,/arxiv_data1/oa_pdf/2b/f1/clin-70-06-393.PMC4462571.pdf
"2013;18:21312, http://dx.doi.org/10.3402/meo.",Non-OADS,/arxiv_data1/oa_pdf/2b/f1/clin-70-06-393.PMC4462571.pdf
"2013;35(3):e1003-e10, http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/2b/f1/clin-70-06-393.PMC4462571.pdf
"2006;34(1):151 –7, http://dx.doi.org/10.1097/01.",Non-OADS,/arxiv_data1/oa_pdf/2b/f1/clin-70-06-393.PMC4462571.pdf
"2014;112(2):231 –45, http://dx.doi.org/10.1093/bja/aet414.",Non-OADS,/arxiv_data1/oa_pdf/2b/f1/clin-70-06-393.PMC4462571.pdf
"2006;40(8):792 –7, http://dx.doi.org/10.1111/med.2006.40.",Non-OADS,/arxiv_data1/oa_pdf/2b/f1/clin-70-06-393.PMC4462571.pdf
"2011;86(6):706 –11, http://dx.doi.org/ 10.1097/ACM.0b013e318217e119.",Non-OADS,/arxiv_data1/oa_pdf/2b/f1/clin-70-06-393.PMC4462571.pdf
"1995;122 (12):951 –4, http://dx.doi.org/10.7326/0003-4819-122-12-199506150-00010.",Non-OADS,/arxiv_data1/oa_pdf/be/a2/clin-70-06-429.PMC4462572.pdf
"2003;167(4):603 –62, http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/be/a2/clin-70-06-429.PMC4462572.pdf
"1989;140(6):1618 –22, http://dx.doi.org/10.1164/ajrccm/140.6.1618.",Non-OADS,/arxiv_data1/oa_pdf/be/a2/clin-70-06-429.PMC4462572.pdf
"2003;63(6):535 –53, http://dx.doi.org/10.2165/00003495-200363060-00002.",Non-OADS,/arxiv_data1/oa_pdf/be/a2/clin-70-06-429.PMC4462572.pdf
"2011;305(14):1415 –23, http://dx.doi.org/10.1001/jama.2011.436.",Non-OADS,/arxiv_data1/oa_pdf/be/a2/clin-70-06-429.PMC4462572.pdf
"2013;42(3):721 –32, http://dx.doi.org/10.1183/09031936.00180612.",Non-OADS,/arxiv_data1/oa_pdf/be/a2/clin-70-06-429.PMC4462572.pdf
"2011;16:308 –13, http://dx.doi.org/10.1111/res.2011.16.issue-2.14.",Non-OADS,/arxiv_data1/oa_pdf/be/a2/clin-70-06-429.PMC4462572.pdf
"2010;43(3):285 – 90, http://dx.doi.org/10.1016/S1684-1182(10)60045-X.",Non-OADS,/arxiv_data1/oa_pdf/be/a2/clin-70-06-429.PMC4462572.pdf
(Available at http://www.cdc.gov.,Non-OADS,/arxiv_data1/oa_pdf/be/a2/clin-70-06-429.PMC4462572.pdf
"1996;57(11):849 –56, http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/be/a2/clin-70-06-429.PMC4462572.pdf
"2011;15(4):433 –9, http://dx.doi.org/10.5588/ijtld.09.0439.",Non-OADS,/arxiv_data1/oa_pdf/be/a2/clin-70-06-429.PMC4462572.pdf
"1991;99(2):465 –71, http://dx.doi.org/ 10.1378/chest.99.2.465.",Non-OADS,/arxiv_data1/oa_pdf/be/a2/clin-70-06-429.PMC4462572.pdf
"2001;358(9285):912 –6, http://dx.doi.org/10.1016/S0140-6736(01)06076-7.",Non-OADS,/arxiv_data1/oa_pdf/be/a2/clin-70-06-429.PMC4462572.pdf
"2011;105(3):148 –52, http://dx.doi.org/10.1016/j.trstmh.2010.11.005.",OADS,/arxiv_data1/oa_pdf/be/a2/clin-70-06-429.PMC4462572.pdf
"2011;35(3):413 –8, http://dx.doi.org/10.1007/s00264- 010-1005-9.",Non-OADS,/arxiv_data1/oa_pdf/75/88/clin-70-06-419.PMC4462573.pdf
"2007;21(10 Suppl):S1 –133, http://dx.doi.org/10.1097/ 00005131-200711101-00001.",Non-OADS,/arxiv_data1/oa_pdf/75/88/clin-70-06-419.PMC4462573.pdf
"1999;20(4):250 –78;quiz 279 –80, http://dx.doi.org/10.1086/iche.1999.20.",Non-OADS,/arxiv_data1/oa_pdf/75/88/clin-70-06-419.PMC4462573.pdf
"2010;34(4):583 –8, http://dx.doi.org/10.1007/s00264-009-0832-z.",Non-OADS,/arxiv_data1/oa_pdf/75/88/clin-70-06-419.PMC4462573.pdf
"2006;20(1):76 –9, http://dx.doi.org/ 10.1097/01.bot.0000202997.45274.a1.",Non-OADS,/arxiv_data1/oa_pdf/75/88/clin-70-06-419.PMC4462573.pdf
"2013;44(2):249 –52, http://dx.doi.org/10.1016/j.injury.2012.10.032.",OADS,/arxiv_data1/oa_pdf/75/88/clin-70-06-419.PMC4462573.pdf
"2005;87(4):489 –95, http://dx.doi.org/10.1302/0301-620X.",Non-OADS,/arxiv_data1/oa_pdf/75/88/clin-70-06-419.PMC4462573.pdf
"2012;94(22):2047 –52, http://dx.doi.org/10.2106/JBJS.K.01088.",Non-OADS,/arxiv_data1/oa_pdf/75/88/clin-70-06-419.PMC4462573.pdf
"2009;23(7):502 –6, http://dx.doi.org/10.1097/BOT.0b013e3181a18235.",Non-OADS,/arxiv_data1/oa_pdf/75/88/clin-70-06-419.PMC4462573.pdf
"2001;22(10):607 –12, http://dx.doi.org/10.1086/iche.2001.22.issue-10.",Non-OADS,/arxiv_data1/oa_pdf/75/88/clin-70-06-419.PMC4462573.pdf
"2003;4(6):477 –86, http://dx.doi.org/10.2174/1389450033490939.",Non-OADS,/arxiv_data1/oa_pdf/75/88/clin-70-06-419.PMC4462573.pdf
"2002;288(20):2579 –88, http://dx.doi.org/10.1001/jama.288.20.2579.",Non-OADS,/arxiv_data1/oa_pdf/75/88/clin-70-06-419.PMC4462573.pdf
"2000;45(3):173 –84, http://dx.doi.org/10.1053/jhin.2000.0736.Table 3 - Multivariate Logistic Regression Analysis of Risk Factors for SSI.",OADS,/arxiv_data1/oa_pdf/75/88/clin-70-06-419.PMC4462573.pdf
"2011;33(6):e245 –7, http://dx.doi.org/10.1097/ MPH.0b013e3181f466ec.",Non-OADS,/arxiv_data1/oa_pdf/c7/70/clin-70-06-387.PMC4462574.pdf
"2000;36(11):1418 –25, http://dx.doi.org/10.1016/ S0959-8049(00)00074-5.",Non-OADS,/arxiv_data1/oa_pdf/c7/70/clin-70-06-387.PMC4462574.pdf
"2009; 361:1662 –70, http://dx.doi.org/10.1056/ NEJMoa0810613.",Non-OADS,/arxiv_data1/oa_pdf/c7/70/clin-70-06-387.PMC4462574.pdf
"2008;43(11):1973 –81, http://dx.doi.org/ 10.1016/j.jpedsurg.2008.05.031.",OADS,/arxiv_data1/oa_pdf/c7/70/clin-70-06-387.PMC4462574.pdf
"2014;26(1):29 –36, http://dx.doi.org/10.1097/MOP.",Non-OADS,/arxiv_data1/oa_pdf/c7/70/clin-70-06-387.PMC4462574.pdf
"2002;94(4):1111 –20, http://dx.doi.org/10.1002/(ISSN)1097-0142.",Non-OADS,/arxiv_data1/oa_pdf/c7/70/clin-70-06-387.PMC4462574.pdf
"2009;44(11):2083 –7, http://dx.doi.org/10.1016/j.jpedsurg.",OADS,/arxiv_data1/oa_pdf/c7/70/clin-70-06-387.PMC4462574.pdf
"2008;13 (7):812 –20, http://dx.doi.org/10.1634/theoncologist.2008-0011.",Non-OADS,/arxiv_data1/oa_pdf/c7/70/clin-70-06-387.PMC4462574.pdf
"2014;26(3):362 –9, http://dx.doi.org/10.1097/ MOP.0000000000000081.",Non-OADS,/arxiv_data1/oa_pdf/c7/70/clin-70-06-387.PMC4462574.pdf
"Eur J Surg Oncol.2014;40(11):1533 –9, http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/c7/70/clin-70-06-387.PMC4462574.pdf
"2004;100(5):1070 –6, http://dx.doi.org/10.1002/(ISSN)1097-0142.",Non-OADS,/arxiv_data1/oa_pdf/c7/70/clin-70-06-387.PMC4462574.pdf
"1997;130(4):557 –60, http://dx.doi.org/10.1016/S0022-3476(97)70239-7.",Non-OADS,/arxiv_data1/oa_pdf/c7/70/clin-70-06-387.PMC4462574.pdf
"2013;37(4):390 –5, http://dx.doi.org/10.1016/j.canep.",OADS,/arxiv_data1/oa_pdf/c7/70/clin-70-06-387.PMC4462574.pdf
"2004;39(9):1321 –7, http://dx.doi.org/ 10.1016/j.jpedsurg.2004.05.020.",OADS,/arxiv_data1/oa_pdf/c7/70/clin-70-06-387.PMC4462574.pdf
"1997;74(6):593 –9, http://dx.doi.org/10.1002/(ISSN)1097-0215.",Non-OADS,/arxiv_data1/oa_pdf/c7/70/clin-70-06-387.PMC4462574.pdf
"2009;53(6):1016 –22, http://dx.doi.org/ 10.1002/pbc.v53:6.",OADS,/arxiv_data1/oa_pdf/c7/70/clin-70-06-387.PMC4462574.pdf
"2011;81(2):134 –40, http://dx.doi.org/10.4174/jkss.2011.81.2.134.",Non-OADS,/arxiv_data1/oa_pdf/c7/70/clin-70-06-387.PMC4462574.pdf
"2012;47(7):1331 –9, http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/c7/70/clin-70-06-387.PMC4462574.pdf
"2014;26(1):19 –28, http://dx.doi.org/10.1097/MOP.0000000000000046.",Non-OADS,/arxiv_data1/oa_pdf/c7/70/clin-70-06-387.PMC4462574.pdf
"2011;29:3301 –6, http://dx.doi.org/ 10.1200/JCO.2010.29.3837.",Non-OADS,/arxiv_data1/oa_pdf/c7/70/clin-70-06-387.PMC4462574.pdf
"2012;48(10):1543 –9, http://dx.doi.org/10.1016/ j.ejca.2011.12.011.",OADS,/arxiv_data1/oa_pdf/c7/70/clin-70-06-387.PMC4462574.pdf
"2011;43(1):161 –4, http://dx.doi.org/10.1016/ j.transproceed.2010.11.013.",OADS,/arxiv_data1/oa_pdf/c7/70/clin-70-06-387.PMC4462574.pdf
"J Crit Care 1995;10(2):56 –63, http://dx.doi.org/10.1016/0883-9441(95)90017-9.",Non-OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"2009;53(4):425 –35, http://dx.doi.org/10.1111/aas.",Non-OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"2009;33(9):434 –41, http://dx.doi.org/10.1016/j.medin.2009.03.008.",OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"2006;82 (8):1031 –6, http://dx.doi.org/10.1097/01.tp.0000235825.97538.d5.",Non-OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"1993;87 (1):230 –9, http://dx.doi.org/10.1161/01.CIR.87.1.230.",Non-OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"2002;34(6):2359 –60, http://dx.doi.org/ 10.1016/S0041-1345(02)03283-9.",OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"2012;67(1):69 – 75, http://dx.doi.org/10.6061/clinics.",Non-OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"2012;44(7):2213 –8, http://dx.doi.org/10.1016/j.transproceed.2012.07.108.",OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"2013;183(1):419 –26, http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"2002;34(1):185 –6, http://dx.doi.org/10.1016/S0041-1345 (01)02720-8.",Non-OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"2002;124(6):1087 –98, http://dx.doi.org/10.1067/mtc.2002.124887.",Non-OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"1986;41(5):520 –4, http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"2004;4(2):210 –5, http://dx.doi.org/10.1046/j.1600-6143.2003.00317.x.",Non-OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"2005;80(4):500 –5, http://dx.doi.org/ 10.1097/01.tp.0000167723.46580.78.",Non-OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"2012;27(7):465 –70, http://dx.doi.org/ 10.1590/S0102-86502012000700006.",Non-OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"2009;23 Suppl 21:2 –9, http://dx.doi.org/10.1111/ ctr.2009.23.issue-s21.",Non-OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"2012;56(8):995 – 1005, http://dx.doi.org/10.1111/aas.2012.56.issue-8.",Non-OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"2012;56(8):1006 –12, http://dx.doi.org/10.1111/aas.2012.56.issue-8.",Non-OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"2000;232(6):804 –13, http://dx.doi.org/10.1097/00000658- 200012000-00009.23.",Non-OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"2002;34(4):330 –8, http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"2003;64(5):1874 –82, http://dx.doi.org/10.1046/j.1523-1755.2003.00272.x.",Non-OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"2008;86(1):148 –54, http://dx.doi.org/10.1097/TP.0b013e31817ba53a.",Non-OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"2006;6(12):2903 –11, http://dx.doi.org/10.1111/ ajt.2006.6.issue-12.",Non-OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"Transplantation 1999;67(3):343 –8, http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"2000;19(5):414 –8, http://dx.doi.org/10.1016/S1053- 2498(00)00073-5.",OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"2002;166(1):98 –104, http://dx.doi.org/10.1164/rccm.200109-016OC.",Non-OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"2011;1(1):27, http://dx.doi.org/10.1186/2110-5820-1-27.",Non-OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"1996;61(1):190 –6, http://dx.doi.org/10.1006/ jsre.1996.0103.",Non-OADS,/arxiv_data1/oa_pdf/2a/2d/clin-70-06-446.PMC4462575.pdf
"1999;42(6):1071 –9, http://dx.doi.org/10.1002/1529-0131(199906)42:6 o41.0.CO;2-J.",Non-OADS,/arxiv_data1/oa_pdf/68/7d/clin-70-06-408.PMC4462576.pdf
"1997;81(1):29 –55, http://dx.doi.org/10.1016/S0025-7125(05) 70504-6.",Non-OADS,/arxiv_data1/oa_pdf/68/7d/clin-70-06-408.PMC4462576.pdf
"1998;68:315 –32, http://dx.doi.org/ 10.1016/S0065-2776(08)60563-5.",OADS,/arxiv_data1/oa_pdf/68/7d/clin-70-06-408.PMC4462576.pdf
"1998;20(1-2):5 –22, http://dx.doi.org/10.1007/BF00831996.",Non-OADS,/arxiv_data1/oa_pdf/68/7d/clin-70-06-408.PMC4462576.pdf
"2004;50(11):3729 –31, http://dx.doi.org/10.1002/(ISSN) 1529-0131.9.",Non-OADS,/arxiv_data1/oa_pdf/68/7d/clin-70-06-408.PMC4462576.pdf
"2006;36(2):88 –98, http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/68/7d/clin-70-06-408.PMC4462576.pdf
"1992;89(6):2033 –9, http://dx.doi.org/10.1172/JCI115814.",Non-OADS,/arxiv_data1/oa_pdf/68/7d/clin-70-06-408.PMC4462576.pdf
"2004;51(5):853 –63, http://dx.doi.org/10.1002/(ISSN)1529-0131.",Non-OADS,/arxiv_data1/oa_pdf/68/7d/clin-70-06-408.PMC4462576.pdf
"1996;97(9):2027 –37, http://dx.doi.org/10.1172/JCI118638.",Non-OADS,/arxiv_data1/oa_pdf/68/7d/clin-70-06-408.PMC4462576.pdf
"1999; 100(21):2135 –9, http://dx.doi.org/10.1161/01.",Non-OADS,/arxiv_data1/oa_pdf/68/7d/clin-70-06-408.PMC4462576.pdf
"2000; 101(25):2883 –8, http://dx.doi.org/10.1161/ 01.CIR.101.25.2883.",Non-OADS,/arxiv_data1/oa_pdf/68/7d/clin-70-06-408.PMC4462576.pdf
"1998;102(2-3):131 –47, http://dx.doi.org/10.1016/ S0047-6374(97)00161-9.",Non-OADS,/arxiv_data1/oa_pdf/68/7d/clin-70-06-408.PMC4462576.pdf
"1998;41 (12):2108 –16, http://dx.doi.org/10.1002/(ISSN)1529-0131.",Non-OADS,/arxiv_data1/oa_pdf/68/7d/clin-70-06-408.PMC4462576.pdf
"2010;131(3):301 –9, http://dx.doi.org/10.1111/imm.2010.131.issue-3.",Non-OADS,/arxiv_data1/oa_pdf/68/7d/clin-70-06-408.PMC4462576.pdf
"2006; 19(4):811 –24, http://dx.doi.org/ 10.1016/j.beha.2006.06.004.",OADS,/arxiv_data1/oa_pdf/68/7d/clin-70-06-408.PMC4462576.pdf
"1988;31(3):315 –24, http://dx.doi.org/10.1002/(ISSN)1529-0131.",Non-OADS,/arxiv_data1/oa_pdf/68/7d/clin-70-06-408.PMC4462576.pdf
"1984;76 (3):377 –84, http://dx.doi.org/10.1016/0002-9343(84)90654-5.",Non-OADS,/arxiv_data1/oa_pdf/68/7d/clin-70-06-408.PMC4462576.pdf
"1994;33(9):832 –3, http://dx.doi.org/10.1093/rheumatology/33.9.832.",Non-OADS,/arxiv_data1/oa_pdf/68/7d/clin-70-06-408.PMC4462576.pdf
"1998;41(5):817 – 22, http://dx.doi.org/10.1002/(ISSN)1529-0131.",Non-OADS,/arxiv_data1/oa_pdf/68/7d/clin-70-06-408.PMC4462576.pdf
Available from: http://www.allelefrequencies.net/ default.asp.,OADS,/arxiv_data1/oa_pdf/68/7d/clin-70-06-408.PMC4462576.pdf
"2005;23:225 –74, http://dx.doi.org/10.1146/annurev.immunol.23.021704.115526.",Non-OADS,/arxiv_data1/oa_pdf/68/7d/clin-70-06-408.PMC4462576.pdf
"2010; 52(3):760 –7, http://dx.doi.org/10.1016/j.jvs.2010.01.049.",OADS,/arxiv_data1/oa_pdf/9a/b0/clin-70-06-435.PMC4462577.pdf
"2002;36(6):1104 –11, http://dx.doi.org/10.1067/mva.2002.129638.",Non-OADS,/arxiv_data1/oa_pdf/9a/b0/clin-70-06-435.PMC4462577.pdf
"2010;362(20):1863 –71, http://dx.doi.org/ 10.1056/NEJMoa0909305.",Non-OADS,/arxiv_data1/oa_pdf/9a/b0/clin-70-06-435.PMC4462577.pdf
"2014; 69(9):641 –6, http://dx.doi.org/10.6061/clinics.",Non-OADS,/arxiv_data1/oa_pdf/9a/b0/clin-70-06-435.PMC4462577.pdf
"2012;367(21):1988 –97, http://dx.doi.org/10.1056/NEJMoa1207481.",Non-OADS,/arxiv_data1/oa_pdf/9a/b0/clin-70-06-435.PMC4462577.pdf
"2010;39(5):529 –36, http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/9a/b0/clin-70-06-435.PMC4462577.pdf
"2012;56(2):285 –290, http://dx.doi.org/10.1016/j.jvs.2012.01.043.",OADS,/arxiv_data1/oa_pdf/9a/b0/clin-70-06-435.PMC4462577.pdf
"2010;39(4):431 –5, http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/9a/b0/clin-70-06-435.PMC4462577.pdf
"2008;48(6 Suppl):30S-36S;discussion 36S, http://dx.doi.org/10.1016/j.jvs.2008.08.096.",OADS,/arxiv_data1/oa_pdf/9a/b0/clin-70-06-435.PMC4462577.pdf
"2009;16(5):598 –602, http://dx.doi.org/10.1583/09-2787.1.",Non-OADS,/arxiv_data1/oa_pdf/9a/b0/clin-70-06-435.PMC4462577.pdf
"2010;34(3):222 –4, http://dx.doi.org/10.1111/j.1525-1594.",Non-OADS,/arxiv_data1/oa_pdf/9a/b0/clin-70-06-435.PMC4462577.pdf
"2010;34(2):105 –12, http://dx.doi.org/10.1111/aor.2010.34.issue-2.",Non-OADS,/arxiv_data1/oa_pdf/9a/b0/clin-70-06-435.PMC4462577.pdf
"2009;8(2):148 –53, http://dx.doi.org/10.1590/S1677-54492009000200009.",Non-OADS,/arxiv_data1/oa_pdf/9a/b0/clin-70-06-435.PMC4462577.pdf
"2005;4(4):353 –56, http://dx.doi.org/10.1590/S1677-54492005000400010.Table 1 - Descriptive measures of the angiotomographic parameters of 49 patients with juxtarenal aneurysm.",Non-OADS,/arxiv_data1/oa_pdf/9a/b0/clin-70-06-435.PMC4462577.pdf
"Psychiatric history (DSM-IV diagnoses from SCID-I interviews), family history (assessed with Family Interview for Genetic Studies)34and demographic information of the deceased were obtained via psychological autopsy performed by trained clinicians with informants best acquainted with the deceased among their ﬁrst-degree family members, as described earlier.35This proxy-based assessment of psychological autopsy has been extensively investigated and found to produce valid information, demonstrating similar information obtained from the informant and from the subject.35–38 A custom-designed 400 K promoter tiling array (Agilent Technologies, Santa Clara, CA, USA) provided information about 23 551 gene promoters (1200 bp upstream and 400 bp downstream of the transcription start sites of genes) described in Ensembl version 55 (http://www.ensembl.org).",Non-OADS,/arxiv_data1/oa_pdf/39/23/tp201532a.PMC4462598.pdf
"To view a copy of this license, visit http:// creativecommons.org/licenses/by-nc-sa/4.0/ Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)Maternal depression and DNA methylation changes Z Nemoda et al 8 Translational Psychiatry (2015), 1 –8",Non-OADS,/arxiv_data1/oa_pdf/39/23/tp201532a.PMC4462598.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)Prenatal LPA exposure induces behavioral changes H Mirendil et al 10 Translational Psychiatry (2015), 1 –10",Non-OADS,/arxiv_data1/oa_pdf/f2/3e/tp201533a.PMC4462599.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)Early-life stress amygdalar behavior is reversible MG Arnett et al 8 Translational Psychiatry (2015), 1 –8",Non-OADS,/arxiv_data1/oa_pdf/25/d0/tp201535a.PMC4462600.pdf
"Surgical Neurology InternationalEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comCase Report A case of angiographically occult, distal small anterior inferior  cerebellar artery aneurysm Hisashi Kubota, Yasuhiro Sanada, Kazuhiro Nagatsuka, Amami Kato Department of Neurosurgery, Kinki University, Faculty of Medicine, Osaka, Japan E‑mail: *Hisashi Kubota ‑ kubopo@gmail.com; Yasuhiro Sanada ‑ ysanada@med.kindai.ac.jp; Kazuhiro Nagatsuka ‑ kaznagatu@med.kindai.ac.jp;   Amami Kato ‑ akato‑osk@umin.org   *Corresponding author Received: 22 December 14  Accepted: 26 February 15  Published: 04 Jun 15 Abstract Background: A small aneurysm at an unusual location, such as a distal anterior  inferior cerebellar artery (AICA) aneurysm, may conceal as a computed tomography  angiography (CTA) and digital subtraction angiography (DSA)‑occult aneurysm.",Non-OADS,/arxiv_data1/oa_pdf/ac/a2/SNI-6-97.PMC4462615.pdf
"Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2015/6/1/97/158206 Copyright: © 2015 Kubota H.  This is an open‑access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,   distribution, and reproduction in any medium, provided the original author and source are credited.",Non-OADS,/arxiv_data1/oa_pdf/ac/a2/SNI-6-97.PMC4462615.pdf
"Surgical Neurology International 2015, 6:97  http://www.surgicalneurologyint.com/content/6/1/97aneurysm measuring 1 mm in maximum diameter was  depicted with 3DRA at the meatal segment of the left  AICA [Figure 2a].",Non-OADS,/arxiv_data1/oa_pdf/ac/a2/SNI-6-97.PMC4462615.pdf
"Surgical Neurology International 2015, 6:97  http://www.surgicalneurologyint.com/content/6/1/97REFERENCES 1.",Non-OADS,/arxiv_data1/oa_pdf/ac/a2/SNI-6-97.PMC4462615.pdf
"Surgical Neurology InternationalEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comOriginal Article Outcome of cerebral arteriovenous malformations after linear  accelerator reirradiation Paulo L. Moraes, Rodrigo S. Dias1, Eduardo Weltman2, Adelmo J. Giordani1, Salomon Benabou3,  Helena R. C. Segreto1, Roberto A. Segreto1 Serviço de Radioterapia do Hospital São Joaquim – Beneficência Portuguesa de São Paulo and Universidade Federal de São Paulo/Escola Paulista de Medicina –  UNIFESP/EPM, 1Universidade Federal de São Paulo/Escola Paulista de Medicina - UNIFESP/EPM, 2Hospital Israelita Albert Einstein, and Faculdade de Medicina  da Universidade de São Paulo, 3Serviço de Radioterapia e Radiocirurgia do Hospital Bandeirantes, São Paulo, S.P ., Brazil E-mail: *Paulo L. Moraes - paulolazarodemoraes@gmail.com; Rodrigo S. Dias - rodrigo.radioterapia@gmail.com;   Eduardo Weltman - eweltman@einstein.br; Adelmo J. Giordani - adelmogiordani@ig.com.br; Salomon Benabou - s.benabou@uol.com.br;   Helena R. C. Segreto -  segreto.dmed@epm.br; Roberto A. Segreto - segreto.dmed@epm.br   *Corresponding author Received: 17 October 14  Accepted: 05 February 15  Published: 04 Jun 15 Access this article  online Website: www.surgicalneurologyint.com DOI:   10.4103/2152-7806.158205  Quick Response Code: Abstract Background:  The aim of this study was to evaluate the clinical outcome of patients  undergoing single‑dose reirradiation using the Linear Accelerator (LINAC) for brain  arteriovenous malformations (AVM).",Non-OADS,/arxiv_data1/oa_pdf/f3/95/SNI-6-96.PMC4462616.pdf
Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2015/6/1/96/158205 Copyright: © 2015 Moraes PL.,Non-OADS,/arxiv_data1/oa_pdf/f3/95/SNI-6-96.PMC4462616.pdf
"Surgical Neurology International 2015, 6:96  http://www.surgicalneurologyint.com/content/6/1/96INTRODUCTION Arteriovenous malformation (AVM) of the brain is a  vascular alteration of embryonal origin, with a network  of tangled vessels also named nidus.",Non-OADS,/arxiv_data1/oa_pdf/f3/95/SNI-6-96.PMC4462616.pdf
"Surgical Neurology International 2015, 6:96  http://www.surgicalneurologyint.com/content/6/1/96numerical variables (dose, nidus volume, number of  nutrition vessels, conformity index, number of fields,  patient age), the Mann–Whitney test was used.",Non-OADS,/arxiv_data1/oa_pdf/f3/95/SNI-6-96.PMC4462616.pdf
"Surgical Neurology International 2015, 6:96  http://www.surgicalneurologyint.com/content/6/1/96volume (Vn12) was 35.3 cm3 and 20.6 cm3, respectively.",Non-OADS,/arxiv_data1/oa_pdf/f3/95/SNI-6-96.PMC4462616.pdf
"Surgical Neurology International 2015, 6:96  http://www.surgicalneurologyint.com/content/6/1/96was possible in three patients (11.1%), with total AVM  cure in 2/3 of the patients.",Non-OADS,/arxiv_data1/oa_pdf/f3/95/SNI-6-96.PMC4462616.pdf
"Surgical Neurology International 2015, 6:96  http://www.surgicalneurologyint.com/content/6/1/96Factors related to rupture of the blood barrier were  prescription  dose in the first procedure  ≥15.5  Gy  and  nidus volume before reirradiation ≤1.5  cm3.",Non-OADS,/arxiv_data1/oa_pdf/f3/95/SNI-6-96.PMC4462616.pdf
"Surgical Neurology International 2015, 6:96  http://www.surgicalneurologyint.com/content/6/1/9685 patients, Hayhurst et al.,  observed that 50% of those  patients exhibited some alteration on serial T2‑weighted  MRI.",OADS,/arxiv_data1/oa_pdf/f3/95/SNI-6-96.PMC4462616.pdf
"Surgical Neurology International 2015, 6:96  http://www.surgicalneurologyint.com/content/6/1/96A systematic review and meta-analysis.",Non-OADS,/arxiv_data1/oa_pdf/f3/95/SNI-6-96.PMC4462616.pdf
http://dx.doi.org/10.1016/S0968 -0004(99)01438-3 .,OADS,/arxiv_data1/oa_pdf/d8/12/mBio.00591-15.PMC4462617.pdf
http://dx.doi.org/10.1128/ecosalplus.ESP-0001-2012 .,Non-OADS,/arxiv_data1/oa_pdf/d8/12/mBio.00591-15.PMC4462617.pdf
http://dx.doi.org/10.1371/journal.pone.0096757 .,Non-OADS,/arxiv_data1/oa_pdf/d8/12/mBio.00591-15.PMC4462617.pdf
http://dx.doi.org/ 10.1074/jbc.M113.525618 .,Non-OADS,/arxiv_data1/oa_pdf/d8/12/mBio.00591-15.PMC4462617.pdf
http://dx.doi.org/ 10.1021/bi952269e .,Non-OADS,/arxiv_data1/oa_pdf/d8/12/mBio.00591-15.PMC4462617.pdf
http://dx.doi.org/10.1016/ j.chembiol.2009.12.007 .,OADS,/arxiv_data1/oa_pdf/d8/12/mBio.00591-15.PMC4462617.pdf
http://dx.doi.org/10.3201/eid1412.080435 .,Non-OADS,/arxiv_data1/oa_pdf/d8/12/mBio.00591-15.PMC4462617.pdf
"http://dx.doi.org/10.1111/ mmi.12460 .10.Barker DF, Campbell AM .",OADS,/arxiv_data1/oa_pdf/d8/12/mBio.00591-15.PMC4462617.pdf
http://dx.doi.org/ 10.1016/0378-1119(85)90011-3 .,OADS,/arxiv_data1/oa_pdf/d8/12/mBio.00591-15.PMC4462617.pdf
http://dx.doi.org/ 10.1073/pnas.1206411109 .,Non-OADS,/arxiv_data1/oa_pdf/d8/12/mBio.00591-15.PMC4462617.pdf
J Mol Biol 278:787– 800. http://dx.doi.org/10.1006/ jmbi.1998.1733 .,OADS,/arxiv_data1/oa_pdf/d8/12/mBio.00591-15.PMC4462617.pdf
http://dx.doi.org/10.1111/mmi.12170 .,Non-OADS,/arxiv_data1/oa_pdf/d8/12/mBio.00591-15.PMC4462617.pdf
http://dx.doi.org/10.1007/BF00325688 .,Non-OADS,/arxiv_data1/oa_pdf/d8/12/mBio.00591-15.PMC4462617.pdf
Proc Natl Acad Sci U S A 104:6037– 6042. http://dx.doi.org/ 10.1073/pnas.0609675104 .Role of Biotin Utilization in Bacterial Virulence May/June 2015 Volume 6 Issue 3 e00591-15®mbio.asm.org 9,Non-OADS,/arxiv_data1/oa_pdf/d8/12/mBio.00591-15.PMC4462617.pdf
Infect Genet Evol 21:602– 615. http://dx.doi.org/10.1016/ j.meegid.2013.08.011 .,OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
Reprod Nutr Dev 43:439 – 457. http://dx.doi.org/ 10.1051/rnd:2003031 .,OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
http://dx.doi.org/10.1016/j.meegid.2013.06.012 .,OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
http://dx.doi.org/10.1016/j.imlet.2013.01.004 .,OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
Nat J Commun5:5438. http://dx.doi.org/10.1038/ncomms6438 .,OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
http://dx.doi.org/10.1038/nature11724 .,Non-OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
Annu Rev Microbiol 67:629 – 650. http://dx.doi.org/10.1146/annurev-micro-092412-155746 .,Non-OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
http://dx.doi.org/10.1073/ pnas.1305121110 .,Non-OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
http://dx.doi.org/10.1128/JCM.43.3.1278-1284.2005 .,OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
http://dx.doi.org/10.1016/j.micinf.2006.03.004 .,OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
http://dx.doi.org/10.1016/j.vetmic.2005.07.006 .,OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
http://dx.doi.org/10.1271/bbb.64.2631 .,Non-OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
http://dx.doi.org/10.1007/s12088-013-0359-2 .,Non-OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
http://dx.doi.org/10.1128/ CDLI.10.2.272-277.2003 .,Non-OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
Vet Res 43:42. http://dx.doi.org/ 10.1186/1297-9716-43-42 .,Non-OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
http://dx.doi.org/10.1016/j.vetmic.2007.05.016 .,OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
http://dx.doi.org/10.1016/j.micpath.2010.07.002 .,OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
CellHost Microbe 14:453– 459. http://dx.doi.org/10.1016/ j.chom.2013.09.005 .,OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
Front Cell Infect Microbiol 2:12. http://dx.doi.org/10.3389/fcimb.2012.00012 .,Non-OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
BMC Genomics 11:439. http://dx.doi.org/10.1186/1471-2164-11-439 .,OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
Br J Phar- macol 149:666 – 675. http://dx.doi.org/10.1038/sj.bjp.0706912 .,Non-OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
http://dx.doi.org/10.1111/j.1462-5822.2006.00709.x .,Non-OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
http://dx.doi.org/10.1016/j.tim.2013.10.004 .,OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
http://dx.doi.org/ 10.1371/journal.ppat.1000703 .,Non-OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
http://dx.doi.org/10.1371/journal.pone.0001120 .,Non-OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
http://dx.doi.org/10.4049/ jimmunol.164.5.2745 .,Non-OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
http://dx.doi.org/10.1016/j.vetmic.2012.10.025 .,OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
http://dx.doi.org/10.1128/IAI.00095-13 .,Non-OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
http://dx.doi.org/10.1007/978-1 -59745-467-4_3 .,Non-OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
http://dx.doi.org/10.3791/50788 .,Non-OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
http://dx.doi.org/10.1159/000319855 .LukMF =Kills Migrating Neutrophils through CCR1 May/June 2015 Volume 6 Issue 3 e00335-15®mbio.asm.org 9,Non-OADS,/arxiv_data1/oa_pdf/e2/88/mBio.00335-15.PMC4462618.pdf
http://dx.doi.org/10.1016/j.cll.2010.01.002 .,OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.1016/j.vetmic.2009.08.024 .,OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.1016/S0166 -3542(02)00206-1 .,OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.1128/ JVI.77.1.25-36.2003 .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.3109/00365549609027160 .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.1016/S0264-410X(02)00811-3 .,OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.1099/ vir.0.011437-0 .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
J Infect Dis 201:2– 4. http://dx.doi.org/ 10.1086/648731 .,OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.3201/ eid1810.120621 .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.1111/trf.12764 .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.1371/ journal.pone.0047912 .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.1099/ 0022-1317-72-11-2705 .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.3201/eid1701.100051 .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/ 10.1086/431153 .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.1371/journal.pone.0081214 .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.1111/2049 -632X.12178 .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.1093/jmedent/ 30.1.295 .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
Experientia 49: 802– 805. http://dx.doi.org/10.1007/BF01923553 .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
Tick-borne ﬂavivirus infection in Ixodes scapularis larvae: de- velopment of a novel method for synchronous viral infection of ticks.Virology 365:410 – 418. http://dx.doi.org/10.1016/j.virol.2007.03.057 .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.1016/S0140-6736(08)60800-4 .,OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
Rev Med Virol 22:69 – 87. http://dx.doi.org/10.1002/rmv.712 .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.1038/226325a0 .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.1016/j.virol.2008.08.030 .,OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.1128/ JVI.03404-13 .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.1016/S0168 -1702(01)00274-X .,OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/ 10.1074/jbc.M110.192500 .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
J Virol 79:8388 – 8399. http://dx.doi.org/ 10.1128/JVI.79.13.8388-8399.2005 .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
Virology 179: 821– 826. http://dx.doi.org/10.1016/0042-6822(90)90150-P .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
J Virol 88:8720 – 8723. http://dx.doi.org/10.1128/ JVI.00707-14 .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.1016/0092-8674(81)90298-1 .,OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
Science 343: 881– 885. http://dx.doi.org/10.1126/ science.1247749 .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.1046/j.1440 -1711.2003.01157.x .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.1128/ JVI.00157-12 .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.1128/JVI.75.22.10787-10799.2001 .,OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.1093/bib/ bbs017 .,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
http://dx.doi.org/10.1038/nbt.1754 .Analysis of Tick-Borne Flavivirus Persistence in 293T Cells May/June 2015 Volume 6 Issue 3 e00614-15®mbio.asm.org 11,Non-OADS,/arxiv_data1/oa_pdf/67/d4/mBio.00614-15.PMC4462619.pdf
"A maximum-likelihoodphylogeny with 100 bootstrap replicates was generated usingRAxML v8.0.16 (17), using the ASC_GTRGAMMA substitutionmodel, and visualized using FigTree v1.3.1 ( http://tree.bio.ed.ac.uk/ software/ﬁgtree/ ).",OADS,/arxiv_data1/oa_pdf/3f/be/mBio.00501-15.PMC4462620.pdf
http://dx.doi.org/10.1016/S0140 -6736(13)60844-2 .,OADS,/arxiv_data1/oa_pdf/3f/be/mBio.00501-15.PMC4462620.pdf
http://dx.doi.org/10.1016/ j.micinf.2009.10.002 .,OADS,/arxiv_data1/oa_pdf/3f/be/mBio.00501-15.PMC4462620.pdf
http://dx.doi.org/10.1128/IAI.00459-07 .,Non-OADS,/arxiv_data1/oa_pdf/3f/be/mBio.00501-15.PMC4462620.pdf
http://dx.doi.org/10.1128/CVI.05194-11 .,Non-OADS,/arxiv_data1/oa_pdf/3f/be/mBio.00501-15.PMC4462620.pdf
http://dx.doi.org/10.1586/erv.12.12 .,Non-OADS,/arxiv_data1/oa_pdf/3f/be/mBio.00501-15.PMC4462620.pdf
http://dx.doi.org/10.1128/JCM.02432-09 .,Non-OADS,/arxiv_data1/oa_pdf/3f/be/mBio.00501-15.PMC4462620.pdf
http://dx.doi.org/10.1128/JCM.42.7.3100-3107.2004 .,Non-OADS,/arxiv_data1/oa_pdf/3f/be/mBio.00501-15.PMC4462620.pdf
J Bacteriol 190:6881– 6893. http://dx.doi.org/10.1128/JB.00619-08 .,Non-OADS,/arxiv_data1/oa_pdf/3f/be/mBio.00501-15.PMC4462620.pdf
http://dx.doi.org/10.1371/ journal.pgen.1000344 .,Non-OADS,/arxiv_data1/oa_pdf/3f/be/mBio.00501-15.PMC4462620.pdf
http://dx.doi.org/10.1128/JCM.00471-07 .,Non-OADS,/arxiv_data1/oa_pdf/3f/be/mBio.00501-15.PMC4462620.pdf
Outbreaks of cholera-like diarrhoea caused by enterotoxigenic Escherichia coli in the Brazilian Amazon rainforest.Trans R Soc Trop Med Hyg 99:669 – 674. http://dx.doi.org/10.1016/ j.trstmh.2005.03.007 .,Non-OADS,/arxiv_data1/oa_pdf/3f/be/mBio.00501-15.PMC4462620.pdf
http://dx.doi.org/10.1186/gb-2004-5-2-r12 .,Non-OADS,/arxiv_data1/oa_pdf/3f/be/mBio.00501-15.PMC4462620.pdf
"http://dx.doi.org/10.7717/ peerj.332 .19.Hyatt D, Chen GL, Locascio PF, Land ML, Larimer FW, Hauser LJ .",OADS,/arxiv_data1/oa_pdf/3f/be/mBio.00501-15.PMC4462620.pdf
BMC Bioinformatics 11:119. http://dx.doi.org/10.1186/ 1471-2105-11-119 .,OADS,/arxiv_data1/oa_pdf/3f/be/mBio.00501-15.PMC4462620.pdf
http://dx.doi.org/10.1093/ bioinformatics/btq461 .,OADS,/arxiv_data1/oa_pdf/3f/be/mBio.00501-15.PMC4462620.pdf
BMC Biol 4:41. http://dx.doi.org/ 10.1186/1741-7007-4-41 .,OADS,/arxiv_data1/oa_pdf/3f/be/mBio.00501-15.PMC4462620.pdf
Mol Syst Biol 2:2006.0007. http://dx.doi.org/10.1038/ msb4100049 .,OADS,/arxiv_data1/oa_pdf/3f/be/mBio.00501-15.PMC4462620.pdf
http://dx.doi.org/10.1056/NEJMoa1106920 .,OADS,/arxiv_data1/oa_pdf/3f/be/mBio.00501-15.PMC4462620.pdf
http://dx.doi.org/10.1128/IAI.00932-10 .,Non-OADS,/arxiv_data1/oa_pdf/3f/be/mBio.00501-15.PMC4462620.pdf
http://dx.doi.org/10.1086/345817 .,Non-OADS,/arxiv_data1/oa_pdf/3f/be/mBio.00501-15.PMC4462620.pdf
http://dx.doi.org/10.1016/S0732 -8893(02)00504-7 .Sahl et al.,OADS,/arxiv_data1/oa_pdf/3f/be/mBio.00501-15.PMC4462620.pdf
Infect Immun 70:4729 – 4734. http://dx.doi.org/10.1128/IAI.70.8.4729-4734.2002 .,Non-OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
http://dx.doi.org/10.1086/588383 .,OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
http://dx.doi.org/10.1128/IAI.05114-11 .,Non-OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
http://dx.doi.org/10.1111/j.1365 -2958.2005.04918.x .,Non-OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
http://dx.doi.org/10.1099/mic.0.25833-0 .,Non-OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
http://dx.doi.org/10.1016/j.chom.2009.08.003 .,OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
J Bacteriol 191: 4492– 4501. http://dx.doi.org/10.1128/JB.00315-09 .,Non-OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
Proc Natl Acad Sc iUSA 111: 4988 – 4993. http://dx.doi.org/ 10.1073/pnas.1321364111 .,Non-OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
http://dx.doi.org/10.1371/journal.pgen.1000141 .,Non-OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
http://dx.doi.org/10.1007/s10295-012-1117-x .,Non-OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
BMC Res Notes 7:13.http://dx.doi.org/10.1186/1756-0500-7-13 .,Non-OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
http://dx.doi.org/10.1016/0092-8674(76)90055-6 .,OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
http://dx.doi.org/10.1038/ nprot.2011.417 .,Non-OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
http://dx.doi.org/ 10.1109/TCBB.2012.83 .,Non-OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
http://dx.doi.org/10.1128/IAI.00619-06 .,Non-OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
http://dx.doi.org/10.1016/j.cell.2012.05.042 .,OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
http://dx.doi.org/10.1371/journal.pone.0046783 .,Non-OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
http://dx.doi.org/10.1371/ journal.ppat.1000622 .,Non-OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
Infect Immun 77:4925– 4933. http://dx.doi.org/10.1128/IAI.00671-09 .,Non-OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
http://dx.doi.org/10.1074/jbc.M300794200 .,Non-OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
Am J Respir Crit Care Med155:432– 435. http://dx.doi.org/10.1164/ajrccm.155.2.9032174 .,Non-OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
http://dx.doi.org/10.1111/j.1365 -2958.2011.07758.x .,Non-OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
http://dx.doi.org/10.1128/AAC.02327-12 .,Non-OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
http://dx.doi.org/10.1128/ JB.00053-08 .,Non-OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
Infect Immun 70:4406 – 4413. http://dx.doi.org/10.1128/ IAI.70.8.4406-4413.2002 .,Non-OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
http://dx.doi.org/10.1371/journal.pgen.1003716 .,Non-OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
http://dx.doi.org/10.1093/nar/gkr483 .,Non-OADS,/arxiv_data1/oa_pdf/f6/3f/mBio.00775-15.PMC4462621.pdf
http://dx.doi.org/10.1038/441300a .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
Annu Rev Microbiol 54:49 – 80. http://dx.doi.org/10.1146/ annurev.micro.54.1.49 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
Curr Opin Microbiol 10:638 – 643. http://dx.doi.org/10.1016/j.mib.2007.09.006 .,OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1038/nrmicro2960 .,OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
Environ Microbiol 15:848 – 864. http://dx.doi.org/10.1111/j.1462 -2920.2012.02860.x .,OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
Mol Microbiol 85:418 – 430. http://dx.doi.org/ 10.1111/j.1365-2958.2012.08109.x .,OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1104/pp.103.028712 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1111/j.1365-2958.2005.05020.x .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1111/j.1365-2958.2004.04440.x .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1073/ pnas.1306390110 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1111/j.1365-2958.2012.08101.x .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1111/j.1365-2958.2005.05019.x .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1016/0014 -5793(95)01432-2 .,OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1128/JB.187.4.1357-1368.2005 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1038/ emboj.2011.36 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1046/j.1365 -2958.2000.02148.x .,OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
J Bacteriol 193: 679 – 685. http://dx.doi.org/10.1128/ JB.01186-10 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
Mol Microbiol 74:876 – 887. http://dx.doi.org/10.1111/j.1365-2958.2009.06900.x .,OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/ 10.1111/j.1365-2958.2008.06369.x .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/ 10.1016/j.mib.2011.09.016 .,OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1111/j.1574-6976.2009.00199.x .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
Genes Dev 27:887– 899. http://dx.doi.org/10.1101/gad.215244.113 .,OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1073/ pnas.1103630108 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1128/JB.00028 -13.,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
J Bacteriol 192:6352– 6356. http://dx.doi.org/10.1128/ JB.01025-10 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1128/AEM.07036-11 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1099/mic.0.066597-0 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1128/JB.00014-12 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1111/ j.1365-2958.2010.07514.x .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.7554/eLife.01501 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1128/JB.185.8.2635-2643.2003 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/ 10.1128/JB.182.7.1794-1801.2000 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
J Bacteriol 191:4767– 4775. http://dx.doi.org/10.1128/JB.00348-09 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
ProcNatl Acad Sc iUSA 104: 8113– 8118. http://dx.doi.org/10.1073/ pnas.0610226104 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
J Bacteriol 191: 4103– 4110. http://dx.doi.org/10.1128/ JB.00314-09 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1111/ j.1462-2920.2011.02582.x .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1128/mBio.00944-13 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1128/JB.182.11.3072-3080.2000 .,OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1128/ JB.186.12.3749-3759.2004 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1371/ journal.ppat.1004205 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
J Bacteriol 185: 6448 – 6455. http://dx.doi.org/10.1128/ JB.185.21.6448-6455.2003 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1042/ BJ20130412 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/ 10.1016/S0005-2728(00)00283-8 .,OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1128/MMBR.69.1.12-50.2005 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1128/mBio.01667-14 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1128/JB.00564-07 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1371/journal.ppat.1001104 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1111/mmi.12902 .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/ 10.1111/j.1574-6968.2001.tb10518.x .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
http://dx.doi.org/10.1002/(SICI)1097-0061 (19960315)12:3 /H11021259::AID-YEA901 /H110223.0.CO;2-C .,Non-OADS,/arxiv_data1/oa_pdf/33/53/mBio.00392-15.PMC4462622.pdf
The MLST allelic sequencesand sequence type (ST) are available online ( http://mlst.mycologylab.org/ defaultinfo.aspx?Page /H11005CN).,OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
"The index of congruence ( Icong) was calculated using online calcula - tion (58) ( http://mobyle.pasteur.fr/cgi-bin/portal.py#welcome ) for test- ing topological similarity between haplotypes trees by comparing pairwisecombination (here, 21 combinations for 7 MLST loci) and calculating thePvalue for each combination.",OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1097/QAD.0b013e328322ffac .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
Fungal Genet Biol http://dx.doi.org/10.1016/ j.fgb.2015.02.009 .,OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
FEMS Yeast Res6:614 – 619. http://dx.doi.org/10.1111/j.1567-1364.2006.00081.x .,OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1371/journal.pmed.0040021 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/ 10.1146/annurev.micro.60.080805.142102 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1371/ journal.ppat.0030114 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/ 10.1046/j.1365-294x.2000.01021.x .,OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1534/ g3.111.001255 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1128/ IAI.69.1.115-122.2001 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1128/EC.2.6.1162-1168.2003 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1128/JCM.06750-11 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1371/journal.pgen.0030186 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/ 10.1080/13693780902953886 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1534/ genetics.105.046672 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1111/j.1755-0998.2008.02196.x .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/ 10.1371/journal.pone.0009124 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1371/journal.ppat.1002495 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1099/mic.0.2007/015594-0 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
Int J Syst Bac- teriol 47:432– 442. http://dx.doi.org/10.1099/00207713-47-2-432 .,OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.3201/eid0902.020246 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1002/(SICI)1522 -2683(19990101)20:8 /H110211790::AID-ELPS1790 /H110223.0.CO;2-2 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1128/ JCM.43.2.556-564.2005 .,OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1016/ j.jinf.2004.07.013 .,OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
Infect Immun 71:4831– 4841. http://dx.doi.org/ 10.1128/IAI.71.9.4831-4841.2003 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1128/IAI.70.9.5225 -5235.2002 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1186/gb-2008-9-2-r41 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1128/mBio.00091-10 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1128/mBio.00158-11 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1111/j.1567-1364.2006.00087.x .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1038/nrmicro1245 .,OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1093/ clinids/23.1.82 .,OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1111/j.1439-0507.1997.tb00235.x .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1016/S1087 -1845(03)00046-X .,OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/ 10.1093/molbev/msl070 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1146/annurev.phyto.43.040204.135958 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1016/j.femsyr.2005.05.005 .,OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1128/mBio.00196-12 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1128/IAI.00168-08 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
Eukaryot Cell 11:820 – 826. http://dx.doi.org/10.1128/EC.00121-12 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
Am J Pathol 166:421– 432. http://dx.doi.org/10.1016/S0002-9440(10)62265-1 .,OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/ 10.1097/00002030-200402200-00024 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1006/fgbi.2000.1192 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1093/molbev/msr121 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1093/bioinformatics/17.12.1230 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1046/j.1471-8278.2000.00014.x .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1093/bioinformatics/btm500 .,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
http://dx.doi.org/10.1371/ journal.pbio.1001653 .Desnos-Ollivier et al.,Non-OADS,/arxiv_data1/oa_pdf/e1/93/mBio.00311-15.PMC4462623.pdf
"Draftgenomes were annotated using MaGe (27, 28) and submitted to EMBL.16S rRNA sequences from draft genomes were assessed using BLASTn( http://blast.ncbi.nlm.nih.gov ) and were submitted to GenBank.",OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
"Fisher’s exact test, implemented within the py-thon package scipy ( http://www.scipy.org ), was used to identify gene fam- ilies or domains that were over- or underrepresented in a particular clade.A cutoff of P/H110210.05 was used to determine signiﬁcance.",OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1038/nature10433 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1007/s00253 -009-2092-7 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1126/science.1223813 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
ISME J 9:615– 628 http://dx.doi.org/ 10.1038/ismej.2014.152 .,OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1126/science.1198719 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
Science 341: 667– 669. http://dx.doi.org/10.1126/science.1240659 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
BMC Genomics 12:235. http://dx.doi.org/10.1186/1471-2164-12-235 .,OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
Proc Natl Acad Sc iUSA 108(Suppl 1):4599 – 4606. http://dx.doi.org/10.1073/ pnas.1000071108 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1111/ j.1558-5646.2009.00913.x .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/ 10.1371/journal.pone.0023545 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1371/ journal.pone.0101691 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1111/j.1558 -5646.2011.01547.x .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1128/AEM.01715-09 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
Parasitology 99:77– 81. http://dx.doi.org/10.1017/S0031182000061047 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1111/j.1462-2920.2011.02663.x .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1128/ AEM.70.9.5621-5627.2004 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1016/j.jip.2010.01.005 .,OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
Nucleic Acids Res 34: 53– 65. http://dx.doi.org/10.1093/nar/gkj406 .,OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.2307/1268249 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1086/ 670612 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1016/S0929 -1393(96)00121-7 .,OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1073/ pnas.0335320100 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
Appl Environ Microbiol 80: 4277– 4285. http://dx.doi.org/10.1128/AEM.00768-14 .,OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1128/JB.00092-11 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
J Agric Food Chem 60:4053– 4059. http://dx.doi.org/10.1021/ jf204351f .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1111/1462 -2920.12417 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
Med Res Rev http://dx.doi.org/10.1002/med.21321 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
Appl Environ Microbiol 81:422– 431. http://dx.doi.org/10.1128/AEM.02921-14 .,OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/ 10.1111/j.1365-2958.2005.04747.x .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1007/82_2011_172 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1371/ journal.pone.0013933 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1128/JB.185.10.3147-3154.2003 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1111/j.1462-5822.2005.00585.x .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1093/bioinformatics/ btp348 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1002/0471250953.bi1105s31 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1371/journal.pone.0058387 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1002/ 0471142727.mb1911s96 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1093/molbev/msn083 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1093/nar/gkr201 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1016/0306 -4565(94)90047-7 .,OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1128/JB.188.7.2706-2710.2006 .,OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/ 10.1093/bioinformatics/13.5.555 .,OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/ 10.1007/978-1-62703-646-7_8 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/ 10.1016/j.jtbi.2005.08.037 .,OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1093/nar/gkt1223 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.2307/2412810 .,Non-OADS,/arxiv_data1/oa_pdf/18/cc/mBio.00076-15.PMC4462624.pdf
http://dx.doi.org/10.1111/j.1365 -2672.2007.03706.x .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1146/ annurev.phyto.39.1.225 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
ClinMicrobiol Infect 16:821– 830. http://dx.doi.org/10.1111/j.1469 -0691.2010.03237.x .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1128/ IAI.00743-09 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1128/ IAI.72.12.7220-7230.2004 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
Infect Immun 77:4102– 4110. http://dx.doi.org/10.1128/IAI.00398-09 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1128/IAI.01249-07 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1111/j.1365 -313X.2010.04131.x .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
Front PlantSci4:139. http://dx.doi.org/10.3389/fpls.2013.00139 .,OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/ 10.1146/annurev-biochem-060713-035600 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1046/j.1365-313X.1999.00265.x .,OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/ 10.1104/pp.106.079467 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1046/j.1365-313X.1999.00451.x .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1038/nature05286 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1111/j.1365 -313X.2009.04086.x .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
Proc Natl Acad Sc iUSA 92:4189 – 4196. http://dx.doi.org/ 10.1073/pnas.92.10.4189 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/ 10.1073/pnas.0404536101 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1002/cbic.200700693 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
J Endotoxin Res 13:69 – 84. http://dx.doi.org/10.1177/ 0968051907079399 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
Front Microbiol 2:159. http://dx.doi.org/10.3389/fmicb.2011.00159 .,OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1128/JB.00153-07 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1111/j.1365-2958.2012.08154.x .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1038/35074106 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/ 10.1093/pcp/pcg042 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1105/ tpc.105.037648 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
Plant Cell 18:465– 476. http://dx.doi.org/ 10.1105/tpc.105.036574 .,OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1016/S1097-2765(00)80265-8 .,OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1074/ jbc.M114.562603 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1105/tpc.106.045096 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1128/IAI.01338-07 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1111/j.1462-2920.2012.02828.x .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1074/jbc.M113.489914 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1111/j.1462 -5822.2005.00674.x .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
Microbiology 156:72– 80. http://dx.doi.org/10.1099/mic.0.030700-0 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/ 10.1016/j.tplants.2005.02.008 .Khodai-Kalaki et al.,OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/ 10.1038/ng1639 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
BMC Microbiol 11:11.http://dx.doi.org/10.1186/1471-2180-11-11 .,OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1038/516165a .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1105/tpc.109.066464 .,OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1002/chem.200601406 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/ 10.1016/j.pmpp.2005.06.001 .,OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
Mol Plant Microbe Interact 17:686 – 695. http://dx.doi.org/ 10.1094/MPMI.2004.17.6.686 .,OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/ 10.1094/Phyto-79-284 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1146/ annurev.py.33.090195.001045 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1099/mic.0.027607-0 .,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/ 10.1194/jlr.D500014-JLR200 .,OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
http://dx.doi.org/10.1126/science.1086770 .Pathogenicity of B. cenocepacia inA.,Non-OADS,/arxiv_data1/oa_pdf/04/4f/mBio.00679-15.PMC4462625.pdf
"The ImageJ software package (ImageJ;National Institutes of Health, Bethesda, MD; http://imagej.nih.gov/ij/ ) was used for band quantitation.",OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1016/j.canlet.2009.07.004 .,OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1038/ nrc2888 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1038/onc.2009.351 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1146/ annurev.pathol.1.110304.100133 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1016/B978 -0-12-800098-4.00002-7 .,OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
Front Microbiol 3:44. http://dx.doi.org/10.3389/ fmicb.2012.00044 .,OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1182/ blood-2003-08-2781 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1158/0008-5472.CAN-04-2822 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1124/ pr.107.07104 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/ 10.1016/j.taap.2013.05.010 .,OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1158/ 1078-0432.CCR-04-2159 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1038/onc.2012.244 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
Physiol Rev86:583– 650. http://dx.doi.org/10.1152/physrev.00011.2005 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1016/ j.bcp.2010.07.014 .,OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
Curr Pharm Des 14:473– 486. http://dx.doi.org/10.2174/138161208783597399 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1016/S0092 -8674(04)00045-5 .,OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/ 10.1007/s00430-007-0070-1 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
Front Microbiol 3:165. http://dx.doi.org/10.3389/fmicb.2012.00165 .,OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1038/nature05992 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/ 10.1128/JVI.01804-07 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/ 10.1093/emboj/cdf516 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1093/nar/ gkq212 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1096/fj.06 -6346fje .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1074/jbc.M111.220178 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/ 10.1126/science.1069861 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1016/j.gene.2012.12.009 .,OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1128/ JVI.05558-11 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/ 10.1128/JVI.01620-13 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1128/JVI.01147-12 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1371/ journal.ppat.1000742.s004 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1128/JVI.01019-12 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
Trends Cell Biol 23:421– 432. http://dx.doi.org/10.1016/ j.tcb.2013.04.001 .,OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
Nat Genet 36:683– 685. http://dx.doi.org/10.1038/ng1383 .,OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
Nat Genet 36: 687– 693. http://dx.doi.org/10.1038/ng1384 .,OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1016/ j.virol.2004.07.008 .,OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/ 10.3324/haematol.2012.063651 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1371/ journal.ppat.1003584 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
Viruses 6:4005– 4023. http://dx.doi.org/10.3390/v6104005 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1146/ annurev.micro.112408.134243 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1128/JVI.01473-12 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1074/jbc.M500166200 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
Biomed Res Int 2013: 210604. http://dx.doi.org/10.1155/2013/210604 .,OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/ 10.1006/bbrc.1996.0637 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1128/MCB.00700-06 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/ 10.1371/journal.ppat.1004460 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/ 10.1128/JVI.01334-09 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1128/AAC.03957-14 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
Curr Opin Oncol 19:452– 457. http://dx.doi.org/10.1097/CCO.0b013e3281eb8ea7 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
Cancer Res 68:4640 – 4648. http://dx.doi.org/10.1158/0008-5472.CAN-07-5988 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1080/01913120802343871 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1002/ijc.27849 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1016/j.virol.2004.03.049 .,OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1371/ journal.pone.0111502.t002 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/10.1016/ j.jviromet.2013.06.001 .,OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
http://dx.doi.org/ 10.1083/jcb.143.7.1871 .,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
Curr Protoc Mol Biol Chapter15:Unit 15.1. http://dx.doi.org/10.1002/0471142727.mb1510s95 .KSHV Induction of HO-1 in Endothelial Cells May/June 2015 Volume 6 Issue 3 e00668-15®mbio.asm.org 11,Non-OADS,/arxiv_data1/oa_pdf/4e/25/mBio.00668-15.PMC4462627.pdf
J Cell Biol 91: 601– 613. http://dx.doi.org/10.1083/jcb.91.3.601 .,OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
http://dx.doi.org/10.1371/ journal.ppat.1001329 .,Non-OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
http://dx.doi.org/10.1128/JVI.76.20.10455-10464.2002 .,OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
Annu Rev Cell Dev Biol 12:575– 625. http://dx.doi.org/10.1146/annurev.cellbio.12.1.575 .,OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
http://dx.doi.org/10.1016/S0168-1702(03)00159-X .,OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
http://dx.doi.org/ 10.1016/0962-8924(92)90130-F .,OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
http://dx.doi.org/ 10.1099/vir.0.059477-0 .,Non-OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
J Antimicrob Chemother64:1– 4. http://dx.doi.org/10.1093/jac/dkp161 .,OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
http://dx.doi.org/10.1073/ pnas.1312374110 .,Non-OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
Nature 463: 813– 817. http://dx.doi.org/10.1038/ nature08699 .,Non-OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
http://dx.doi.org/10.1016/j.cell.2009.12.017 .,OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
Biochem Biophys Res Commun 259: 401– 407. http://dx.doi.org/10.1006/bbrc.1999.0700 .,OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
http://dx.doi.org/10.1126/ science.1110656 .,Non-OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
J Virol 86:6537– 6545. http://dx.doi.org/ 10.1128/JVI.00094-12 .,Non-OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
http://dx.doi.org/10.4049/ jimmunol.167.4.2172 .,Non-OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
http://dx.doi.org/10.1074/jbc.M400304200 .,Non-OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
http://dx.doi.org/ 10.1128/JVI.02277-12 .,Non-OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
http://dx.doi.org/10.4049/ jimmunol.167.4.2172 .,Non-OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
http://dx.doi.org/10.1371/journal.ppat.1003151 .,Non-OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
Cell Microbiol 10:828 – 835. http://dx.doi.org/10.1111/j.1462 -5822.2007.01113.x .,OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
http://dx.doi.org/10.1016/ j.virol.2006.01.007 .,OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
http://dx.doi.org/10.1016/j.micinf.2011.01.012 .,OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
Cell 40:431– 439. http://dx.doi.org/10.1016/0092 -8674(85)90157-6 .,OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
http://dx.doi.org/10.1083/ jcb.105.6.2887 .,Non-OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
http://dx.doi.org/10.1371/journal.ppat.1003701 .,Non-OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
Curr Protoc Cy-tom Chapter 12: Unit 12.30. http://dx.doi.org/10.1002/ 0471142956.cy1230s65 .,Non-OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
Biochem J 363: 417– 429. http://dx.doi.org/10.1042/0264 -6021:3630417 .,OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
Virology143:651– 656. http://dx.doi.org/10.1016/0042-6822(85)90407-6 .,Non-OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
http://dx.doi.org/10.1128/JVI.00800-14 .,Non-OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
http://dx.doi.org/10.1371/ journal.pone.0068450 .Edinger et al.,OADS,/arxiv_data1/oa_pdf/3c/2e/mBio.00297-15.PMC4462628.pdf
"For ED, stem cell injection into the corpus cavernosum  or periprostatic implantation improves erectile functions in Current status of stem cell therapy in urology Jae Heon Kim, Yun Seob Song Department of Urology, Soonchunyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Korean J Urol 2015;56:409-411. http://dx.doi.org/10.4111/kju.2015.56.6.409 pISSN 2005-6737  •  eISSN 2005-6745Editorial Corresponding Author:  Yun Seob Song Department of Urology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, 59 Daesagwan-ro, Yongsan-gu, Seoul  140-743, Korea TEL: +82-2-709-9375, FAX: +82-2-709-9378, E-mail: yssong@schmc.ac.kr ⓒ The Korean Urological Association, 2015 diabetic, hyperlipidemic rat models, as well as in neurogenic  ED models.",Non-OADS,/arxiv_data1/oa_pdf/1f/ed/kju-56-409.PMC4462629.pdf
"orgKim and Song http://dx.doi.org/10.4111/kju.2015.56.6.409 stem cells to investigate the specific cancer risk, whereas  less therapeutic effort for future possible translational  studies has been made.",Non-OADS,/arxiv_data1/oa_pdf/1f/ed/kju-56-409.PMC4462629.pdf
"Keywords:  Acute kidney injury; Cell- and tissue-based therapy; Chronic kidney failure; Clinical trial; Evaluation studies  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Korean J Urol 2015;56:412-421. http://dx.doi.org/10.4111/kju.2015.56.6.412 pISSN 2005-6737  •  eISSN 2005-6745Review Article  Received:  16 April, 2015   •  Accepted:  6 May, 2015 Corresponding Author:  James J. Yoo Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA TEL: +1-336-713-7294, FAX: +1-336-713-7290, E-mail: jyoo@wakehealth.edu ⓒ The Korean Urological Association, 2015 renal disease should promote efficient regeneration of  functional renal-specific cells [5]; thus, cell-based approach  that can replace or restore damaged renal cells may be an  excellent alternative to the current treatment.",Non-OADS,/arxiv_data1/oa_pdf/99/47/kju-56-412.PMC4462630.pdf
orgChung et al http://dx.doi.org/10.4111/kju.2015.56.6.412 treatment of renal failure.,OADS,/arxiv_data1/oa_pdf/99/47/kju-56-412.PMC4462630.pdf
"orgChung et al http://dx.doi.org/10.4111/kju.2015.56.6.412 MSCs into renal specific cell types, particularly renal tubular  cells [63], podocytes [64], mesanglial cells [65], and glomerular  cells [66].",OADS,/arxiv_data1/oa_pdf/99/47/kju-56-412.PMC4462630.pdf
orgChung et al http://dx.doi.org/10.4111/kju.2015.56.6.412 CONFLICTS OF INTEREST The authors have nothing to disclose.,Non-OADS,/arxiv_data1/oa_pdf/99/47/kju-56-412.PMC4462630.pdf
